<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">

 <title>TmmGeek</title>
 <link href="http://lanyon.getpoole.com/atom.xml" rel="self"/>
 <link href="http://lanyon.getpoole.com/"/>
 <updated>2016-01-30T17:32:55-06:00</updated>
 <id>http://lanyon.getpoole.com</id>
 <author>
   <name>TmmGeek</name>
   <email>davidliangtmm@gmail.com</email>
 </author>

 
 <entry>
   <title>Extract PPT slide number and title</title>
   <link href="http://lanyon.getpoole.com/text%20editing/2016/01/28/Extract-PPT-slide-title/"/>
   <updated>2016-01-28T00:00:00-06:00</updated>
   <id>http://lanyon.getpoole.com/text%20editing/2016/01/28/Extract-PPT-slide-title</id>
   <content type="html">&lt;p&gt;Today, I am going to introduce a cool method with which you could extract all the titles of your PPT slide and the slide number accordingly. So often, we have to go through ton of PPT files with huge number of slides. Isn’t it nice that if we could programatically extract all the titles from slides of all the PPT files? So that we could review them, or in the case of a school scenario, it is very helpful to review and memorize slide titles sometime before exam or quiz.&lt;/p&gt;

&lt;!--break--&gt;

&lt;p&gt;This post is written precisely for this goal and you will be amazed when you could do so within just a minute.&lt;/p&gt;

&lt;p&gt;First, I need to disclose my system information, so that in the case if my method does not work on your machine, you could troubleshoot easier.&lt;/p&gt;

&lt;p&gt;I use
Macbook Pro Retina Display, early 2013. 
OS X Yosemite Version 10.10.5
Microsoft office Mac 2011(Through Microsoft 365).&lt;/p&gt;

&lt;p&gt;You could also read on this following post 
&lt;a href=&quot;http://www.pptfaq.com/FAQ00332_Export_Slide_Number_and_Title_Text_to_a_text_file.htm&quot;&gt;Export Slide Number and Title Text to a text file&lt;/a&gt; from the site “PPTools” as my method is based on it.&lt;/p&gt;

&lt;h2 id=&quot;procedure&quot;&gt;Procedure&lt;/h2&gt;

&lt;p&gt;If you have a PPT file, you could use your own, or you could find one from &lt;a href=&quot;https://www.google.com/#q=regression+ppt&quot;&gt;Google&lt;/a&gt;.&lt;/p&gt;

&lt;p&gt;Open a PPT file, then from the &lt;strong&gt;Tool&lt;/strong&gt; dropdown menu, choose &lt;strong&gt;Marco&lt;/strong&gt; then &lt;strong&gt;Visual Basic Editor&lt;/strong&gt;
&lt;img src=&quot;https://dl.dropboxusercontent.com/u/49272502/TextEditing%20Series%20Blog/assets/extractPPTSlideTitles/0f.png&quot; alt=&quot;ddd&quot; /&gt;&lt;/p&gt;

&lt;p&gt;Then a Project window will pop up, and you will see the name of the PPT file you want to extract on the list. Right click into the file name and you shall see &lt;strong&gt;Insert&lt;/strong&gt; then &lt;strong&gt;Module&lt;/strong&gt;. 
&lt;img src=&quot;https://dl.dropboxusercontent.com/u/49272502/TextEditing%20Series%20Blog/assets/extractPPTSlideTitles/1f.png&quot; alt=&quot;ddd&quot; /&gt;&lt;/p&gt;

&lt;p&gt;After inserting a new Module, copy the code I provided below into the Module console. 
&lt;img src=&quot;https://dl.dropboxusercontent.com/u/49272502/TextEditing%20Series%20Blog/assets/extractPPTSlideTitles/2f.png&quot; alt=&quot;ddd&quot; /&gt;&lt;/p&gt;

&lt;p&gt;Then make sure you choose the function name “GatherTitles” from the dropdown menu on the upper right of the Console. 
&lt;img src=&quot;https://dl.dropboxusercontent.com/u/49272502/TextEditing%20Series%20Blog/assets/extractPPTSlideTitles/3f.png&quot; alt=&quot;ddd&quot; /&gt;&lt;/p&gt;

&lt;p&gt;Then hit the &lt;strong&gt;Run&lt;/strong&gt; button from the VB editor navigation bar. 
&lt;img src=&quot;https://dl.dropboxusercontent.com/u/49272502/TextEditing%20Series%20Blog/assets/extractPPTSlideTitles/4f.png&quot; alt=&quot;ddd&quot; /&gt;&lt;/p&gt;

&lt;p&gt;Then a copy of a &lt;strong&gt;txt&lt;/strong&gt; is created and saved in the same directory as your PPT file, open the txt file you shall see all the titles of your PPT file.&lt;/p&gt;

&lt;p&gt;Voila, now you are an expert of PPT title extraction.&lt;/p&gt;

&lt;p&gt;If you like this post please share it.&lt;/p&gt;

&lt;p&gt;Thanks.&lt;/p&gt;

&lt;p&gt;Code that you need&lt;/p&gt;

&lt;pre&gt;
	&lt;code&gt;
Sub GatherTitles()

On Error GoTo ErrorHandler

Dim oSlide As Slide
Dim strTitles As String
Dim strFilename As String
Dim intFileNum As Integer
Dim PathSep as String 

If ActivePresentation.Path = &quot;&quot; Then
    MsgBox &quot;Please save the presentation then try again&quot;
    Exit Sub
End If

#If Mac Then
    PathSep = &quot;:&quot;
#Else
    PathSep = &quot;\&quot;
#End If

On Error Resume Next  &#39; in case there&#39;s no title placeholder on the slide
For Each oSlide In ActiveWindow.Presentation.Slides
    strTitles = strTitles _
        &amp;amp; &quot;Slide: &quot; _
        &amp;amp; CStr(oSlide.SlideIndex) &amp;amp; vbCrLf _
        &amp;amp; oSlide.Shapes.Title.TextFrame.TextRange.Text _
        &amp;amp; vbCrLf &amp;amp; vbCrLf
Next oSlide
On Error GoTo ErrorHandler

intFileNum = FreeFile

&#39; PC-Centricity Alert!
&#39; This assumes that the file has a .PPT extension and strips it off to make the text file name.
strFilename = ActivePresentation.Path _
    &amp;amp; PathSep _
    &amp;amp; Mid$(ActivePresentation.Name, 1, Len(ActivePresentation.Name) - 4) _
    &amp;amp; &quot;_Titles.TXT&quot;

Open strFilename For Output As intFileNum
Print #intFileNum, strTitles

NormalExit:
Close intFileNum
Exit Sub

ErrorHandler:
MsgBox Err.Description
Resume NormalExit

End Sub
	&lt;/code&gt;
&lt;/pre&gt;
</content>
 </entry>
 
 <entry>
   <title>How to Twine Your Note Into a Webpage</title>
   <link href="http://lanyon.getpoole.com/twine/2016/01/18/twine-makes-study-easy/"/>
   <updated>2016-01-18T00:00:00-06:00</updated>
   <id>http://lanyon.getpoole.com/twine/2016/01/18/twine-makes-study-easy</id>
   <content type="html">&lt;!-- Google Tag Manager --&gt;
&lt;noscript&gt;&lt;iframe src=&quot;//www.googletagmanager.com/ns.html?id=GTM-5FWTRL&quot; height=&quot;0&quot; width=&quot;0&quot; style=&quot;display:none;visibility:hidden&quot;&gt;&lt;/iframe&gt;&lt;/noscript&gt;
&lt;script&gt;(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({&#39;gtm.start&#39;:
new Date().getTime(),event:&#39;gtm.js&#39;});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!=&#39;dataLayer&#39;?&#39;&amp;l=&#39;+l:&#39;&#39;;j.async=true;j.src=
&#39;//www.googletagmanager.com/gtm.js?id=&#39;+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,&#39;script&#39;,&#39;dataLayer&#39;,&#39;GTM-5FWTRL&#39;);&lt;/script&gt;

&lt;!-- End Google Tag Manager --&gt;

&lt;p&gt;Today, I am going to introduce to you this amazing tool called &lt;a href=&quot;http://twinery.org&quot;&gt;Twine&lt;/a&gt;&lt;/p&gt;

&lt;!--break--&gt;

&lt;p&gt;&lt;img src=&quot;https://www.glorioustrainwrecks.com/files/screens/ct2-38_twine.jpg&quot; alt=&quot;twine&quot; /&gt;&lt;/p&gt;

&lt;h3 id=&quot;video-tutorial&quot;&gt;video tutorial&lt;/h3&gt;
&lt;iframe width=&quot;760&quot; height=&quot;523&quot; src=&quot;https://www.youtube.com/embed/T4Hzt9LtR7g&quot; frameborder=&quot;0&quot; allowfullscreen=&quot;&quot;&gt;&lt;/iframe&gt;

&lt;p&gt;&lt;a href=&quot;http://twinery.org&quot;&gt;Twine&lt;/a&gt; is an open-source tool for telling interactive, nonlinear stories. It was developed by &lt;a href=&quot;http://chrisklimas.com&quot;&gt;Chris Klimas&lt;/a&gt; back in 2009.&lt;/p&gt;

&lt;p&gt;And the good news is that you don’t need any expert experience with software or web development in order to Twine!&lt;/p&gt;

&lt;p&gt;So, what exactly can Twine help you? I think its usefulness has no boundary.&lt;/p&gt;

&lt;p&gt;Let’s get you started with a twine project that I created for my upcoming boring exam.&lt;/p&gt;

&lt;p&gt;(Showing the example)&lt;/p&gt;

&lt;p&gt;Here are some of the uses that I came up with, such as making&lt;/p&gt;

&lt;p&gt;Mind Mapping
Taking note during class 
create simple interactive webpage. 
write interactive books. 
etc&lt;/p&gt;

&lt;p&gt;What about you? Please pause a while to think about what you can do with Twine.&lt;/p&gt;

&lt;p&gt;Ok, let’s start building a very simple project to illustrate the workflow of Twine.&lt;/p&gt;

&lt;p&gt;Before I walk you through the nitty gritty, let’s make sure that you have Twine downloaded. &lt;a href=&quot;http://twinery.org&quot;&gt;Download Twine&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;You must be surprise that for ordinary users who do not program, you really only need to learn one syntax.&lt;/p&gt;

&lt;h2 id=&quot;remember-these-two-syntaxs&quot;&gt;remember these two syntaxs&lt;/h2&gt;

&lt;h1 id=&quot;and-&quot;&gt;”[[]]”  and “##”&lt;/h1&gt;

&lt;h2 id=&quot;section&quot;&gt;-&lt;/h2&gt;
&lt;p&gt;-&lt;/p&gt;

&lt;h2 id=&quot;adding-html-image-tax&quot;&gt;Adding HTML image tax&lt;/h2&gt;

&lt;h2 id=&quot;img&quot;&gt;&lt;img /&gt;&lt;/h2&gt;

&lt;h2 id=&quot;abc-example&quot;&gt;ABC example&lt;/h2&gt;

&lt;p&gt;Let’s create a loop with A, B, C. First, we create 3 new passages and name them A, B 
and C. Then we can type in the following accordingly.&lt;/p&gt;

&lt;p&gt;(see video)&lt;/p&gt;

&lt;h2 id=&quot;subject-example&quot;&gt;Subject example&lt;/h2&gt;

&lt;p&gt;Say you are taking note for a class, it is always different to take note using 
traditional method. So often the professor start talking about one subject A, then changes into another subject, B, C, etc. he then would jump back and forth between subjects and this makes it very different for students to make good note.&lt;/p&gt;

&lt;p&gt;How, with Twine at your disposal, you can turn this challenging task into a piece of cake. Let’s build a simple subject note project.&lt;/p&gt;

&lt;p&gt;(see video)&lt;/p&gt;

&lt;h2 id=&quot;adding-images&quot;&gt;Adding images&lt;/h2&gt;
&lt;p&gt;How about adding some images
There are many ways to add image, but I usually prefer to use &lt;a href=&quot;https://www.dropbox.com/business?home=300&amp;amp;f=1&amp;amp;_tk=sem_b_goog&amp;amp;_camp=sem-b-goog-us-eng-top-exact&amp;amp;_kw=dropbox|e&amp;amp;_ad=47393997462|1t1|c&amp;amp;gclid=CLzFxcL6ucoCFYOEaQodpNgApQ&quot;&gt;Dropbox&lt;/a&gt; because it is the easiest way. I first upload my images in a folder in the dropbox public folder, then I create public links to embed in my note. You can use the html image tag(see the following code) to achieve this.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;&amp;lt;img src = &amp;quot;your link&amp;quot;&amp;gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;Let’s add an example image to our newly created note
(see video)&lt;/p&gt;

&lt;h2 id=&quot;publish-your-work&quot;&gt;publish your work&lt;/h2&gt;
&lt;p&gt;Now, the last step is to publish your result. 
The finished product is a html file, you can copy and paste it on your dropbox public folder, and then generate a public link and share it with your friends.&lt;/p&gt;

&lt;p&gt;Finally, these are the most basic functions you should learn about Twine, if you are interested in web programming and want to explore more, I recommand you to subcribe to the channel &lt;a href=&quot;https://www.youtube.com/watch?v=HZzChB75DFs&quot;&gt;VegetarianZombie&lt;/a&gt; on YouTube which is an amazing video series to walk you through all the details of Twine or you could read the Twine &lt;a href=&quot;http://twinery.org/wiki/&quot;&gt;documentation&lt;/a&gt; to explore more.&lt;/p&gt;

&lt;p&gt;Thank you!&lt;/p&gt;

</content>
 </entry>
 
 <entry>
   <title>Introducing Regular expression</title>
   <link href="http://lanyon.getpoole.com/regular%20expression/2016/01/18/regular-expression-video-project/"/>
   <updated>2016-01-18T00:00:00-06:00</updated>
   <id>http://lanyon.getpoole.com/regular%20expression/2016/01/18/regular-expression-video-project</id>
   <content type="html">&lt;p&gt;This tutorial is made to show you how you can use &lt;a href=&quot;https://www.google.com/?gws_rd=ssl#q=regular+expression&quot;&gt;Regular Expression&lt;/a&gt; and a text editor to make your day to day office work easier.&lt;/p&gt;

&lt;p&gt;&lt;img src=&quot;https://viblo.asia/uploads/images/d9a2a14598974e7cc9ea922a835c70496648865f/8b06b3b2f79f332104e71323d7865d2c6de7379d.png&quot; alt=&quot;ddd&quot; /&gt;&lt;/p&gt;

&lt;!--break--&gt;
&lt;ul id=&quot;markdown-toc&quot;&gt;
  &lt;li&gt;&lt;a href=&quot;#prerequsite&quot; id=&quot;markdown-toc-prerequsite&quot;&gt;prerequsite&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#download-and-install-sublime-text-editorhttpwwwsublimetextcom2&quot; id=&quot;markdown-toc-download-and-install-sublime-text-editorhttpwwwsublimetextcom2&quot;&gt;download and install &lt;a href=&quot;http://www.sublimetext.com/2&quot;&gt;sublime text editor&lt;/a&gt;&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#download-the-text-file-you-will-need-for-this-tutorial-here&quot; id=&quot;markdown-toc-download-the-text-file-you-will-need-for-this-tutorial-here&quot;&gt;download the text file you will need for this tutorial &lt;a href=&quot;&quot;&gt;here&lt;/a&gt;&lt;/a&gt;&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#introduction&quot; id=&quot;markdown-toc-introduction&quot;&gt;Introduction&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#getting-started&quot; id=&quot;markdown-toc-getting-started&quot;&gt;Getting started&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#shushy-words-example&quot; id=&quot;markdown-toc-shushy-words-example&quot;&gt;Shushy words example&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#speech-coach-example&quot; id=&quot;markdown-toc-speech-coach-example&quot;&gt;Speech coach example&lt;/a&gt;&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#refex-for-a-moment&quot; id=&quot;markdown-toc-refex-for-a-moment&quot;&gt;refex for a moment&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#the-visual-regex-testerhttpwwwocpsoftorgtutorialsregular-expressionsjava-visual-regex-tester&quot; id=&quot;markdown-toc-the-visual-regex-testerhttpwwwocpsoftorgtutorialsregular-expressionsjava-visual-regex-tester&quot;&gt;The &lt;a href=&quot;http://www.ocpsoft.org/tutorials/regular-expressions/java-visual-regex-tester/&quot;&gt;visual Regex Tester&lt;/a&gt;&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#regex-cheatsheet&quot; id=&quot;markdown-toc-regex-cheatsheet&quot;&gt;Regex Cheatsheet&lt;/a&gt;&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#practical-use-with-text-editors-for-everyone&quot; id=&quot;markdown-toc-practical-use-with-text-editors-for-everyone&quot;&gt;Practical use with text editors for everyone.&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;h2 id=&quot;prerequsite&quot;&gt;prerequsite&lt;/h2&gt;

&lt;h3 id=&quot;download-and-install-sublime-text-editorhttpwwwsublimetextcom2&quot;&gt;download and install &lt;a href=&quot;http://www.sublimetext.com/2&quot;&gt;sublime text editor&lt;/a&gt;&lt;/h3&gt;
&lt;p&gt;you can use either PC or Mac for this tutorial.&lt;/p&gt;

&lt;h3 id=&quot;download-the-text-file-you-will-need-for-this-tutorial-here&quot;&gt;download the text file you will need for this tutorial &lt;a href=&quot;&quot;&gt;here&lt;/a&gt;&lt;/h3&gt;

&lt;h2 id=&quot;introduction&quot;&gt;Introduction&lt;/h2&gt;

&lt;p&gt;So, What is &lt;a href=&quot;https://www.google.com/?gws_rd=ssl#q=regular+expression&quot;&gt;Regular expression&lt;/a&gt; ? Let’s pull up a 
&lt;a href=&quot;https://en.wikipedia.org/wiki/Regular_expression&quot;&gt;wikipedia defintion&lt;/a&gt;&lt;/p&gt;

&lt;h2 id=&quot;getting-started&quot;&gt;Getting started&lt;/h2&gt;

&lt;h3 id=&quot;shushy-words-example&quot;&gt;Shushy words example&lt;/h3&gt;

&lt;p&gt;Let’s get to the practical side of the story.&lt;/p&gt;

&lt;p&gt;To start simple, let’s say you want to extract certain characters out of a text file.&lt;/p&gt;

&lt;p&gt;For example, the following&lt;/p&gt;

&lt;p&gt;famous tourist tongue twister.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Sh&lt;/strong&gt;e sells sea-&lt;strong&gt;sh&lt;/strong&gt;ells on the sea-&lt;strong&gt;sh&lt;/strong&gt;ore.&lt;/p&gt;

&lt;p&gt;The &lt;strong&gt;sh&lt;/strong&gt;ells &lt;strong&gt;sh&lt;/strong&gt;e sells are sea-&lt;strong&gt;sh&lt;/strong&gt;ells, I’m &lt;strong&gt;su&lt;/strong&gt;re.&lt;/p&gt;

&lt;p&gt;For if &lt;strong&gt;sh&lt;/strong&gt;e sells sea-&lt;strong&gt;sh&lt;/strong&gt;ells on the sea-&lt;strong&gt;sh&lt;/strong&gt;ore&lt;/p&gt;

&lt;p&gt;Then I’m &lt;strong&gt;su&lt;/strong&gt;re &lt;strong&gt;sh&lt;/strong&gt;e sells sea-&lt;strong&gt;sh&lt;/strong&gt;ore &lt;strong&gt;sh&lt;/strong&gt;ells.&lt;/p&gt;

&lt;p&gt;By using some simple regular expression syntax, I can extract all the words with the&lt;/p&gt;

&lt;p&gt;“Sh” sound.&lt;/p&gt;

&lt;p&gt;To illustrate the idea, I wrote a program in java to fulfill such task.&lt;/p&gt;

&lt;div style=&quot;width:700px;height:300px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
&lt;code&gt;
	class FindAllTheShWords{
 public void FindAllTheShushyWords(String args) {
 
      String script = args;
      Pattern pattern = Pattern.compile(&quot;(\\w*(sh|ti|su)\\w*)&quot;);
      Matcher matcher = pattern.matcher(script);
      while (matcher.find()){
        System.out.printf(&quot;%s is a shushy word because of %s. %n&quot;,
                        matcher.group(1),
                        matcher.group(2));
      } 
  }
&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;

&lt;p&gt;(you don’t have to study the code above if you are not a programmer)&lt;/p&gt;

&lt;h3 id=&quot;speech-coach-example&quot;&gt;Speech coach example&lt;/h3&gt;

&lt;p&gt;Ok, now let’s get more complicated, how about I were a speech couch, and I want to&lt;/p&gt;

&lt;p&gt;select all the words that have the “Sh” sound to help my students to practice&lt;/p&gt;

&lt;p&gt;speaking them?&lt;/p&gt;

&lt;p&gt;Here is another Java program I wrote to fullfill this task.&lt;/p&gt;

&lt;div style=&quot;width:700px;height:300px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
&lt;code&gt;
class FindAllWordsWith {
  public void AllTheWordsEndWithED(String args) {
 
      String script = args;
      Pattern pattern = Pattern.compile(&quot;(\\w*(ed)\\b)&quot;);
      Matcher matcher = pattern.matcher(script);
      while (matcher.find()){
        System.out.printf(
          
          &quot; you must emphasize &quot;+
                        matcher.group(2)+&quot; sound in the word &quot; +
                        matcher.group(1)+&quot;%n&quot;);
      }
      
    }
    public void AllTheWordsEndWithTorD(String args) {
 
      String script = args;
      Pattern pattern = Pattern.compile(&quot;(\\w*(d|t)\\b)&quot;);
      Matcher matcher = pattern.matcher(script);
      while (matcher.find()){
        System.out.printf(
          
          &quot; you must emphasize &quot;+
                        matcher.group(2)+&quot; sound in the word &quot; +
                        matcher.group(1)+&quot;%n&quot;);
      }
      
    } 
}
&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;

&lt;p&gt;Now, by using some basic combination of &lt;em&gt;regular expression&lt;/em&gt;, you can do a lot of&lt;/p&gt;

&lt;p&gt;things that could have no limit but your imagination. For example, the many DNA sequencing softwares such as the powerful &lt;a href=&quot;http://blast.ncbi.nlm.nih.gov/Blast.cgi&quot;&gt;Blast on NCBI&lt;/a&gt;, or how about the post office wants to build an App that can recognize all &lt;a href=&quot;http://stackoverflow.com/questions/578406/what-is-the-ultimate-postal-code-and-zip-regex&quot;&gt;Postal code patterns&lt;/a&gt; around the world, in order to make their shipment task easier? Or how about &lt;a href=&quot;http://www.r-bloggers.com/slightly-more-than-basic-sentiment-analysis/&quot;&gt;sentiment analysis&lt;/a&gt; or spotting trends from twitter feeds or Facebook etc.&lt;/p&gt;

&lt;p&gt;Now, you may say, wait a minute, you showed me the defintion of Regular Expression and&lt;/p&gt;

&lt;p&gt;I more or less grasp some of its powerful functionalities, but I still don’t&lt;/p&gt;

&lt;p&gt;exactly know to use it and how it could benefit my works? besides, I am not programmer&lt;/p&gt;

&lt;p&gt;and I don’t write code. Don’t worry, you don’t have to be a programmer in order to use the functions of “regular expression”&lt;/p&gt;

&lt;h2 id=&quot;refex-for-a-moment&quot;&gt;refex for a moment&lt;/h2&gt;
&lt;p&gt;Before I walk you through all the basic details, I would like you to pause for a&lt;/p&gt;

&lt;p&gt;few seconds and reflex.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;What are some of the other possibilities you have in mind?&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;and do you remember what is the definiton of Regular Expression?&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;(the same quizs on video)&lt;/p&gt;

&lt;h2 id=&quot;the-visual-regex-testerhttpwwwocpsoftorgtutorialsregular-expressionsjava-visual-regex-tester&quot;&gt;The &lt;a href=&quot;http://www.ocpsoft.org/tutorials/regular-expressions/java-visual-regex-tester/&quot;&gt;visual Regex Tester&lt;/a&gt;&lt;/h2&gt;

&lt;p&gt;Now let’s introduce a few very basic expression syntaxs in the table below.&lt;/p&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th&gt;Function&lt;/th&gt;
      &lt;th&gt;Syntax&lt;/th&gt;
      &lt;th&gt; &lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;all the letters&lt;/td&gt;
      &lt;td&gt;\w&lt;/td&gt;
      &lt;td&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;all the words&lt;/td&gt;
      &lt;td&gt;\w*&lt;/td&gt;
      &lt;td&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;all the words with the letter d&lt;/td&gt;
      &lt;td&gt;\w*(d)&lt;/td&gt;
      &lt;td&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;or&lt;/td&gt;
      &lt;td&gt; &lt;/td&gt;
      &lt;td&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;all the words with d or t&lt;/td&gt;
      &lt;td&gt;\w*(d|t)&lt;/td&gt;
      &lt;td&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;all the words end with d or t&lt;/td&gt;
      &lt;td&gt;\w*(d|t)\b&lt;/td&gt;
      &lt;td&gt; &lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;Now, I encourage you to open &lt;a href=&quot;http://www.ocpsoft.org/tutorials/regular-expressions/java-visual-regex-tester/&quot;&gt;visual Regex Tester&lt;/a&gt; and following along as I show you in the video.&lt;/p&gt;

&lt;h3 id=&quot;regex-cheatsheet&quot;&gt;Regex Cheatsheet&lt;/h3&gt;
&lt;p&gt;Besides these few simple expressions, you can visit &lt;a href=&quot;http://www.rexegg.com/regex-quickstart.html&quot;&gt;The Regex Cheetsheet&lt;/a&gt; or &lt;a href=&quot;https://www.google.com/?gws_rd=ssl#q=regular+expression+documentation&quot;&gt;some other documentation sites&lt;/a&gt; to learn more useful expressions.&lt;/p&gt;

&lt;h2 id=&quot;practical-use-with-text-editors-for-everyone&quot;&gt;Practical use with text editors for everyone.&lt;/h2&gt;

&lt;p&gt;Now, Let’s demonstrate how you can use Regular Expression with text editors.&lt;/p&gt;

&lt;p&gt;There are many good &lt;a href=&quot;https://en.wikipedia.org/wiki/List_of_text_editors&quot;&gt;text editors&lt;/a&gt; out there, but I personally love the sublime text and you can &lt;a href=&quot;http://www.sublimetext.com/2&quot;&gt;download it here&lt;/a&gt;.&lt;/p&gt;

&lt;p&gt;(see demonstrating from video)&lt;/p&gt;

&lt;p&gt;I hope you would benefit from this, please leave your feedback and comments.&lt;/p&gt;

&lt;p&gt;share the resources
http://www.rexegg.com/regex-quickstart.html&lt;/p&gt;

</content>
 </entry>
 
 <entry>
   <title>Regular Expression Java</title>
   <link href="http://lanyon.getpoole.com/2016/01/18/regular-expression-Java/"/>
   <updated>2016-01-18T00:00:00-06:00</updated>
   <id>http://lanyon.getpoole.com/2016/01/18/regular-expression-Java</id>
   <content type="html">&lt;p&gt;developing&lt;/p&gt;

&lt;!--break--&gt;

&lt;p&gt;[](http://www.tutorialspoint.com/java/java_regular_expressions.htm)&lt;/p&gt;

&lt;p&gt;import java.io.Console;
import java.util.regex.Pattern;
import java.util.regex.Matcher;&lt;/p&gt;

&lt;p&gt;class Reggie {
  public void main(String args) {
    Console console = System.console();
    // Your amazing code below
  String zipCode = args;
    if (zipCode.matches(“^\d{5}(-\d{4})?$”)){
      System.out.printf(“%s is a valid zip code%n”, zipCode);
    }else{
    System.out.printf(“%s is not a valid zip code%n”, zipCode);
    }
  String skills = “JavaScript, HTML, CSS, Java”;
    for (String skill:skills.split(“\W+”)){
        System.out.printf(“Skill: %s %n”, skill);
    }
  }
}&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Java Note</title>
   <link href="http://lanyon.getpoole.com/java/2016/01/18/Java-study-note/"/>
   <updated>2016-01-18T00:00:00-06:00</updated>
   <id>http://lanyon.getpoole.com/java/2016/01/18/Java-study-note</id>
   <content type="html">&lt;h2 id=&quot;receiving-input&quot;&gt;Receiving Input&lt;/h2&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th&gt;&lt;a href=&quot;https://docs.oracle.com/javase/tutorial/java/data/characters.html&quot;&gt;escape sequence&lt;/a&gt;&lt;/th&gt;
      &lt;th&gt;explaination&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;%s&lt;/td&gt;
      &lt;td&gt;The use of %s will result in the toString() method being called on the object, and thus will work for any type T&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;/n&lt;/td&gt;
      &lt;td&gt;break line&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;The following Java code prints out “Hello, my name is …”&lt;/p&gt;

&lt;pre&gt;
	&lt;code&gt;
import java.io.Console;
 
public class Introductions {
  
    public static void main(String[] args) {
        Console console = System.console();
        // console.readLine(&quot;prompt&quot;) takes input after prompting, and send it to the 	// variable firstName.
        String firstName = console.readLine(&quot;What is your name? &quot;); 
        console.printf(&quot;Hello, my name is %s\n&quot;,firstName);
        console.printf(&quot;%s is learning how to write Java\n&quot;,firstName);
  
    }
}
	&lt;/code&gt;
&lt;/pre&gt;

&lt;p&gt;Input and Output - Source and Destination, check out &lt;a href=&quot;http://tutorials.jenkov.com/java-io/overview.html&quot;&gt;IO package&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;float chart of IO&lt;/p&gt;
&lt;svg width=&quot;100%&quot; height=&quot;100&quot;&gt;

    &lt;svg y=&quot;10&quot; x=&quot;30&quot;&gt;
        &lt;path d=&quot;M110,35 l38,0 l0,-5 l10,5 l-10,5 l0,-5&quot; style=&quot;stroke: #336633; stroke-width: 1;  fill:#669966; &quot; /&gt;
        &lt;path d=&quot;M260,35 l38,0 l0,-5 l10,5 l-10,5 l0,-5&quot; style=&quot;stroke: #336633; stroke-width: 1;  fill:#669966; &quot; /&gt;


        &lt;svg x=&quot;0&quot; y=&quot;0&quot;&gt;
            &lt;rect x=&quot;10&quot; y=&quot;10&quot; width=&quot;100&quot; height=&quot;50&quot; rx=&quot;2&quot; ry=&quot;2&quot; style=&quot;stroke: #669966; stroke-width: 1; fill: #ccffcc;&quot; /&gt;
            &lt;text x=&quot;30&quot; y=&quot;40&quot; style=&quot;stroke: none; fill: #000000; font-family: Arial; font-size: 16px;&quot;&gt;Source&lt;/text&gt;
        &lt;/svg&gt;

        &lt;svg x=&quot;150&quot; y=&quot;0&quot;&gt;
            &lt;rect x=&quot;10&quot; y=&quot;10&quot; width=&quot;100&quot; height=&quot;50&quot; rx=&quot;2&quot; ry=&quot;2&quot; style=&quot;stroke: #669966; stroke-width: 1; fill: #ccffcc;&quot; /&gt;
            &lt;text x=&quot;30&quot; y=&quot;40&quot; style=&quot;stroke: none; fill: #000000; font-family: Arial; font-size: 16px;&quot;&gt;Program&lt;/text&gt;
        &lt;/svg&gt;


        &lt;svg x=&quot;300&quot; y=&quot;0&quot;&gt;
            &lt;rect x=&quot;10&quot; y=&quot;10&quot; width=&quot;100&quot; height=&quot;50&quot; rx=&quot;2&quot; ry=&quot;2&quot; style=&quot;stroke: #669966; stroke-width: 1; fill: #ccffcc;&quot; /&gt;
            &lt;text x=&quot;20&quot; y=&quot;40&quot; style=&quot;stroke: none; fill: #000000; font-family: Arial; font-size: 16px;&quot;&gt;Destination&lt;/text&gt;
        &lt;/svg&gt;
    &lt;/svg&gt;

&lt;/svg&gt;
</content>
 </entry>
 
 <entry>
   <title>Javascript basics - How to build a steganography</title>
   <link href="http://lanyon.getpoole.com/javascript/2016/01/03/javascript-basics-steganography/"/>
   <updated>2016-01-03T00:00:00-06:00</updated>
   <id>http://lanyon.getpoole.com/javascript/2016/01/03/javascript-basics-steganography</id>
   <content type="html">&lt;p&gt;The following code is for building a steganography. It connects to a project that I built for my E portfolio, which is a final projects of a Coursera course &lt;a href=&quot;https://www.coursera.org/learn/duke-programming-web/home/welcome&quot;&gt;Programming and the Web for Beginners&lt;/a&gt;that I am taking. 
&lt;!--break--&gt;
The logic behinds this program is very simple, simply manipulating the values of pixels of the images of interest.
To see a full introduction of the code please visit my &lt;a href=&quot;http://codepen.io/JizongL/pen/mVRXop&quot;&gt;CodePen&lt;/a&gt;.&lt;/p&gt;

&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
&lt;code&gt;
// steganography


// function for computing bit
function bitToUse(bit){
    result = Math.pow(2,bit);
    return result;
}


// function for cropping the an image 
function crop(image,width,height)
{ var output= new SimpleImage(width,height);
  for(var outpx of output.values())
  { var x=outpx.getX();
    var y=outpx.getY();
    var px= image.getPixel(x,y);
    outpx.setRed(px.getRed());
    outpx.setGreen(px.getGreen());
    outpx.setBlue(px.getBlue());
  }
  return output;
}


// Helper function for &quot;chop2hide&quot; for to eliminate the last 4 bits of every pixel
function pixchange(pixval,bit){
    var x = Math.floor(pixval/bit) * bit;
    return x;
}
// function to convert an image to be ready for hiding information in it. 
function chop2hide(image,bit){
    bit = bitToUse(bit);
    for(var px of image.values()){
        px.setRed(pixchange(px.getRed(),bit));
        px.setGreen(pixchange(px.getGreen(),bit));
        px.setBlue(pixchange(px.getBlue(),bit));
    }
    return image;
}

// function for shifting the pixel of the hide image to have only 4 bits.
function shift(im,bit){
    bit=bitToUse(bit);
  var nim = new SimpleImage(im.getWidth(), 
                            im.getHeight());
  for(var px of im.values()){
    var x = px.getX();
    var y = px.getY();
    var npx = nim.getPixel(x,y);
    npx.setRed(Math.floor(px.getRed()/bit));
    npx.setGreen(Math.floor(px.getGreen()/bit));
    npx.setBlue(Math.floor(px.getBlue()/bit));
  }
  return nim;
}

// combine function for adding the start and hide images together. 
function combine(start,hide){
var combinedImage = new SimpleImage(start.getWidth(),start.getHeight());
for(var cPixel of combinedImage.values()){
    x =cPixel.getX();
    y = cPixel.getY();
    sPixel = start.getPixel(x,y); // pixel on start corresponding to pp
    hPixel = hide.getPixel(x,y); // pixel on hide corresponding to pp
    cPixel.setRed(sPixel.getRed()+hPixel.getRed())
    cPixel.setBlue(sPixel.getBlue()+hPixel.getBlue())
    cPixel.setGreen(sPixel.getGreen()+hPixel.getGreen())
    }
return combinedImage
}

// function for decoding the combined image
function decode(im,bit){
    bit = bitToUse(bit);
    var nim = new SimpleImage(im.getWidth(),
                              im.getHeight());
        for(var px of im.values()){
            var x = px.getX();
            var y = px.getY();
            var npx = nim.getPixel(x,y);
            npx.setRed(bit*(px.getRed()-(bit*Math.floor(px.getRed()/bit)))); // follow the math;
            // original pixel from combined say 133, let 133/16 and round the result to no deximal
            npx.setGreen(bit*(px.getGreen()-(bit*Math.floor(px.getGreen()/bit))));
            npx.setBlue(bit*(px.getBlue()-(bit*Math.floor(px.getBlue()/bit))));
            
        }
return nim;
}


var ShowImage= new SimpleImage(&quot;vanGohCrop.png&quot;);
var HideImage= new SimpleImage(&quot;qrCode.jpg&quot;);

var crw=Math.min(ShowImage.getWidth(),HideImage.getWidth());
var crh=Math.min(ShowImage.getHeight(),HideImage.getHeight());

var crSImg= crop(ShowImage,crw,crh);
var crHImg= crop(HideImage,crw,crh);

var bit = 6

start = chop2hide(crSImg,bit);
hide = shift(crHImg,bit);

combined = combine(start,hide);
decoded = decode(combined,bit)

//print(start)
//print(hide)
print(&#39;ShowImage before processing&#39;)
print(ShowImage)
print(&#39;HideImage before processing&#39;)
print(HideImage)
print(&#39;the Show and Hide images are combined, the Hide image is hidden&#39;)
print(combined)
print(&#39;decode the Steganography&#39;)
print(decoded)


&lt;/code&gt;

&lt;/pre&gt;
&lt;/div&gt;
</content>
 </entry>
 
 <entry>
   <title>Javascript basics</title>
   <link href="http://lanyon.getpoole.com/javascript/2015/12/24/javascript-basics/"/>
   <updated>2015-12-24T00:00:00-06:00</updated>
   <id>http://lanyon.getpoole.com/javascript/2015/12/24/javascript-basics</id>
   <content type="html">&lt;p&gt;You can open the home page of the &lt;a href=&quot;http://dukelearntoprogram.com/course1/&quot;&gt;JavaScript Programming Environment&lt;/a&gt; by Duke university to test the code in my note.&lt;/p&gt;

&lt;!--break--&gt;

&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
&lt;code&gt;
var image = new SimpleImage(200,200);
w = image.getWidth();
for (var pixel of image.values()) {
        pixel.setRed(255);
        pixel.setGreen(0);
        pixel.setBlue(0);
        x = pixel.getX();
        y = pixel.getY();
        
    if ( x &amp;gt;=w/2 &amp;amp;&amp;amp; y &amp;lt;= w/2)  {
        pixel.setGreen(255);
        pixel.setRed(0);       
        }
    if ( x&amp;lt; w/2 &amp;amp;&amp;amp; y &amp;gt; w/2 ){
        pixel.setRed(255);
        pixel.setBlue(255);
    }
    if(x&amp;gt;=w/2 &amp;amp;&amp;amp; y&amp;gt;=w/2){
        pixel.setBlue(255);
        pixel.setRed(0);
    }
    
    
}
    
print(image);

&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;

&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
&lt;code&gt;
var image = new SimpleImage(200,200);

for (var pixel of image.values()) {
     x = pixel.getX();
     y = pixel.getY();
 if(x &amp;gt; y){
       pixel.setRed(255);
   }    
     if (x + y &amp;lt; 200) {
          pixel.setRed(255);
     }
}
 print(image)
 
var image = new SimpleImage(200,200);
for (var pixel of image.values()){
     x = pixel.getX();
     y = pixel.getY();
   if(x &amp;gt; y){
       pixel.setRed(255);
   }
   if (x+y &amp;gt; 200) {
       pixel.setRed(255);
   }
   } 


print(image)
&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;

&lt;p&gt;fgImage
bgImage
output&lt;/p&gt;

&lt;p&gt;for (var pixel of fgImage.values()) {&lt;/p&gt;

&lt;pre&gt;&lt;code&gt;if(pixel.getGreen == 255){
	var x = pixel.getX
	var y = pixel.getY
	var bgPixel = bgImage.getPixel(x,y);
	output.setPixel(x,y, bgPixel);
} }
&lt;/code&gt;&lt;/pre&gt;

&lt;p&gt;else{
	output.setPixel(x,y,pixel)&lt;/p&gt;

&lt;p&gt;}&lt;/p&gt;

&lt;h2 id=&quot;function-exercise&quot;&gt;function exercise&lt;/h2&gt;

&lt;p&gt;Write a JavaScript program that has a function named swapRedGreen with one parameter pixel. This function should swap the red and green values of the pixel. Pick an image, print the image, then apply swapRedGreen to every pixel in the image, and print the new image. The choice of your image is important. For some images you may not notice any change. Think about what type of image you should use for testing your function.&lt;/p&gt;

&lt;p&gt;I created a “swapRedGreen” function as instructed and then 
I created a “createImage”function that would produce a square image of any size with 2 colors.
I applied the swapRedGreen inside the “createImage” function to test if it would swap the color correctly.&lt;/p&gt;

&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding;5px&quot;&gt;
  &lt;pre&gt;
    &lt;code&gt;
// swapRedGreen function 
function swapRedGreen(pixel){
    var red = pixel.getRed();
    var green = pixel.getGreen();
    pixel.setGreen(red)
    pixel.setRed(green)
    return pixel;
}

// function for creating a flexible test image
function createImage(L,W,R,G,B){
var image = new SimpleImage(L,W);

for (var p of image.values()) {
    var x = p.getX();
var y = p.getY();
    if (x &amp;lt; image.getWidth()/2) { // remember the getWidth() must be set to image, not p. 
        p.setGreen(G)
    }
    else {
p.setRed(R)
p.setBlue(B)
        
    }
}
print(image);
for(var pixel of image.values()){
swapRedGreen(pixel)}
print(image)
}

createImage(300,300,255,255,0) // create a 300 by 300 image with half red and half green

    &lt;/code&gt;
  &lt;/pre&gt;
&lt;/div&gt;

&lt;p&gt;Then I applied the “swapRedGreen” function to an image and test if it works.&lt;/p&gt;
&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding;5px&quot;&gt;
  &lt;pre&gt;
    &lt;code&gt;
function swapRedGreen(pixel){
    var red = pixel.getRed();
    var green = pixel.getGreen();
    pixel.setGreen(red)
    pixel.setRed(green)
    return pixel;
}

var image = new SimpleImage(&quot;lion.jpg&quot;);
for(var pixel of image.values()){
swapRedGreen(pixel)}

print(image)
    &lt;/code&gt;
  &lt;/pre&gt;
&lt;/div&gt;

&lt;p&gt;2: Write a JavaScript program to make an image have more red in it, by adding a given value to the red, making sure it doesn’t go over 255. Your program should have a function called moreRed with two parameters, a pixel and a value to increase the red by. Run your program on an image to see it get redder.&lt;/p&gt;

&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding;5px&quot;&gt;
  &lt;pre&gt;
    &lt;code&gt;  
function moreRed(pixel,addedRed){   // create a &quot;moreRed&quot; function 
    var red = pixel.getRed();
    if (red &amp;lt; 255){ pixel.setRed(red+addedRed)
    } 
    else if (red+addedRed == 255){        // make sure that the addedRed value does not go over 255. 
        pixel.setRed(255)
    }
}

var image = new SimpleImage(&quot;lion.jpg&quot;);// load an image
for (var pixel of image.values()){        // apply the moreRed function
    moreRed(pixel,266)}
print(image)
    &lt;/code&gt;
  &lt;/pre&gt;  
&lt;/div&gt;

&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding;5px&quot;&gt;
  &lt;pre&gt;
    &lt;code&gt;  

// border frame using a function, refactored
function setBlack(pixel){
    pixel.setRed(0);
    pixel.setGreen(0);
    pixel.setBlue(0);
    return pixel;
}
function pixelOnEdge(pixel,image,borderWidth){
    var x = pixel.getX();
    var y = pixel.getY();
    if (x &amp;lt; borderWidth) return true;
    if (y &amp;lt; borderWidth) return true;
    if (x &amp;gt;= image.getWidth() - borderWidth) return true;
    if (y &amp;gt;= image.getHeight() - borderWidth) return true;
    return false;
}
var image = new SimpleImage(&quot;lion.jpg&quot;);
for (var pixel of image.values()) {
   if (pixelOnEdge(pixel,image,10)){
       pixel = setBlack(pixel);
   }
}
print(image);

    &lt;/code&gt;
  &lt;/pre&gt;  
&lt;/div&gt;

&lt;p&gt;Based on the above code with a little refinement, I can now set the thickness of the borders separately 
for either the Horizontal and Vertical borders.&lt;/p&gt;

&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding;5px&quot;&gt;
  &lt;pre&gt;
    &lt;code&gt;  
// border frame using a function, refactored
function setBlack(pixel){
    pixel.setRed(0);
    pixel.setGreen(0);
    pixel.setBlue(0);
    return pixel;
}
function pixelOnEdgeDifferentThickness(pixel,image,HorWidth,VerWidth){
    var x = pixel.getX();
    var y = pixel.getY();
    if (x &amp;lt; HorWidth) return true;
    if (y &amp;lt; VerWidth) return true;
    if (x &amp;gt;= image.getWidth() - HorWidth) return true;
    if (y &amp;gt;= image.getHeight() - VerWidth) return true;
    return false;
}
var image = new SimpleImage(&quot;lion.jpg&quot;);
for (var pixel of image.values()) {
   if (pixelOnEdgeDifferentThickness(pixel,image,1,30)){
       pixel = setBlack(pixel);
   }
}
print(image);
    &lt;/code&gt;
  &lt;/pre&gt;  
&lt;/div&gt;

&lt;p&gt;Steganography&lt;/p&gt;

&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding;5px&quot;&gt;
  &lt;pre&gt;
    &lt;code&gt;  


// steganography


// function for computing bit
function bitToUse(bit){
    result = Math.pow(2,bit);
    return result;
}


// function for cropping the an image 
function crop(image,width,height)
{ var output= new SimpleImage(width,height);
  for(var outpx of output.values())
  { var x=outpx.getX();
    var y=outpx.getY();
    var px= image.getPixel(x,y);
    outpx.setRed(px.getRed());
    outpx.setGreen(px.getGreen());
    outpx.setBlue(px.getBlue());
  }
  return output;
}


// Helper function for &quot;chop2hide&quot; for to eliminate the last 4 bits of every pixel
function pixchange(pixval,bit){
    var x = Math.floor(pixval/bit) * bit;
    return x;
}
// function to convert an image to be ready for hiding information in it. 
function chop2hide(image,bit){
    bit = bitToUse(bit);
    for(var px of image.values()){
        px.setRed(pixchange(px.getRed(),bit));
        px.setGreen(pixchange(px.getGreen(),bit));
        px.setBlue(pixchange(px.getBlue(),bit));
    }
    return image;
}

// function for shifting the pixel of the hide image to have only 4 bits.
function shift(im,bit){
    bit=bitToUse(bit);
  var nim = new SimpleImage(im.getWidth(), 
                            im.getHeight());
  for(var px of im.values()){
    var x = px.getX();
    var y = px.getY();
    var npx = nim.getPixel(x,y);
    npx.setRed(Math.floor(px.getRed()/bit));
    npx.setGreen(Math.floor(px.getGreen()/bit));
    npx.setBlue(Math.floor(px.getBlue()/bit));
  }
  return nim;
}

// combine function for adding the start and hide images together. 
function combine(start,hide){
var combinedImage = new SimpleImage(start.getWidth(),start.getHeight());
for(var cPixel of combinedImage.values()){
    x =cPixel.getX();
    y = cPixel.getY();
    sPixel = start.getPixel(x,y); // pixel on start corresponding to pp
    hPixel = hide.getPixel(x,y); // pixel on hide corresponding to pp
    cPixel.setRed(sPixel.getRed()+hPixel.getRed())
    cPixel.setBlue(sPixel.getBlue()+hPixel.getBlue())
    cPixel.setGreen(sPixel.getGreen()+hPixel.getGreen())
    }
return combinedImage
}

// function for decoding the combined image
function decode(im,bit){
    bit = bitToUse(bit);
    var nim = new SimpleImage(im.getWidth(),
                              im.getHeight());
        for(var px of im.values()){
            var x = px.getX();
            var y = px.getY();
            var npx = nim.getPixel(x,y);
            npx.setRed(bit*(px.getRed()-(bit*Math.floor(px.getRed()/bit)))); // follow the math;
            // original pixel from combined say 133, let 133/16 and round the result to no deximal
            npx.setGreen(bit*(px.getGreen()-(bit*Math.floor(px.getGreen()/bit))));
            npx.setBlue(bit*(px.getBlue()-(bit*Math.floor(px.getBlue()/bit))));
            
        }
return nim;
}


var ShowImage= new SimpleImage(&quot;astrachan.jpg&quot;);
var HideImage= new SimpleImage(&quot;MessageCSEveryone.jpg&quot;);

var crw=Math.min(ShowImage.getWidth(),HideImage.getWidth());
var crh=Math.min(ShowImage.getHeight(),HideImage.getHeight());

var crSImg= crop(ShowImage,crw,crh);
var crHImg= crop(HideImage,crw,crh);

var bit = 4

start = chop2hide(crSImg,bit);
hide = shift(crHImg,bit);

combined = combine(start,hide);
decoded = decode(combined,bit)

//print(start)
//print(hide)
print(&#39;ShowImage before processing&#39;)
print(ShowImage)
print(&#39;HideImage before processing&#39;)
print(HideImage)
print(&#39;the Show and Hide images are combined, the Hide image is hidden&#39;)
print(combined)
print(&#39;decode the Steganography&#39;)
print(decoded)





    &lt;/code&gt;
  &lt;/pre&gt;  
&lt;/div&gt;

&lt;h2 id=&quot;creating-a-duplicate-function&quot;&gt;creating a duplicate function&lt;/h2&gt;
&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding;5px&quot;&gt;
  &lt;pre&gt;
    &lt;code&gt;  

function duplicate(image){

var outputImage = new SimpleImage(image.getWidth() * 2, image.getHeight() * 2);

for (var pixel of outputImage.values()){

var outputX = pixel.getX();

var outputY = pixel.getY();

if(outputX &amp;gt;= image.getWidth()){

outputX = outputX - image.getWidth();

}

if(outputY &amp;gt;= image.getHeight()){

outputY = outputY - image.getHeight();

}

if(outputX &amp;gt;= image.getWidth() &amp;amp;&amp;amp; outputY &amp;gt; image.getHeight()){

outputX = outputX - image.getWidth();

outputY = outputY - image.getHeight();

}

var inputPixel = image.getPixel(outputX, outputY);

pixel.setRed(inputPixel.getRed());

pixel.setGreen(inputPixel.getGreen());

pixel.setBlue(inputPixel.getBlue());

}

return outputImage;

}

var image = new SimpleImage(&quot;chapel.png&quot;);

image = duplicate(image);

print(image);

    &lt;/code&gt;
  &lt;/pre&gt;  
&lt;/div&gt;

&lt;h2 id=&quot;create-an-image-from-scratch&quot;&gt;create an image from scratch&lt;/h2&gt;
&lt;p&gt;In this example, we are going to create an image that looks like two planets in space, using mathematical functions.&lt;/p&gt;
&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding;5px&quot;&gt;
  &lt;pre&gt;
    &lt;code&gt;  
 function dist(pixel, x,y) {
     var dx = pixel.getX() - x;  // x and y are the center of the circle to be created.
     var dy = pixel.getY() - y;
     return Math.sqrt(dx * dx + dy *dy);
 }
 //start with a blank image
 var output = new SimpleImage(4,4);
 
 //Make something here!
 for (var pixel of output.values()){
     //print(pixel.getX());
     var dx = pixel.getX() - 2;
     var dy = pixel.getY() - 2;
     print(dx)
     print(dy)
     print(Math.sqrt(dx * dx + dy *dy));
     
     if (dist(pixel, 2,2)&amp;lt; 2){
            pixel.setRed(255-5*dist(pixel,2,2));
     }
     
 }
 print(output);
     &lt;/code&gt;
  &lt;/pre&gt;  
&lt;/div&gt;

&lt;p&gt;modifying an image&lt;/p&gt;
&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding;5px&quot;&gt;
  &lt;pre&gt;
    &lt;code&gt; 
// blur by moving random pixels

function combine(start,hide){
var combinedImage = new SimpleImage(start.getWidth(),start.getHeight());
for(var cPixel of combinedImage.values()){
    x =cPixel.getX();
    y = cPixel.getY();
    sPixel = start.getPixel(x,y); // pixel on start corresponding to pp
    hPixel = hide.getPixel(x,y); // pixel on hide corresponding to pp
    cPixel.setRed(sPixel.getRed()+hPixel.getRed())
    cPixel.setBlue(sPixel.getBlue()+hPixel.getBlue())
    cPixel.setGreen(sPixel.getGreen()+hPixel.getGreen())
    }
return combinedImage
}

function ensureInImage (coordinate, size) {
    // coordinate cannot be negative
    if (coordinate &amp;lt; 0) {
        return 0;
    }
    // coordinate must be in range [0 .. size-1]
    if (coordinate &amp;gt;= size) {
        return size - 1;
    }
    return coordinate;
}

function getPixelNearby (image, x, y, diameter) {
    var dx = Math.random() * diameter - diameter / 2;
    var dy = Math.random() * diameter - diameter / 2;
    var nx = ensureInImage(x + dx, image.getWidth());
    var ny = ensureInImage(y + dy, image.getHeight());
    return image.getPixel(nx, ny);
}


var image = new SimpleImage(&quot;beautiful-autumn-scenery-6341-706.jpg&quot;);
var image2 = new SimpleImage(&quot;beautiful-autumn-scenery-6341-706.jpg&quot;);
for (var p of image.values()) {
    var avg = (p.getGreen() + p.getRed() + p.getBlue()) / 3;
    //var avg = 0.3 * p.getRed() + 0.59 * p.getGreen() + 0.11 * p.getBlue();
    p.setRed(avg);
    p.setBlue(avg);
    p.setGreen(avg);
   
}

var output = new SimpleImage(image.getWidth(), image.getHeight());

for (var pixel of image.values()) {
    var x = pixel.getX();
    var y = pixel.getY();
    if (Math.random() &amp;gt; 0.5) {
        var other = getPixelNearby(image, x, y, 10);
        output.setPixel(x, y, other);
    }
    else {
        output.setPixel(x, y, pixel);
    }
}

combined = combine(image2,output);

print(output);
print(combined);
     &lt;/code&gt;
  &lt;/pre&gt;  
&lt;/div&gt;

&lt;p&gt;In this problem we want to create an image that is a copy of the original image, but is twice as wide and twice as high. We begin by creating the new blank image with the new dimensions. Then we need to set the red, green, and blue values of each of the new pixels so that the overall image of the new picture is the same as the original picture.&lt;/p&gt;

&lt;p&gt;Consider, for example, enlarging a picture with dimensions 100 by 100 pixels. The new picture will be 200 by 200 pixels. What about the pixel at point (0,100) in the new picture? That pixel is on the leftmost edge, halfway down. Its corresponding pixel in the old picture is also on the leftmost edge, halfway down. In the original 100 by 100 picture that point would be (0, 50). Further examples confirm this pattern, that to find the corresponding pixel in the original image we divide both the x and y values by 2.&lt;/p&gt;

&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding;5px&quot;&gt;
  &lt;pre&gt;
    &lt;code&gt; 

function duplicate(image){

var outputImage = new SimpleImage(image.getWidth() * 2, image.getHeight() * 2);

for (var pixel of outputImage.values()){

var outputX = pixel.getX();

var outputY = pixel.getY();

if(outputX &amp;gt;= image.getWidth()){

outputX = outputX - image.getWidth();

}

if(outputY &amp;gt;= image.getHeight()){

outputY = outputY - image.getHeight();

}

if(outputX &amp;gt;= image.getWidth() &amp;amp;&amp;amp; outputY &amp;gt; image.getHeight()){

outputX = outputX - image.getWidth();

outputY = outputY - image.getHeight();

}

var inputPixel = image.getPixel(outputX, outputY);

pixel.setRed(inputPixel.getRed());

pixel.setGreen(inputPixel.getGreen());

pixel.setBlue(inputPixel.getBlue());

}

return outputImage;

}

var image = new SimpleImage(&quot;chapel.png&quot;);

image = duplicate(image);

print(image);
    &lt;/code&gt;
  &lt;/pre&gt;  
&lt;/div&gt;
</content>
 </entry>
 
 <entry>
   <title>ellipse and scatter plot</title>
   <link href="http://lanyon.getpoole.com/geometry/2015/12/24/ellipse-and-scatterplot/"/>
   <updated>2015-12-24T00:00:00-06:00</updated>
   <id>http://lanyon.getpoole.com/geometry/2015/12/24/ellipse-and-scatterplot</id>
   <content type="html">&lt;p&gt;&lt;a href=&quot;http://onlinelibrary.wiley.com/store/10.1002/9780470750711.app1/asset/app1.pdf;jsessionid=3A2DE2804CD8C8119197F67F47DDCA4C.f01t01?v=1&amp;amp;t=iikpr60j&amp;amp;s=f9c64f839ce4d43efb8aa1f24ffd41a2d31b4f7a&quot;&gt;confidence ellipse&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.mathopenref.com/ellipseeccentricity.html&quot;&gt;Eccentricity an Ellipse&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.visiondummy.com/2014/04/draw-error-ellipse-representing-covariance-matrix/&quot;&gt;How to draw a covariance error ellipse?&lt;/a&gt;&lt;/p&gt;

</content>
 </entry>
 
 <entry>
   <title>Dynamic modeling</title>
   <link href="http://lanyon.getpoole.com/biology/2015/12/24/dynamic-modeling/"/>
   <updated>2015-12-24T00:00:00-06:00</updated>
   <id>http://lanyon.getpoole.com/biology/2015/12/24/dynamic-modeling</id>
   <content type="html">&lt;p&gt;copy paste the original source from the signalling website&lt;/p&gt;

&lt;p&gt;mathlab code(explain every line)&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>How to time my R code</title>
   <link href="http://lanyon.getpoole.com/r/2015/12/13/timing-my-code/"/>
   <updated>2015-12-13T00:00:00-06:00</updated>
   <id>http://lanyon.getpoole.com/r/2015/12/13/timing-my-code</id>
   <content type="html">&lt;p&gt;&lt;a href=&quot;http://www.ats.ucla.edu/stat/r/faq/timing_code.htm&quot;&gt;source&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;x &amp;lt;- c(0.18, -1.54, 0.42, 0.95)
w &amp;lt;- c(2, 1, 3, 1)
l = c(.147,.0025,.3,1.077)&lt;/p&gt;

&lt;!--break--&gt;

&lt;p&gt;ptm &amp;lt;- proc.time()
for (i in c(
        .147,
        .0025,
        .3,
        1.077)
){print(min(sum(w*(x-i)^2)))}
proc.time() - ptm&lt;/p&gt;

&lt;p&gt;user  system elapsed 
0.002   0.001   0.004&lt;/p&gt;

&lt;p&gt;ptm &amp;lt;- proc.time()
sapply(l,function(l) sum(w*(x-l)^2))
proc.time() - ptm&lt;/p&gt;

&lt;p&gt;user  system elapsed 
0.000   0.001   0.002&lt;/p&gt;

</content>
 </entry>
 
 <entry>
   <title>Google Map Api 2</title>
   <link href="http://lanyon.getpoole.com/2015/12/07/google-map-api-2/"/>
   <updated>2015-12-07T00:00:00-06:00</updated>
   <id>http://lanyon.getpoole.com/2015/12/07/google-map-api-2</id>
   <content type="html">&lt;p&gt;&amp;lt;!DOCTYPE html&amp;gt;&lt;/p&gt;
&lt;html&gt;
&lt;head&gt;
  &lt;title&gt;getElementById example&lt;/title&gt;
  &lt;script&gt;
  function changeColor(newColor) {
    var elem = document.getElementById(&quot;para1&quot;);
    elem.style.color = newColor;
  }

function changeFont(newFont){
	var elem2 = document.getElementById(&quot;dar&quot;);
	elem2.style.fontsize = newFont;
}

  &lt;/script&gt;
&lt;/head&gt;
&lt;body&gt;
  &lt;p id=&quot;para1&quot;&gt;Some text here&lt;/p&gt;
  &lt;button onclick=&quot;changeColor(&#39;blue&#39;);&quot;&gt;blue&lt;/button&gt;
  &lt;button onclick=&quot;changeColor(&#39;red&#39;);&quot;&gt;red&lt;/button&gt;

&lt;p id=&quot;dar&quot;&gt;some more text here&lt;/p&gt;
  &lt;button onclick=&quot;changeFont(&#39;10&#39;);&quot;&gt;10&lt;/button&gt;
  &lt;button onclick=&quot;changeFont(&#39;5&#39;);&quot;&gt;5&lt;/button&gt;
&lt;/body&gt;
&lt;/html&gt;
</content>
 </entry>
 
 <entry>
   <title>Google Map Api</title>
   <link href="http://lanyon.getpoole.com/2015/12/07/google-map-api/"/>
   <updated>2015-12-07T00:00:00-06:00</updated>
   <id>http://lanyon.getpoole.com/2015/12/07/google-map-api</id>
   <content type="html"> &lt;!DOCTYPE html&gt;
&lt;html&gt;
&lt;head&gt;
&lt;script src=&quot;http://maps.googleapis.com/maps/api/js&quot;&gt;&lt;/script&gt;
&lt;script&gt;
function initialize() {
  var mapProp = {
    center:new google.maps.LatLng(32.273202,-89.985916),
    zoom:5,
    mapTypeId:google.maps.MapTypeId.ROADMAP
  };
  var map=new google.maps.Map(document.getElementById(&quot;googleMap&quot;),mapProp);
}
google.maps.event.addDomListener(window, &#39;load&#39;, initialize);
function loadScript() {
  var script = document.createElement(&quot;script&quot;);
  script.src = &quot;http://maps.googleapis.com/maps/api/js?callback=initialize&quot;;
  document.body.appendChild(script);
}

window.onload = loadScript; 
&lt;/script&gt;
&lt;/head&gt;

&lt;body&gt;
&lt;div id=&quot;googleMap&quot; style=&quot;width:500px;height:380px;&quot;&gt;&lt;/div&gt;
&lt;/body&gt;

&lt;/html&gt; </content>
 </entry>
 
 <entry>
   <title>statistics study note</title>
   <link href="http://lanyon.getpoole.com/statistics/2015/12/02/statistics-study-note/"/>
   <updated>2015-12-02T00:00:00-06:00</updated>
   <id>http://lanyon.getpoole.com/statistics/2015/12/02/statistics-study-note</id>
   <content type="html">&lt;p&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=BJZpx7Mdde4&quot;&gt;calculating power and probability of Type II Error&lt;/a&gt;&lt;/p&gt;

</content>
 </entry>
 
 <entry>
   <title>Linear Algebra study note</title>
   <link href="http://lanyon.getpoole.com/linear%20algebra/2015/11/22/linear-algebra_study_note/"/>
   <updated>2015-11-22T00:00:00-06:00</updated>
   <id>http://lanyon.getpoole.com/linear%20algebra/2015/11/22/linear-algebra_study_note</id>
   <content type="html">&lt;p&gt;This is my note for my personal study of Linear Algebra
&lt;!--break--&gt;&lt;/p&gt;

&lt;ul id=&quot;markdown-toc&quot;&gt;
  &lt;li&gt;&lt;a href=&quot;#definition-of-mathbf-rn-and-mathbf-r&quot; id=&quot;markdown-toc-definition-of-mathbf-rn-and-mathbf-r&quot;&gt;Definition of &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^n&lt;/script&gt; and &lt;script type=&quot;math/tex&quot;&gt;\mathbf R&lt;/script&gt;&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#vector-transformation&quot; id=&quot;markdown-toc-vector-transformation&quot;&gt;vector transformation&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#formal-understanding-of-functions&quot; id=&quot;markdown-toc-formal-understanding-of-functions&quot;&gt;Formal understanding of functions&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#the-concept-of-linear-independance&quot; id=&quot;markdown-toc-the-concept-of-linear-independance&quot;&gt;The concept of Linear independance&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#test-of-linear-dependance&quot; id=&quot;markdown-toc-test-of-linear-dependance&quot;&gt;Test of linear dependance&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#example-1&quot; id=&quot;markdown-toc-example-1&quot;&gt;Example 1&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#example-3&quot; id=&quot;markdown-toc-example-3&quot;&gt;example 3&lt;/a&gt;&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#parametric-representation-of-lines&quot; id=&quot;markdown-toc-parametric-representation-of-lines&quot;&gt;Parametric representation of lines&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#dimension-of-the-column-space-or-rank&quot; id=&quot;markdown-toc-dimension-of-the-column-space-or-rank&quot;&gt;Dimension of the Column Space or Rank&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#linear-subspaces&quot; id=&quot;markdown-toc-linear-subspaces&quot;&gt;Linear subspaces&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#a-trival-example-in-mathbf-r3&quot; id=&quot;markdown-toc-a-trival-example-in-mathbf-r3&quot;&gt;a trival example in &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^3&lt;/script&gt;&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#example-2&quot; id=&quot;markdown-toc-example-2&quot;&gt;example 2&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#example-3-1&quot; id=&quot;markdown-toc-example-3-1&quot;&gt;example 3&lt;/a&gt;&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#basis&quot; id=&quot;markdown-toc-basis&quot;&gt;Basis&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#example-1-1&quot; id=&quot;markdown-toc-example-1-1&quot;&gt;example 1&lt;/a&gt;&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#linear-transformation&quot; id=&quot;markdown-toc-linear-transformation&quot;&gt;Linear transformation&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#linear-transformations-as-matrix-vector-products&quot; id=&quot;markdown-toc-linear-transformations-as-matrix-vector-products&quot;&gt;Linear transformations as matrix vector products&lt;/a&gt;&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#dot-product&quot; id=&quot;markdown-toc-dot-product&quot;&gt;Dot product&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#definition&quot; id=&quot;markdown-toc-definition&quot;&gt;definition&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#vector-into-components-projection&quot; id=&quot;markdown-toc-vector-into-components-projection&quot;&gt;vector into components: projection&lt;/a&gt;&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#projection&quot; id=&quot;markdown-toc-projection&quot;&gt;Projection&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#example&quot; id=&quot;markdown-toc-example&quot;&gt;example&lt;/a&gt;&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#expressing-a-projection-on-to-a-line-as-matrix-vector-projection&quot; id=&quot;markdown-toc-expressing-a-projection-on-to-a-line-as-matrix-vector-projection&quot;&gt;Expressing a projection on to a line as matrix vector projection&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#example-1-2&quot; id=&quot;markdown-toc-example-1-2&quot;&gt;example 1&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#criterias-of-projection&quot; id=&quot;markdown-toc-criterias-of-projection&quot;&gt;2 criterias of projection&lt;/a&gt;&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h2 id=&quot;definition-of-mathbf-rn-and-mathbf-r&quot;&gt;Definition of &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^n&lt;/script&gt; and &lt;script type=&quot;math/tex&quot;&gt;\mathbf R&lt;/script&gt;&lt;/h2&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec X \in \mathbf R^n&lt;/script&gt;

&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;\mathbf R^n = \begin{cases}
n-tuple\\
(x_1,x_2 \cdots x_n)\end{cases}&lt;/script&gt;
&lt;script type=&quot;math/tex&quot;&gt;\bigr| x_1,x_2,\cdots x_n \in \mathbf R&lt;/script&gt;&lt;/p&gt;

&lt;h2 id=&quot;vector-transformation&quot;&gt;vector transformation&lt;/h2&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec x = \begin{bmatrix}
	x_1\\
	x_2\\
	\vdots\\
	x_n
	\end{bmatrix}
	\vec y = \begin{bmatrix}
	y_1\\
	y_2\\
	\vdots\\
	y_m
	\end{bmatrix}&lt;/script&gt;

&lt;p&gt;let &lt;script type=&quot;math/tex&quot;&gt;\vec x \in \mathbf R^n \text{and} \vec y \in \mathbf R^m&lt;/script&gt;&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;f:\mathbf R^n \implies \mathbf R^m&lt;/script&gt;

&lt;p&gt;for example&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;f:\mathbf R^3 \implies \mathbf R^2&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\begin{bmatrix}
	x_1\\
	x_2\\
	x_3\\
	\end{bmatrix}
	=
	\begin{bmatrix}
	x_1+2x_2\\
	3x_3\\
	\end{bmatrix}&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\begin{bmatrix}
	1\\
	1\\
	1\\
	\end{bmatrix}
	=
	\begin{bmatrix}
	3\\
	3\\
	\end{bmatrix}&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\begin{bmatrix}
	2\\
	4\\
	1\\
	\end{bmatrix}
	=
	\begin{bmatrix}
	10\\
	3\\
	\end{bmatrix}&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;T:\mathbf R^3 \implies\mathbf R^2&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;T(x_1,x_2,x_3) \implies (x_1+2x_2, 3x_3)&lt;/script&gt;

&lt;h2 id=&quot;formal-understanding-of-functions&quot;&gt;Formal understanding of functions&lt;/h2&gt;

&lt;p&gt;if a function g(x) maps the single number 2.&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;g(x_1,x_2) = 2&lt;/script&gt;

&lt;p&gt;Then, the domain is &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^2&lt;/script&gt; and the codomain is &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^3&lt;/script&gt; but the range is 2.&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;h:\mathbf R^2 \implies \mathbf R^3&lt;/script&gt;

&lt;p&gt;In this, the domain is &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^2&lt;/script&gt; and the codomain and the range are &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^3&lt;/script&gt;, for example&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf h (x_1,x_2) = (x_1+x_2, x_2-x_1,x_2x_1)&lt;/script&gt;

&lt;h2 id=&quot;the-concept-of-linear-independance&quot;&gt;The concept of Linear independance&lt;/h2&gt;

&lt;p&gt;The main idea is that there is no redundent vectors in the space&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;c_1\vec v_1+c_2\vec v_2 + \cdots c_n\vec v_n = \mathbf 0| c_1=c_2 \cdots c_n = 0&lt;/script&gt;

&lt;p&gt;&lt;a href=&quot;https://www.khanacademy.org/math/linear-algebra/vectors_and_spaces/linear_independence/v/span-and-linear-independence-example&quot;&gt;see&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;test-of-linear-dependance&quot;&gt;Test of linear dependance&lt;/h3&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;s = \{\vec v_1 \vec v_2, \cdots\vec v_n\} \iff c_1\vec v_1 + c_2\vec v_2 \cdots c_n\vec v_n = \mathbf 0&lt;/script&gt;

&lt;p&gt;For some &lt;script type=&quot;math/tex&quot;&gt;c_i&lt;/script&gt;, not all are 0. (at least 1 is non-zero)&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/linear%20algebra/2015/11/18/proof-linear-algebra/#linear_dependence&quot;&gt;see proof&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;example-1&quot;&gt;Example 1&lt;/h3&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\left( \mathbf A =
\begin{bmatrix}
2\\
1\\
\end{bmatrix}
,
\mathbf B =
\begin{bmatrix}
2\\
1\\
\end{bmatrix}
\right)&lt;/script&gt;

&lt;p&gt;to test if A and B are independent&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;c_1
\begin{bmatrix}
2\\
1\\
\end{bmatrix}
+ c_2
\begin{bmatrix}
2\\
1\\
\end{bmatrix}
= 0&lt;/script&gt;

&lt;p&gt;To satisify the conditon above, if either &lt;script type=&quot;math/tex&quot;&gt;c_1&lt;/script&gt; or &lt;script type=&quot;math/tex&quot;&gt;c_2&lt;/script&gt; are non-zero, then A and B are dependent 
If both &lt;script type=&quot;math/tex&quot;&gt;c_1,c_2&lt;/script&gt; are 0, then A and B are independent&lt;/p&gt;

&lt;p&gt;adapted from &lt;a href=&quot;https://www.khanacademy.org/math/linear-algebra/vectors_and_spaces/linear_independence/v/more-on-linear-independence&quot;&gt;Khanacademy&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;example-3&quot;&gt;example 3&lt;/h3&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\left(\begin{bmatrix}
1\\
-1\\
2\\
\end{bmatrix},

\begin{bmatrix}
1\\
1\\
3
\end{bmatrix}
,
\begin{bmatrix}
-1\\
0\\
2\\
\end{bmatrix}\right)
 = \mathbf Span(s) \ = \mathbf R^3?&lt;/script&gt;

&lt;h2 id=&quot;parametric-representation-of-lines&quot;&gt;Parametric representation of lines&lt;/h2&gt;

&lt;!--break--&gt;
&lt;p&gt;let &lt;script type=&quot;math/tex&quot;&gt;\vec V = \begin{bmatrix}
		2\\
        1\\
\end{bmatrix}&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;then the span is 
&lt;script type=&quot;math/tex&quot;&gt;\ \mathbf S = \{ c\vec V | c \in \mathbf R \}&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;let &lt;script type=&quot;math/tex&quot;&gt;\vec X = \begin{bmatrix}
			2\\
			4\\	
			\end{bmatrix}&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;To find a line passes through &lt;script type=&quot;math/tex&quot;&gt;\vec X&lt;/script&gt;  and parellel to &lt;script type=&quot;math/tex&quot;&gt;\vec V&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;we can use this formula&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;L =\{\vec X + t\vec V| t\in \mathbf R\}&lt;/script&gt;

&lt;p&gt;To find a line passes through both &lt;script type=&quot;math/tex&quot;&gt;\vec a and \vec b&lt;/script&gt;, use either&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;L = \{\vec b + t(\vec b-\vec a| t \in \mathbf R)\}&lt;/script&gt;

&lt;p&gt;or&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;L = \{\vec a + t(\vec b-\vec a| t \in \mathbf R)\}&lt;/script&gt;

&lt;p&gt;example&lt;/p&gt;

&lt;p&gt;let &lt;script type=&quot;math/tex&quot;&gt;\vec a = \begin{bmatrix}
			2\\
			1\\
			\end{bmatrix}&lt;/script&gt;
	  &lt;script type=&quot;math/tex&quot;&gt;\vec b = \begin{bmatrix}
	  		0\\
			3\\
			\end{bmatrix}&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;then &lt;script type=&quot;math/tex&quot;&gt;L = \{\begin{bmatrix}
			2\\
			1\\
			\end{bmatrix} + t(\begin{bmatrix}
			0\\
			3\\
			\end{bmatrix}
			-\begin{bmatrix}
			2\\
			1\\
			\end{bmatrix}) | t\in \mathbf R\}&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;To see full from this video&lt;/p&gt;

&lt;p&gt;&lt;a style=&quot;color: #111; font-family: helvetica;&quot; target=&quot;_blank&quot; href=&quot;https://www.khanacademy.org/video/linear-algebra-parametric-representations-of-lines?utm_campaign=embed&quot;&gt;&lt;/a&gt;&lt;/p&gt;
&lt;iframe frameborder=&quot;0&quot; scrolling=&quot;no&quot; width=&quot;560&quot; height=&quot;355&quot; src=&quot;https://www.khanacademy.org/embed_video?v=hWhs2cIj7Cw&quot; allowfullscreen=&quot;&quot; webkitallowfullscreen=&quot;&quot; mozallowfullscreen=&quot;&quot;&gt;&lt;/iframe&gt;

&lt;h2 id=&quot;dimension-of-the-column-space-or-rank&quot;&gt;Dimension of the Column Space or Rank&lt;/h2&gt;

&lt;p&gt;The following is adapted from &lt;a href=&quot;https://www.khanacademy.org/math/linear-algebra/vectors_and_spaces/null_column_space/v/dimension-of-the-column-space-or-rank&quot;&gt;Khanacademy&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a style=&quot;color: #111; font-family: helvetica;&quot; target=&quot;_blank&quot; href=&quot;https://www.khanacademy.org/video/dimension-of-the-column-space-or-rank?utm_campaign=embed&quot;&gt;&lt;/a&gt;&lt;/p&gt;

&lt;iframe frameborder=&quot;0&quot; scrolling=&quot;no&quot; width=&quot;560&quot; height=&quot;355&quot; src=&quot;https://www.khanacademy.org/embed_video?v=JUgrBkPteTg&quot; allowfullscreen=&quot;&quot; webkitallowfullscreen=&quot;&quot; mozallowfullscreen=&quot;&quot;&gt;&lt;/iframe&gt;

&lt;p&gt;Rank is the dimension of the basis of a matrix.&lt;/p&gt;

&lt;p&gt;In order to be a basis, it has to satisfy that&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;vectors span &lt;script type=&quot;math/tex&quot;&gt;\mathbf A&lt;/script&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;all the column vectors of a basis are linear independent&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;for example&lt;/p&gt;
&lt;p align=&quot;right&quot;&gt;(1)&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;% &lt;![CDATA[
\mathbf A = \begin{bmatrix}
        1 &amp; 0 &amp; -1 &amp; 0 &amp; 4 \\
        2 &amp; 1 &amp; 0 &amp; 0 &amp; 9 \\
        -1 &amp; 2 &amp; 5 &amp; 1 &amp; -5 \\
        1 &amp; -1 &amp; -3 &amp; -2 &amp; 9
        \end{bmatrix} %]]&gt;&lt;/script&gt;

&lt;p&gt;the column space of &lt;script type=&quot;math/tex&quot;&gt;\mathbf A&lt;/script&gt; is&lt;/p&gt;

&lt;p align=&quot;right&quot;&gt;(2)&lt;/p&gt;
&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;C(\mathbf A) = span\{\vec a_1,\vec a_2,\vec a_3,\vec a_4, \vec a_5\}&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;However, we don’t know if all the  column vectors in the span are linear independant&lt;/p&gt;

&lt;p&gt;To find the basis, let’s convert to reduced echelon form &lt;script type=&quot;math/tex&quot;&gt;A_e&lt;/script&gt;&lt;/p&gt;
&lt;p align=&quot;right&quot;&gt;(3)&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;% &lt;![CDATA[
\mathbf A_e = \begin{bmatrix}
        1 &amp; 0 &amp; -1 &amp; 0 &amp; 4 \\
        0 &amp; 1 &amp; 2 &amp; 0 &amp; 1 \\
        0 &amp; 0 &amp; 0 &amp; 1 &amp; -3 \\
        0 &amp; 0 &amp; 0 &amp; 0 &amp; 0
        \end{bmatrix} %]]&gt;&lt;/script&gt;

&lt;p&gt;let &lt;script type=&quot;math/tex&quot;&gt;\vec r_i&lt;/script&gt; denote the columns of A&lt;/p&gt;
&lt;p align=&quot;right&quot;&gt;(4)&lt;/p&gt;

&lt;p&gt;we see that &lt;script type=&quot;math/tex&quot;&gt;\{\vec r_1,\vec r_3,\vec r_4\}&lt;/script&gt; are linear independent and for the basis of &lt;script type=&quot;math/tex&quot;&gt;\mathbf A_e&lt;/script&gt;, and the 1s in these column vectors are also called the &lt;a href=&quot;https://en.wikibooks.org/wiki/Linear_Algebra/Row_Reduction_and_Echelon_Forms#Pivot_Positions&quot;&gt;pivot entries&lt;/a&gt;. Moreover, &lt;script type=&quot;math/tex&quot;&gt;\{\vec r_3,\vec r_5\}&lt;/script&gt; can be represented as linear combinations of &lt;script type=&quot;math/tex&quot;&gt;\{\vec r_1,\vec r_2,\vec r_4\}&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;Therefore, we can conclude that  &lt;script type=&quot;math/tex&quot;&gt;\{\vec a_1,\vec a_2,\vec a_4,\} in \mathbf A&lt;/script&gt; are also linear independent and they are the basis of &lt;script type=&quot;math/tex&quot;&gt;\mathbf A&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;And the Rank of A is just the dimension of the basis, so &lt;script type=&quot;math/tex&quot;&gt;rank(\mathbf A) = 3&lt;/script&gt;&lt;/p&gt;

&lt;h2 id=&quot;linear-subspaces&quot;&gt;Linear subspaces&lt;/h2&gt;

&lt;p&gt;In order to be a subspace, a set must satisfy the following 3 criterias&lt;/p&gt;

&lt;p&gt;let&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf R^n \leftarrow \left( 
\begin{bmatrix}
x_1\\
x_2\\
\vdots\\
x_n
\end{bmatrix} | x_i \in \mathbf R \ 1\le i \le n
\right)&lt;/script&gt;

&lt;p&gt;Let’s assume &lt;script type=&quot;math/tex&quot;&gt;\mathbf V&lt;/script&gt; is a subspace of &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^n&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;then&lt;/p&gt;

&lt;p&gt;1:&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf V \ contains  \ \mathbf 0 = \begin{bmatrix}
0\\
\vdots\\
0
\end{bmatrix}&lt;/script&gt;

&lt;p&gt;2:&lt;/p&gt;

&lt;p&gt;And if &lt;script type=&quot;math/tex&quot;&gt;\vec x \in \mathbf V \ \text{then} \ c\vec x \ \ also \ in \mathbf V&lt;/script&gt;
This is defined as closure under scalar multiplication&lt;/p&gt;

&lt;p&gt;3:&lt;/p&gt;

&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;\vec a \in \mathbf V \ and \ \vec b \ \in \mathbf V, \ then \ \vec a + \vec b \ is \ also \ in \mathbf V&lt;/script&gt;
This is defined as closure under addition&lt;/p&gt;

&lt;h3 id=&quot;a-trival-example-in-mathbf-r3&quot;&gt;a trival example in &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^3&lt;/script&gt;&lt;/h3&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf V \ = \ {\mathbf 0} = \begin{bmatrix}
0\\
0\\
0\\
\end{bmatrix}&lt;/script&gt;

&lt;p&gt;it satisifies the 3 criterias&lt;/p&gt;

&lt;p&gt;1: it contains the zero vector.&lt;/p&gt;

&lt;p&gt;2: when it is multiplied by any real number scalar c, it is still itself. This implies it is still a member of &lt;script type=&quot;math/tex&quot;&gt;\mathbf 
R^3&lt;/script&gt; and satisify closure under multiplication&lt;/p&gt;

&lt;p&gt;3: when &lt;script type=&quot;math/tex&quot;&gt;\mathbf V + \mathbf V = \mathbf 0&lt;/script&gt;, this implies it satisifies closure under addition&lt;/p&gt;

&lt;p&gt;so it is a subspace.&lt;/p&gt;

&lt;h3 id=&quot;example-2&quot;&gt;example 2&lt;/h3&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf S = { \begin{bmatrix}
x_1\\
x_2
\end{bmatrix}
\in \ \mathbf R^2 | x_1 \ge 0 and x_2 \ge 0 }&lt;/script&gt;

&lt;p&gt;is &lt;script type=&quot;math/tex&quot;&gt;\mathbf S&lt;/script&gt; a subspace of &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^2&lt;/script&gt;?&lt;/p&gt;

&lt;p&gt;1:&lt;/p&gt;

&lt;p&gt;because &lt;script type=&quot;math/tex&quot;&gt;x_1, x_2 \ge 0&lt;/script&gt;, so it contains the zero vector.&lt;/p&gt;

&lt;p&gt;2:&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\begin{bmatrix}
a\\
b
\end{bmatrix}
+
\begin{bmatrix}
c\\
d
\end{bmatrix}
=
\begin{bmatrix}
a+c\\
b+d
\end{bmatrix}&lt;/script&gt;

&lt;p&gt;it satisifies the closure of addition&lt;/p&gt;

&lt;p&gt;3: however, if&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;-1
\begin{bmatrix}
a\\
b
\end{bmatrix}
=
\begin{bmatrix}
-a\\
-b
\end{bmatrix}&lt;/script&gt;

&lt;p&gt;This does not satisify the closure of multiplication because the result falls out of the restricted set. 
(it is less than 0)&lt;/p&gt;

&lt;h3 id=&quot;example-3-1&quot;&gt;example 3&lt;/h3&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;let \ \mathbf U = \ span \ (\vec v_1,\vec v_2, \vec v_3)&lt;/script&gt;

&lt;p&gt;Is it subspace of &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^3&lt;/script&gt;?&lt;/p&gt;

&lt;p&gt;1: if&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;(0\vec v_1 +0\vec v_2+ 0\vec v_3 = \vec 0)&lt;/script&gt;

&lt;p&gt;so it contains the zero vector.&lt;/p&gt;

&lt;p&gt;2:&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec X =c_1\vec v_1+c_2\vec v_2+ c_3\vec v_3&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;a\vec X =ac_1\vec v_1+ac_2\vec v_2+ ac_3\vec v_3&lt;/script&gt;

&lt;p&gt;if we let &lt;script type=&quot;math/tex&quot;&gt;ac_i = j_i&lt;/script&gt;&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;a\vec X =j_1\vec v_1+j_2\vec v_2+ j_3\vec v_3&lt;/script&gt;

&lt;p&gt;clear, it is just a linear combination of the 3 vectors and it is in the span of the 3 vectors, therefore it satisifies the closure of multiplication.&lt;/p&gt;

&lt;p&gt;3:&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec Y =d_1\vec v_1+d_2\vec v_2+ d_3\vec v_3&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec X + \vec Y =(c_1+d_1)\vec v_1+(c_2+d_2)\vec v_2+ (c_3+d_3)\vec v_3&lt;/script&gt;

&lt;p&gt;It clearly satisify the closure under addition&lt;/p&gt;

&lt;p&gt;so it is a subspace of &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^3&lt;/script&gt;&lt;/p&gt;

&lt;h2 id=&quot;basis&quot;&gt;Basis&lt;/h2&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf S = 
\left(\begin{bmatrix}
2\\
3
\end{bmatrix}
,
(\begin{bmatrix}
7\\
0
\end{bmatrix}
\right)&lt;/script&gt;

&lt;p&gt;What is the span of $$\mathbf S?&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf S = 
\left(c_1\begin{bmatrix}
2\\
3
\end{bmatrix}
+c_2\begin{bmatrix}
7\\
0
\end{bmatrix}
\right)&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;2c_1+7c_2 = x_1 \\
3c_1 + 0 = x_2 \\
c_1=\frac {x_2}{3} , c_2 = \frac{x_1}{7}-\frac{2}{21}x_2&lt;/script&gt;

&lt;p&gt;is &lt;script type=&quot;math/tex&quot;&gt;\mathbf S&lt;/script&gt; linear independent?&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf S = 
\left(c_1\begin{bmatrix}
2\\
3
\end{bmatrix}
+c_2\begin{bmatrix}
7\\
0
\end{bmatrix} 
\right) =
= \begin{bmatrix}
0\\
0
\end{bmatrix}&lt;/script&gt;

&lt;p&gt;from above&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;c_1=\frac {x_2}{3} , c_2 = \frac{x_1}{7}-\frac{2}{21}x_2 \\
c_1=\frac {0_2}{3} , c_2 = \frac{x_1}{7}-\frac{2}{21}0 \\
c_1 = 0, c_2 = 0&lt;/script&gt;

&lt;p&gt;Since &lt;script type=&quot;math/tex&quot;&gt;\mathbf S \ spans \ \mathbf R^2&lt;/script&gt; and it is linear independent, so &lt;script type=&quot;math/tex&quot;&gt;\mathbf S&lt;/script&gt; is a basis for &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^2&lt;/script&gt;.&lt;/p&gt;

&lt;h3 id=&quot;example-1-1&quot;&gt;example 1&lt;/h3&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf T = 
\left(\begin{bmatrix}
1\\
0
\end{bmatrix}
,
(\begin{bmatrix}
0\\
1
\end{bmatrix}
\right)&lt;/script&gt;

&lt;p&gt;What is the span of &lt;script type=&quot;math/tex&quot;&gt;\mathbf T&lt;/script&gt;?&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf T = 
\left(x_1\begin{bmatrix}
1\\
0
\end{bmatrix}
+x_2\begin{bmatrix}
0\\
1
\end{bmatrix} 
\right) =
= \begin{bmatrix}
x_1\\
x_2
\end{bmatrix}&lt;/script&gt;

&lt;p&gt;from above we know that the span is &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^2&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;Is it linear independent?&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf T = 
\left(x_1\begin{bmatrix}
1\\
0
\end{bmatrix}
+x_2\begin{bmatrix}
0\\
1
\end{bmatrix} 
\right) =
= \begin{bmatrix}
0\\
0
\end{bmatrix}&lt;/script&gt;

&lt;p&gt;to satisify the above, &lt;script type=&quot;math/tex&quot;&gt;x_1,x_2&lt;/script&gt; have to be 0.&lt;/p&gt;

&lt;p&gt;so &lt;script type=&quot;math/tex&quot;&gt;\mathbf T&lt;/script&gt; is a basis.&lt;/p&gt;

&lt;p&gt;In fact, &lt;script type=&quot;math/tex&quot;&gt;\mathbf T&lt;/script&gt; is the unit vector &lt;script type=&quot;math/tex&quot;&gt;\hat i \ and \ \hat j&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;conclusion&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf P {v_1,v_2 \cdots v_n} = Basis \ for \ \mathbf U&lt;/script&gt;

&lt;p&gt;any member of the set &lt;script type=&quot;math/tex&quot;&gt;\mathbf U&lt;/script&gt; is a unique combination of the basis &lt;script type=&quot;math/tex&quot;&gt;\mathbf P&lt;/script&gt;&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec a \in U \vec a = c_1\vec v_1 + c_2\vec v_2 + \cdots c_n\vec v_n&lt;/script&gt;

&lt;p&gt;let’s prove the uniqueness by contraditon&lt;/p&gt;

&lt;p&gt;assume that they are not unique&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec a = c_1\vec v_1 + c_2\vec v_2 + \cdots c_n\vec v_n&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec a = d_1\vec d_1 + d_2\vec v_2 + \cdots d_n\vec v_n&lt;/script&gt;

&lt;p&gt;then if&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec a = c_1\vec v_1 + c_2\vec v_2 + \cdots c_n\vec v_n \\
\vec a = d_1\vec v_1 + d_2\vec v_2 + \cdots d_n\vec v_n \\
0 = (c_1-d_1)\vec v_1 +(c_2-d_2)\vec v_2 + \cdots (c_1-d_n)\vec v_n&lt;/script&gt;

&lt;p&gt;since &lt;script type=&quot;math/tex&quot;&gt;\mathbf P&lt;/script&gt; is the basis of &lt;script type=&quot;math/tex&quot;&gt;\mathbf U&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;so it has to be linear independent, thus &lt;script type=&quot;math/tex&quot;&gt;c_i-d_i = 0&lt;/script&gt;, therefore, &lt;script type=&quot;math/tex&quot;&gt;c_i&lt;/script&gt; is unique.&lt;/p&gt;

&lt;h2 id=&quot;linear-transformation&quot;&gt;Linear transformation&lt;/h2&gt;

&lt;p&gt;&lt;a href=&quot;https://www.khanacademy.org/math/linear-algebra/matrix_transformations/linear-transformations/a/visualizing-linear-transformations&quot;&gt;Visualizing linear transformations&lt;/a&gt; from Khanacademy provides excellent illustration about the concept.&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf T(\vec a + \vec b) = \mathbf T(\vec a) + \mathbf T(\vec b)&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf T(c \vec a)= c\mathbf T(\vec a)&lt;/script&gt;

&lt;p&gt;A matrix product with a vector is always a linear transformation&lt;/p&gt;

&lt;h3 id=&quot;linear-transformations-as-matrix-vector-products&quot;&gt;Linear transformations as matrix vector products&lt;/h3&gt;

&lt;p&gt;standard basis for &lt;script type=&quot;math/tex&quot;&gt;\mathbf R^n&lt;/script&gt;&lt;/p&gt;

&lt;h2 id=&quot;dot-product&quot;&gt;Dot product&lt;/h2&gt;

&lt;h3 id=&quot;definition&quot;&gt;definition&lt;/h3&gt;

&lt;p id=&quot;geo_def&quot;&gt;&lt;/p&gt;
&lt;p&gt;Geometric definition 
&lt;script type=&quot;math/tex&quot;&gt;\vec v\cdot\vec w = \left\|v\right\|\left\|w\right\|cos\theta \quad\text{Where}\quad\theta\quad \text{is the angle between}\quad\vec v \ \text{and} \ \vec w \quad and 0 \le \theta\le\pi&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;Algebraic definition 
&lt;script type=&quot;math/tex&quot;&gt;\vec v\cdot\vec w = v_1w_1+v_2w_2+v_3w_3.&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/linear%20algebra/2015/11/18/proof-linear-algebra/#linear_dependence&quot;&gt;see proof&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;vector-into-components-projection&quot;&gt;vector into components: projection&lt;/h3&gt;

&lt;p&gt;From the figure, we see that &lt;script type=&quot;math/tex&quot;&gt;\vec v&lt;/script&gt; is broken into two components &lt;script type=&quot;math/tex&quot;&gt;\vec v_{parallel} \ \vec v_{prep}&lt;/script&gt; and they are 
perpendicular, respectively, to a given nonzero vector, &lt;script type=&quot;math/tex&quot;&gt;\vec u&lt;/script&gt; Figure from &lt;a href=&quot;http://www.amazon.com/Calculus-Single-Variable-Deborah-Hughes-Hallett/dp/0470089156&quot;&gt;Hughes-Hallett 5e&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;img src=&quot;/assets/LinearAlgebra/projection.png&quot; alt=&quot;projection&quot; /&gt;&lt;/p&gt;

&lt;p&gt;To compute &lt;script type=&quot;math/tex&quot;&gt;\left\|\vec v_{parallel}\right\| = \left\|\vec v\right\|cos\theta = \vec v\cdot\vec u \quad (since \ \left\|\vec u\right\| =1)&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;then&lt;script type=&quot;math/tex&quot;&gt;\vec v_{parallel}\text{is a scalar multiple of $\vec u$, and since $\vec u$ is a unit vector}&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;\vec v_{parallel} = (\left\|\vec v\right\|cos\theta)\vec u = (\vec v\cdot\vec u)\vec u.&lt;/script&gt; according to the&lt;/p&gt;
&lt;p&gt;&lt;a href=&quot;#geo_def&quot;&gt;geometric definition&lt;/a&gt;&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec v_{prep} = \vec v - \vec v_{parallel}&lt;/script&gt;

&lt;h2 id=&quot;projection&quot;&gt;Projection&lt;/h2&gt;

&lt;p align=&quot;right&quot;&gt;(1)&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;Proj(\vec x)=c\vec v = \frac {\vec x \cdot \vec v}{||\vec v||^2}\vec v&lt;/script&gt;

&lt;p&gt;&lt;img src=&quot;http://www.leadinglesson.com/image/ahNzfmxlYWRpbmdsZXNzb24taHJkcg0LEgVJbWFnZRi8vzkM&quot; alt=&quot;projection&quot; /&gt;&lt;/p&gt;

&lt;p&gt;The essent of this formula is to find the closest distance between the tip of &lt;script type=&quot;math/tex&quot;&gt;\vec x&lt;/script&gt; to a unique point in &lt;script type=&quot;math/tex&quot;&gt;\vec v&lt;/script&gt; to make a new distance vector (the dash line from the figure for example) that is orthogonal to &lt;script type=&quot;math/tex&quot;&gt;\vec v&lt;/script&gt;. Visually, it looks as if it is a shadow casted by direct sun light on &lt;script type=&quot;math/tex&quot;&gt;\vec x&lt;/script&gt; to &lt;script type=&quot;math/tex&quot;&gt;\vec v&lt;/script&gt;, so it is formally named the projection of &lt;script type=&quot;math/tex&quot;&gt;\vec x&lt;/script&gt; onto &lt;script type=&quot;math/tex&quot;&gt;\vec v&lt;/script&gt;. The key to find this point is to get the value c, which scale &lt;script type=&quot;math/tex&quot;&gt;\vec v&lt;/script&gt; to the unique length.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/linear%20algebra/2015/11/18/proof-linear-algebra/#linear_dependence&quot;&gt;see proof&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;Further illustration of this the concept of the formula above.&lt;/p&gt;

&lt;p&gt;We can imagine that &lt;script type=&quot;math/tex&quot;&gt;\left\lVert v \right\rVert&lt;/script&gt; as 1, then the formula becomes &lt;script type=&quot;math/tex&quot;&gt;c\vec v = (\vec x\cdot\vec v)\vec v&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;alternatively, if &lt;script type=&quot;math/tex&quot;&gt;\left\lVert\ v right\rVert&lt;/script&gt; is not one, we can create a unit vector &lt;script type=&quot;math/tex&quot;&gt;\hat u = \frac{1}{\left\lVert \vec v \right\rVert}\vec v&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;Then input &lt;script type=&quot;math/tex&quot;&gt;\hat u&lt;/script&gt; into the formula &lt;script type=&quot;math/tex&quot;&gt;Proj_L(\vec x) = (\vec x\cdot\hat u)\hat u&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;In this, we normalize the original &lt;script type=&quot;math/tex&quot;&gt;\vec v&lt;/script&gt; into a unit vector &lt;script type=&quot;math/tex&quot;&gt;\hat u&lt;/script&gt;, sort of like a quntum portion, then when &lt;script type=&quot;math/tex&quot;&gt;\vec x\cdot\vec v&lt;/script&gt; it creates a scalar, which is used to signify the scalar multiple of the quntum portion per se.&lt;/p&gt;

&lt;h3 id=&quot;example&quot;&gt;example&lt;/h3&gt;

&lt;p&gt;let&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf L = \begin{bmatrix}
2\\
1
\end{bmatrix}

\vec x = \begin{bmatrix}
2\\
3
\end{bmatrix}&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;Proj_L (\vec x) = \frac{
	\begin{bmatrix}
2\\
3
\end{bmatrix}
	\cdot
\begin{bmatrix}
2\\
1
\end{bmatrix}
}{
	\begin{bmatrix}
2\\
1
\end{bmatrix} \cdot 
\begin{bmatrix}
2\\
1
\end{bmatrix}
}
\begin{bmatrix}
2\\
1
\end{bmatrix} = 7&lt;/script&gt;

&lt;h2 id=&quot;expressing-a-projection-on-to-a-line-as-matrix-vector-projection&quot;&gt;Expressing a projection on to a line as matrix vector projection&lt;/h2&gt;

&lt;p&gt;According to the formula (1) above, we can imagine &lt;script type=&quot;math/tex&quot;&gt;\left\lVert\vec v\right\rVert= 1&lt;/script&gt; as a unit vector.&lt;/p&gt;

&lt;p&gt;then formula (1) becomes &lt;script type=&quot;math/tex&quot;&gt;(\vec x\vec v)\vec v&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;In real practice, if &lt;script type=&quot;math/tex&quot;&gt;\left\lVert\vec v\right\rVert&lt;/script&gt; is not a unit vector, we can transform it into &lt;script type=&quot;math/tex&quot;&gt;\vec u = \frac{1}{\left\lVert\vec v\right\rVert} \vec v given \vec v \neq 1&lt;/script&gt;&lt;/p&gt;

&lt;h3 id=&quot;example-1-2&quot;&gt;example 1&lt;/h3&gt;

&lt;p&gt;define&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec v = \begin{bmatrix}
2\\
1
\end{bmatrix}
,
\vec x =\begin{bmatrix}
2\\
3
\end{bmatrix}&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\left\lVert\vec v\right\rVert = \sqrt{2^2+1^2}= \sqrt{5}&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\hat u =1/\sqrt{5}\begin{bmatrix}
2\\
1
\end{bmatrix}&lt;/script&gt;

&lt;h3 id=&quot;criterias-of-projection&quot;&gt;2 criterias of projection&lt;/h3&gt;

&lt;p&gt;criteria 1 The projection of the sum of the vectors is equal to the sum of the projection of the vectors.&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;Proj_L (\vec a+\vec b) = ((\vec a+ \vec b)\cdot \hat u)\hat u&lt;/script&gt;

&lt;p&gt;according to the distributive property.&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;(\vec a\cdot\hat u+\vec b\cdot\hat u)\hat u&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;=(\vec a\cdot\hat u)\hat u+(\vec b\cdot\hat u)\hat u&lt;/script&gt;

&lt;p&gt;criteria 2 Projection of a scalar multiple vector is the scalar multiple of the projection vector.&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;Proj_L(c\vec a)= (c\vec a\cdot\hat u)\hat u&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;=c(\vec a\cdot\hat u)\hat u&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;=c(Proj_l \vec a)&lt;/script&gt;

</content>
 </entry>
 
 <entry>
   <title>Proof in vector space</title>
   <link href="http://lanyon.getpoole.com/linear%20algebra/2015/11/18/proof-linear-algebra/"/>
   <updated>2015-11-18T00:00:00-06:00</updated>
   <id>http://lanyon.getpoole.com/linear%20algebra/2015/11/18/proof-linear-algebra</id>
   <content type="html">&lt;ul id=&quot;markdown-toc&quot;&gt;
  &lt;li&gt;&lt;a href=&quot;#prove-that-a-vector-space-has-only-one-zero-vector&quot; id=&quot;markdown-toc-prove-that-a-vector-space-has-only-one-zero-vector&quot;&gt;Prove that a vector space has only one zero vector.&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#proof-of-linear-dependence&quot; id=&quot;markdown-toc-proof-of-linear-dependence&quot;&gt;proof of linear dependence&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#proof-of-projection-formula&quot; id=&quot;markdown-toc-proof-of-projection-formula&quot;&gt;proof of projection formula&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;h2 id=&quot;prove-that-a-vector-space-has-only-one-zero-vector&quot;&gt;Prove that a vector space has only one zero vector.&lt;/h2&gt;

&lt;p&gt;(Exercise 4.2, 19.) 
&lt;!--break--&gt;
Solution: Suppose that z1 and z2 are two zero vectors of the vector space.
Since z1 is a zero vector, and z2 another vector, by the third property (page 189) in the definition of a vector space. 
z2 ⊕z1 =z1 ⊕z2 =z2&lt;/p&gt;

&lt;p&gt;Comment: That is, just plug in z1 where you see 0, and z2 where you see u. Similarly, since
z2 is a zero vector, and z1 is another vector, we have:
z1 ⊕z2 =z2 ⊕z1 =z1&lt;/p&gt;

&lt;p&gt;By the two equations above, we have
z1 ⊕ z2 = z1 = z2
Thus z1 = z2. That is, any two zero vectors must be equal, so that the zero vector is unique.&lt;/p&gt;

&lt;ol&gt;
  &lt;li&gt;Prove that a vector u in a vector space has only one negative, -u. (Exercise 4.2, 20.)&lt;/li&gt;
&lt;/ol&gt;

&lt;p&gt;Solution: Suppose that v and w are two additive inverses of u. Since w is an additive inverse&lt;/p&gt;

&lt;p&gt;Add v to both sides.&lt;/p&gt;

&lt;p&gt;v⊕u⊕w = v⊕0 v⊕u⊕w = v
􏰂 􏰁􏰀 􏰃
0
u⊕w=0
(property 3 in vector space defn)
(property 4, since v is an additive inverse) (property 3)
￼￼0⊕w = v w= v
Thus, w = v, so that the additive inverse of u is unique.&lt;/p&gt;

&lt;p id=&quot;linear_dependence&quot;&gt;&lt;/p&gt;

&lt;h2 id=&quot;proof-of-linear-dependence&quot;&gt;proof of linear dependence&lt;/h2&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec v_1 = c_2\vec v_2 + c_3\vec c_3 + \cdots c_n\vec v_n&lt;/script&gt;

&lt;p&gt;Then at least one of the constant is non-zero&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;0 = -1\vec v_1 + c_2\vec c_2 + a_3\vec c_3 + \cdots c_n\vec v_n&lt;/script&gt;

&lt;p&gt;assume c1 is non-zero&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec v_1 + \frac{c_2}{c1}\vec v_2 + \cdots + \frac{c_n}{c_1}\vec v_n = 0&lt;/script&gt;

&lt;p id=&quot;doc_product_loc&quot;&gt;&lt;/p&gt;
&lt;p&gt;Suppose that &lt;script type=&quot;math/tex&quot;&gt;% &lt;![CDATA[
0&lt;\theta&lt;\pi, \ \text{so that the vectors} \ \vec v \ and \ \vec w %]]&gt;&lt;/script&gt;  form a triangle. By the law of Cosines&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\left\|\vec v-\vec w\right\|^2 = \left\|\vec v\right\| + \left\|\vec w\right\| -2\left\|\vec v\right\| cos\theta&lt;/script&gt;

&lt;p&gt;also true for &lt;script type=&quot;math/tex&quot;&gt;\theta = 0 \ and \ \theta = \pi&lt;/script&gt;&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\left\|\vec v\right\|^2 = v_1^2+v_2^2+v_3^2&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\left\|\vec w\right\|^2 = w_1^2+w_2^2+w_3^2&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\left\|\vec v-\vec w\right\|^2 =(v_1-w_1)^2+(v_3-w_3)^2+(v_3-w_3)^2
=v_1^2 -2v_1w_1+w_1^2+v_2^2 - 2v_2w_2 + w_2^2+v_3^2-2v_3w_3+w_3^2&lt;/script&gt;

&lt;p&gt;Substitute into the Law of Cosines&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;-2v_1w_1-2v_2w_2-2v_3w_3=-2\left\|\vec v\right\|\left\|\vec w\right\|cos \theta&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;v_1w_1-v_2w_2-v_3w_3=\left\|\vec v\right\|\left\|\vec w\right\|cos \theta&lt;/script&gt;

&lt;h2 id=&quot;proof-of-projection-formula&quot;&gt;proof of projection formula&lt;/h2&gt;

&lt;p&gt;&lt;img src=&quot;http://www.leadinglesson.com/image/ahNzfmxlYWRpbmdsZXNzb24taHJkcg0LEgVJbWFnZRi8vzkM&quot; alt=&quot;projection&quot; /&gt;&lt;/p&gt;

&lt;p&gt;let&lt;/p&gt;

&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;L = proj_v(\vec x)&lt;/script&gt; be shadow of &lt;script type=&quot;math/tex&quot;&gt;\vec x \ onto \ \vec v)&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;then&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;L = c\vec v| c \in \mathbf R&lt;/script&gt;

&lt;p&gt;and&lt;/p&gt;

&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;\vec x - c\vec v&lt;/script&gt; is orthgonal to &lt;script type=&quot;math/tex&quot;&gt;\vec v&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;so if&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;(\vec x - c\vec v ) \cdot \vec v = 0&lt;/script&gt;

&lt;p&gt;rearrange the formula to get c&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\vec x \cdot \vec v - c \vec v\cdot\vec v=0&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;c= \frac{\vec x\cdot\vec v}{\vec v\cdot\vec v}&lt;/script&gt;

&lt;p&gt;to input c in the formula earlier&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf L = c\vec v = \frac{\vec x\cdot\vec v}{\vec v\cdot\vec v}\vec v&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\mathbf L = c\vec v = (\vec x\cdot\vec v)\frac{\vec v}{||\vec v||^2}&lt;/script&gt;
</content>
 </entry>
 
 <entry>
   <title>Statistics for Genomic Data Science</title>
   <link href="http://lanyon.getpoole.com/genomic%20data%20science/2015/11/14/Genomic-Data-Science-JH/"/>
   <updated>2015-11-14T00:00:00-06:00</updated>
   <id>http://lanyon.getpoole.com/genomic%20data%20science/2015/11/14/Genomic-Data-Science-JH</id>
   <content type="html">&lt;p&gt;Statistics for Genomic Data Science&lt;/p&gt;

&lt;p&gt;week 1&lt;/p&gt;

&lt;p&gt;week 2&lt;/p&gt;

&lt;p&gt;Asian Institute in Statistical Genetics and Genomics
&lt;a href=&quot;http://www.biostat.jhsph.edu/~iruczins/teaching/kogo/&quot;&gt;Statistical Genomics&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;linear-models-with-categorical-covariateshttpsdocsgooglecompresentationd1pqjeviktzvmmsmsrdn30urxhgmptq-b0ucgoh7qeekoeditslideidgc6c125a130233&quot;&gt;&lt;a href=&quot;https://docs.google.com/presentation/d/1pqjeVIkTZVMmsmSrDn30UrxhgMPTQ-b0uCgoh7QEeko/edit#slide=id.gc6c125a13_0_233&quot;&gt;Linear models with Categorical Covariates&lt;/a&gt;&lt;/h3&gt;

&lt;p&gt;Thomas Lumley &amp;amp; Ken Rice
&lt;a href=&quot;http://faculty.washington.edu/kenrice/teaching.html&quot;&gt;Ken Rice&lt;/a&gt;
&lt;a href=&quot;http://faculty.washington.edu/kenrice/sisg/sisg-lie11-04.pdf&quot;&gt;slides&lt;/a&gt; in pdf format
&lt;a href=&quot;http://faculty.washington.edu/kenrice/sisg/session4lie11.R&quot;&gt;R code&lt;/a&gt; of the slides&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.statsci.org/smyth/pubs/limma-biocbook-reprint.pdf&quot;&gt;Limma: Linear Models for Microarray Data&lt;/a&gt;&lt;/p&gt;

</content>
 </entry>
 
 <entry>
   <title>correlation study</title>
   <link href="http://lanyon.getpoole.com/statistics/2015/10/30/correlation-study/"/>
   <updated>2015-10-30T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/statistics/2015/10/30/correlation-study</id>
   <content type="html">&lt;p&gt;&lt;a href=&quot;https://cran.r-project.org/web/packages/corrplot/vignettes/corrplot-intro.html&quot;&gt;An Introduction to corrplot package&lt;/a&gt;&lt;/p&gt;

</content>
 </entry>
 
 <entry>
   <title>Ipython and Jupyter study</title>
   <link href="http://lanyon.getpoole.com/python/2015/10/30/Ipython-Jupyter-study/"/>
   <updated>2015-10-30T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/python/2015/10/30/Ipython-Jupyter-study</id>
   <content type="html">&lt;p&gt;video resource&lt;/p&gt;

&lt;p&gt;IPython &amp;amp; Jupyter in depth: high productivity interactive and parallel python - PyCon 2015&lt;/p&gt;

&lt;iframe width=&quot;560&quot; height=&quot;315&quot; src=&quot;https://www.youtube.com/embed/05fA_DXgW-Y&quot; frameborder=&quot;0&quot; allowfullscreen=&quot;&quot;&gt;&lt;/iframe&gt;
</content>
 </entry>
 
 <entry>
   <title>exam2 review note from textbooks and others</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/10/13/exam2-review-textbook/"/>
   <updated>2015-10-13T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/10/13/exam2-review-textbook</id>
   <content type="html">&lt;h2 id=&quot;wbc-and-lymphoid&quot;&gt;WBC and Lymphoid&lt;/h2&gt;

&lt;h3 id=&quot;keywords&quot;&gt;keywords&lt;/h3&gt;
&lt;!--break--&gt;
&lt;p&gt;&lt;a href=&quot;https://en.wikipedia.org/wiki/Emperipolesis#/media/File:Emperipolesis_-_very_high_mag.jpg&quot;&gt;emperipolesis&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;an intact cell within the cytoplasm of another cell&lt;/p&gt;

&lt;h2 id=&quot;note-from-books&quot;&gt;note from books&lt;/h2&gt;

&lt;h3 id=&quot;acute-leukemias-in-general&quot;&gt;Acute Leukemias in general&lt;/h3&gt;

&lt;p&gt;oncogenic tyrosine kinases activate RAS and its two downstream signaling arms, the PI3K/AKT and MAPK pathways&lt;/p&gt;

&lt;p&gt;B-ALL and CML -&amp;gt; BCR-ABL fusion gene (9,22) translocation, philiadelphia chromosome.&lt;/p&gt;

&lt;p&gt;some T-ALLs -&amp;gt; NUP214-ABL (similar to BCR-ABL)&lt;/p&gt;

&lt;p&gt;Acute leukemias have the following characteristics:&lt;/p&gt;

&lt;p&gt;a lack of CD7 expression could insinuate mycosis fungoides (MF) or Sezary syndrome (SS).&lt;/p&gt;

&lt;h4 id=&quot;laboratory-findings-in-acute-leukemias&quot;&gt;Laboratory Findings in Acute Leukemias&lt;/h4&gt;

&lt;p&gt;(WBC count) variable; maybe &amp;gt; 100,000 cells/μL, in 50% of patient, &amp;lt; 10,000 cells/μL.&lt;/p&gt;

&lt;p&gt;Anemia is almost always present&lt;/p&gt;

&lt;p&gt;platelet count 00,000/μL&lt;/p&gt;

&lt;p&gt;Neutropenia&lt;/p&gt;

&lt;h4 id=&quot;all-immunophenotypic-features&quot;&gt;ALL Immunophenotypic Features&lt;/h4&gt;

&lt;p&gt;Terminal deoxynucleotidyl transferase (TdT) -&amp;gt; pre-B and pre-T cells&lt;/p&gt;

&lt;p&gt;Further subtyping of ALL -&amp;gt; lineage-specific markers, such as CD19 (B cell) and CD3 (T cell).&lt;/p&gt;

&lt;h4 id=&quot;b-lymphoblastic-leukemialymphoma-immunophenotype&quot;&gt;B lymphoblastic leukemia/lymphoma: Immunophenotype&lt;/h4&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;CD19 – pan-B-cell marker&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD10  - Common Acute Lymphoblastic Leukemia Antigen (CALLA), most cases&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD34 – stem cell marker, most cases&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;TdT – nearly all cases&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Cytoplasmic IgM heavy chain (μ chain)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Only in the more mature “late pre-B” cases&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Otherwise, ALL are negative for Ig&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Distinguishes ALL from mature B-cell leukemia/lymphoma&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h4 id=&quot;t-lymphoblastic-leukemialymphoma-immunophenotype&quot;&gt;T lymphoblastic leukemia/lymphoma: Immunophenotype&lt;/h4&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;TdT – many cases&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Most T-cell antigens positive: CD1a, CD2, cytoplasmic CD3, CD5, and CD7&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD1a - T-cell markers often negative: surface CD3, CD4 and CD8&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD4 and CD8 often negative in more immature forms&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD4 and CD8 often positive in more mature forms&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h4 id=&quot;b-lymphoblastic-leukemialymphoma-genetics&quot;&gt;B lymphoblastic leukemia/lymphoma: genetics&lt;/h4&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Abnormality&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Frequency&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Prognosis&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;t(v;11q23), MLL, early precursor&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;2-3%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;&lt;strong&gt;unfavorable&lt;/strong&gt;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;t(9;22), Ph1, BCR-ABL1&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;3-4%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;&lt;strong&gt;unfavorable&lt;/strong&gt;&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;(25% adults)&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;t(12;21) TEL/AML1&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;16-19%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;favorable&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Hyperdiploid &amp;gt; 50&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;20-25%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;favorable&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Hypodiploid&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;5%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;&lt;strong&gt;unfavorable&lt;/strong&gt;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Antigen  Designation&lt;/th&gt;
      &lt;th style=&quot;text-align: left&quot;&gt;Normal Cellular Distribution&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Primarily T-Cell Associated&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD1&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Thymocytes and Langerhans cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD3&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Thymocytes, mature T cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD4&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Helper T cells, subset of thymocytes&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD5&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;T cells and a small subset of B cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD8&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Cytotoxic T cells, subset of thymocytes, and some NK cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Primarily B-Cell Associated&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;BCL6&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;a transcription factor required for the generation of germinal center B cells.&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD10&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Pre-B cells and germinal-center B cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD19&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Pre-B cells and mature B cells but not plasma cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD20&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Pre-B cells after C19 and mature B cells but not plasma  cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD21&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;EBV receptor; mature B cells and follicular dendritic cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD23&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Activated mature B cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD79a&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Marrow pre-B cells and mature B cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Primarily Monocyte or Macrophage Associated&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD11c&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Granulocytes, monocytes, and macrophages; also  expressed by hairy cell leukemias&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD13&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Immature and mature monocytes and granulocytes&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD14&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Monocytes&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD15&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Granulocytes; Reed-Sternberg cells and variants&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD33&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Myeloid progenitors and monocytes&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD64&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Mature myeloid cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Primarily NK-Cell Associated&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD16&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;NK cells and granulocytes&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD56&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;NK cells and a subset of T cells&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Primarily Stem Cell and Progenitor Cell Associated&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD34&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Pluripotent hematopoietic stem cells and progenitor cells  of many lineages&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Activation Markers&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD30&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;Activated B cells, T cells, and monocytes; Reed-Sternberg  cells and variants&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Present on All Leukocytes&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;CD45&lt;/td&gt;
      &lt;td style=&quot;text-align: left&quot;&gt;All leukocytes; also known as leukocyte common antigen  (LCA)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Diagnosis&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Cell of Origin&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Genotype&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Salient Clinical Features&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Neoplasms of Immature B and T Cells&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;B-cell acute lymphoblastic  leukemia/lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Bone marrow precursor  B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Diverse chromosomal translocations;  t(12;21) involving RUNX1 and ETV6  present in 25%&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Predominantly children; symptoms relating to marrow  replacement and pancytopenia; aggressive&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;T-cell acute lymphoblastic  leukemia/lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Precursor T cell (often  of thymic origin)&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Diverse chromosomal translocations,  NOTCH1 mutations (50%-70%)&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Predominantly adolescent males; thymic masses and  variable bone marrow involvement; aggressive&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Neoplasms of Mature B Cells&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Burkitt lymphoma*&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Germinal-center B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Translocations involving MYC and lg loci,  usually t(8;14); subset EBV-associated&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Adolescents or young adults with extranodal masses;  uncommonly presents as “leukemia”; aggressive&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Diffuse large B-cell  lymphoma†&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Germinal-center or  postgerminal center  B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Diverse chromosomal rearrangements,  most often of BCL6 (30%), BCL2 (10%),  or MYC (5%)&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;All ages, but most common in older adults; often appears  as a rapidly growing mass; 30% extranodal; aggressive&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Extranodal marginal zone  lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Memory B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;t(11;18), t(1;14), and t(14;18) creating  MALT1-IAP2, BCL10-IgH, and  MALT1-IgH fusion genes, respectively&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Arises at extranodal sites in adults with chronic  inflammatory diseases; may remain localized; indolent&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Follicular lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Germinal-center B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;t(14;18) creating BCL2-IgH fusion gene&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Older adults with generalized lymphadenopathy and  marrow involvement; indolent&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Hairy cell leukemia&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Memory B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Activating BRAF mutations&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Older males with pancytopenia and splenomegaly; indolent&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Mantle cell lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Naive B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;t(11;14) creating CyclinD1-IgH fusion gene&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Older males with disseminated disease; moderately  aggressive&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Multiple myeloma/solitary  plasmacytoma†&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Post-germinal-center  bone marrow homing  plasma cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Diverse rearrangements involving IgH; 13q  deletions&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Myeloma: older adults with lytic bone lesions, pathologic  fractures, hypercalcemia, and renal failure; moderately  aggressive&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Plasmacytoma: isolated plasma cell masses in bone or  soft tissue; indolent&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Small lymphocytic  lymphoma/chronic  lymphocytic leukemia&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Naive B cell or memory  B cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Trisomy 12, deletions of 11q, 13q, and  17p&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Older adults with bone marrow, lymph node, spleen, and  liver disease; autoimmune hemolysis and  thrombocytopenia in a minority; indolent&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Neoplasms of Mature T Cells or NK Cells&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Adult T-cell leukemia/ lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Helper T cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;HTLV-1 provirus present in tumor cells&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Adults with cutaneous lesions, marrow involvement, and  hypercalcemia; occurs mainly in Japan, West Africa,  and the Caribbean; aggressive&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Peripheral T-cell lymphoma,  unspecified&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Helper or cytotoxic   T cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;No specific chromosomal abnormality&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Mainly older adults; usually presents with  lymphadenopathy; aggressive&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Anaplastic large-cell  lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Cytotoxic T cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Rearrangements of ALK (anaplastic large  cell lymphoma kinase) in a subset&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Children and young adults, usually with lymph node and  soft-tissue disease; aggressive&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Extranodal NK/T-cell  lymphoma&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;NK-cell (common) or  cytotoxic T cell (rare)&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;EBV-associated; no specific chromosomal  abnormality&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Adults with destructive extranodal masses, most  commonly sinonasal; aggressive&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Mycosis fungoides/Sézary  syndrome&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Helper T cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;No specific chromosomal abnormality&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Adult patients with cutaneous patches, plaques, nodules,  or generalized erythema; indolent&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Large granular lymphocytic  leukemia&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Two types: cytotoxic T  cell and NK cell&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Point mutations in STAT3&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Adult patients with splenomegaly, neutropenia, and  anemia, sometimes, accompanied by autoimmune  disease&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;*Most common tumors in children&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;†Most common tumors in adults.&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;EBV, Epstein-Barr virus; HIV, human immunodeficiency virus; Ig, immunoglobulin; NK, natural killer.&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;Immunophenotype of chronic B-cell neoplasms&lt;/p&gt;

&lt;table&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;neoplasm&lt;/td&gt;
      &lt;td&gt;CD19CD20&lt;/td&gt;
      &lt;td&gt;CD5&lt;/td&gt;
      &lt;td&gt;CD10&lt;/td&gt;
      &lt;td&gt;CD23&lt;/td&gt;
      &lt;td&gt;sIg&lt;/td&gt;
      &lt;td&gt;CD103&lt;/td&gt;
      &lt;td&gt;Cyclin D1&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;:—:&lt;/td&gt;
      &lt;td&gt;:—:&lt;/td&gt;
      &lt;td&gt;:—:&lt;/td&gt;
      &lt;td&gt;:—:&lt;/td&gt;
      &lt;td&gt;:—:&lt;/td&gt;
      &lt;td&gt;:—:&lt;/td&gt;
      &lt;td&gt;:—:&lt;/td&gt;
      &lt;td&gt;:—:&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;CLL/SLL&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-/+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;MCL&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;FL&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;++&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;MZL&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;+++&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;HCL&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;-&lt;/td&gt;
      &lt;td&gt;+++&lt;/td&gt;
      &lt;td&gt;+&lt;/td&gt;
      &lt;td&gt;+/-&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h4 id=&quot;leukocyte-alkaline-phosphatase&quot;&gt;Leukocyte alkaline phosphatase&lt;/h4&gt;

&lt;p&gt;Leukocyte alkaline phosphatase (LAP) is found within mature white blood cells. White blood cell levels of LAP can help in the diagnosis of certain conditions.&lt;/p&gt;

&lt;p&gt;Higher levels are seen in polycythemia vera (PV), essential thrombocytosis (ET), primary myelofibrosis (PM), and the leukemoid reaction.
Lower levels are found in chronic myelogenous leukemia(CML), paroxysmal nocturnal hemoglobinuria (PNH) and acute myelogenous leukaemia (AML).&lt;/p&gt;

&lt;h4 id=&quot;cllsll&quot;&gt;CLL/SLL&lt;/h4&gt;

&lt;p&gt;circulating  nucleated  red  cells  could  stem  from  premature  release  of  progenitors  in  the  face  of  severe anemia&lt;/p&gt;

&lt;p&gt;The most promising new therapy is BTK inhibitors, described earlier.&lt;/p&gt;

&lt;h3 id=&quot;blood-count-note&quot;&gt;blood count note&lt;/h3&gt;

&lt;p&gt;observing CBC and blood count&lt;/p&gt;

&lt;p&gt;platlet count -&amp;gt; thrombocytopenia&lt;/p&gt;

&lt;p&gt;Normal bone marrow -&amp;gt; exclude acute lymphoid or myeloid leukemia&lt;/p&gt;

&lt;p&gt;reduction in RBCs, WBCs, and platelet production -&amp;gt; aplastic anemia&lt;/p&gt;

&lt;p&gt;band neutrophil -&amp;gt; left shift -&amp;gt; inflammatory condition&lt;/p&gt;

</content>
 </entry>
 
 <entry>
   <title>Hemodynamics Supplimentary Material</title>
   <link href="http://lanyon.getpoole.com/2015/10/12/hemodynamics-supplimentary-material/"/>
   <updated>2015-10-12T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/2015/10/12/hemodynamics-supplimentary-material</id>
   <content type="html">
&lt;hr /&gt;
&lt;p&gt;layout: post
comments: True
title: Bleeding and Thrombotic Disorders
category: Pathology
tags: [pathology, diseases, textbook, Lab Med]
—&lt;/p&gt;

&lt;h2 id=&quot;hemodynamics-and-bleeding-disorders&quot;&gt;Hemodynamics and bleeding disorders&lt;/h2&gt;

&lt;p&gt;TABLE 2.-Causes of Pleural Effusions&lt;/p&gt;

&lt;h3 id=&quot;transudates&quot;&gt;Transudates&lt;/h3&gt;
&lt;!--break--&gt;
&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Congestive heart failure&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Cirrhosis with ascites&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Nephrotic syndrome Hypoalbuminemia&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Peritoneal dialysis Atelectasis,acute&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Superior vena cava obstruction Subclavian catheter misplacement Early mediastinal malignancy&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;exudates&quot;&gt;Exudates&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Parapneumonic effusion (bacterial pneumonia) Pulmonary infarction&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Malignancy (direct pleural involvement, late mediasti-&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;nalinvolvement)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Viral disease&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Connective tissue disease (lupus, rheumatoid, mixed) Tuberculosis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Fungal disease&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Parasitic disease (Entamoeba histolytica, Paragonimus&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;westermani)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Gastrpintestinal disease (pancreatitis, esophageal rup-&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;ture, subphrenic abscess)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Drug reaction (nitrofurantoin, methysergide) Asbestos&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Meigs’ syndrome&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Postmyocardial infarction and postcardiac surgical&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;operation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Trapped lung Lymphatic abnormality Uremic pleurisy Atelectasis,chronic Chylothorax Sarcoidosis&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;
</content>
 </entry>
 
 <entry>
   <title>Assignment 4 Creating graphs for your data</title>
   <link href="http://lanyon.getpoole.com/data%20science/2015/10/11/assignment4-creating-graph/"/>
   <updated>2015-10-11T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/data%20science/2015/10/11/assignment4-creating-graph</id>
   <content type="html">&lt;p&gt;to download my python code &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/TempDataScienceCourse/Assignment%204/Assignment%204.py&quot;&gt;click here&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;to download the dataset &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/TempDataScienceCourse/Assignment%204/gapminder.csv&quot;&gt;click here&lt;/a&gt;&lt;/p&gt;

&lt;!--break--&gt;

&lt;p&gt;to download the ipython notebook file &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/TempDataScienceCourse/Assignment%204/Assignment%204.ipynb.json&quot;&gt;click here&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;To visit my assignment result, please &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/TempDataScienceCourse/Assignment%204/Assignment%204.html&quot;&gt;click here&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;to visit my previous assignments for reference, &lt;a href=&quot;http://jizongl.github.io/DataManagement/&quot;&gt;please click here&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;instructions&quot;&gt;instructions&lt;/h3&gt;

&lt;p&gt;Continue with the program you’ve successfully run.&lt;/p&gt;

&lt;p&gt;STEP 1: Create graphs of your variables one at a time (univariate graphs).&lt;/p&gt;

&lt;p&gt;Examine both their center and spread.&lt;/p&gt;

&lt;p&gt;STEP 2: Create a graph showing the association between your explanatory and response variables (bivariate graph).&lt;/p&gt;

&lt;p&gt;Your output should be interpretable (i.e. organized and labeled).&lt;/p&gt;

&lt;h3 id=&quot;review-criteria-less&quot;&gt;Review Criteria less&lt;/h3&gt;

&lt;p&gt;Your assessment will be based on the evidence you provide that you have completed all of the steps. When relevant, gradients in the scoring will be available to reward clarity (for example, you will get one point for submitting graphs that do not accurately represent your data, but two points if the data is accurately represented). In all cases, consider that the peer assessing your work is likely not an expert in the field you are analyzing. You will be assessed equally on your description of your frequency distributions.&lt;/p&gt;

&lt;p&gt;Specific rubric items, and their point values, are as follows:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Was a univariate graph created for each of the selected variables? (2 points)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Was a bivariate graph created for the selected variables? (2 points)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Did the summary describe what the graphs revealed in terms of the individual&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;variables and the relationship between them? (2 points)&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

</content>
 </entry>
 
 <entry>
   <title>Assignment 3 Data Management and EDA</title>
   <link href="http://lanyon.getpoole.com/data%20science/2015/10/04/Data-Management-Assignment3/"/>
   <updated>2015-10-04T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/data%20science/2015/10/04/Data-Management-Assignment3</id>
   <content type="html">&lt;h2 id=&quot;instructions&quot;&gt;Instructions&lt;/h2&gt;

&lt;p&gt;This week, you will be making and implementing decisions about data management for the variables that you have chosen to examine based on the steps reviewed in the videos and supplemental materials. This assignment is important because it offers you the opportunity to practice making sound data management decisions and think about how these decisions will impact your research.&lt;/p&gt;

&lt;!--break--&gt;

&lt;p&gt;You can download my python code file &lt;a href=&quot;/assets/couseraAssignment/DataManagement/week3/week3assignment.py&quot;&gt;here&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;And you can download the gapminder dataset &lt;a href=&quot;/assets/couseraAssignment/DataManagement/week3/gapminder.csv&quot;&gt;csv file here&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;And you can review my Assignment for the codebook &lt;a href=&quot;http://jizongl.github.io/data%20science/2015/09/19/Data-Management-Assignment1/&quot;&gt;here&lt;/a&gt;&lt;/p&gt;

&lt;ul id=&quot;markdown-toc&quot;&gt;
  &lt;li&gt;&lt;a href=&quot;#instructions&quot; id=&quot;markdown-toc-instructions&quot;&gt;Instructions&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#import-the-entire-dataset-to-memory&quot; id=&quot;markdown-toc-import-the-entire-dataset-to-memory&quot;&gt;import the entire dataset to memory&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#some-house-keeping-to-the-dataset&quot; id=&quot;markdown-toc-some-house-keeping-to-the-dataset&quot;&gt;some house keeping to the dataset&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#i-am-interested-to-divided-urbanrate-into-4-percentiles-so-i-coded-with-both-methods-introduced-from-the-video-as-follow&quot; id=&quot;markdown-toc-i-am-interested-to-divided-urbanrate-into-4-percentiles-so-i-coded-with-both-methods-introduced-from-the-video-as-follow&quot;&gt;I am interested to divided urbanrate into 4 percentiles, so I coded with both methods introduced from the video as follow&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#result&quot; id=&quot;markdown-toc-result&quot;&gt;result&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#use-crosstab-function-to-make-cross-counts-for-both-newly-created-variables-urbanratenew--urbanratenew2-and-the-original-variable-urbanrate&quot; id=&quot;markdown-toc-use-crosstab-function-to-make-cross-counts-for-both-newly-created-variables-urbanratenew--urbanratenew2-and-the-original-variable-urbanrate&quot;&gt;Use &lt;strong&gt;crosstab()&lt;/strong&gt; function to make cross counts for both newly created variables (urbanrateNew &amp;amp; urbanrateNew2) and the original variable urbanrate.&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#result-of-crosstable-count-for-both-methods&quot; id=&quot;markdown-toc-result-of-crosstable-count-for-both-methods&quot;&gt;result of crosstable count for both methods&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#review-criteria&quot; id=&quot;markdown-toc-review-criteria&quot;&gt;Review Criteria&lt;/a&gt;&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;import-the-entire-dataset-to-memory&quot;&gt;import the entire dataset to memory&lt;/h3&gt;
&lt;pre&gt;
pre&lt;code&gt;
import pandas
import numpy
&lt;/code&gt;
&lt;/pre&gt;

&lt;h3 id=&quot;some-house-keeping-to-the-dataset&quot;&gt;some house keeping to the dataset&lt;/h3&gt;

&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
&lt;code&gt;	
print(&quot;Import the entire dataset to memory&quot;)
data = pandas.read_csv(&quot;gapminder.csv&quot;, low_memory = False)

print(&quot;upper case all DataFrame column names&quot;)
data.columns = map(str.lower, data.columns)

print(&quot;avoid run time error message&quot;)
pandas.set_option(&#39;display.float_format&#39;, lambda x:&#39;%f&#39;%x)

print(&quot;convert strings to numerics&quot;)
data[&#39;alcconsumption&#39;] = data[&#39;alcconsumption&#39;].convert_objects(convert_numeric=True)
data[&#39;alcconsumption&#39;] = data[&#39;alcconsumption&#39;].convert_objects(convert_numeric=True)
data[&#39;relectricperperson&#39;] = data[&#39;relectricperperson&#39;].convert_objects(convert_numeric=True)
data[&#39;urbanrate&#39;] = data[&#39;urbanrate&#39;].convert_objects(convert_numeric=True)
data[&#39;internetuserate&#39;] = data[&#39;internetuserate&#39;].convert_objects(convert_numeric=True)
data[&#39;hivrate&#39;] = data[&#39;hivrate&#39;].convert_objects(convert_numeric=True)

print(&quot;Set mission data to NAN&quot;)
data[&#39;alcconsumption&#39;] = data[&#39;alcconsumption&#39;].replace(0, numpy.nan)
data[&quot;lifeexpectancy&quot;] = data[&quot;lifeexpectancy&quot;].replace(0, numpy.nan)
data[&quot;relectricperperson&quot;] = data[&quot;relectricperperson&quot;].replace(0, numpy.nan)
data[&#39;urbanrate&#39;] = data[&#39;urbanrate&#39;].replace(0, numpy.nan)
data[&quot;internetuserate&quot;] = data[&quot;internetuserate&quot;].replace(0, numpy.nan)
data[&#39;hivrate&#39;] = data[&#39;hivrate&#39;].replace(0, numpy.nan)
&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;

&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
&lt;code&gt;	
print(&#39;create sub2 dataset to include only variables of interest.&#39;)
sub2 = data[[&#39;alcconsumption&#39;,&#39;lifeexpectancy&#39;,&#39;relectricperperson&#39;,&#39;urbanrate&#39;, &#39;internetuserate&#39;,&#39;hivrate&#39;]]

print(&#39;preview dataset&#39;)
print(sub2.head(n=10))

   alcconsumption lifeexpectancy  relectricperperson  urbanrate  \
0        0.030000         48.673                 nan  24.040000   
1        7.290000         76.918          636.341383  46.720000   
2        0.690000         73.131          590.509814  65.220000   
3       10.170000                                nan  88.920000   
4        5.570000         51.093          172.999227  56.700000   
5        8.170000                                nan  30.460000   
6        9.350000         75.901          768.428300  92.000000   
7       13.660000         74.241          603.763058  63.860000   
8             nan         75.246                 nan  46.780000   
9       10.210000         81.907         2825.391095  88.740000   

   internetuserate  hivrate  
0         3.654122      nan  
1        44.989947      nan  
2        12.500073 0.100000  
3        81.000000      nan  
4         9.999954 2.000000  
5        80.645455      nan  
6        36.000335 0.500000  
7        44.001025 0.100000  
8        41.800889      nan  
9        75.895654 0.100000  
&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;

&lt;h3 id=&quot;i-am-interested-to-divided-urbanrate-into-4-percentiles-so-i-coded-with-both-methods-introduced-from-the-video-as-follow&quot;&gt;I am interested to divided urbanrate into 4 percentiles, so I coded with both methods introduced from the video as follow&lt;/h3&gt;

&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
&lt;code&gt;	
print(&#39;create new variable urbanrateNew2 to cut urbanrate into 4 percentile&#39;)
sub2[&#39;urbanrateNew&#39;]= pandas.qcut(sub2.urbanrate, 4, labels = [&quot;1=25%tile&quot;,&quot;2=50%tile&quot;, &quot;3=75%tile&quot;, &quot;4=100%tile&quot;])
print(&#39;create new variable urbanrateNew2 to cut urbanrate into 4 categories&#39;)
sub2[&quot;urbanrateNew2&quot;] = pandas.cut(sub2.urbanrate,[10,40,70,100])

print(&#39;frequency count for method 1&#39;)
c1 = sub2[&quot;urbanrateNew&quot;].value_counts(sort=False,dropna=True)
print(c1)
print(&quot;percentage count for method 1&quot;)
p1 = sub2[&quot;urbanrateNew&quot;].value_counts(sort=False, normalize=True)
print(p1)

print(&#39;frequency count for method 2&#39;)
c2 = sub2[&quot;urbanrateNew2&quot;].value_counts(sort=False,dropna=True)
print(c2)
print(&quot;percentage count for method 2&quot;)
p2 = sub2[&quot;urbanrateNew2&quot;].value_counts(sort=False, normalize=True)
print(p2)
&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;

&lt;h3 id=&quot;result&quot;&gt;result&lt;/h3&gt;
&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
&lt;code&gt;	
frequency count for method 2
1=25%tile     51
2=50%tile     51
3=75%tile     50
4=100%tile    51
dtype: int64
percentage count for method 1
1=25%tile    0.239437
2=50%tile    0.239437
3=75%tile    0.234742
4=100%tile   0.239437
dtype: float64
frequency count for method 2
(10, 40]     59
(40, 70]     80
(70, 100]    64
dtype: int64
percentage count for method 2
(10, 40]    0.276995
(40, 70]    0.375587
(70, 100]   0.300469
dtype: float64
&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;

&lt;h3 id=&quot;use-crosstab-function-to-make-cross-counts-for-both-newly-created-variables-urbanratenew--urbanratenew2-and-the-original-variable-urbanrate&quot;&gt;Use &lt;strong&gt;crosstab()&lt;/strong&gt; function to make cross counts for both newly created variables (urbanrateNew &amp;amp; urbanrateNew2) and the original variable urbanrate.&lt;/h3&gt;

&lt;pre&gt;
&lt;code&gt;	
print(&#39;crosstable function for count of oberservation within each category&#39;)
print(pandas.crosstab(sub2[&quot;urbanrateNew&quot;], sub2[&quot;urbanrate&quot;]))
print(pandas.crosstab(sub2[&quot;urbanrateNew2&quot;], sub2[&quot;urbanrate&quot;]))

&lt;/code&gt;
&lt;/pre&gt;

&lt;h3 id=&quot;result-of-crosstable-count-for-both-methods&quot;&gt;result of crosstable count for both methods&lt;/h3&gt;
&lt;div style=&quot;width:700px;height:500px;line-height:3em;overflow:auto;padding:5px;&quot;&gt;
&lt;pre&gt;
&lt;code&gt;	
crosstable function for count of oberservation within each category
urbanrate     10.400000   12.540000   12.980000   13.220000   14.320000   \
urbanrateNew                                                               
1=25%tile              1           1           1           1           1   
2=50%tile              0           0           0           0           0   
3=75%tile              0           0           0           0           0   
4=100%tile             0           0           0           0           0   

urbanrate     15.100000   16.540000   17.000000   17.240000   17.960000   \
urbanrateNew                                                               
1=25%tile              1           1           1           1           1   
2=50%tile              0           0           0           0           0   
3=75%tile              0           0           0           0           0   
4=100%tile             0           0           0           0           0   

urbanrate        ...      92.680000   93.160000   93.320000   94.220000   \
urbanrateNew     ...                                                       
1=25%tile        ...               0           0           0           0   
2=50%tile        ...               0           0           0           0   
3=75%tile        ...               0           0           0           0   
4=100%tile       ...               1           1           1           1   

urbanrate     94.260000   95.640000   97.360000   98.320000   98.360000   \
urbanrateNew                                                               
1=25%tile              0           0           0           0           0   
2=50%tile              0           0           0           0           0   
3=75%tile              0           0           0           0           0   
4=100%tile             1           1           1           1           1   

urbanrate     100.000000  
urbanrateNew              
1=25%tile              0  
2=50%tile              0  
3=75%tile              0  
4=100%tile             6  

[4 rows x 194 columns]
urbanrate      10.400000   12.540000   12.980000   13.220000   14.320000   \
urbanrateNew2                                                               
(10, 40]                1           1           1           1           1   
(40, 70]                0           0           0           0           0   
(70, 100]               0           0           0           0           0   

urbanrate      15.100000   16.540000   17.000000   17.240000   17.960000   \
urbanrateNew2                                                               
(10, 40]                1           1           1           1           1   
(40, 70]                0           0           0           0           0   
(70, 100]               0           0           0           0           0   

urbanrate         ...      92.680000   93.160000   93.320000   94.220000   \
urbanrateNew2     ...                                                       
(10, 40]          ...               0           0           0           0   
(40, 70]          ...               0           0           0           0   
(70, 100]         ...               1           1           1           1   

urbanrate      94.260000   95.640000   97.360000   98.320000   98.360000   \
urbanrateNew2                                                               
(10, 40]                0           0           0           0           0   
(40, 70]                0           0           0           0           0   
(70, 100]               1           1           1           1           1   

urbanrate      100.000000  
urbanrateNew2              
(10, 40]                0  
(40, 70]                0  
(70, 100]               6  

[3 rows x 194 columns]

Process finished with exit code 0


&lt;/code&gt;
&lt;/pre&gt;
&lt;/div&gt;

&lt;h3 id=&quot;review-criteria&quot;&gt;Review Criteria&lt;/h3&gt;

&lt;p&gt;Your assessment will be based on the evidence you provide that you have completed all of the steps. When relevant, gradients in the scoring will be available to reward clarity (for example, you will get one point for submitting output that is not understandable, but two points if it is understandable). In all cases, consider that the peer assessing your work is likely not an expert in the field you are analyzing. You will be assessed equally on your description of your frequency distributions.&lt;/p&gt;

&lt;p&gt;Specific rubric items, and their point values, are as follows:&lt;/p&gt;

&lt;pre&gt;&lt;code&gt;Was the program output interpretable (i.e. organized and labeled)? (1 point)
Does the program output display three data managed variables as frequency tables? (1 point)
Did the summary describe the frequency distributions in terms of the values the variables take, how often they take them, the presence of missing data, etc.? (2 points)
&lt;/code&gt;&lt;/pre&gt;
</content>
 </entry>
 
 <entry>
   <title>keywords and figures</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/10/02/pathology-exam-2-keywords-review/"/>
   <updated>2015-10-02T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/10/02/pathology-exam-2-keywords-review</id>
   <content type="html">&lt;ul id=&quot;markdown-toc&quot;&gt;
  &lt;li&gt;&lt;a href=&quot;#multiple-myeloma&quot; id=&quot;markdown-toc-multiple-myeloma&quot;&gt;Multiple Myeloma&lt;/a&gt;    &lt;ul&gt;
      &lt;li&gt;&lt;a href=&quot;#pathogenesis&quot; id=&quot;markdown-toc-pathogenesis&quot;&gt;Pathogenesis&lt;/a&gt;&lt;/li&gt;
      &lt;li&gt;&lt;a href=&quot;#monoclonal-gammopathy-of-undetermined-significance-mgus&quot; id=&quot;markdown-toc-monoclonal-gammopathy-of-undetermined-significance-mgus&quot;&gt;Monoclonal gammopathy of undetermined significance (MGUS)&lt;/a&gt;&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;!--break--&gt;

&lt;h3 id=&quot;multiple-myeloma&quot;&gt;Multiple Myeloma&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;a plasma cell neoplasm commonly associated with lytic bone lesions, hypercalcemia, renal failure, and acquired immune abnormalities.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;It principally involves the bone marrow and usually is associated with lytic lesions throughout the skeletal system.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;M protein produced is IgG (60%), followed by IgA (20% to 25%); rarely are IgM, IgD, or IgE M proteins observed. In the remaining 15% to 20% of cases, the plasma cells produce only κ or λ light chains.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h4 id=&quot;pathogenesis&quot;&gt;Pathogenesis&lt;/h4&gt;

&lt;ul&gt;
  &lt;li&gt;frequent rearrangements involving the IgH locus and various proto-oncogenes&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;*&lt;/p&gt;

&lt;h4 id=&quot;monoclonal-gammopathy-of-undetermined-significance-mgus&quot;&gt;Monoclonal gammopathy of undetermined significance (MGUS)&lt;/h4&gt;

</content>
 </entry>
 
 <entry>
   <title>Regression indepth study</title>
   <link href="http://lanyon.getpoole.com/statistics/2015/09/29/regression-study/"/>
   <updated>2015-09-29T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/statistics/2015/09/29/regression-study</id>
   <content type="html">&lt;ul id=&quot;markdown-toc&quot;&gt;
  &lt;li&gt;&lt;a href=&quot;#derivation-of-linear-regression-equations&quot; id=&quot;markdown-toc-derivation-of-linear-regression-equations&quot;&gt;Derivation of linear regression equations&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#include-r-code-to-illustrate-why-it-is-0&quot; id=&quot;markdown-toc-include-r-code-to-illustrate-why-it-is-0&quot;&gt;include R code to illustrate why it is 0.&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#regression-through-the-origin&quot; id=&quot;markdown-toc-regression-through-the-origin&quot;&gt;Regression through the origin&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#derivation-of-regression-formula-through-calculus&quot; id=&quot;markdown-toc-derivation-of-regression-formula-through-calculus&quot;&gt;derivation of regression formula through calculus&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Some key points about Least Square Model&lt;/p&gt;

&lt;!--break--&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\hat \beta_1 = Cor(Y, X)\frac{Sd(Y)}{Sd(X)}&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\hat \beta_0 = \bar Y - \hat \beta_1 \bar X&lt;/script&gt;

&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;\hat \beta_1&lt;/script&gt; has the unit of &lt;script type=&quot;math/tex&quot;&gt;\frac{Y}{X}&lt;/script&gt;, &lt;script type=&quot;math/tex&quot;&gt;\hat \beta_0&lt;/script&gt; has the unit of Y.&lt;/p&gt;

&lt;p&gt;The line passes through the point (&lt;script type=&quot;math/tex&quot;&gt;\bar X&lt;/script&gt;,&lt;script type=&quot;math/tex&quot;&gt;\bar Y&lt;/script&gt;)&lt;/p&gt;

&lt;p&gt;The slope of the regression line with X as the outcome and Y as the predictor is Cor(Y,X)Sd(X)/Sd(Y)&lt;/p&gt;

&lt;p&gt;The slope is the same one you would get if you centered the data&lt;script type=&quot;math/tex&quot;&gt;(X_i - \bar X, Y_i - \bar Y)&lt;/script&gt;, and did regression through the origin.&lt;/p&gt;

&lt;p&gt;If you normalized the data, &lt;script type=&quot;math/tex&quot;&gt;{\frac{X_i - \bar X}{Sd(X)} , \frac{Y_i-\bar Y}{Sd(Y)}}&lt;/script&gt;, the slope is Cor(Y,X) because Sd(X) = Sd(Y) = 1.&lt;/p&gt;

&lt;h2 id=&quot;derivation-of-linear-regression-equations&quot;&gt;Derivation of linear regression equations&lt;/h2&gt;

&lt;p&gt;The following is adapted from &lt;a href=&quot;http://seismo.berkeley.edu/~kirchner/eps_120/Toolkits/Toolkit_10.pdf&quot;&gt;Data Analysis Toolkit #10: Simple linear regression&lt;/a&gt;. However, there are some important supplementary information I want to include here.&lt;/p&gt;
&lt;p align=&quot;right&quot;&gt;(1)&lt;/p&gt;
&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;Q = \sum_{i = 1}^n (Y_i - \hat Y)^2 = \sum_{i = 1}^n (Y_i - a - bX_i)^2&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;Then, Q will be minimized at the values of a and b for which ∂Q / ∂a = 0 and ∂Q / ∂b = 0&lt;/p&gt;
&lt;p align=&quot;right&quot;&gt;(2)&lt;/p&gt;
&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;\frac{\partial Q}{\partial a} = \sum_{i=1}^n -2(Y_i - a -bX_i) = 2(na + b\sum_{i}^n X_i - \sum_{i=1}^n Y_i) = 0&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;divide through by 2 and solve for a&lt;/p&gt;
&lt;p align=&quot;right&quot;&gt;(3)&lt;/p&gt;
&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;a = \bar Y - b \bar X&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;which says that the constant a (the y-intercept) is set such that the line must go through the mean of x and y. This makes sense, because this point is the “center” of the data cloud. The second condition for minimizing Q is,&lt;/p&gt;
&lt;p align=&quot;right&quot;&gt;(4)&lt;/p&gt;
&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;\frac{\partial Q}{\partial b} = \sum_{i=1}^n -2X_i(Y_i - a -bX_i) = \sum_{i=1}^n -2 (X_iY_i - aX_i - bX_i^2) = 0&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;If we substitute the expression for a from (3) into (4), then we get&lt;/p&gt;
&lt;p align=&quot;right&quot;&gt;(5)&lt;/p&gt;
&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;\sum_{i=1}^n(X_iY_i - X_i\bar Y) + bX_i\bar X -bX_i^2)=0&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;separate this into two sums&lt;/p&gt;
&lt;p align=&quot;right&quot;&gt;(6)&lt;/p&gt;
&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;\sum_{i=1}^n(X_iY_i-X_i\bar Y)-b \sum_{i=1}^n (X_i^2-X_i\bar X)&lt;/script&gt;&lt;/p&gt;
&lt;p align=&quot;right&quot;&gt;(7)&lt;/p&gt;
&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;b=\frac{\sum_{i=1}^n (X_iY_i-X_i\bar Y)}{\sum_{i=1}^n (X_i^2-X_i\bar X)} = \frac{\sum_{i=1}^n (X_iY_i)-n\bar X\bar Y}{\sum_{i=1}^n (X_i^2)- n\bar X^2}&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;Because
&lt;script type=&quot;math/tex&quot;&gt;\sum_{i=1}^n (\bar X^2-X_i\bar X) = 0  and  \sum_{i=1}^n (\bar X\bar Y -Y_i\bar X) = 0&lt;/script&gt;&lt;/p&gt;

&lt;h2 id=&quot;include-r-code-to-illustrate-why-it-is-0&quot;&gt;include R code to illustrate why it is 0.&lt;/h2&gt;

&lt;p align=&quot;right&quot;&gt;(1)&lt;/p&gt;
&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;Y_i = \alpha + |beta X_i + \epsilon_i&lt;/script&gt;&lt;/p&gt;

&lt;p align=&quot;right&quot;&gt;(2)&lt;/p&gt;
&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;E(Y_i) = \alpha + \beta E(X_i)&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;subtract (2) from one (1)&lt;/p&gt;

&lt;p align=&quot;right&quot;&gt;(3)&lt;/p&gt;
&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;Y_i - E(Y_i) = \beta(X_i-E(X_i)+ \epsilon_i)&lt;/script&gt;&lt;/p&gt;

&lt;p align=&quot;right&quot;&gt;(4)&lt;/p&gt;
&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;E(Y_i) = \bar Y and E(X_i) = \bar X&lt;/script&gt;&lt;/p&gt;

&lt;p align=&quot;right&quot;&gt;(5)&lt;/p&gt;
&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;Y_i - \bar Y = \beta(X_i-\bar X)+ \epsilon_i)&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;then &lt;script type=&quot;math/tex&quot;&gt;\beta&lt;/script&gt; becomes&lt;/p&gt;
&lt;p align=&quot;right&quot;&gt;(6)&lt;/p&gt;
&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;\beta = \frac{\sum_{i}^n (X_i-\bar X)(Y_i-\bar Y)}{\sum_{i}^n (X_i- \bar X)^2}&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;and we could divide both the numerator and denomator by n&lt;/p&gt;

&lt;p align=&quot;right&quot;&gt;(7)&lt;/p&gt;
&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;\beta = \frac{\frac{\sum_{i}^n (X_i-\bar X)(Y_i-\bar Y)}{n}}{\frac{\sum_{i}^n (X_i- \bar X)^2}{n}}&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;deriving alpha&lt;/p&gt;
&lt;p align=&quot;right&quot;&gt;(8)&lt;/p&gt;
&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;E(Y_i) = \alpha + \hat\beta E(X_i)&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;according to (4)&lt;/p&gt;
&lt;p align=&quot;right&quot;&gt;(9)&lt;/p&gt;
&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;\hat\alpha = \bar Y - \hat\beta E(X_i)&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;Generalize to multiple linear regression&lt;/p&gt;

&lt;h2 id=&quot;regression-through-the-origin&quot;&gt;Regression through the origin&lt;/h2&gt;

&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;\begin{bmatrix}
        x_{1} \\
        \vdots \\
        x_{n} \\
        \end{bmatrix}&lt;/script&gt;
&lt;script type=&quot;math/tex&quot;&gt;\begin{bmatrix}
        y_{1} \\
        \vdots \\
        y_{n} \\
        \end{bmatrix}&lt;/script&gt;
&lt;script type=&quot;math/tex&quot;&gt;x \in \mathbb R^2&lt;/script&gt;
&lt;script type=&quot;math/tex&quot;&gt;y \in \mathbb R^2&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;Consider regression through the origin, let’s minimize&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;||y-x\beta||^2 where \beta \in \mathbb R&lt;/script&gt;

&lt;p&gt;which can be expressed as&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;(y-x\beta)^T(y-x\beta)&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;y^Ty - 2y^Tx\beta+x^Tx\beta^2&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\frac{\partial}{\partial\beta} = -2y^T+2x^Tx\beta&lt;/script&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;% &lt;![CDATA[
\hat\beta = \frac{y^Tx}{x^Tx} = \frac{&lt;y,x&gt;}{&lt;x,x&gt;} %]]&gt;&lt;/script&gt;

&lt;p&gt;we can do a second derivative to test &lt;script type=&quot;math/tex&quot;&gt;\beta&lt;/script&gt;&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\frac{\partial^2}{2\beta^2} = 2x^Tx&gt;0&lt;/script&gt;

&lt;p&gt;The above formula could be further enhanced to be&lt;/p&gt;

&lt;script type=&quot;math/tex; mode=display&quot;&gt;\hat\beta = \frac{\sum\frac{y_{i}x_{i}}{n}}{\sum\frac{x_{i}x_{i}}{n}}&lt;/script&gt;

&lt;p&gt;Since we could center x and y, therefore &lt;script type=&quot;math/tex&quot;&gt;\bar x=\bar y=0&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;\hat\beta = \frac{\sum\frac{(y_{i}-\bar y)(x_{i}-\bar x)}{n}}{\sum\frac{(x_{i}-\bar x)^2}{n}}&lt;/script&gt;
&lt;script type=&quot;math/tex&quot;&gt;=\frac{\hat cov(y,x)}{\hat var (x)}&lt;/script&gt;
&lt;script type=&quot;math/tex&quot;&gt;=\hat cor (y,x)\frac{\hat sd (y)}{\hat sd(x)}&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;R code examples&lt;/p&gt;

&lt;pre&gt;
 &lt;code class=&quot;r&quot;&gt;
library(UsingR)
data(galton)
library(dplyr); library(ggplot2)
y &amp;lt;- galton$child
x &amp;lt;- galton$parent
beta1 &amp;lt;- cor(y,x) * sd(y) / sd(x)
beta0 &amp;lt;- mean(y) - beta1 * mean(x)
rbind(c(beta0,beta1), coef(lm(y~x)))
  &lt;/code&gt;
&lt;/pre&gt;

&lt;pre&gt;
&lt;code&gt;
    (Intercept)         x
[1,]    23.94153 0.6462906
[2,]    23.94153 0.6462906	
&lt;/code&gt;
&lt;/pre&gt;

&lt;h2 id=&quot;derivation-of-regression-formula-through-calculus&quot;&gt;derivation of regression formula through calculus&lt;/h2&gt;
&lt;p&gt;&lt;a href=&quot;http://seismo.berkeley.edu/~kirchner/eps_120/Toolkits/Toolkit_10.pdf&quot;&gt;adapted from Berkeley&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;script type=&quot;math/tex&quot;&gt;\sum_{i=1}^n (\bar X^2 - X_i\bar X ) = 0&lt;/script&gt; and &lt;script type=&quot;math/tex&quot;&gt;\sum_{i=1}^n (\bar X \bar Y - Y_i \bar X) = 0&lt;/script&gt;&lt;/p&gt;

&lt;p&gt;The following is simulation with R to prove the above terms are true.&lt;/p&gt;

&lt;pre&gt;
&lt;code class=&quot;r&quot;&gt;
x = c(3,2,4,5,3,2,4,3)
y = c(3,4,2,4,5,3,2,6)
sum((mean(d))^2-d*mean(d))
sum(mean(d)*mean(e)-e*mean(d))
&lt;/code&gt;
&lt;/pre&gt;

&lt;pre&gt;
&lt;code class=&quot;r&quot;&gt;
[1] 0
[1] 0
&lt;/code&gt;
&lt;/pre&gt;

</content>
 </entry>
 
 <entry>
   <title>block2 exam review</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/09/29/blcok-2-pathology-exam-review/"/>
   <updated>2015-09-29T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/09/29/blcok-2-pathology-exam-review</id>
   <content type="html">&lt;p&gt;Infectious Mononucleosis&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://library.med.utah.edu/WebPath/jpeg5/HEME045.jpg&quot;&gt;reed-sternberg cells&lt;/a&gt;
Reed-Sternberg cells, the hallmark of Hodgkin lymphoma, often are seen.&lt;/p&gt;

&lt;p&gt;(Monospot test)&lt;/p&gt;

&lt;!--break--&gt;

&lt;h2 id=&quot;keyword-with-pictures&quot;&gt;keyword with pictures&lt;/h2&gt;

&lt;p&gt;&lt;a href=&quot;https://www.med-ed.virginia.edu/courses/path/innes/wcd/lymphoma.cfm&quot;&gt;tingible body macrophages&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.medical-labs.net/wp-content/uploads/2014/03/Smudge-cells.jpg&quot;&gt;Smudge cell&lt;/a&gt;&lt;/p&gt;

&lt;h2 id=&quot;video-temp&quot;&gt;video temp&lt;/h2&gt;

&lt;iframe width=&quot;420&quot; height=&quot;315&quot; src=&quot;https://www.youtube.com/embed/it0lwR3Fls0&quot; frameborder=&quot;0&quot; allowfullscreen=&quot;&quot;&gt;&lt;/iframe&gt;

&lt;p&gt;acute nonspecific lymphadenitis&lt;/p&gt;

&lt;p&gt;Sinus Histiocytosis. This reactive pattern is characterized by distention and prominence of the lymphatic sinusoids, owing to a marked hypertrophy of lining endothelial cells and an infiltrate of macrophages (histiocytes). It often is encountered in lymph nodes draining cancers and may represent an immune response to the tumor or its products.&lt;/p&gt;

&lt;h2 id=&quot;laboratory-findings&quot;&gt;Laboratory Findings&lt;/h2&gt;

&lt;p&gt;ALL&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The white cell count is variable; it may be greater than 100,000 cells/μL but in about half of the patients is less than 10,000 cells/μL. Anemia is almost always present, and the platelet count usually is below 100,000/μL. Neutropenia is another common finding.&lt;/li&gt;
&lt;/ul&gt;

&lt;h2 id=&quot;genetic-features&quot;&gt;Genetic Features.&lt;/h2&gt;

&lt;p&gt;ALL&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;non-random karyotypic abnormalities.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;common in child- hood pre-B cell tumors are hyperdiploidy&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;a cryptic (12;21) translocation involving the TEL1 and AML1 genes&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;25% of adult pre-B cell tumors harbor the (9;22) translocation involving the ABL and BCR genes&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Chronic lymphocytic leukemia (CLL) and small lympho- cytic lymphoma (SLL)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;exceeds 4000 cells/μL, the patient is diagnosed with CLL; if it does not, a diagnosis of SLL is made.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CLL/SLL is much less common in Asia.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CLL is more common than SLL in the west.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;immune dysregulation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;accumulation of CLL/SLL cells suppresses normal B cell function(unclear mechanism), -&amp;gt; hypogammaglobulinemia&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;proliferation centers&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;chromosomal translocations are rare.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Approximately 50% of tumors have karyotypic abnormalities, the most common of which are trisomy 12 and deletions of chromosomes 11, 13, and 17.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Follicular l􏰎ym􏰁phom􏰁a&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Express BCL2&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;(14;18) translocation, fuses the BCL2 on chromosome 18 to IgH locus on chromosome 14.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;nodular proliferation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;predominant neoplastic cells are slightly larger than resting lymphocytes that have angular “cleaved” nuclei with prominent indentations and linear infoldings (Fig. 11–16, B). The nuclear chromatin is coarse and condensed, and nucleoli are indistinct. These small, cleaved cells are mixed with variable numbers of larger cells with vesicular chromatin, several nucleoli, and modest amounts of cytoplasm. In most tumors, large cells are a minor component of the &lt;strong&gt;overall cellularity&lt;/strong&gt;, mitoses are infrequent, and single necrotic cells (cells undergoing apoptosis) are not seen. These features help to distinguish follicular lymphoma from &lt;strong&gt;follicular hyperplasia&lt;/strong&gt;, in which mitoses and apoptosis are prominent.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Mantle Cell l􏰎ym􏰁phom􏰁a&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Mantle cell lymphoma is composed of cells resembling the naive B cells found in the mantle zones of normal lymphoid follicles.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;lymphomatoid polyposis. (11;14) translocation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;that fuses the cyclin D1 gene to the IgH locus.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;distinguished from CLL/SLL by the absence of proliferation centers and the presence of cyclin D1 protein.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Diffuse 􏰂large B􏰀 Cell 􏰂lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;most common type of lymphoma in adults, 50% of NHLs.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;About one third of tumors have rearrangements of the BCL6 gene,located on 3q27, and an even higher fraction of tumors have activating point mutations in the BCL6 promotor. resulted in increased levels of BCL6 protein. transcriptional regulator of gene expression in germinal center B cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Another 30% of tumors have a (14,18) translocation involving the BCL2 gene that results in overexpression of BCL2 protein. loss-of-function mutations in genes encoding histone acetyl transferases.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Aneuploidy and high S phase&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Burkitt lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;highly associated with translocations involving the MYC gene on chromosome 8. Most translocations fuse MYC with the IgH gene on chromo- some 14, but variant translocations involving the κ and λ light chain loci on chromosomes 2 and 22, respectively, are also observed.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;“starry sky” pattern.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;usually is present in the jaw or abdomen&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Muliple Myeloma and Related Plasma Cell Tumors&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The plasma cell neoplasms can be divided into six major variants: (1) multiple myeloma, (2) solitary plasmacytoma, (3) lymphoplasmacytic lymphoma, (4) heavy-chain disease, (5) primary amyloidosis, and (6) MGUS. The focus here is on the most important of these disorders, multiple myeloma and lymphoplasmacytic lymphoma, with a brief discussion of the other disorders.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Multiple Myeloma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;It principally involves the bone marrow and usually is associated with lytic lesions throughout the skeletal system.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;M protein produced by myeloma cells is IgG (60%), followed by IgA (20% to 25%); only rarely are IgM, IgD, or IgE M proteins observed. In the remaining 15% to 20% of cases, the plasma cells produce only κ or λ light chains.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;dysregulation of D cyclins is common in multiple myeloma.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;cytokine interleukin 6 (IL-6) support proliferation of myeloma&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Patients with myeloma are immunosuppressed.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;myeloma cells interfere with the function of normal plasma cells, leading to defects in antibody production.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Renal dysfunction is a common, serious problem in myeloma. Proteinaceous casts, formed in the distal convoluted tubules and the collecting ducts. 
The casts consist mostly of Bence Jones proteins along with variable amounts of complete immunoglobulins, Tamm-Horsfall protein, and albumin&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;hypercalcemia&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Solitary Plasmacytoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;involving the skeleton or the soft tissues&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;occur in the same locations as does multiple myeloma and usually progress to full-blown multiple myeloma over a period of 5 to 10 years&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;IL-LB and IL-6 stimulate RANK-ligand.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Monoclonal gammopathy of undetermined significance (MGUS)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;the term applied to an asymptomatic monoclonal gammopathy of undetermined significance(MGUS).&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;a precursor lesion with a tendency to evolve to multiple myeloma.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Lymphoplasmacytic Lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Waldenström macroglobulinemia&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Heavy-Chain Disease&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;IgA heavy-chain disease&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;a variant of extranodal marginal zone lymphoma&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Primary Amyloidosis&lt;/p&gt;

&lt;p&gt;Lymphoplasmacytic lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Waldenström macroglobulinemia, the size of macroglobulins cause the blood to become viscous.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Visual impairment&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Cryoglobulinemia&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;hodgkin-lymphoma&quot;&gt;Hodgkin lymphoma&lt;/h3&gt;

&lt;p&gt;Basic facts&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;“classic” RS cells are common in the &lt;strong&gt;mixed-cellularity subtype&lt;/strong&gt;, uncommon in the &lt;strong&gt;nodular sclerosis subtype&lt;/strong&gt;, and rare in the lymphocyte- predominance subtype; in these latter two subtypes, other characteristic RS cell variants predominate.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;https://classconnection.s3.amazonaws.com/261/flashcards/663261/png/nodular_sclerosing_hodgkins_lymphoma1319950956443.png&quot;&gt;Nodular sclerosis Hodgkin lymphoma&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;striking propensity to involve the lower cervical, supraclavicular, and mediastinal lymph nodes&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;http://library.med.utah.edu/WebPath/HEMEHTML/HEME110.html&quot;&gt;the lacunar cell&lt;/a&gt; which a single multilobate nucleus, multiple small nucleoli and abundant, pale-staining cytoplasm leaving the nucleus lying in an empty space (a lacune)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;also see &lt;strong&gt;Fig. 11–21&lt;/strong&gt; from text book.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;http://www.webpathology.com/slides-13/slides/LymphNode_HodgkinsLymphoma_MixedCellularity2.jpg&quot;&gt;Mixed-cellularity Hodgkin lymphoma&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;male predominance&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Classic RS cells, within a heterogeneous inflammatory infiltrate&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;small lymphocytes, eosinophils, plasma cells, and macrophages&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;https://upload.wikimedia.org/wikipedia/commons/5/55/Nodular_lymphocyte_predominant_Hodgkin_lymphoma_-_very_high_mag.jpg&quot;&gt;Lymphocyte-Predominance Hodgkin lymphoma&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;presence of lymphohistiocytic (L&amp;amp;H) variant RS cells that have a delicate multilobed, puffy nucleus resembling popped corn (“popcorn cell”)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;typical RS cells are rare&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;http://www.webpathology.com/slides-13/slides/Stomach_Lymphoma_MALToma1.jpg&quot;&gt;Extranodal Marginal Zone Lymphoma&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;tend to develop in the setting of autoimmune disorders(sjogren and Hashimoto thyroiditis) or chronic infection like H. pylori gastritis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;(11,18) translocation involving the MALT1 and IAP2 genes. it is predictive of the failure of gastric tumors to respond to antibiotic treatment.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.pathpedia.com/education/eatlas/histopathology/blood_cells/hairy_cell_leukemia_classic/hairy-cell-leukemia-%5B5-bl089-1%5D.jpeg?Width=600&amp;amp;Height=450&amp;amp;Format=4&quot;&gt;Hairy Cell Leukemia&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;activating mutations in the serine/threo- nine kinase BRAF&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;mainly in older males, infiltration of bone marrow and splenomegaly, Pancytopenia.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;rara lymph node involvement.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;pancytopenia and infections cause the major clinical problems.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;sensistive to chemotherapeutic agents, particularly purine nucleosides&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;http://media.tumblr.com/tumblr_mc01t2BA101r9he9m.jpg&quot;&gt;Mycosis Fungoides and Sézary Syndrome&lt;/a&gt; (also cutaneous T cell lymphoma)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Sézary syndrome is a clinical variant characterized by (1) a generalized exfoliative erythroderma (2) tumor cells( Sezary cells) in peripheral blood.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;circulating tumor cells present in 25 % of cases of plaque or tumor-phase mycosis fungoides.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;with mycosis fungoides, survival for many years, tumor-phase disease, visceral disease, or sezary syndrome, survival for 1 to 3 years.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;http://pathy.med.nagoya-u.ac.jp/atlas/img/t2/img0024.jpg&quot;&gt;Adult T Cell Leukemia/Lymphoma&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Neoplasm of CD4+ T cells, caused by a retrovirus, human T cell leukemia virus type 1 (HTLV-1).&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;some patients develop a chronic course resembling that of mycosis fungoides.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;short survival time (8 months)&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;&quot;&gt;Peripheral T Cell Lymphomas&lt;/a&gt;&lt;/p&gt;

&lt;h2 id=&quot;immunotyping&quot;&gt;immunotyping&lt;/h2&gt;

&lt;p&gt;ALL&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Terminal deoxynucleotidyl transferase (TdT), an enzyme specifically expressed in pre-B and pre-T cells, is present in more than 95% of cases. Further subtyping of ALL into pre-B and pre-T cell types relies on stains for lineage-specific markers, such as CD19 (B cell) and CD3 (T cell).&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;CLL/SLL&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;a neoplasm of mature B cells expressing the pan-B cell markers CD19, CD20, and CD23 and surface immunoglobulin heavy and light chains.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;tumor cells also express CD5&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Folicular Lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;These tumors express pan-B cell markers (CD19 and CD20), CD10, and BCL6, a transcription factor required for the generation of germinal center B cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Follicular lymphoma mainly occurs in adults older than 50 years of age and affects males and females equally.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Mantle cell lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The tumor cells usually coexpress surface IgM and IgD, pan-B cell antigens (CD19 and CD20), and CD5.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Diffuse 􏰂large B􏰀 Cell 􏰂lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;These mature B cell tumors express pan-B cell antigens, such as CD19 and CD20. Many also express surface IgM and/or IgG. Other antigens (e.g., CD10, BCL2) are variably expressed.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Burkitt lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;These B cell tumors express surface IgM, the pan-B cell markers CD19 and CD20, and the germinal center B cell markers CD10 and BCL6.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Hodgkin lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Typical RS cells and variants have a characteristic immunophenotype, as they express CD15 and CD30 and fail to express CD45(common leukocyte antigen)
The immunophenotype of lacunar variants is identical to that of other RS cells found in classical subtypes.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;L&amp;amp;H variants express B cell markers (e.g., CD20) and usually fail to express CD15 and CD30.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Hairy Cell leukemia&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The tumor cells express pan-B cell markers (CD19 and CD20), surface immunoglobulin, and CD11c and CD103; the latter two antigens are not present on most other B cell tumors, making them diagnostically useful.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Adult T Cell Leukemia/Lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;In addition to CD4, the leukemic cells express high levels of CD25, the IL-2 receptor α chain.&lt;/li&gt;
&lt;/ul&gt;

&lt;h2 id=&quot;prognosis&quot;&gt;Prognosis&lt;/h2&gt;

&lt;p&gt;ALL&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;2 to 10 years of age have the best prognosis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;worse outcomes includes male gender; age younger than 2 or older than 10 years; a high leukocyte count at diagnosis; and molecular evidence of persistent disease on day 28 of treatment.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;good prognosis - chromosomal aberrations (such as the t[12;21] and hyperdiploidy) are common in the 2- to 10-year age group&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;bad prognosis - rearrangements of the gene MLL or the presence of a BCR-ABL fusion gene, both associated with poor outcomes in B cell tumors, are most common in children younger than 2 years of age and adult&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;CLL/SLL&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;lymphadenopathy and hepatosplenomegaly are present in 50% to 60% of patients.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;half has Hypogammaglobulinemia (susceptibility to bacterial infections)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;autoimmune hemolytic anemia and thrombocytopenia (less common)&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Follicular lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;painless, generalized lymphadenopathy.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;not curable&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;therapy with cytotoxic drugs and rituximab (anti-CD20 antibody) is reserved for those with bulky, symptomatic disease.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Diffuse Large B Cell Lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Kaposi sarcoma herpesvirus (KSHV), also called human herpesvirus type 8 (HHV-8), is associated with rare primary effusion lym- phomas,&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Mediastinal large B cell lymphoma occurs most often in young women and shows a predilec- tion for spread to abdominal viscera and the central nervous system.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h2 id=&quot;cluster-of-differentiation&quot;&gt;cluster of differentiation&lt;/h2&gt;

&lt;p&gt;CD19 (B cell) 
CD3 (T cell).
pan-B cell markers CD19, CD20, and CD23
CLL/SLL and mantle cell lymphoma express CD5.
BCL6, a transcription factor required for the generation of germinal center B cells.
Typical RS cells express CD15 and CD30 and fail to express CD45 (common leukocyte antigen), B cell antigens, and T cell antigens
CD68 is a macrophage (histiocyte) marker
T-cell markers CD2 and CD7.
CLL/SLL has a distinctive immuno- phenotype. The tumor cells express the pan B-cell markers CD19 and CD20, as well as CD23 and CD5, the latter a marker that is found on a small subset of normal B cells.
Plasma cell tumors are positive for CD138, an adhesion molecule also known as syndecan-1, and often express CD56,
CD45 - leukocyte common antigen (LCA)
CD15 - expressed on granulocytes
Myeloperoxidase (MPO) – myeloid cells
CD34, CD117 - blast/stem cell marker
Hemoglobin - erythroid precursors
CD61, Factor VIII related antigen - megakaryocytic precursors&lt;/p&gt;

&lt;p&gt;Flow Cytometry
for AML
Myeloid markers:
Myeloperoxidase
CD13
CD33
CD117
Blast/stem cell marker:
CD34, CD117
Monocytic marker:
CD4, CD14, CD64
Megakaryocytic markers:
CD41
CD61
Erythroid markers:
CD71 (transferrin receptor)
glycophorin
Miscellaneous:
HLA-DR (early myeloid and B-cells)&lt;/p&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Hodgkin lymphoma&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Non-Hodgkin lymphoma&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;More often localized to a single More frequent involvement of axial group of nodes cervical, multiple peripheral nodes mediastinal, para-aortic&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;More frequent involvement of multiple peripheral nodes&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;orderly spread by contiguity Noncontiguous spread&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Noncontiguous spread&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Mesenteric nodes and Waldeyer Mesenteric nodes and Waldeyer ring rarely involved ring commonly involved&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Mesenteric nodes and Waldeyer ring commonly involved&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Extranodal involvement uncommon&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Extranodal involvement common&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h2 id=&quot;screenshot-list&quot;&gt;screenshot list&lt;/h2&gt;

&lt;h3 id=&quot;robbins-basic-pathology&quot;&gt;Robbins Basic Pathology&lt;/h3&gt;

&lt;p&gt;Figure 11–14 Morphologic comparison of lymphoblasts and myeloblasts. A, Lymphoblastic leukemia/lymphoma. Lymphoblasts have condensed nuclear chromatin, small nucleoli, and scant agranular cytoplasm. B, Acute myeloid leukemia. Myeloblasts have delicate nuclear chromatin, prominent nucleoli, and fine azurophilic cytoplasmic granules. 433&lt;/p&gt;

&lt;p&gt;Figure 11–13 Origin of lymphoid neoplasms. Stages of B and T cell differentiation from which specific lymphoid and tumors emerge are shown. BLB, pre-B lymphoblast; CLP, common lymphoid progenitor; DN, CD4−/CD8− (double-negative) pro-T cell; DP, CD4+/CD8+ (double-positive) pre-T cell; GC, germinal center B cell; MC, mantle zone B cell; MZ, marginal zone B cell; NBC, naive B cell; PC, plasma cell; PTC, peripheral T cell.&lt;/p&gt;

&lt;p&gt;Figure 11–15 Small lymphocytic lymphoma/chronic lymphocytic leukemia—lymph node. A, Low-power view shows diffuse effacement of nodal architecture. B, At high power, a majority of the tumor cells have the appearance of small, round lymphocytes. A “prolymphocyte,” a larger cell with a centrally placed nucleolus, also is present in this field (arrow).    2&lt;/p&gt;

&lt;p&gt;Figure 11–16 Follicular lymphoma—lymph node. A, Nodular aggregates of lymphoma cells are present throughout. B, At high magnification, small lymphoid cells with condensed chromatin and irregular or cleaved nuclear outlines (centrocytes) are mixed with a population of larger cells with nucleoli (centroblasts).  2&lt;/p&gt;

&lt;p&gt;Figure 11–17 Diffuse large B cell lymphoma—lymph node. The tumor cells have large nuclei with open chromatin and prominent nucleoli.   1&lt;/p&gt;

&lt;p&gt;Figure 11–18 Burkitt lymphoma—lymph node. The tumor cells and their nuclei are fairly uniform, giving a monotonous appearance. Note the high level of mitotic activity (arrowheads) and prominent nucleoli. The “starry sky” pattern produced by interspersed, lightly staining, normal macrophages is better appreciated at a lower magnification.&lt;/p&gt;

&lt;p&gt;Figure 11–19 Multiple myeloma. A, Radiograph of the skull, lateral view. The sharply punched-out bone defects are most obvious in the calvaria. B, Bone marrow aspirate. Normal marrow cells are largely replaced by plasma cells, including atypical forms with multiple nuclei, prominent nucleoli, and cytoplasmic droplets containing immunoglobulin.		2&lt;/p&gt;

&lt;p&gt;Figure 11–20 Hodgkin lymphoma—lymph node. A binucleate Reed- Sternberg cell with large, inclusion-like nucleoli and abundant cytoplasm is surrounded by lymphocytes, macrophages, and an eosinophil. 1&lt;/p&gt;

&lt;p&gt;Figure 11–21 Hodgkin lymphoma, nodular sclerosis type—lymph node. A distinctive “lacunar cell” with a multilobed nucleus containing many small nucleoli is seen lying within a clear space created by retraction of its cytoplasm. It is surrounded by lymphocytes.&lt;/p&gt;

&lt;p&gt;Figure 11–22 Hodgkin lymphoma, nodular sclerosis type—lymph node. A low-power view shows well-defined bands of pink, acellular collagen that have subdivided the tumor cells into nodules. 1&lt;/p&gt;

&lt;h3 id=&quot;basis-of-disease&quot;&gt;Basis of Disease&lt;/h3&gt;

&lt;p&gt;Figure 13-2  Reactive changes in neutrophils. Neutrophils containing coarse  purple  cytoplasmic  granules  (toxic  granulations)  and  blue  cytoplasmic  patches of dilated endoplasmic reticulum (Döhle bodies, arrow) are observed  in this peripheral blood smear prepared from a patient with bacterial sepsis.&lt;/p&gt;

</content>
 </entry>
 
 <entry>
   <title>Assignment2 Running Your First Program</title>
   <link href="http://lanyon.getpoole.com/data%20science/2015/09/27/pythonhomework/"/>
   <updated>2015-09-27T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/data%20science/2015/09/27/pythonhomework</id>
   <content type="html">&lt;h3 id=&quot;i-have-completed-all-the-requirments-for-this-assignment&quot;&gt;I have completed all the requirments for this assignment.&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;Please check the result &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/TempDataScienceCourse/Assignment2/index.html&quot;&gt;here&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;!--break--&gt;

&lt;ul&gt;
  &lt;li&gt;And download the python script &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/TempDataScienceCourse/Assignment2/firstPyProGapMinderAssign.py&quot;&gt;here&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;For codebook reference and other details, you can access my 1st assignment post &lt;a href=&quot;http://jizongl.github.io/data%20science/2015/09/19/Data-Management-Assignment1/&quot;&gt;here&lt;/a&gt;&lt;/p&gt;

&lt;h2 id=&quot;review-criterialess&quot;&gt;Review Criterialess&lt;/h2&gt;

&lt;p&gt;Your assessment will be based on the evidence you provide that you have completed all of the steps. When relevant, gradients in the scoring will be available to reward clarity (for example, you will get one point for submitting output that is not understandable, but two points if it is understandable). In all cases, consider that the peer assessing your work is likely not an expert in the field you are analyzing. You will be assessed equally on your description of your frequency distributions.&lt;/p&gt;

&lt;p&gt;Specific rubric items, and their point values, are as follows:&lt;/p&gt;

&lt;p&gt;Was the program output interpretable (i.e. organized and labeled)? (1 point)
Does the program output display three data managed variables as frequency tables? (1 point)
Did the summary describe the frequency distributions in terms of the values the variables take, how often they take them, the presence of missing data, etc.? (2 points)&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>web crawling with python</title>
   <link href="http://lanyon.getpoole.com/python/2015/09/26/webcrawling/"/>
   <updated>2015-09-26T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/python/2015/09/26/webcrawling</id>
   <content type="html">&lt;h3 id=&quot;goals&quot;&gt;goals&lt;/h3&gt;
&lt;p&gt;Say we are shopping on this&lt;a href=&quot;http://www.ebay.ie/sch/Clothes-Shoes-Accessories-/11450/i.html?_catref=1&quot;&gt;eBay&lt;/a&gt;, we see numerous items and vast number of pages. We really do not have time to sort through the item one by one right away, but however we want to make a file with a list of all the links to all the items from all the pages, with specified title. How do we achieve this? Python and a 2 libraries will make this easy.&lt;/p&gt;

&lt;!--break--&gt;

&lt;h3 id=&quot;preparatory&quot;&gt;preparatory&lt;/h3&gt;

&lt;p&gt;In order to perform this task, you need to install &lt;a href=&quot;https://www.python.org/downloads/&quot;&gt;python 3.4&lt;/a&gt; or newer, and I recommand an &lt;a href=&quot;https://en.wikipedia.org/wiki/Integrated_development_environment&quot;&gt;IDE&lt;/a&gt; like &lt;a href=&quot;https://www.jetbrains.com/pycharm/&quot;&gt;PyCharm&lt;/a&gt;. If you are not familiar with those basic, you should learn them first. You will also need to install 2 python libraries.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;http://www.crummy.com/software/BeautifulSoup/bs4/doc/&quot;&gt;BeautifulSoup&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;http://www.python-requests.org/en/latest/&quot;&gt;requests&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;what-is-beautifulsoup&quot;&gt;What is “BeautifulSoup”?&lt;/h3&gt;

&lt;p&gt;Beautiful Soup is a Python library for pulling data out of HTML and XML files. It works with your favorite parser to provide 
idiomatic ways of navigating, searching, and modifying the parse tree. It commonly saves programmers hours or days of work. &lt;a href=&quot;http://www.crummy.com/software/BeautifulSoup/bs4/doc/&quot;&gt;Click for detail&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-is-requests-&quot;&gt;What is “requests” ?&lt;/h3&gt;
&lt;p&gt;Requests is an Apache2 Licensed HTTP library, written in Python, for human beings. &lt;a href=&quot;http://www.python-requests.org/en/latest/&quot;&gt;click for detail&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;procedure&quot;&gt;procedure&lt;/h3&gt;

&lt;p&gt;start a new .py file then copy and paste the following code&lt;/p&gt;

&lt;p&gt;this chunk is for importing the libraries&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;import requests
from bs4 import BeautifulSoup&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;this chunk is for building a “while loop” to crawl through the source code of the site.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;def trade_spider(max_pages):      ## build a helper function to enact the task
    page = 1
    while page &amp;lt;= max_pages:      ## set dummy variables to represent page numbers to be queried.
        url = &amp;quot;http://www.ebay.ie/sch/Clothes-Shoes-Accessories-/11450/i.html?_catref=&amp;quot; + str(page)
        source_code = requests.get(url)     ## machine for getting info from url
        plain_text = source_code.text       ## machine for storing info from url
        soup = BeautifulSoup(plain_text)    ## machine for converting text into soup format.
        for link in soup.findAll(&amp;#39;a&amp;#39;,{&amp;#39;class&amp;#39;:&amp;#39;vip&amp;#39;}):    ##  look for an item that is unique for that link.
            href = &amp;quot;https://www.thenewboston.com&amp;quot; + link.get(&amp;#39;href&amp;#39;)   ## paste the main url to the specific sublinks
            title = link.string   ## include titles by using link.string
            print(href)           ## print href
            print(title)          ## print title
        page += 1

trade_spider(1)    ## print only 1 page&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;
</content>
 </entry>
 
 <entry>
   <title>Include Mathematical notation in your Jekyll blog</title>
   <link href="http://lanyon.getpoole.com/jekyll/2015/09/26/test/"/>
   <updated>2015-09-26T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/jekyll/2015/09/26/test</id>
   <content type="html">&lt;p&gt;In order to use Mathjax with Jekyll markdown, you need to make change to the followings in your &lt;strong&gt;_layouts&lt;/strong&gt; folder&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;page.html&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;post.html&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;config.yml&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;first add the following into both your &lt;em&gt;page.html&lt;/em&gt; and &lt;em&gt;post.html&lt;/em&gt; files, this is to load the MathJax javascript for your blog posts and pages. 
see &lt;a href=&quot;https://docs.mathjax.org/en/latest/configuration.html&quot;&gt;MathJax&lt;/a&gt; Document for further details.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;&amp;lt;script type=&amp;quot;text/javascript&amp;quot;
    src=&amp;quot;http://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML&amp;quot;&amp;gt;
&amp;lt;/script&amp;gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;then add the following into your config.yml file. This is to make redcarpet behave like GitHub Flavored Markdown. &lt;strong&gt;note&lt;/strong&gt;, simply adding redcarpet is not enough, you must include the extensions as follow. See &lt;a href=&quot;http://sholsinger.com/2014/03/jekyll-github-flavored-markdown&quot;&gt;this link&lt;/a&gt; for further details.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;# Make redcarpet behave like GitHub Flavored Markdown 
redcarpet: 
extensions: [&amp;quot;no_intra_emphasis&amp;quot;, &amp;quot;fenced_code_blocks&amp;quot;, &amp;quot;autolink&amp;quot;, &amp;quot;strikethrough&amp;quot;, &amp;quot;superscript&amp;quot;, &amp;quot;with_toc_data&amp;quot;]&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;When this is done, you can begin writing your blog with mathematical notations. I personally find this &lt;a href=&quot;http://meta.math.stackexchange.com/questions/5020/mathjax-basic-tutorial-and-quick-reference&quot;&gt;link from Mathematics meta&lt;/a&gt; very helpful, it list many useful notation scripts for reference.&lt;/p&gt;

&lt;p&gt;good luck.&lt;/p&gt;

</content>
 </entry>
 
 <entry>
   <title>Include Mathematical notation in your Jekyll blog</title>
   <link href="http://lanyon.getpoole.com/jekyll/2015/09/26/include-math-symbol-in-jekyllblog/"/>
   <updated>2015-09-26T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/jekyll/2015/09/26/include-math-symbol-in-jekyllblog</id>
   <content type="html">&lt;p&gt;In order to use Mathjax with Jekyll markdown, you need to make change to the followings in your &lt;strong&gt;_layouts&lt;/strong&gt; folder&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;page.html&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;post.html&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;config.yml&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;!--break--&gt;

&lt;p&gt;first add the following into both your &lt;em&gt;page.html&lt;/em&gt; and &lt;em&gt;post.html&lt;/em&gt; files, this is to load the MathJax javascript for your blog posts and pages. 
see &lt;a href=&quot;https://docs.mathjax.org/en/latest/configuration.html&quot;&gt;MathJax&lt;/a&gt; Document for further details.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;&amp;lt;script type=&amp;quot;text/javascript&amp;quot;
    src=&amp;quot;http://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML&amp;quot;&amp;gt;
&amp;lt;/script&amp;gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;then add the following into your config.yml file. This is to make redcarpet behave like GitHub Flavored Markdown. &lt;strong&gt;note&lt;/strong&gt;, simply adding redcarpet is not enough, you must include the extensions as follow. See &lt;a href=&quot;http://sholsinger.com/2014/03/jekyll-github-flavored-markdown&quot;&gt;this link&lt;/a&gt; for further details.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;# Make redcarpet behave like GitHub Flavored Markdown 
redcarpet: 
extensions: [&amp;quot;no_intra_emphasis&amp;quot;, &amp;quot;fenced_code_blocks&amp;quot;, &amp;quot;autolink&amp;quot;, &amp;quot;strikethrough&amp;quot;, &amp;quot;superscript&amp;quot;, &amp;quot;with_toc_data&amp;quot;]&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;When this is done, you can begin writing your blog with mathematical notations. I personally find this &lt;a href=&quot;http://meta.math.stackexchange.com/questions/5020/mathjax-basic-tutorial-and-quick-reference&quot;&gt;link from Mathematics meta&lt;/a&gt; very helpful, it list many useful notation scripts for reference.&lt;/p&gt;

&lt;p&gt;good luck.&lt;/p&gt;

</content>
 </entry>
 
 <entry>
   <title>ANOVA indepth study and resource</title>
   <link href="http://lanyon.getpoole.com/statistics/2015/09/24/ANOVA-study/"/>
   <updated>2015-09-24T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/statistics/2015/09/24/ANOVA-study</id>
   <content type="html">&lt;h2 id=&quot;r-resources&quot;&gt;R resources&lt;/h2&gt;

&lt;p&gt;1: Pretty straightforward &lt;a href=&quot;http://www.stat.columbia.edu/~martin/W2024/R3.pdf&quot;&gt;One Way ANOVA with R&lt;/a&gt;&lt;/p&gt;

&lt;h2 id=&quot;basic-and-advance-math-behind-anova&quot;&gt;basic and advance math behind ANOVA&lt;/h2&gt;

&lt;p&gt;1: The basic math behind &lt;a href=&quot;https://stat.ethz.ch/education/semesters/as2010/anova/ANOVA_how_to_do.pdf&quot;&gt;ANOVA&lt;/a&gt;&lt;/p&gt;

&lt;!--break--&gt;

&lt;h2 id=&quot;video-resources&quot;&gt;Video resources&lt;/h2&gt;

&lt;p&gt;One Way ANOVA with great explanation by Brandon Foltz. I encourage you to subscribe &lt;a href=&quot;https://www.youtube.com/channel/UCFrjdcImgcQVyFbK04MBEhA&quot;&gt;his channel&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;additional recource&lt;/p&gt;

&lt;p&gt;To understand the computational formula for Total sum of squares, see &lt;a href=&quot;http://www.psychology.emory.edu/clinical/mcdowell/PSYCH560/Basics/var.html&quot;&gt;Derivation of Computational Forumla for the Variance&lt;/a&gt;. Just pay attention to the numerator in the proof.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=R5KfO5HpzLE&quot;&gt;Complete Randomized Block Design&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;One way ANOVA&lt;/p&gt;

&lt;iframe width=&quot;560&quot; height=&quot;315&quot; src=&quot;https://www.youtube.com/embed/UrRYITjDOww&quot; frameborder=&quot;0&quot; allowfullscreen=&quot;&quot;&gt;&lt;/iframe&gt;

&lt;p&gt;Two way ANOVA&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/Statistics/PDF/ANOVAderivation.pdf&quot;&gt;Detail formula derivation&lt;/a&gt;
&lt;a href=&quot;/assets/Statistics/PDF/twoway.pdf&quot;&gt;TWO- AND THREE-FACTOR ANOVA&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;anova-table&quot;&gt;ANOVA table&lt;/h3&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Source&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;SS&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;df&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;MS&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;F&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;F table (5%)&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Regression&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;SSR&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;1&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;SSR&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;&lt;script type=&quot;math/tex&quot;&gt;F = \frac{Sd(Y)}{Sd(X)}\&lt;/script&gt;&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;qt(0.95,1,n-2)&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Error&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;SSE&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;n-2&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;&lt;script type=&quot;math/tex&quot;&gt;s^2 \ = \frac{SSE}{n-2}\&lt;/script&gt;&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;Total&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;SST&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;n-1&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt; &lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

</content>
 </entry>
 
 <entry>
   <title>Exploratory Data Analysis through correlation in R</title>
   <link href="http://lanyon.getpoole.com/statistics/2015/09/19/correlation-exploratory-data-analysis/"/>
   <updated>2015-09-19T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/statistics/2015/09/19/correlation-exploratory-data-analysis</id>
   <content type="html">&lt;p&gt;This post introduces the procedure of performing basic correlation and exploratory data analysis. I will go through the steps on how to do some basic data cleaning, such as removing NA values and factors elements. How to conduct correlation analysis and form a correlation matrix. Finally, we will test if the correlation matrix is accurate by doing a pair of random selected identifier. You will also learn how to do basic subsetting of data and locating values from specific rows or columns.&lt;/p&gt;

&lt;!--break--&gt;
&lt;p&gt;House keeping&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;fileUrl &lt;span class=&quot;o&quot;&gt;&amp;lt;-&lt;/span&gt; &lt;span class=&quot;s&quot;&gt;&amp;quot;https://raw.githubusercontent.com/JizongL/jizongL.github.io/master/assets/blog/Rblog/correlation/09192015correlation/gapminder.csv&amp;quot;&lt;/span&gt;

download.file&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;fileUrl&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; destfile &lt;span class=&quot;o&quot;&gt;=&lt;/span&gt; &lt;span class=&quot;s&quot;&gt;&amp;quot;./gapminder.csv&amp;quot;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; method &lt;span class=&quot;o&quot;&gt;=&lt;/span&gt; &lt;span class=&quot;s&quot;&gt;&amp;quot;curl&amp;quot;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;data &lt;span class=&quot;o&quot;&gt;=&lt;/span&gt; read.csv&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;s&quot;&gt;&amp;quot;./gapminder.csv&amp;quot;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;
data1 &lt;span class=&quot;o&quot;&gt;&amp;lt;-&lt;/span&gt; na.omit&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;data&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;
&lt;span class=&quot;kp&quot;&gt;names&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;data1&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;##  [1] &amp;quot;country&amp;quot;              &amp;quot;incomeperperson&amp;quot;      &amp;quot;alcconsumption&amp;quot;      
##  [4] &amp;quot;armedforcesrate&amp;quot;      &amp;quot;breastcancerper100th&amp;quot; &amp;quot;co2emissions&amp;quot;        
##  [7] &amp;quot;femaleemployrate&amp;quot;     &amp;quot;hivrate&amp;quot;              &amp;quot;internetuserate&amp;quot;     
## [10] &amp;quot;lifeexpectancy&amp;quot;       &amp;quot;oilperperson&amp;quot;         &amp;quot;polityscore&amp;quot;         
## [13] &amp;quot;relectricperperson&amp;quot;   &amp;quot;suicideper100th&amp;quot;      &amp;quot;employrate&amp;quot;          
## [16] &amp;quot;urbanrate&amp;quot;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h2 id=&quot;setting-a-correlation-matrixremove-the-country-because-it-is-a-factor&quot;&gt;setting a correlation matrix,remove the country because it is a factor&lt;/h2&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;&lt;span class=&quot;kn&quot;&gt;library&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;reshape&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;
data2 &lt;span class=&quot;o&quot;&gt;&amp;lt;-&lt;/span&gt; data1&lt;span class=&quot;p&quot;&gt;[,&lt;/span&gt; &lt;span class=&quot;m&quot;&gt;-1&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;]&lt;/span&gt;
&lt;span class=&quot;kp&quot;&gt;names&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;data2&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;##  [1] &amp;quot;incomeperperson&amp;quot;      &amp;quot;alcconsumption&amp;quot;       &amp;quot;armedforcesrate&amp;quot;     
##  [4] &amp;quot;breastcancerper100th&amp;quot; &amp;quot;co2emissions&amp;quot;         &amp;quot;femaleemployrate&amp;quot;    
##  [7] &amp;quot;hivrate&amp;quot;              &amp;quot;internetuserate&amp;quot;      &amp;quot;lifeexpectancy&amp;quot;      
## [10] &amp;quot;oilperperson&amp;quot;         &amp;quot;polityscore&amp;quot;          &amp;quot;relectricperperson&amp;quot;  
## [13] &amp;quot;suicideper100th&amp;quot;      &amp;quot;employrate&amp;quot;           &amp;quot;urbanrate&amp;quot;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;d_cor &lt;span class=&quot;o&quot;&gt;&amp;lt;-&lt;/span&gt; &lt;span class=&quot;kp&quot;&gt;as.matrix&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;cor&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;data2&lt;span class=&quot;p&quot;&gt;))&lt;/span&gt;
d_cor_melt &lt;span class=&quot;o&quot;&gt;&amp;lt;-&lt;/span&gt; arrange&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;melt&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;d_cor&lt;span class=&quot;p&quot;&gt;),&lt;/span&gt; &lt;span class=&quot;o&quot;&gt;-&lt;/span&gt;&lt;span class=&quot;kp&quot;&gt;abs&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;value&lt;span class=&quot;p&quot;&gt;))&lt;/span&gt;
d_cor_melt&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;##                       X1                   X2       value
## 1        incomeperperson      incomeperperson  1.00000000
## 2         alcconsumption       alcconsumption  1.00000000
## 3        armedforcesrate      armedforcesrate  1.00000000
## 4   breastcancerper100th breastcancerper100th  1.00000000
## 5           co2emissions         co2emissions  1.00000000
## 6       femaleemployrate     femaleemployrate  1.00000000
## 7                hivrate              hivrate  1.00000000
## 8        internetuserate      internetuserate  1.00000000
## 9         lifeexpectancy       lifeexpectancy  1.00000000
## 10          oilperperson         oilperperson  1.00000000
## 11           polityscore          polityscore  1.00000000
## 12    relectricperperson   relectricperperson  1.00000000
## 13       suicideper100th      suicideper100th  1.00000000
## 14            employrate           employrate  1.00000000
## 15             urbanrate            urbanrate  1.00000000
## 16       internetuserate      incomeperperson  0.82300755
## 17       incomeperperson      internetuserate  0.82300755
## 18    relectricperperson      incomeperperson  0.80803700
## 19       incomeperperson   relectricperperson  0.80803700
## 20        lifeexpectancy      internetuserate  0.76916000
## 21       internetuserate       lifeexpectancy  0.76916000
## 22            employrate     femaleemployrate  0.75953615
## 23      femaleemployrate           employrate  0.75953615
## 24       internetuserate breastcancerper100th  0.74545445
## 25  breastcancerper100th      internetuserate  0.74545445
## 26        lifeexpectancy      incomeperperson  0.73245246
## 27       incomeperperson       lifeexpectancy  0.73245246
## 28    relectricperperson      internetuserate  0.71730923
## 29       internetuserate   relectricperperson  0.71730923
## 30  breastcancerper100th      incomeperperson  0.70870641
## 31       incomeperperson breastcancerper100th  0.70870641
## 32    relectricperperson breastcancerper100th  0.64073128
## 33  breastcancerper100th   relectricperperson  0.64073128
## 34             urbanrate      internetuserate  0.62837641
## 35       internetuserate            urbanrate  0.62837641
## 36        lifeexpectancy breastcancerper100th  0.58024660
## 37  breastcancerper100th       lifeexpectancy  0.58024660
## 38          oilperperson      incomeperperson  0.56832284
## 39       incomeperperson         oilperperson  0.56832284
## 40             urbanrate       lifeexpectancy  0.55208423
## 41        lifeexpectancy            urbanrate  0.55208423
## 42             urbanrate      incomeperperson  0.55175903
## 43       incomeperperson            urbanrate  0.55175903
## 44    relectricperperson       lifeexpectancy  0.55158140
## 45        lifeexpectancy   relectricperperson  0.55158140
## 46        lifeexpectancy              hivrate -0.54250579
## 47               hivrate       lifeexpectancy -0.54250579
## 48           polityscore breastcancerper100th  0.53192879
## 49  breastcancerper100th          polityscore  0.53192879
## 50             urbanrate breastcancerper100th  0.53106183
## 51  breastcancerper100th            urbanrate  0.53106183
## 52          oilperperson      armedforcesrate  0.52487245
## 53       armedforcesrate         oilperperson  0.52487245
## 54             urbanrate         oilperperson  0.50197420
## 55          oilperperson            urbanrate  0.50197420
## 56       internetuserate       alcconsumption  0.46509554
## 57        alcconsumption      internetuserate  0.46509554
## 58             urbanrate   relectricperperson  0.46251094
## 59    relectricperperson            urbanrate  0.46251094
## 60       suicideper100th       alcconsumption  0.45834251
## 61        alcconsumption      suicideper100th  0.45834251
## 62          oilperperson      internetuserate  0.44164454
## 63       internetuserate         oilperperson  0.44164454
## 64          oilperperson       lifeexpectancy  0.42291135
## 65        lifeexpectancy         oilperperson  0.42291135
## 66           polityscore      internetuserate  0.38803948
## 67       internetuserate          polityscore  0.38803948
## 68       internetuserate     femaleemployrate  0.38696564
## 69      femaleemployrate      internetuserate  0.38696564
## 70  breastcancerper100th       alcconsumption  0.38654294
## 71        alcconsumption breastcancerper100th  0.38654294
## 72    relectricperperson         oilperperson  0.38628947
## 73          oilperperson   relectricperperson  0.38628947
## 74           polityscore      armedforcesrate -0.37492095
## 75       armedforcesrate          polityscore -0.37492095
## 76           polityscore       alcconsumption  0.35133104
## 77        alcconsumption          polityscore  0.35133104
## 78           polityscore       lifeexpectancy  0.34484282
## 79        lifeexpectancy          polityscore  0.34484282
## 80      femaleemployrate       alcconsumption  0.34438970
## 81        alcconsumption     femaleemployrate  0.34438970
## 82      femaleemployrate      incomeperperson  0.32125406
## 83       incomeperperson     femaleemployrate  0.32125406
## 84    relectricperperson     femaleemployrate  0.31856727
## 85      femaleemployrate   relectricperperson  0.31856727
## 86      femaleemployrate breastcancerper100th  0.31717282
## 87  breastcancerper100th     femaleemployrate  0.31717282
## 88           polityscore      incomeperperson  0.29850030
## 89       incomeperperson          polityscore  0.29850030
## 90          co2emissions      incomeperperson  0.29424580
## 91       incomeperperson         co2emissions  0.29424580
## 92      femaleemployrate      armedforcesrate -0.28084508
## 93       armedforcesrate     femaleemployrate -0.28084508
## 94            employrate      incomeperperson  0.28000427
## 95       incomeperperson           employrate  0.28000427
## 96          co2emissions breastcancerper100th  0.27716789
## 97  breastcancerper100th         co2emissions  0.27716789
## 98            employrate   relectricperperson  0.27427813
## 99    relectricperperson           employrate  0.27427813
## 100           employrate              hivrate -0.27211131
## 101              hivrate           employrate -0.27211131
## 102            urbanrate       alcconsumption  0.27009139
## 103       alcconsumption            urbanrate  0.27009139
## 104 breastcancerper100th      armedforcesrate -0.26847241
## 105      armedforcesrate breastcancerper100th -0.26847241
## 106       lifeexpectancy     femaleemployrate  0.26812937
## 107     femaleemployrate       lifeexpectancy  0.26812937
## 108   relectricperperson         co2emissions  0.26331050
## 109         co2emissions   relectricperperson  0.26331050
## 110         oilperperson breastcancerper100th  0.25901913
## 111 breastcancerper100th         oilperperson  0.25901913
## 112           employrate      armedforcesrate -0.24247267
## 113      armedforcesrate           employrate -0.24247267
## 114           employrate         oilperperson  0.23037392
## 115         oilperperson           employrate  0.23037392
## 116            urbanrate          polityscore  0.23014522
## 117          polityscore            urbanrate  0.23014522
## 118      internetuserate              hivrate -0.22652361
## 119              hivrate      internetuserate -0.22652361
## 120       lifeexpectancy       alcconsumption  0.21854104
## 121       alcconsumption       lifeexpectancy  0.21854104
## 122      suicideper100th       lifeexpectancy -0.21833549
## 123       lifeexpectancy      suicideper100th -0.21833549
## 124           employrate       lifeexpectancy  0.21033357
## 125       lifeexpectancy           employrate  0.21033357
## 126   relectricperperson          polityscore  0.20908881
## 127          polityscore   relectricperperson  0.20908881
## 128           employrate      internetuserate  0.19051364
## 129      internetuserate           employrate  0.19051364
## 130      suicideper100th     femaleemployrate  0.18778683
## 131     femaleemployrate      suicideper100th  0.18778683
## 132           employrate          polityscore -0.18711922
## 133          polityscore           employrate -0.18711922
## 134            urbanrate     femaleemployrate  0.17822695
## 135     femaleemployrate            urbanrate  0.17822695
## 136     femaleemployrate         co2emissions  0.17238628
## 137         co2emissions     femaleemployrate  0.17238628
## 138   relectricperperson      armedforcesrate -0.16898440
## 139      armedforcesrate   relectricperperson -0.16898440
## 140         oilperperson     femaleemployrate  0.15953621
## 141     femaleemployrate         oilperperson  0.15953621
## 142           employrate       alcconsumption -0.14626247
## 143       alcconsumption           employrate -0.14626247
## 144      internetuserate         co2emissions  0.14309235
## 145         co2emissions      internetuserate  0.14309235
## 146       alcconsumption      incomeperperson  0.13723859
## 147      incomeperperson       alcconsumption  0.13723859
## 148              hivrate     femaleemployrate -0.13357235
## 149     femaleemployrate              hivrate -0.13357235
## 150         co2emissions      armedforcesrate -0.13055412
## 151      armedforcesrate         co2emissions -0.13055412
## 152            urbanrate      armedforcesrate  0.12937141
## 153      armedforcesrate            urbanrate  0.12937141
## 154            urbanrate           employrate  0.12523556
## 155           employrate            urbanrate  0.12523556
## 156   relectricperperson       alcconsumption  0.12292871
## 157       alcconsumption   relectricperperson  0.12292871
## 158              hivrate      armedforcesrate -0.12215132
## 159      armedforcesrate              hivrate -0.12215132
## 160           employrate         co2emissions  0.11792695
## 161         co2emissions           employrate  0.11792695
## 162      internetuserate      armedforcesrate -0.11644553
## 163      armedforcesrate      internetuserate -0.11644553
## 164              hivrate      incomeperperson -0.11500444
## 165      incomeperperson              hivrate -0.11500444
## 166            urbanrate      suicideper100th -0.11497281
## 167      suicideper100th            urbanrate -0.11497281
## 168      armedforcesrate       alcconsumption -0.10485225
## 169       alcconsumption      armedforcesrate -0.10485225
## 170          polityscore         oilperperson -0.10420992
## 171         oilperperson          polityscore -0.10420992
## 172       lifeexpectancy         co2emissions  0.10399038
## 173         co2emissions       lifeexpectancy  0.10399038
## 174         oilperperson       alcconsumption -0.10193469
## 175       alcconsumption         oilperperson -0.10193469
## 176      suicideper100th              hivrate  0.10098194
## 177              hivrate      suicideper100th  0.10098194
## 178              hivrate breastcancerper100th -0.08969369
## 179 breastcancerper100th              hivrate -0.08969369
## 180      armedforcesrate      incomeperperson -0.08854208
## 181      incomeperperson      armedforcesrate -0.08854208
## 182            urbanrate         co2emissions  0.08796496
## 183         co2emissions            urbanrate  0.08796496
## 184         oilperperson         co2emissions  0.08526168
## 185         co2emissions         oilperperson  0.08526168
## 186          polityscore              hivrate  0.07565524
## 187              hivrate          polityscore  0.07565524
## 188         oilperperson              hivrate -0.07406404
## 189              hivrate         oilperperson -0.07406404
## 190          polityscore         co2emissions  0.07308423
## 191         co2emissions          polityscore  0.07308423
## 192      suicideper100th      internetuserate  0.07286536
## 193      internetuserate      suicideper100th  0.07286536
## 194   relectricperperson              hivrate -0.06584784
## 195              hivrate   relectricperperson -0.06584784
## 196            urbanrate              hivrate -0.06106555
## 197              hivrate            urbanrate -0.06106555
## 198           employrate breastcancerper100th  0.06002107
## 199 breastcancerper100th           employrate  0.06002107
## 200      suicideper100th         oilperperson -0.05819842
## 201         oilperperson      suicideper100th -0.05819842
## 202      suicideper100th      incomeperperson -0.05759281
## 203      incomeperperson      suicideper100th -0.05759281
## 204          polityscore     femaleemployrate  0.04549128
## 205     femaleemployrate          polityscore  0.04549128
## 206           employrate      suicideper100th -0.04075238
## 207      suicideper100th           employrate -0.04075238
## 208      suicideper100th   relectricperperson -0.03981433
## 209   relectricperperson      suicideper100th -0.03981433
## 210      suicideper100th      armedforcesrate -0.03859743
## 211      armedforcesrate      suicideper100th -0.03859743
## 212              hivrate       alcconsumption  0.03580681
## 213       alcconsumption              hivrate  0.03580681
## 214      suicideper100th breastcancerper100th -0.03450769
## 215 breastcancerper100th      suicideper100th -0.03450769
## 216      suicideper100th          polityscore  0.03262108
## 217          polityscore      suicideper100th  0.03262108
## 218      suicideper100th         co2emissions  0.03116024
## 219         co2emissions      suicideper100th  0.03116024
## 220       lifeexpectancy      armedforcesrate  0.02364780
## 221      armedforcesrate       lifeexpectancy  0.02364780
## 222         co2emissions       alcconsumption  0.01656709
## 223       alcconsumption         co2emissions  0.01656709
## 224              hivrate         co2emissions  0.01004384
## 225         co2emissions              hivrate  0.01004384&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h2 id=&quot;looking-for-a-specific-values-from-columns-and-build-index&quot;&gt;looking for a specific values from columns and build index&lt;/h2&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;index&lt;span class=&quot;o&quot;&gt;=&lt;/span&gt;&lt;span class=&quot;kp&quot;&gt;which&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;kp&quot;&gt;grepl&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;s&quot;&gt;&amp;quot;polityscore&amp;quot;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; d_cor_melt&lt;span class=&quot;o&quot;&gt;$&lt;/span&gt;X1&lt;span class=&quot;p&quot;&gt;))&lt;/span&gt;
index2&lt;span class=&quot;o&quot;&gt;=&lt;/span&gt; &lt;span class=&quot;kp&quot;&gt;which&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;kp&quot;&gt;grepl&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;s&quot;&gt;&amp;quot;urbanrate&amp;quot;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt;d_cor_melt&lt;span class=&quot;o&quot;&gt;$&lt;/span&gt;X2&lt;span class=&quot;p&quot;&gt;))&lt;/span&gt;
index&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;##  [1]  11  48  66  74  76  78  88 117 127 133 170 186 190 204 217&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;index2&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;##  [1]  15  35  41  43  51  55  59 103 117 135 153 155 167 183 197&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h2 id=&quot;find-common-elements-by-intersect&quot;&gt;find common elements by intersect()&lt;/h2&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;targetrow &lt;span class=&quot;o&quot;&gt;&amp;lt;-&lt;/span&gt; &lt;span class=&quot;kp&quot;&gt;intersect&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;index&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt;index2&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;
targetrow&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;## [1] 117&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h2 id=&quot;locate-the-target&quot;&gt;locate the target&lt;/h2&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;d_cor_melt&lt;span class=&quot;p&quot;&gt;[&lt;/span&gt;targetrow&lt;span class=&quot;p&quot;&gt;,]&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;##              X1        X2     value
## 117 polityscore urbanrate 0.2301452&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;To get those corrleations which are above 0.5 and less than 1.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;d_cor_melt&lt;span class=&quot;p&quot;&gt;[&lt;/span&gt;d_cor_melt&lt;span class=&quot;o&quot;&gt;$&lt;/span&gt;value&lt;span class=&quot;o&quot;&gt;&amp;gt;=&lt;/span&gt;&lt;span class=&quot;m&quot;&gt;0.5&lt;/span&gt; &lt;span class=&quot;o&quot;&gt;&amp;amp;&lt;/span&gt; d_cor_melt&lt;span class=&quot;o&quot;&gt;$&lt;/span&gt;value&lt;span class=&quot;o&quot;&gt;&amp;lt;&lt;/span&gt;&lt;span class=&quot;m&quot;&gt;1&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,])&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-text&quot; data-lang=&quot;text&quot;&gt;##                      X1                   X2     value
## 16      internetuserate      incomeperperson 0.8230076
## 17      incomeperperson      internetuserate 0.8230076
## 18   relectricperperson      incomeperperson 0.8080370
## 19      incomeperperson   relectricperperson 0.8080370
## 20       lifeexpectancy      internetuserate 0.7691600
## 21      internetuserate       lifeexpectancy 0.7691600
## 22           employrate     femaleemployrate 0.7595362
## 23     femaleemployrate           employrate 0.7595362
## 24      internetuserate breastcancerper100th 0.7454545
## 25 breastcancerper100th      internetuserate 0.7454545
## 26       lifeexpectancy      incomeperperson 0.7324525
## 27      incomeperperson       lifeexpectancy 0.7324525
## 28   relectricperperson      internetuserate 0.7173092
## 29      internetuserate   relectricperperson 0.7173092
## 30 breastcancerper100th      incomeperperson 0.7087064
## 31      incomeperperson breastcancerper100th 0.7087064
## 32   relectricperperson breastcancerper100th 0.6407313
## 33 breastcancerper100th   relectricperperson 0.6407313
## 34            urbanrate      internetuserate 0.6283764
## 35      internetuserate            urbanrate 0.6283764
## 36       lifeexpectancy breastcancerper100th 0.5802466
## 37 breastcancerper100th       lifeexpectancy 0.5802466
## 38         oilperperson      incomeperperson 0.5683228
## 39      incomeperperson         oilperperson 0.5683228
## 40            urbanrate       lifeexpectancy 0.5520842
## 41       lifeexpectancy            urbanrate 0.5520842
## 42            urbanrate      incomeperperson 0.5517590
## 43      incomeperperson            urbanrate 0.5517590
## 44   relectricperperson       lifeexpectancy 0.5515814
## 45       lifeexpectancy   relectricperperson 0.5515814
## 48          polityscore breastcancerper100th 0.5319288
## 49 breastcancerper100th          polityscore 0.5319288
## 50            urbanrate breastcancerper100th 0.5310618
## 51 breastcancerper100th            urbanrate 0.5310618
## 52         oilperperson      armedforcesrate 0.5248724
## 53      armedforcesrate         oilperperson 0.5248724
## 54            urbanrate         oilperperson 0.5019742
## 55         oilperperson            urbanrate 0.5019742&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

</content>
 </entry>
 
 <entry>
   <title>Assignment 1 Getting Your Research Project Started</title>
   <link href="http://lanyon.getpoole.com/data%20science/2015/09/19/Data-Management-Assignment1/"/>
   <updated>2015-09-19T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/data%20science/2015/09/19/Data-Management-Assignment1</id>
   <content type="html">&lt;h3 id=&quot;brief-summary-and-introduction&quot;&gt;Brief summary and introduction&lt;/h3&gt;

&lt;p&gt;My name is &lt;a href=&quot;https://www.linkedin.com/in/jizongliang&quot;&gt;Jizong Liang&lt;/a&gt; and you can call me &lt;a href=&quot;http://jizongl.github.io/&quot;&gt;TmmGeek&lt;/a&gt;, I am a PhD student in Pathology at the cancer research Institute at &lt;a href=&quot;https://www.umc.edu/&quot;&gt;University of Mississippi Medical Center&lt;/a&gt;, In addition, I am also a computer geek and extremely interested in statistical analysis and Data Science. As a result, anything related to diseases and data analysis would be my areas of interests.&lt;/p&gt;

&lt;!--break--&gt;

&lt;p&gt;Recently, I have done indepth study in HIV and AIDS and have developed a thorougly understanding of its pathology and molecular mechanism and I am quite facinated with this devilish disease which is by far one of the most clever viruses known to us. and as a biomedical scientist, I believe that my priority is to focus on bringing better health care to people and conduct innovative research to improve disease treatments, and I believe in the near future, the mystery of HIV and AIDS will be resolved and million of people will have their second chance to relive their life.&lt;/p&gt;

&lt;p&gt;Nevertheless, diseases, especially HIV and AIDS, could also be studied at different angles other than just biomedical research, such as their effects and ramifications woven into all levels of social strata, their influences on human behaviors in different cultures, economic status, how they may influence life expectancy in different countries, how different cultural practices would either promote or discourage them. All these different domains mentioned above along with numerous others, as I am strongly convinced, would provide unexpected additional evidence for scientists, medical professionals, social workers and many other related personnels to work together in order to understand disease epidemiology better and develop more effective personalized treatment plans.&lt;/p&gt;

&lt;p&gt;Here I want to say thank you to &lt;a href=&quot;https://www.coursera.org/&quot;&gt;Coursera&lt;/a&gt; which provides this amazing course &lt;a href=&quot;https://www.coursera.org/learn/data-visualization&quot;&gt;Data Management and Visualization&lt;/a&gt; by &lt;a href=&quot;http://www.wesleyan.edu/&quot;&gt;Wesleyan University&lt;/a&gt;. I am motivated by the structure of this course which gives me freedom and a mature guideline to venture into the unknowns of Data Science. The following contents are my effort to complete &lt;a href=&quot;https://www.coursera.org/learn/data-visualization/peer/ntBWz/getting-your-research-project-started&quot;&gt;the step by step guidelines&lt;/a&gt; to get my project started.&lt;/p&gt;

&lt;ul id=&quot;markdown-toc&quot;&gt;
  &lt;li&gt;&lt;a href=&quot;#brief-summary-and-introduction&quot; id=&quot;markdown-toc-brief-summary-and-introduction&quot;&gt;Brief summary and introduction&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#choose-a-data-set-that-you-would-like-to-work-with&quot; id=&quot;markdown-toc-choose-a-data-set-that-you-would-like-to-work-with&quot;&gt;1: Choose a data set that you would like to work with.&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#identify-a-specific-topic-of-interest&quot; id=&quot;markdown-toc-identify-a-specific-topic-of-interest&quot;&gt;2: identify a specific topic of interest&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#codebook&quot; id=&quot;markdown-toc-codebook&quot;&gt;3: Codebook&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#identify-a-second-topic-that-you-would-like-to-explore-in-terms-of-its-association-with-your-original-topic&quot; id=&quot;markdown-toc-identify-a-second-topic-that-you-would-like-to-explore-in-terms-of-its-association-with-your-original-topic&quot;&gt;4: Identify a second topic that you would like to explore in terms of its association with your original topic.&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#add-questionsitemsvariables-documenting-this-second-topic-to-your-personal-codebook&quot; id=&quot;markdown-toc-add-questionsitemsvariables-documenting-this-second-topic-to-your-personal-codebook&quot;&gt;5: Add questions/items/variables documenting this second topic to your personal codebook.&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#perform-a-literature-review-to-see-what-research-has-been-previously-done-on-this-topic&quot; id=&quot;markdown-toc-perform-a-literature-review-to-see-what-research-has-been-previously-done-on-this-topic&quot;&gt;6: Perform a literature review to see what research has been previously done on this topic.&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#hypothesis&quot; id=&quot;markdown-toc-hypothesis&quot;&gt;7: Hypothesis&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#reference&quot; id=&quot;markdown-toc-reference&quot;&gt;Reference&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#recourses&quot; id=&quot;markdown-toc-recourses&quot;&gt;Recourses&lt;/a&gt;&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;#review-criteria&quot; id=&quot;markdown-toc-review-criteria&quot;&gt;Review Criteria&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;choose-a-data-set-that-you-would-like-to-work-with&quot;&gt;1: Choose a data set that you would like to work with.&lt;/h3&gt;
&lt;p&gt;After looking through all the datasets available, I have chosen the &lt;a href=&quot;https://d396qusza40orc.cloudfront.net/phoenixassets/data-management-visualization/GapMinder%20Codebook%20.pdf&quot;&gt;Gapminder&lt;/a&gt; dataset because it is closely related to my areas of interests. The dataset is availble &lt;a href=&quot;https://raw.githubusercontent.com/JizongL/jizongL.github.io/master/assets/blog/Rblog/correlation/09192015correlation/gapminder.csv&quot;&gt;here&lt;/a&gt;.&lt;/p&gt;

&lt;h3 id=&quot;identify-a-specific-topic-of-interest&quot;&gt;2: identify a specific topic of interest&lt;/h3&gt;

&lt;p&gt;After studying briefly on the Gapminder dataset, I found that there is an &lt;strong&gt;HIV&lt;/strong&gt; identifier that caught my attention, along with a few others related identifers that I am interested in, such as &lt;em&gt;life expectancy&lt;/em&gt;, &lt;em&gt;urban rate&lt;/em&gt;, &lt;em&gt;Internet user rate&lt;/em&gt; etc.(please see Codebook for further details)&lt;/p&gt;

&lt;p&gt;Intuitively, I would ask the question wheather &lt;strong&gt;HIV Prevalence&lt;/strong&gt; might more or less correlate with &lt;strong&gt;urbanization&lt;/strong&gt;, at least in the developed countries. Or perhaps there might be different patterns of HIV rate between developed and developing countries. Furthermore, would the patterns be different between the western and eastern worlds?&lt;/p&gt;

&lt;p&gt;Besides, I personally incline to believe that the &lt;strong&gt;Internet&lt;/strong&gt; might play a critical role in influencing people’s awareness on HIV infection and prevention. Or would the many misleading information people could have access from the web actually contribute to people making less informed decisions about their sexual orientation or behaviors, or rather not? I am excited to experiment on the data deeper as the course proceeds and to extract more insightful evidence to support my hypothesis and I believe that the journey will be fun.&lt;/p&gt;

&lt;p&gt;variables available from the &lt;a href=&quot;https://d396qusza40orc.cloudfront.net/phoenixassets/data-management-visualization/GapMinder%20Codebook%20.pdf&quot;&gt;Gapminder&lt;/a&gt; dataset for my primary topic are as followed.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;HIVrate&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;urbanrate&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Internetuserate&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;codebook&quot;&gt;3: Codebook&lt;/h3&gt;

&lt;p&gt;&lt;strong&gt;Note:&lt;/strong&gt; This extracted Codebook includes all the variables details for both my primary and secondary topics&lt;/p&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th&gt;Variable Name&lt;/th&gt;
      &lt;th style=&quot;text-align: center&quot;&gt;Description of Indicator&lt;/th&gt;
      &lt;th style=&quot;text-align: right&quot;&gt;Main Source&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;&lt;strong&gt;incomeperperson&lt;/strong&gt;&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;2010 Gross Domestic Product per capita in constant 2000 US$. The inflation but not the differences in the cost of living between countries has been taken into account.&lt;/td&gt;
      &lt;td style=&quot;text-align: right&quot;&gt;World Bank Work Development Indicators&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;&lt;strong&gt;lifeexpectancy&lt;/strong&gt;&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;2011 life expectancy at birth (years) The average number of years a newborn child would live if current mortality patterns were to stay the same.&lt;/td&gt;
      &lt;td style=&quot;text-align: right&quot;&gt;&lt;strong&gt;I&lt;/strong&gt; Human Mortality Database &lt;strong&gt;II&lt;/strong&gt; World Population Prospects &lt;strong&gt;III&lt;/strong&gt;* Publications and files by history prof. James C Riley &lt;strong&gt;IV&lt;/strong&gt; Human Lifetable Database&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;&lt;strong&gt;relectricperperson&lt;/strong&gt;&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;2008 residential electricity consumption, per person (kWh) The amount of residential electricity consumption per person during the given year, counted in kilowatt-hours (kWh).&lt;/td&gt;
      &lt;td style=&quot;text-align: right&quot;&gt;International Energy Agency&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;&lt;strong&gt;urbanrate&lt;/strong&gt;&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;2008 urban population (% of total) Urban population refers to people living in urban areas as defined by national statistical offices (calculated using World Bank population estimates and urban ratios from the United Nations World UrbanizationProspects).&lt;/td&gt;
      &lt;td style=&quot;text-align: right&quot;&gt;World Bank&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;&lt;strong&gt;Internetuserate&lt;/strong&gt;&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;2010 Internet users (per 100 people) Internet users are people with access to the worldwide network.&lt;/td&gt;
      &lt;td style=&quot;text-align: right&quot;&gt;World Bank&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;&lt;strong&gt;HIVrate&lt;/strong&gt;&lt;/td&gt;
      &lt;td style=&quot;text-align: center&quot;&gt;2009 estimated HIV Prevalence % - (Ages 15-49) Estimated number of people living with HIV per 100 population of age group 15-49.&lt;/td&gt;
      &lt;td style=&quot;text-align: right&quot;&gt;UNAIDS online database&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;h3 id=&quot;identify-a-second-topic-that-you-would-like-to-explore-in-terms-of-its-association-with-your-original-topic&quot;&gt;4: Identify a second topic that you would like to explore in terms of its association with your original topic.&lt;/h3&gt;

&lt;p&gt;After looking at the &lt;a href=&quot;https://d396qusza40orc.cloudfront.net/phoenixassets/data-management-visualization/GapMinder%20Codebook%20.pdf&quot;&gt;Gapminder&lt;/a&gt; Codebook again, I also think of the possiblity to explore the possible relationship between Socioeconomic status and life expectancy. My question to ask is that does income rate necessarily improve life expectancy in general, or the otherwise? As when people become more fiancially confident, they may or may not take better care of themselves. Of course, I would not jump into any conclusion until I could analytically draw more insight from the data along this course. It should be exciting.&lt;/p&gt;

&lt;h3 id=&quot;add-questionsitemsvariables-documenting-this-second-topic-to-your-personal-codebook&quot;&gt;5: Add questions/items/variables documenting this second topic to your personal codebook.&lt;/h3&gt;

&lt;p&gt;Please see Codebook above.&lt;/p&gt;

&lt;h3 id=&quot;perform-a-literature-review-to-see-what-research-has-been-previously-done-on-this-topic&quot;&gt;6: Perform a literature review to see what research has been previously done on this topic.&lt;/h3&gt;

&lt;p&gt;1: HIV/AIDs and Urbanization&lt;/p&gt;

&lt;p&gt;It is well known that levels of HIV prevalence tend to be appreciably higher inurban areas&lt;sup&gt;&lt;a href=&quot;http://onlinelibrary.wiley.com/doi/10.1111/j.1728-4457.2003.00427.x/abstract&quot;&gt;1&lt;/a&gt;&lt;/sup&gt;(&lt;em&gt;Tim Dyson Et.al&lt;/em&gt;). Once in a city, the newly introduced infection would have the opportunity to spread locally among the population and could also spread further along highways and inter- urban transport routes and by airplane. HIV has been, and in Asia is becoming, the best known beneficiary of this dynamic, but many other diseases, such as dengue, stand to benefit.&lt;sup&gt;&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2626828/pdf/8903148.pdf&quot;&gt;2&lt;/a&gt;&lt;/sup&gt;(&lt;em&gt;Stephen S. Morse et.al 1995&lt;/em&gt;)&lt;/p&gt;

&lt;p&gt;Netertheless, we must not easily jump into conclusion based on one side of the story. To look deeper, we must ask how should we effectively discern if there is bias in HIV/AIDS surveillance data collection practice both nationally and globally. For instance, Given the absence of recent and regularly updated census data for many countries in sub-Saharan Africa, global statistics on urban- ization on the subcontinent are often speculative and not particularly reliable&lt;sup&gt;&lt;a href=&quot;http://eau.sagepub.com/content/18/1/155.full.pdf+html&quot;&gt;3&lt;/a&gt;&lt;/sup&gt;(MIRJAM VAN DONK et.al,2015).&lt;/p&gt;

&lt;p&gt;In fact, global HIV/AIDS data are continuously adjusted in response to better HIV surveillance systems and improved software to model the HIV/AIDS epidemic.(6) Global HIV/AIDS data also tend to reflect an implicit urban bias, as sentinel surveillance sites are generally located in urban areas and in larger settle- ments in rural districts. For this reason UNAIDS prefers to use the term “outside major urban areas”, rather than “rural areas”. This distinction is again based on country distinctions, which complicates comparisons between countries.&lt;sup&gt;&lt;a href=&quot;http://eau.sagepub.com/content/18/1/155.full.pdf+html&quot;&gt;3&lt;/a&gt;&lt;/sup&gt;(MIRJAM VAN DONK et.al,2015).&lt;/p&gt;

&lt;p&gt;Though the true trace of HIV/AIDs development in both Urban and Rural areas around the world may indeed be too challenge to detect, we may argue that there could be specific factors that make the HIV/AIDs patterns of HIV/AIDs development distinctly different between Urban and Rural. For example, a Cross-sectional survey data were gathered from 995 respondents in northwest Ethiopia. The findings indicated that urban residents’ concern about and information needs on HIV/AIDS was greater than that of the rural populace. Urban and rural residents were also found to be significantly different in their preferences for specific types of HIV/AIDS-related information. While rurality was found to be associated with a preference for basic HIV transmission and prevention information, urbanity was associated with a preference for information on HIV/AIDS-related care and support&lt;sup&gt;&lt;a href=&quot;http://idv.sagepub.com/content/29/4/323.full.pdf+html?cited-by=yes&amp;amp;legid=spidv;29/4/323#cited-by&quot;&gt;4&lt;/a&gt;&lt;/sup&gt;(Mesfin Awoke Bekalu,2013)&lt;/p&gt;

&lt;p&gt;In 1990, James W.Curran and colleagues mentioned that there are three major epidemiological patterns of HIV infection have been previously described in the world. In pattern I, which occurs mainly in North America, Europe, and Australia, most cases occur in homosexual men and injecting drug users and their sex partners and offspring. Pattern II occurs mainly in sub-Saharan Africa, and increasingly in other parts of the world. Here most people acquire their infection heterosexually, perinatally from their mother, or through blood transfusion. Finally, pattern III includes the remaining countries where HIV was very recently introduced and where small numbers of cases have been infected in various ways.&lt;sup&gt;&lt;a href=&quot;http://journals.lwwcom/jaids/Citation/1990/04000/The_Global_Epidemiology_of_HIV_Infection_.16.aspx&quot;&gt;6&lt;/a&gt;&lt;/sup&gt;(Barney Cohen,2005)&lt;/p&gt;

&lt;p&gt;These findings again suggest the different patterns of HIV/AIDs development between Urban and Rural areas, moreover, the course of HIV/AIDs epidemic may have been further complicated by other factor such as the internet. It may influence people’s sexual behaviors and in term indirectly contribute to the development of HIV/AIDs. For example, Mary McFarlane and colleagues found that Young adults who seek sex on the Internet report substantially different sexual behavior patterns than young adults who do not seek sex on the Internet. Young adults with online partners reported sexual behaviors similar to older respondents who used the Internet to find sex partners; however, older respondents were more likely than young adults to have been tested for sexually transmitted diseases and HIV.&lt;sup&gt;&lt;a href=&quot;http://www.sciencedirect.com/science/article/pii/S1054139X02003737&quot;&gt;7&lt;/a&gt;&lt;/sup&gt;(Mary McFarlane et.al, 2002)&lt;/p&gt;

&lt;p&gt;The internet may also play a critial role in HIV/AIDs prevention and disease management for patients. Unfortunately, health information is not equally accessible, with less educated, economically disadvantaged, and socially marginalized persons least likely to access health information on the Internet (Bolt &amp;amp; Crawford, 2000), and the same demographic characteristics represent the fastest growing populations of people living with HIV/AIDS. In a previous study, we found that 49% of HIV-positive men and women had used the Internet and that 29% were currently using the Internet to access health information (Kalichman, Benotsch, Weinhardt, Austin, &amp;amp; Luke, 2002). We also found evidence of a digital divide in people with HIV/AIDS,with a history of Internet use more common among Whites (77%) than African Americans (42%). A gap therefore exists between persons who do and do not have access to the Internet, with the growing population of people living with HIV/AIDS being among those least likely to access information online.&lt;sup&gt;&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pubmed/?term=Health-related+Internet+use%2C+coping%2C+social+support%2C+and+health+indicators+in+people+living+with+HIV%2FAIDS%3A+preliminary+results+from+a+community+survey.+Health+Psychol.+2003%3B22(1)%3A111-6.&quot;&gt;8&lt;/a&gt;&lt;/sup&gt;(Kalichman SC &amp;amp; Benotsch EG,2003)&lt;/p&gt;

&lt;p&gt;The same study also found that Internet use for health-related information was associated with health-related outcomes. Persons who used the Internet for health information were better informed about HIV disease and reported more use of active coping strategies and greater social support. We found that health-related Internet use was associated with information-seeking coping, a result that is consistent with research showing that information seeking as a coping style is associated with health benefits among some people with chronic medical conditions (Devins &amp;amp; Binik, 1996). These results support the use of interventions that increase active coping strategies, and we suggest including use of the Internet for health- related purposes among active coping strategies. It is likely that persons who seek information on the Internet are actively seeking health information through multiple other information sources as well. However, our cross-sectional study design precludes drawing causal interpretations of the observed associations. Thus, prospec- tive and experimental studies are needed to determine the direction of associations between Internet use, coping strategies, and health outcomes.&lt;sup&gt;&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pubmed/?term=Health-related+Internet+use%2C+coping%2C+social+support%2C+and+health+indicators+in+people+living+with+HIV%2FAIDS%3A+preliminary+results+from+a+community+survey.+Health+Psychol.+2003%3B22(1)%3A111-6.&quot;&gt;8&lt;/a&gt;&lt;/sup&gt;(Kalichman SC &amp;amp; Benotsch EG,2003)&lt;/p&gt;

&lt;p&gt;Based on those studies mentioned above, there are still many potential correlations among the 3 identifiers, HIV/AIDs development rate, Urbanization, and Internet use yet to be discovered, therefore, it is worth looking further into these relationships.&lt;/p&gt;

&lt;p&gt;2: Income levels and life expectancy&lt;/p&gt;

&lt;p&gt;estimates of life expectancy according to education have been reported by Kitagawa and Hauser for white men and white women in the United States.&lt;sup&gt;&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1403677/pdf/pubhealthrep00072-0091.pdf&quot;&gt;13&lt;/a&gt;&lt;/sup&gt;(Rogot E &amp;amp; Sorlie PD,1992) In the same study, Rogot E and colleagues found that Differences in lifeexpectancy at age 25 between the highest and the lowest levels of education completed were about 6 years for white men and aboutSyearsforwhitewomen. Forfamilyincome, differences between the highest and the lowest income groups were about 10 years for white men and4.3yearsforwhitewomen. Thelargestdifer- ences in lifeexpectancy were between employment categories. At age 25, white men in the laborforce lived on average about 12 more years than those notinthelaborforce,andwhitewomen livedon average about 9 more years. For those who were unable to work compared with those in the labor force,thedifferenceforwhitemen wasabout20 years;forwhitewomen, 29 years. &lt;sup&gt;&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1403677/pdf/pubhealthrep00072-0091.pdf&quot;&gt;13&lt;/a&gt;&lt;/sup&gt;(Rogot E &amp;amp; Sorlie PD,1992)&lt;/p&gt;

&lt;p&gt;In 1992, the BMJ published a now famous paper showing a strong negative correlation between income inequality and life expectancy. Among nine Western industrialised countries those which had less income inequality seemed to have higher life expectancy.&lt;sup&gt;&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1121932/pdf/1.pdf&quot;&gt;14&lt;/a&gt;&lt;/sup&gt;(Johan P Mackenbach,2002)&lt;/p&gt;

&lt;p&gt;Moreover, Muller shows that most of the correlation between income inequality and mortality at the aggregate level in the United States can be explained away by differences in average levels of formal education (p 23).21 This is not surprising in itself, because others have shown before that income inequality is strongly and negatively associated with measures of educational achievement in the United States.2 The main issue is whether we should see educational achievement as a confounder or an intermediary between income inequality and mortality.&lt;sup&gt;&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC61654/pdf/23.pdf&quot;&gt;19&lt;/a&gt;&lt;/sup&gt;
(Andreas Muller,2002)&lt;/p&gt;

&lt;p&gt;Another possible explanation is that some of the possible pathways linking income inequality and mortality cannot be expected to operate at this low geographical level. Would individuals feel relatively deprived because of a comparison with others’ incomes in the same small area, or because of comparisons within a larger social environment? Would income inequality be associated with underinvestment in public resources within the same small area, or would this mechanism operate on a larger geographical scale? It would be useful to replicate these analyses with different geographical scales, and in different European countries.&lt;sup&gt;&lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1121932/pdf/1.pdf&quot;&gt;14&lt;/a&gt;&lt;/sup&gt;(Johan P Mackenbach,2002)&lt;/p&gt;

&lt;p&gt;Humerous studies have been conducted on this topic, but these studies only suggest that there are still more confounding factors or unknown correlations remained to be discovered. Or maybe such correlation between income inequality and the health of the population is slowly dissipating? at least in the U.S and who knows? Thereofore, it would be interesting to explore deeper into the unknown water of this study and in the hope of finding more convincing evidence to form better phypothesis in the near future, and as result, come up with more effecitve policies or plans to help improve the social balance of the world we live in.&lt;/p&gt;

&lt;h3 id=&quot;hypothesis&quot;&gt;7: Hypothesis&lt;/h3&gt;

&lt;p&gt;Primary hypothesis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;1: &lt;strong&gt;HIV/AIDs Prevalence&lt;/strong&gt; correlates with &lt;strong&gt;urbanization&lt;/strong&gt; in both the developed and developing nations and have different patterns of development.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;2: The &lt;strong&gt;Internet rate&lt;/strong&gt; plays a critical role in influencing people’s awareness on HIV infection and prevention across the globe.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Secondary hypothesis&lt;/p&gt;

&lt;p&gt;Socioeconomic status and income levels have a direct correlation with life expectancy globally.&lt;/p&gt;

&lt;h3 id=&quot;reference&quot;&gt;Reference&lt;/h3&gt;

&lt;p&gt;1: &lt;a href=&quot;http://onlinelibrary.wiley.com/doi/10.1111/j.1728-4457.2003.00427.x/abstract&quot;&gt;Dyson, T. (2003), HIV/AIDS and Urbanization. Population and Development Review, 29: 427–442. doi: 10.1111/j.1728-4457.2003.00427.x&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;2: &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2626828/pdf/8903148.pdf&quot;&gt;Morse SS. Factors in the emergence of infectious diseases. Emerging Infectious Diseases. 1995;1(1):7-15.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;3: &lt;a href=&quot;http://eau.sagepub.com/content/18/1/155.full.pdf+html&quot;&gt;Mirjam Van Donk “Positive” urban futures in sub-Saharan Africa: HIV/AIDS and the need for ABC (A Broader Conceptualization)Environment and Urbanization April 2006 18: 155-175, doi:10.1177/0956247806063971&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;4: &lt;a href=&quot;http://idv.sagepub.com/content/29/4/323.full.pdf+html?cited-by=yes&amp;amp;legid=spidv;29/4/323#cited-by&quot;&gt;HIV/AIDS-related information needs of urban and rural residents of northwest Ethiopia: Alerting the rural populace and meeting the progressive needs of the urban populace&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;5: &lt;a href=&quot;http://ac.els-cdn.com/S0160791X05000588/1-s2.0-S0160791X05000588-main.pdf?_tid=d268c95a-5f37-11e5-831c-00000aacb360&amp;amp;acdnat=1442713086_4283cba38630c5f1c45bc1c827ef4e70&quot;&gt;Barney Cohen. (2005),Urbanization in developing countries: Current trends, future projections, and key challenges for sustainability, Volume 28, Issues 1–2, January–April 2006, Pages 63–80&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;6: &lt;a href=&quot;http://journals.lww.com/jaids/Citation/1990/04000/The_Global_Epidemiology_of_HIV_Infection_.16.aspx&quot;&gt;Piot P, Laga M, Ryder R, et al. The global epidemiology of HIV infection: continuity, heterogeneity, and change. J Acquir Immune Defic Syndr. 1990;3(4):403-12.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;7: &lt;a href=&quot;http://www.sciencedirect.com/science/article/pii/S1054139X02003737&quot;&gt;Mcfarlane M, Bull SS, Rietmeijer CA. Young adults on the Internet: risk behaviors for sexually transmitted diseases and HIV(1). J Adolesc Health. 2002;31(1):11-6.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;8: &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pubmed/?term=Health-related+Internet+use%2C+coping%2C+social+support%2C+and+health+indicators+in+people+living+with+HIV%2FAIDS%3A+preliminary+results+from+a+community+survey.+Health+Psychol.+2003%3B22(1)%3A111-6.&quot;&gt;Kalichman SC, Benotsch EG, Weinhardt L, Austin J, Luke W, Cherry C. Health-related Internet use, coping, social support, and health indicators in people living with HIV/AIDS: preliminary results from a community survey. Health Psychol. 2003;22(1):111-6.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;9: &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pubmed/26357907&quot;&gt;Green SM, Lockhart E, Marhefka SL. Advantages and disadvantages for receiving Internet-based HIV/AIDS interventions at home or at community-based organizations. AIDS Care. 2015;:1-5.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;10: &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pubmed/26369354&quot;&gt;Bucholz EM, Ma S, Normand ST, Krumholz HM. Race, Socioeconomic Status, and Life Expectancy After Acute Myocardial Infarction. Circulation. 2015;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;11: &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pubmed/26297094&quot;&gt;Love-koh J, Asaria M, Cookson R, Griffin S. The Social Distribution of Health: Estimating Quality-Adjusted Life Expectancy in England. Value Health. 2015;18(5):655-62.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;12: &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pubmed/26251226&quot;&gt;Arjun BY, Unnikrishnan B, Ramapuram JT, et al. Factors Influencing Quality of Life among People Living with HIV in Coastal South India. J Int Assoc Provid AIDS Care. 2015;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;13: &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1403677/pdf/pubhealthrep00072-0091.pdf&quot;&gt;Rogot E, Sorlie PD, Johnson NJ. Life expectancy by employment status, income, and education in the National Longitudinal Mortality Study. Public Health Rep. 1992;107(4):457-61.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;14: &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1121932/pdf/1.pdf&quot;&gt;Mackenbach JP. Income inequality and population health. BMJ. 2002;324(7328):1-2.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;15: &lt;a href=&quot;http://www.tandfonline.com/doi/abs/10.1080/00324728.1979.10410449&quot;&gt;Krasnova TN, Samokhodskaia LM, Ivaninitskiĭ LV, et al. [Impact of interleukin-10 and interleukin-28 gene polymorphisms on the development and course of lupus nephritis]. Ter Arkh. 2015;87(6):40-4.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;16: &lt;a href=&quot;http://ije.oxfordjournals.org/content/35/4/969.full.pdf+html&quot;&gt;Singh GK, Siahpush M. Widening socioeconomic inequalities in US life expectancy, 1980-2000. Int J Epidemiol. 2006;35(4):969-79.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;17: &lt;a href=&quot;http://www.nejm.org/doi/pdf/10.1056/NEJM199307083290208&quot;&gt;Guralnik JM, Land KC, Blazer D, Fillenbaum GG, Branch LG. Educational status and active life expectancy among older blacks and whites. N Engl J Med. 1993;329(2):110-6.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;18: &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2551188/pdf/bmj00618-0048.pdf&quot;&gt;Judge K. Income distribution and life expectancy: a critical appraisal. BMJ. 1995;311(7015):1282-5.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;19: &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC61654/pdf/23.pdf&quot;&gt;Muller A. Education, income inequality, and mortality: a multiple regression analysis. BMJ 2002;324:23-5.&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;recourses&quot;&gt;Recourses&lt;/h3&gt;

&lt;p&gt;1: Citation Machine &lt;a href=&quot;https://mickschroeder.com/citation/?q=2179527&quot;&gt;MICK SCHROEDER&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;2: &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/pubmed&quot;&gt;Pubmed&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;3: &lt;a href=&quot;https://scholar.google.com/schhp?hl=en&amp;amp;as_sdt=0,25&quot;&gt;Google Scholar&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;review-criteria&quot;&gt;Review Criteria&lt;/h3&gt;

&lt;p&gt;Your assessment will be based on the evidence you provide that you have completed all of the steps. When relevant, gradients in the scoring will be available to reward clarity (for example, you will get one point for having a research question presented in an unclear fashion, but two points for being clear). In all cases, consider that the peer assessing your work is likely not an expert in the field you are analyzing. You will be assessed equally on your reflection of the literature you’ve discovered and the project you are proposing.&lt;/p&gt;

&lt;p&gt;Specific rubric items, and their point values, are as follows:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Has the learner selected a data set and indicated that selection? (1 point)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Has the learner clearly stated a research question and hypothesis? (2 points)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Does the literature review include clear information about search terms used? (1 point)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Does the literature review clearly identify references used? (2 points)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Does the literature review clearly present a summary of findings (e.g., variables considered, patterns of findings, etc.)? (2 points)&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;
</content>
 </entry>
 
 <entry>
   <title>Slidify quiz recourse</title>
   <link href="http://lanyon.getpoole.com/slidify%20quiz/2015/09/14/slidify-quiz/"/>
   <updated>2015-09-14T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/slidify%20quiz/2015/09/14/slidify-quiz</id>
   <content type="html">&lt;p&gt;&lt;a href=&quot;http://ramnathv.github.io/user2014-idocs-slides/demos/widgets/quiz-all/#1&quot;&gt;Slidify quiz examples&lt;/a&gt;&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>How to gobally set images size in Slidify</title>
   <link href="http://lanyon.getpoole.com/web%20development/2015/09/14/setting-global-image-size-for-slidify/"/>
   <updated>2015-09-14T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/web%20development/2015/09/14/setting-global-image-size-for-slidify</id>
   <content type="html">&lt;p&gt;This issue can be addressed very easily.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;First, open the css folder in your slidify folder&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;then, open the ribbons.css file, where it stores information for your slidify slides’ style setting.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;!--break--&gt;

&lt;ul&gt;
  &lt;li&gt;Finally, just add the following code at the end of the file. This is to specify a sepecific size for all the figures in your slide. 
For instance, width = 780 and height=520&lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;img {
  width: 780px;
  height: 520px;
}&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;Check out the [Figures review] that I made for my pathology exam review as an example.&lt;/p&gt;

&lt;p&gt;Hope this is helpful.&lt;/p&gt;

&lt;p&gt;Thank you for reading.&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Robbins and Cortran Review note</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/09/14/Robbin-Review-note/"/>
   <updated>2015-09-14T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/09/14/Robbin-Review-note</id>
   <content type="html">&lt;h2 id=&quot;robbins-and-cotran-review-note&quot;&gt;Robbins and Cotran REview note&lt;/h2&gt;

&lt;h3 id=&quot;acute-and-chronic-inflammation&quot;&gt;Acute and Chronic Inflammation&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Lymphocytes are a feature of chronic inflammation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Nonhuman microbial substances such as double-stranded RNA of viruses, bacterial DNA, and bacterial endotoxin, can be recognized by Toll-like receptors (TLRs) on human cells as part of an innate defense mechanism against infection.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;!--break--&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Lectins found on cell surfaces can bind a variety of substances, such as fungal polysaccharides, that trigger cellular defenses.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;T cell receptors respond to peptide antigens to trigger a cell-mediated immune response.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Complement C3a causes increased vascular permeability by releasing histamine from mast cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;This immunoglobulin deficiency prevents opsonization and phagocytosis of microbes. Deficiency of integrins and selectins, or a defect in microtubules, would prevent adhesion and locomotion of neutrophils.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Myeloperoxidase is present in the azurophilic granules of neutrophils. It converts H2O2 into HOCl–&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;NADPH oxidase, resulting in generation of superoxide that is converted by spontaneous dismutation to H2O2.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;This burst can be quantitated by flow cytometric analysis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Bacteria are opsonized by complement C3b and IgG, allowing the bacteria to be more readily phagocytosed.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Integrins have two chains, α and β. A genetic lack of β chains prevents firm adhesion of leukocytes to endothelial cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;c5a that bind to the neutrophil and activate phospholipase C to begin a series of events that culminate in the influx of calcium, which triggers contractile proteins.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;he respiratory burst to kill phagocytized organisms depends on NADPH oxidase, and a deficiency of this enzyme leads to chronic &lt;strong&gt;granulomatous disease.&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Monocytes transforming to macrophages contain cytokine-inducible nitric oxide synthase (iNOS), which generates nitric oxide. Nitric oxide, by itself and on interaction with other reactive oxygen species, has antimicrobial activity.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD4 or CD8 lymphocytes can be the source for interferon-γ (IFN-γ), which stimulates macrophage production of NOS.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Interferon-γ also is important in transforming macrophages into epithelioid cells in a granulomatous inflammatory response&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Leukotriene B4, generated in the lipoxygenase pathway of arachidonic acid metabolism, is a potent neutrophil chemotactic factor.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Binding of agonists such as epinephrine, collagen, or thrombin to platelet surface receptors activates phospholipase C, which catalyzes the release of arachidonic acid from two of the major membrane phospholipids, phosphatidylinositol and phosphatidylcholine.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Bradykinin, generated from the kinin system on surface contact of Hageman factor with collagen and basement membrane from vascular injury, promotes vascular permeability, smooth muscle contraction, and pain&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;C3b may promote phagocytosis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;C1q is generated in the initial stage of complement activation, which can eventually result in cell lysis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Leukotrienes are generated by the lipoxygenase pathway, which is not blocked by &lt;strong&gt;aspirin.&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;important-pathways&quot;&gt;3 important pathways&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Activation of complement may occur via microbial cell wall components such as polysaccharides (alternative pathway) or&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;mannose (lectin pathway),&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;or antibody attached to surface antigens (classic pathway)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Plasmin is generated from plasminogen and helps lyse clots.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Ongoing activation of coagulation generates an inflammatory response that further amplifies coagulation, creating a vicious cycle.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Protein C antagonizes coagulation factor V, which catalyzes activation of prothrombin to thrombin, thereby breaking the cycle of thrombin generation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Complement components can become activated by &lt;strong&gt;plasmin&lt;/strong&gt; (C3) and &lt;strong&gt;kallikrein&lt;/strong&gt; (C5), forming &lt;strong&gt;anaphylatoxins&lt;/strong&gt; (C3a and C5a) that promote inflammation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;A protein-rich exudate results in fibrin accumulation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Granulomatous inflammation is characterized by collections of transformed macrophages called epithelioid cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Acute inflammatory cells, mainly neutrophils, exuded into a body cavity or space form a purulent (suppurative) exudate, typically associated with &lt;strong&gt;liquefactive necrosis.&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;An abscess is a localized collection of neutrophils &lt;strong&gt;within tissues.&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;In fibrinous inflammation, exudation of blood proteins (including fibrinogen, which polymerizes to fibrin) gives a grossly shaggy appearance to surfaces overlying the inflammation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Chronic inflammation occurs when there is a preponderance of mononuclear cells, such as lymphocytes, macrophages, and plasma cells&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Most bacterial pneumonias resolve, and progression to continued chronic inflammation is uncommon.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;In acute inflammation, the healing process of fibrosis and angiogenesis has not begun.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Activated macrophages can secrete various cytokines that promote angiogenesis and fibrosis, including platelet-derived growth factor, fibroblast growth factor, interleukin-1 (IL-1), and tumor necrosis factor (TNF).&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Plasmodium produces malaria, a parasitic infection without a significant degree of lung involvement.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The pyrogens stimulate prostaglandin synthesis in the hypothalamus to “reset the thermostat,” so that fever occurs as a sign of the acute inflammatory response&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Hageman factor initiates the coagulation cascade.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Interleukin-12 (IL-12) released by macrophages &lt;strong&gt;stimulates T-cell responses&lt;/strong&gt;.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;nitric oxide produced in macrophages aids in microbial killing.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;IL-1 and TNF can have autocrine, paracrine, and endocrine effects.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;C-reactive protein (CRP), fibrinogen, and serum amyloid A (SAA) protein. These proteins, particularly fibrinogen, and immunoglobulins increase RBC rouleaux formation to increase the erythrocyte sedimentation rate (ESR), which is a nonspecific indicator of inflammation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CRP production is upregulated by interleukin-6 (IL-6), whereas fibrinogen and SAA are upregulated mainly by tumor necrosis factor (TNF) and interleukin-1 (IL-1).&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Hepatocytes are quiescent (stable) cells that can reenter the cell cycle and proliferate in response to hepatic injury, enabling the liver to regenerate partially.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Acute hepatitis results in hepatocyte necrosis, marked by elevations in AST and ALT.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Vitamin C deficiency leads to scurvy, with reduced lysyl oxidase enzyme activity that helps cross-link fibrillar collagens to provide tensile strength.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;final phase of wound healing, which is extensive by the end of the first month.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The inhibition of metalloproteinases leads to decreased degradation of collagen and impaired connective tissue remodeling in wound repair.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Platelet-derived growth factor (PDGF) can be produced by endothelium, macrophages, smooth muscle cells, and platelets&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;PDGF mediates migration and proliferation of fibroblasts and smooth muscle cells and &lt;strong&gt;migration of monocytes.&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Glucocorticoids inhibit wound healing by impairing collagen synthesis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Serine proteinases are important in wound remodeling.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Organization occurs as granulation tissue is replaced by fibrous tissue&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;If normal tissue architecture is restored, resolution of inflammation has occurred.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Secondary union describes the process by which large wounds fill in and contract.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The elevated creatine kinase level indicates that myocardial necrosis has occurred(The elevation in the CK level is indicative of myocardial cell necrosis, because this intracellular enzyme does not leak in large quantities from intact myocardial cells.)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Coagulative necrosis is typical of myocardial infarction, but after 1 month, a scar would be present.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;cellular-injury&quot;&gt;cellular injury&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Nodular regeneration is typical of hepatocyte injury because hepatocytes are stable cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Accumulation of fat within cells is a common manifestation of sublethal cell injury or, uncommonly, of inborn errors in fat metabolism&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Nodular prostatic hyperplasia (also known as benign prostatic hyperplasia [BPH]) is a common condition in older men that results from proliferation of both prostatic glands and stroma.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Aplasia refers to lack of embryonic development;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Hyaline change (hyalinosis) refers to a nonspecific, pink, glassy eosinophilic appearance of cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Steatosis (fatty change) can lead to hepatomegaly, but not as a regenerative process.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Irreversible cell injury is associated with loss of membrane integrity. This allows intracellular enzymes such as AST and ALT to leak into the serum.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Blunt trauma produces hemorrhage&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Gangrenous necrosis is mainly coagulative necrosis, but occurs over an extensive area of tissues.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Intestinal infarction is a form of coagulative necrosis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Coagulative necrosis is the typical result of ischemia in most solid organs.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Fatty change is most often a feature of hepatocyte injury, and the cell integrity is maintained&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Reduction in oxidative phosphorylation leads to reduction in synthesis of ATP and diminished activity of the plasma membrane sodium pump, which maintains high intracellular potassium concentration. Loss of ATP leads to efflux of intracellular potassium, while net influx of sodium and water promote cell swelling. A marked rise in plasma potassium can indicate significant cell damage or death (such as skeletal muscle crush injury or hemolysis).&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Decreased tissue perfusion from hypotensive shock leads to hypoxemia and depletion of ATP when cell metabolism shifts from aerobic to anaerobic glycolysis. This shift causes depletion of glycogen stores and increased production and accumulation of &lt;strong&gt;lactic acid&lt;/strong&gt;, reducing intracellular pH&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Creatinine would increase with reduced renal function from decreased renal perfusion, but this would not explain the changes in other tissues.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;An increase in troponin I suggests irreversible myocardial injury.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Irreversible cellular injury is likely to occur when cytoplasmic calcium increases&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The excess calcium activates ATPases, phospholipases, proteases, and endonucleases, which injure cell components.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Mitochondrial permeability is increased to release cytochrome c, which activates caspases leading to apoptosis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The drug acetaminophen can be converted to toxic metabolites in this manner. Glutathione in the cytosol helps to reduce cellular injury from many toxic metabolites and free radicals&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Glutathione peroxidase reduces such injury by catalyzing the breakdown of hydrogen peroxide&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Lactate dehydrogenase is present in a variety of cells, and its elevation in the serum is an indicator of cell injury and death.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Phospholipases decrease cellular phospholipids and promote cell membrane injury&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The free iron contributes to generation of cellular free radicals via the Fenton reaction.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Hemosiderin is a storage form of iron from excess local or systemic accumulation of ferritin, and by itself does not cause cell injury until large amounts are present, as with hemochromatosis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The onset of menstruation is orderly, programmed cell death (apoptosis) through hormonal stimuli, an example of the intrinsic (mitochondrial) apoptotic pathway&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The BCL2 gene product inhibits cellular apoptosis by binding to Apaf-1.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The BAX gene product promotes apoptosis,&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The FAS gene encodes for a cellular receptor for Fas ligand that signals apoptosis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Lipases are activated in enzymatic fat necrosis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Granzyme B is a serine protease found in CTLs that can directly trigger apoptosis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CTLs express Fas ligand on their surfaces, and when contacting Fas receptors on the target cell, the ligand can induce apoptosis by the &lt;strong&gt;extrinsic (death receptor–initiated) pathway.&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Endonucleases are generated following caspase activation and lead to nuclear fragmentation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The RIP1-RIP3 complex is called a necrosome&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Decreased serum albumin levels and increased prothrombin time suggest alcohol-induced hepatocyte damag&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Hemosiderin is a storage form of iron that appears in tissues of the mononuclear phagocyte system (e.g., marrow, liver, spleen)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Lipofuscin is a golden brown pigment that increases with aging in cell cytoplasm, mainly in cardiac myocytes and in hepatocytes.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Metastases are mass lesions that impart a tan-to-white appearance to tissues.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Amyloid is an abnormal protein derived from a variety of precursors, such as immunoglobulin light chains&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Steatosis usually occurs with ingestion of hepatotoxins, such as alcohol.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Hypercalcemia can have a variety of causes, including primary and secondary hyperparathyroidism, bone destruction secondary&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Because the solubility product of calcium and phosphorus must be maintained, the serum calcium is depressed, triggering increased parathyroid hormone output to increase the calcium level, which promotes calcium deposition.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The granulomas of tuberculosis have caseous necrosis with dystrophic calcification.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The X chromosome transcribes XIST, a lncRNA that binds to and represses X chromosome expression.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;MicroRNAs (miRNAs) are noncoding RNA sequences that inhibit the translation of mRNAs&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Gene-silencing RNAs (small interfering RNAs [siRNAs]) have the same function as miRNAs, but they are produced synthetically for experimental purposes.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Heterophagocytosis by macrophages requires that endocytosed vacuoles fuse with lysosomes to degrade the engulfed material.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Actin is a microfilament involved with cell movement&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Cytokeratins form cytoskeletal elements of epithelial cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Desmin forms the scaffold in muscle cells on which actin and myosin contract.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Lamin is associated with the nuclear membrane.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;RAS proteins transduce signals from growth factor receptors, such as epidermal growth factor, that have intrinsic tyrosine kinase activity.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The MAP kinase cascade is involved in signaling from activation via cell surface receptors for growth factors. This pathway is particularly important for signaling of EGF and fibroblast growth factor.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;JAK/STAT pathways typically are recruited by cytokine receptors.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Basic fibroblast growth factor is a potent inducer of angiogenesis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Endostatin is an inhibitor of angiogenesis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Platelet-derived growth factor plays a role in vascular remodeling.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;TGF-β stimulates many steps in fibrogenesis, including fibroblast chemotaxis and production of collagen by fibroblasts, while inhibiting degradation of collagen.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Hyaluronan (hyaluronic acid) is a large mucopolysaccharide, one form of proteoglycan, which forms a hydrated, compressible gel contributing to the shock-absorbing function of joint surfaces.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;immune-system-diseases&quot;&gt;immune System diseases&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;The NLR-inflammasome pathway plays a role in the innate immune system recognition of urate crystals and promoting the inflammation associated with gout.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Toll-like receptors (TLRs) in the plasma membrane and endosomal vesicles activate transcription factors that stimulate synthesis and secretion of cytokines and expression of adhesion molecules to recruit and activate leukocytes.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Natural killer (NK) cells have CD16,an Fc receptor that allows them to bind to opsonized cells and lyse them. This is a form of type II hypersensitivity with antibody-mediated disease.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;B cells have surface immunoglobulin, are CD19 positive, and participate in humoral immunity&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD4+ cells are T lymphocytes that are “helper” cells; they have T cell receptors and are CD3 positive.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Dendritic cells elaborate type I interferons that up-regulate antiviral proteins in neighboring cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Because they survive selectively, the CD4+:CD8+ ratio is reversed so that it is typically less than 1 with advanced HIV infection.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Blood monocytes expressing MHC class II antigens can migrate into tissues and become longer-lived macrophages.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Methotrexate is useful in the treatment of graft-versus-host disease and for some malignancies&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Penicillin is an antibiotic that can induce a type I hypersensitivity reaction in sensitized persons.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anticardiolipin, along with anti–β2-glycoprotein “lupus anticoagulant,” are found with antiphospholipid syndrome, which may appear in systemic lupus erythematosus (SLE).&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;antihistone antibodies are characteristic of drug-induced SLE&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anti–SS-A antibody is seen in Sjögren syndrome.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;anti–U1-ribonucleoprotein antibody is seen in mixed connective tissue disease (MCTD).&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anti-Scl-70 (also called anti-topoisomerase I after the type I topoisomerase target[1]) is an anti-topoisomerase antibody-type of anti-nuclear autoantibodies, seen mainly in diffuse systemic scleroderma (with a sensitivity of 28–70%), but is also seen in 10–18% of cases of the more limited form of systemic scleroderma called CREST syndrome.[2] Anti Scl-70 antibodies are associated with more severe scleroderma disease.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Myasthenia gravis is a form of type II hypersensitivity reaction in which antibody is directed against cell surface receptors. Thymic hyperplasia or thymoma is likely to be present.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Immune complex–mediated injury is a feature of dermatomyositis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Muscle lysis by CD8+ T cells occurs in polymyositis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;When antibody is directed at a parasitic infection, there is Fc receptor–mediated inflammation and phagocytosis, characteristic for ADCC. IgG and IgE antibodies bearing Fc receptors coat the parasite. Macrophages, natural killer cells, and neutrophils can then recognize the Fc receptor and destroy the antibody-coated target cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD4+ cells of the TH2 type are essential to the induction of type I hypersensitivity because they can secrete cytokines, such as interleukin (IL)-3, IL-4, IL-5, and
granulocyte-macrophage colony-stimulating factor, which are required for the growth, recruitment, and activation of mast cells and eosinophils&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The TH17 subset of CD4 cells plays a role in delayedtype hypersensitivity reactions. Many persons react to nickel, particularly with body piercing jewelry. IL-17 may also be useful in recruiting neutrophils to fight bacterial as well as fungal infections such as aspergillosis and candidiasis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;IL-5 activates eosinophils as part of a TH2 response.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Perivascular accumulation of T cells, particularly CD4+ cells, is typical of delayed hypersensitivity skin reactions, driven by a TH1 response mediated largely by release of the cytokine interleukin-2.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Streptococcal M proteins cross-react with cardiac glycoproteins, resulting in rheumatic heart disease, a form of autoimmunity.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;This young woman has a classic picture of systemic lupus erythematosus (SLE)—the erythematous malar facial skin rash shown in the figure, and renal failure with proteinuria and hematuria from immune complex deposition in the glomeruli. Defective clearance and hence increased burden of nuclear apoptotic bodies in thymic lymphocyte development is considered a fundamental mechanism that underlies SLE&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Widespread and nonspecific activation of T cells by superantigens occurs in toxic shock syndrome.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Patients with systemic lupus erythematosus (SLE) can develop anti-RBC antibodies, which can cause hemolytic anemia. Cytopenias, including leukopenia, thrombocytopenia, and anemia, also are common.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anticentromere antibody is seen most often with limited scleroderma, whereas anti–DNA topoisomerase I is found with diffuse scleroderma&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Cyclic citrullinated polypeptide and rheumatoid factor are found most often with rheumatoid arthritis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anti–U1-RNP can be found with mixed connective tissue disease.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;A drug-induced systemic lupus erythematosus (SLE)– like condition may be caused by drugs such as isoniazid, procainamide, and hydralazine.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anti–Jo-1 antibody has specificity for polymyositis/dermatomyositis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anti–SS-A antibody is most characteristic of Sjögren syndrome.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;discoid lupus erythematosus, with skin lesions similar to those of systemic lupus erythematosus (SLE), but with systemic involvement much less likely to occur. Self nucleic acids mimic their microbial counterparts, and in conjunction with TLRs, they incite type I interferon production to activate dendritic cells and B cells. (has &lt;strong&gt;follicular plugging&lt;/strong&gt;)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Sjögrensyndromeischaracterizedbyimmunologically mediated destruction of salivary and lacrimal glands and other exocrine glands lining the respiratory and gastrointestinal tracts. Dryness and crusting of the nose can lead to perforation of the nasal septum. In 25% of cases, extraglandular tissues, such as lung, skin, kidney, and muscles, may be involved. The immune dysregulation that accompanies autoimmune diseases increases the risk for B cell lymphoid malignancies, such as MALT lymphoma&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Esophageal dysmotility is a feature of scleroderma.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Nongonococcal urethritis is seen in reactive arthritis, along with conjunctivitis and arthritis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Diffuse systemic sclerosis (scleroderma) initially has widespread skin involvement but rapidly progresses to visceral organ involvement, including the small arteries of the kidney. These are damaged by a hyperplastic arteriolosclerosis that can be complicated by very high blood pressure and renal failure.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Ankylosing spondylitis is one of the spondyloarthropathies; it is characterized by low back pain from sacroiliitis and positive serology for &lt;strong&gt;HLA-B27&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;In rheumatoid arthritis, there is often progressive joint deformity; the serologic tests likely to be positive include rheumatoid factor and antibodies to cyclic citrullinated peptide (anti-CCP).&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Dermatomyositis is a form of inflammatory myopathy in which capillaries are the primary target for antibody and complement-mediated injury. Anti–Jo-1 antibodies, although not present in most cases, are quite specific for inflammatory myopathies.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;In reactive arthritis (with conjunctivitis, arthritis, and nongonococcal urethritis), there is often a positive serology for HLA-B27 and a history of either nongonoccocal urethritis with Chlamydia or gastrointestinal infection with Campylobacter, Salmonella, or Shigella organisms.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Endothelitis with intimal injury occurs with acute rejection, but this can be treated&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Fibrinoid necrosis and thrombosis are more typical of hyperacute rejection,&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Amyloid derived from serum amyloid-associated protein can occur in chronic infections and inflammation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Interstitial and glomerular fibrosis and blood vessel thickening occur in chronic rejection,&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The localized apoptosis with GVHD does not produce significant substrate proteins for amyloid formation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Patients with the hyper-IgM syndrome produce normal (or even supranormal) levels of IgM antibodies to antigens but lack the ability to produce the IgG, IgA, and IgE isotypes; the underlying defect is an inability of T cells to induce B cell isotype switching. The most common genetic abnormality is mutation of the gene encoding CD40L.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;An absence of adenosine deaminase characterizes a form of severe combined immunodeficiency.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The deletion of chromosome 22q11 is a feature of the DiGeorge anomaly&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;HIV infection can be accompanied by opportunistic infections, particularly Pneumocystis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;mutations in the gene encoding an adaptor molecule called SLAM-associated protein (SAP) that binds to a family of cell surface molecules involved in the activation of NK cells and T and B lymphocytes, and result in increased susceptibility to viral infections, particularly Epstein-Barr virus (EBV)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;These findings point to mutations in the gene encoding an adaptor molecule called SLAM-associated protein (SAP) that binds to a family of cell surface molecules involved in the activation of NK cells and T and B lymphocytes, and result in increased susceptibility to viral infections, particularly Epstein-Barr virus (EBV).&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;When the family history indicates males are affected, then SCID is most likely X-linked and due to mutations in the common γ chain that is a part of many cytokine receptors, such as interleukin (IL)-2, IL-4, IL-7, and IL15.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;individuals lacking complement component C2 have some increase in infections, but mainly develop a disease resembling systemic lupus erythematosus.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Hereditary angioedema is a rare autosomal-recessive disorder of the complement pathway in which there is a deficiency of antigenic or functional C1 inhibitor, resulting in recurrent episodes of edema.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;C3 deficiency is accompanied by recurrent infections with pyogenic bacteria.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;β2-Microglobulin is a component of MHC class I; it can be increased with HIV infection and can be a substrate for amyloid fibrils in patients receiving long- term hemodialysis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Individuals with a selective (isolated) IgA deficiency are bothered by minor recurrent sinopulmonary infections and by diarrhea. IgA is useful in innate immunity against bacterial organisms in the respiratory and gastrointestinal tracts.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Immune reactions against fungal and viral infection are me- diated mainly by T cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Pneumocystis infections are seen in patients with more severe acquired or inherited immunodeficiency disorders, particularly patients with AIDS, which affect cell-mediated immunity.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The X-linked disorder known as Wiskott-Aldrich syndrome (WAS) is characterized by thrombocytopenia, ec- zema, and &lt;strong&gt;decreased IgM&lt;/strong&gt;. there is an increased risk of non-Hodgkin lymphoma&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Hypocalcemia is seen in neonates with DiGeorge syndrome that affects parathyroid glands.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The most common neoplasms seen in association with AIDS are B cell non-Hodgkin lymphomas.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The reverse transcriptase gene of HIV undergoes mutation on average once per 2000 replications, a very high rate, which can account for the appearance of drug resistance.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The p24 antigen is a component of the HIV virion and is used to de- tect infection, but it is not a target of drug therapy&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Entry of HIV into cells requires binding to the CD4 molecule and co-receptor molecules, such as CCR5 and CXCR4. These HIV co-receptors are receptors for chemo- kines on the surface of T cells and macrophages.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Three types of cells are most likely to carry HIV: den- dritic cells (Langerhans cells in epithelium, follicular den- dritic cells in lymph nodes), monocyte-macrophages, and CD4+ T cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anti–neutrophil cytoplasmic autoantibody (C-ANCA or P-ANCA) can be seen in some patients with vasculitis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The anti–streptolysin O (ASO) titer is elevated in patients with rheumatic fever, but there is no serious immunosuppres- sion.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Progression of HIV disease is monitored by levels of HIV-1 mRNA in the blood and by CD4+ cell counts&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Kaposi sarcoma is associated with a herpesvirus agent that is sexually transmitted: human her- pesvirus 8 (HHV-8), also called the Kaposi sarcoma herpesvirus.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;HIV, although present in the lymphocytes and monocytes, is not detected in the spindle cells that proliferate in Kaposi sarcoma.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;the follicular dendritic cells and the macrophages are not destroyed in large numbers by the virus and can become a reservoir for infection&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Natural killer cells, CD19+ B cells, and plasma cells are not directly affected by HIV.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Amyloidosis is most often caused by excessive light chain production with plasma cell dyscrasias such as multiple myeloma (AL am- yloid). His spinal lesions are focal collections of neoplastic plasma cells&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Both rheumatoid factor (RF) and C-reactive protein (CRP) are markers for in- flammation, and the amyloid associated with chronic inflam- matory conditions is derived from serum amyloid associated (SAA) protein.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Pro- longed infection also stimulates production of colony- stimulating factors (CSFs), which increase the bone marrow output of leukocytes&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Amyloid derived from β2-microglobulin occurs with hemo- dialysis-associated amyloidosis. Amyloid derived from light chains in association with multiple myeloma has AL fibrils. Cardiac and heredofamilial forms of amyloidosis have fibrils derived from prealbumin transthyretin (TTR).&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;α-Fetoprotein is present during fetal life, but it is best known in adults as a serum tumor marker.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Calcitonin forms the precursor for amyloid deposited in thyroid medullary carcinomas.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;TGF-B also in the development of fibrosis in lung, liver, and kidneys that follows chronic inflammation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;TGF-β is an anti-inflammatory cytokine that serves to limit and terminate inflammatory responses. It does so by inhibiting lymphocyte proliferation and the activity of other leukocytes.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Medical Definition of HETEROPHAGY. : digestion in a fused vacuole and lysosome of material taken into a cell by phagocytosis or pinocytosis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Microsatellite instability occurs with mutation in genes, such as hMSH2, that repair DNA damage.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;E This patient has clinical features of neurofibromatosis type 1. The NF1 gene encodes for a GTPase-activating protein that facilitates the conversion of active (GTP-bound) RAS to inactive (GDP-bound) RAS. Loss of NF1 prevents such con- version and traps RAS in the active signal-transmitting stage that drives cell proliferation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The p53 and c-MYC genes favor this metabolic change, whereas PTEN inhibits tumor cell autophagy, giving cancer cells an edge in growth.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;t(14,18) BCL2, t(8,14) Burkitt Lymphoma, Myc.  t(9,22) Philidelphia&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD44 plays a role in cell adhesion and enables malignant cells to metastasize.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;A paraneoplastic syndrome results from ectopic secretion of a hormone by tumor (e.g., lung cancer cells producing corticotropin). Tumor heterogeneity does not refer to two separate kinds of neoplasms; it refers to heterogeneity with a given tumor or metastasis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;A The oncogenic potential of human papillomavirus (HPV), a sexually transmissible agent, is related to products of two early viral genes—E6 and E7. E7 protein binds to RB protein to cause displacement of normally sequestered transcription factors, which nullifies tumor suppressor activity of the RB protein. E6 protein binds to and inactivates the p53 gene product.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;In- fection with Epstein-Barr virus is associated with various cancers, including Burkitt lymphoma and nasopharyngeal carcinoma&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;intravenous immunoglobulin (IVIG) is a blood product administered intravenously&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;SOLU-MEDROL Sterile Powder is an anti-inflammatory glucocorticoid, which contains methylprednisolone sodium succinate as the active ingredient.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Reiter syndrome is characterized by conjunctivitis, arthritis, and nongonococcal urethritis, with a positive serology for HLA-B27.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;In rheumatoid arthritis, there is often progressive joint deformity; the serologic tests likely to be positive include rheumatoid factor and antibodies to cyclic citrullinated peptide (anti-CCP).&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Aortic dissection is more likely in Reiter syndrome.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Ankylosing spondylitis is marked by kyphosis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Dementia can be seen in patients with AIDS.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;B cells have surface immunoglobulin, are CD19 positive, and participate in humoral immunity&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD4+ cells are T lymphocytes that are “helper” cells; they have T cell receptors and are CD3 positive.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Stem cells are CD34 positive and can give rise to the whole range of cells in the immune system and blood-forming cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;This patient has clinical features of neurofibromatosis type 1. The NF1 gene encodes a GTPase-activating protein that facilitates the conversion of active (GTP-bound) RAS to inactive (GDP-bound) RAS.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

</content>
 </entry>
 
 <entry>
   <title>Immunopathology figures and supplimentary</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/09/11/immunopathology-figures3/"/>
   <updated>2015-09-11T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/09/11/immunopathology-figures3</id>
   <content type="html">&lt;h3 id=&quot;injury-study&quot;&gt;Injury study&lt;/h3&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image11.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InjuryStudyFigure/image11.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;apotosis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;http://www.pathpedia.com/education/eatlas/histopathology/liver_and_bile_ducts/chronic_hepatitis_c.aspx&quot;&gt;refine appearance of apototic cells-see slide 10&lt;/a&gt;&lt;/p&gt;

&lt;!--break--&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/image13.png&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/image13.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The figure shows deep eosinophilic staining, loss of myocardial fiber nuclei, and loss of cell structure consis- tent with an early ischemic injury, resulting in coagulative necrosis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/image14.png&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/image14.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;An ischemic injury to most internal organs produces a pattern of cell death called coagulative necrosis. Note the faint outlines of renal tubules and glomerulus in the figure, but no cellular nuclei&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/image15.png&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/image15.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;There is an apoptotic cell (arrow) that is shrunken and has been converted into a dense eosinophilic mass. There is a surrounding inflammatory reaction with cytotoxic lymphocytes. This pattern is typical of apoptosis. Caspase activation is a universal feature of apoptosis, regardless of the initiating cause. Apoptosis induced in recipient cells from donor lymphocytes occurs with graft-versus-host disease.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/image16.png&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/image16.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The valve is stenotic because of nodular deposits of calcium. The process is “dystrophic” because calcium deposition occurs in damaged tissues. The damage in this patient is a result of excessive wear and tear with aging.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image19.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InjuryStudyFigure/image19.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;notice the congested blood capillary&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.pathologyatlas.ro/pathology_atlas_imagini/cholesterolosis_02.jpg&quot;&gt;Cholesterolosis of the gallbladder&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image23.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InjuryStudyFigure/image23.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://library.med.utah.edu/WebPath/CINJHTML/CINJ047.html&quot;&gt;dystrophic calcification with labeled explanation&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image25.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InjuryStudyFigure/image25.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;*Granulomatous Inflammation, Lung.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://edc2.healthtap.com/ht-staging/user_answer/avatars/913735/large/open-uri20130308-28336-dwqobc.jpeg?1386611344&quot;&gt;labeled explanation&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/image17.png&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/image17.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image28.png&quot;&gt;&amp;lt;
&lt;img src=&quot;/assets/pathology/test1/InjuryStudyFigure/image28.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://library.med.utah.edu/WebPath/CINJHTML/CINJ026.html&quot;&gt;necrosis of the pancreas explanation&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image29.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InjuryStudyFigure/image29.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.pathologyatlas.ro/pathology_atlas_imagini/lobar_pneumonia_leukocytic_alveolitis.jpg&quot;&gt;Pneumonia&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;inflammation-and-repair&quot;&gt;Inflammation and Repair&lt;/h3&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image5.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image5.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Hypertrophic Cardiac Myocytes&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image9.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image9.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Hyperplasia of prostate glands&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image12.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image12.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image20.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image20.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;Proximal renal tubules normal (L), hydropic change (R)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Karyolysis—fading of chromatin&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Pyknosis—nuclear shrinkage, basophilia&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Karyorrhexis—nuclear fragmentation&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image25.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image25.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Coagulative necrosis, kidney&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image31.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image31.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Fat Necrosis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image35.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image35.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Polyarteritis Nodosa (fibrinoid necrosis)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image43.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image43.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Apoptotic cells show nuclear chromatin condensation with cellular shrinkage and formation of apoptotic bodies composed of membrane bound&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;vesicles of cytosol and organelles.&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image44.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image44.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Mechanisms of Apoptosis Death Receptor (Intrinsic) &amp;amp; (Extrinsic) Pathway&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image45.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image45.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;intracellular-accumulations&quot;&gt;Intracellular Accumulations&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Four pathways:&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Inadequate removal of normal substances&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Accumulation of abnormal endogenous substances&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Failure to degrade a metabolite&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Deposition /accumulation of exogenous substances&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Accumulation of  cholesterol within the gallbladder&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image46.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image46.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Cholesterol within an atheromatous plaque in a coronary artery&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image47.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image47.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Accumulation of  protein within liver cells (hepatocytes) The eosinophilic cytoplasmic inclusions seen above (in the middle) are Mallory-Denk bodies composed of intermediate filaments (cytokeratins) often seen in alcoholic liver diseas&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image66.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image66.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Serous Inflammation in a Skin Blister&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image67.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image67.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Fibrinous Pericarditis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image68.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image68.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Fibrinous Pericarditis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image70.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image70.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Bronchopneumonia&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image71.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image71.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Abscess&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image77.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image77.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;complement pathways&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/1.png&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image1.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/2.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/2.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image78.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image78.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Chronic gastritis The lamina propria is infiltrated by plasma cells&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image80.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image80.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Granulomatous Inflammation with Caseous Necrosis
A granuloma with central necrosis, surrounded by “epithelioid histiocytes,” giant cells, and a collar of lymphocytes&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image80.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image80.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Aspiration Pneumonia&lt;/li&gt;
  &lt;li&gt;Aspiration pneumonia with abundant neutrophils and a foreign body giant cell reaction to a piece of aspirated plant material from gastric contents&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image80.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image80.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Caseating Granuloma&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Notice&lt;/strong&gt; the prominent epithelioid histiocytes surrounding the necrosis&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image80.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image80.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Non-Caseating Granulomas Sarcoidosis involving the lung&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image87.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image87.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;A: Granulation tissue: Blood vessels (angiogenesis), tissue edema with loose extracellular matrix containing occasional inflammatory cells, mainly macrophages&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;B: Mature scar with dense collagen staining blue with a trichrome stain&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Glucocorticoids:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;May result in weakness of scar–inhibition of TGF-β&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anti-inflammatory properties may be desirable in some cases&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InflammationRepairLecture/image91.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/InflammationRepairLecture/image91.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;Keloid showing “keloidal collagen” (arrows&lt;/p&gt;

&lt;h3 id=&quot;immunopathology-study&quot;&gt;Immunopathology study&lt;/h3&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image32.jpeg&quot;&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image32.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image32.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.biomedcentral.com/1471-230X/11/36/figure/F4?highres=y&quot;&gt;diffuse Duodenal Nodular Lymphoid Hyperplasia&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image30.jpeg&quot;&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image32.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image30.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://www.mja.com.au/sites/default/files/issues/198_03_180213/war11518_fm-2.jpg&quot;&gt;see figure with label&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image32.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image29.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.jacobspublishers.com/images/micro_11.3.jpg&quot;&gt;Liver core biopsy with lymphocytic infiltration of the portal tract&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image32.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image27.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;Histological examination of nodules shows that they consist of a shell of fibrous tissue surrounding a center of fibrinoid necrosis. Pea sized nodules have one centre. Larger nodules tend to be multilocular, with many separate shells or with connections between the necrotic centres. Individual necrotic centres may contain a cleft or several centres of necrosis may all open on to a large bursal pocket containing synovial fluid.&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image32.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image29.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.pathologystudent.com/wp-content/uploads/2009/04/hashimotos-follicle-thyroid-glands-2.jpg&quot;&gt;Hashimotos&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image32.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image6.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image32.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image38.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.pathologystudent.com/?p=3566&quot;&gt;explanation between pemphigus vulgaris and Bullous pemphigoid&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image32.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image8.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://library.med.utah.edu/WebPath/GIHTML/GI147.html&quot;&gt;pernicious anemia in gastritis&lt;/a&gt;&lt;/p&gt;

&lt;h2 id=&quot;additonal-images-mentioned-from-lectures&quot;&gt;additonal images mentioned from lectures&lt;/h2&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/4.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/4.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
&lt;em&gt;Primary biliary cirrhosis&lt;/em&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/3.png&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/3.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
&lt;em&gt;close up&lt;/em&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;check &lt;a href=&quot;https://www.youtube.com/watch?v=Jj8ozr_IttM&quot;&gt;video explanation&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/1.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/1.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
&lt;em&gt;Chronic Active Hepatitis&lt;/em&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=CzKGvWZrUpU&quot;&gt;video explanation&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/2.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/2.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
&lt;em&gt;[piece meal necrosis&lt;/em&gt;
&lt;strong&gt;from slide 44 Autoimmune disease ppt&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/11.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/11.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Goodpasture epithelial crescent/type II/IF&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/8.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/8.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Farmer’s Lung/granulomas&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/9.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/9.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Granulomas&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/10.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/10.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;Note&lt;/strong&gt; lack of necrosis of the vascular walls&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=805YGsF5jJ0&quot;&gt;Goodpasture syndrome video explanation&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/12.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/12.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Lymphorrhage  associated with muscle atrophy in myasthenia gravis patient&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/13.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/13.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Dermatomyositis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;perivesicular inflammation, atrophy of muscle&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/14.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/14.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
* Polymyositis&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Polymyositis showing extensive degeneration and focal necrosis of muscle fibers with phagocytosis and focal lymphocytic infiltration.
variation of muscle fiber sizes&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;inflammatory myopathy IgG and C3&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/14.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/14.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;pancreas&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;note&lt;/strong&gt; : juvenle Diabetes is autoimmune/Adult is not*&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;IgG4 Related Disease&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/15.jpg&quot;&gt;Polyarteritis  Nodosa&lt;/a&gt;
(/assets/pathology/test1/Immunopathologyfigures/media/lectures/16.jpg)&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/17.jpg&quot;&gt;Polyarteritis  Nodosa in pancreas&lt;/a&gt;
&lt;a href=&quot;http://www.proteinatlas.org/images_dictionary/pancreas__1__example_1__overview.jpg&quot;&gt;compare to normal pancrease&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;postulated as being associated with hepytitis B antigen&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=57s-GoqXSbs&quot;&gt;video explanation&lt;/a&gt;
&lt;em&gt;note: the fribinoid necrosis&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;&quot;&gt;Temporal Arteritis&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/18.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/18.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
* cross reactivity &lt;em&gt;note the middle figure&lt;/em&gt;&lt;/a&gt;&lt;/p&gt;

&lt;h5 id=&quot;hyperacute-rejection&quot;&gt;Hyperacute rejection&lt;/h5&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/19.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/19.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
Kidney Hyperacute Rejection: Note endothelium of lumen in artery&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/19.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/19.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/20.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/20.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
Kidney glomerulus in Hypercute Rejection – &lt;strong&gt;Note Fibrin Plugs&lt;/strong&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;note&lt;/strong&gt; major difference between hyperacute and acute rejection is that&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;hyperacute is more about glomerulus and fibrin plugs&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;acute is more about tubular infultration by lymphocytes&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h5 id=&quot;acute-rejection&quot;&gt;Acute Rejection&lt;/h5&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/21.png&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/21.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Acute Rejection Kidney – Note: Pale, Swollen with Subcapsular Hemorrhage&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/22.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/22.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Acute Rejection Kidney – Note Hemorrhagic Medullary Areas&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/23.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/23.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
* Acute Rejection Kidney -  Note: Lymphocytic Infiltration in Interstitium Attacking Tubule Basement Membrane&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=e181JDaw8LM&quot;&gt;Acute Rejection video explanation&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/24.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/24.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Acute Rejection Kidney Glomerulus Spared – Note: Lymphocytic Infiltration in Interstitium attacking tubule basement membranes&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/25.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/25.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/26.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/26.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/27.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/27.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Acute Rejection Kidney showing T-cells attacking Tubule Basement Membranes&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/28.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/28.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Acute Rejection Kidney – Note: Numerous T-cells in Interstitium attacking tubules&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/29.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/29.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/31.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/31.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/32.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/32.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Positive C4d Staining of Peritubular Capillaries demonstrating Humoral Ab&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/33.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/33.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/34.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/34.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Vascular Rejection of Renal Artery – Note: Marked Proliferation of Endothelial Cells with Partial Occlusion of Lumen&lt;/li&gt;
&lt;/ul&gt;

&lt;h4 id=&quot;chronic-rejection&quot;&gt;Chronic rejection&lt;/h4&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/47.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/47.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/48.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/48.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Arteriosclerotic-type Lesion of Artery in Chronic Rejection&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/49.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/49.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Arteriosclerotic Type of Chronic Rejection with Intimal Proliferation&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/50.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/50.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/51.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/51.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=qYQ6ynfY1_E&quot;&gt;Check video explanation&lt;/a&gt;&lt;/p&gt;

&lt;h4 id=&quot;graft-vs-host-disease&quot;&gt;Graft-vs-Host Disease&lt;/h4&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/40.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/40.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
* Destruction of Basal Layer Cells in Skin during GVH Disease&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/41.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/41.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Crypts of Lieberkuhn of Gut demonstrating Infiltration of Transplanted T-Cells in GVH Disease&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/42.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/42.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Cross Section of Crypts being Destruction by T-Cells&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/43.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/43.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Normal Vessel in Liver – Note: Bile Duct Destruction by Donor T-Cells&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/44.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/44.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Portal Area of Liver with Extensive Donor T-Cells in GVH Disease&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/45.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/45.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Veno-Occlusive Disease of Central Vein in Liver – GVH Disease&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/46.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/46.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Hyperacute GVH Disease in Pediatric Case&lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;autoimmune-diseases&quot;&gt;Autoimmune Diseases&lt;/h3&gt;

&lt;h5 id=&quot;systemic-lupus-erythematosus&quot;&gt;Systemic lupus erythematosus&lt;/h5&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image11.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image11.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Discoid SLE(localized)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image22.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image22.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
* the giant cell in middle is an LE cell. 
&lt;a href=&quot;https://en.wikipedia.org/wiki/LE_cell&quot;&gt;Check for further details&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image23.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image23.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/image39.jpg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/lectures/image39.jpg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;h5 id=&quot;sjgrens-syndrome&quot;&gt;Sjögren’s syndrome&lt;/h5&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image33.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image33.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;A, Enlargement of the salivary gland. B, Histopathologic findings include intense lymphocytic and plasma cell infiltration with ductal epithelial hyperplasia.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image35.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image35.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Salivary gland duct &lt;strong&gt;lining cell&lt;/strong&gt; staining for antibody in about 15% of Sjögren cases&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image38.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image38.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;h5 id=&quot;wegener-granulomatosis&quot;&gt;Wegener granulomatosis&lt;/h5&gt;

&lt;ul&gt;
  &lt;li&gt;Extensive inflammatory cells in maxillary and ethmoid sinus bx in Wegener granulomatosis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image42.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image42.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
* Obliterative necrotizing arteritis of vasculature in Wegener granulamotosis&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=-sNcAiRWLTU&quot;&gt;video explanation for WG&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image43.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image43.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Anti-neutrophil cytoplasmic antibody (ANCA) in systemic vasculitidies&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image44.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image44.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Necrotizing arteritis in Wegener granulomatosis.  Marked destruction of vessel wall with heavy lymphocytic infiltrate together with some polymorphonuclear leukocytes&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image45.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image45.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Later phase of previous slide showing early fibroblastic proliferation and chronic inflammatory cells (lymphocytes) (Wegener granulamatosis)&lt;/li&gt;
&lt;/ul&gt;

&lt;h5 id=&quot;progressive--systemic--sclerosis&quot;&gt;Progressive  Systemic  Sclerosis&lt;/h5&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image47.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image47.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image51.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image51.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Skin in scleroderma (progressive systemic sclerosis. Note prominent collagen deposition in the dermis yet skin appendages are still intact.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image52.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image52.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Extensive collagen deposition and disappearance of appendages, due to loss of their blood supply and thinning of the epidermis in scleroderma (PSS)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image53.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image53.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;h5 id=&quot;mixed-connective-tissue-disease&quot;&gt;mixed connective tissue disease&lt;/h5&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image60.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image60.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Mixed connective tissue disease: skin with collagenous thickening of papillary and reticular dermis, mild perivascular mononuclear cell infiltration and mild atrophy and hyperkeratosis of the epidermis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image62.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image62.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Speckled (other particulate) pattern of nuclear fluorescence of epidermal nuclei in mixed connective tissue disease&lt;/li&gt;
&lt;/ul&gt;

&lt;h5 id=&quot;rheumatoid-arthritis&quot;&gt;Rheumatoid Arthritis&lt;/h5&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image67.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image67.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;Aspirate of synovial joint in rheumatoid arthritis showing inflammatory cells and fibrin deposits&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image71.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image71.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image73.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image73.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
* Histopathology of rheumatoid nodule showing central fibrinoid necrosis surrounded by macrophages rimmed by granulation tissue and lymphocytes&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image75.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image75.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
* &lt;strong&gt;Pannus&lt;/strong&gt; formation with inflammatory destruction of articular cartilage followed by erosion of bone in rheumatoid arthritis&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=ZcTi28aBY1s&quot;&gt;video explanation for RA&lt;/a&gt;&lt;/p&gt;

&lt;h5 id=&quot;amyloidosis&quot;&gt;Amyloidosis&lt;/h5&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image76.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image76.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image77.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image77.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image82.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/3rdLecture-AutoImmuneDisease/image82.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Congo red stain of amyloid in vascular wall. (left)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Silver birefringence of same stain viewed by polarizing light microscopy. (right)&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;primary-immunodeficiences&quot;&gt;Primary Immunodeficiences&lt;/h3&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image4.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image4.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Interference at 12 weeks gestation leads to immunodeficiency with hypoparathyroidism&lt;/li&gt;
&lt;/ul&gt;

&lt;h4 id=&quot;digeorge-syndrome&quot;&gt;DiGeorge Syndrome&lt;/h4&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image5.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image5.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;DiGeorge syndrome thymus showing &lt;strong&gt;small Hassal’s corpuscles&lt;/strong&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image6.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image6.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Lymph node in DiGeorge syndrome showing depleted T cell-dependent areas, whereas B cell areas are intact&lt;/li&gt;
&lt;/ul&gt;

&lt;h4 id=&quot;x-linked-infantile-hypogammaglobulinemia&quot;&gt;X-linked Infantile Hypogammaglobulinemia&lt;/h4&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image9.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image9.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;Barium Swallow Radiograph; Boy with malabsorption syndrome. &lt;strong&gt;Giardia lamblia&lt;/strong&gt; frequent cause&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image15.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image15.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Lymph node biopsy after Ag stimulation showing corticomedullary differentiation but absence of B cell dependent areas (lack of follicles). T cell areas are intact.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image16.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image16.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Thymus in Bruton’s showing normal architecture with Hassal’s corpuscles&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image21.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image21.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;SCID / Open lung biopsy showing Pneumosystis jiroveci microorganisms&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image22.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image22.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;
* SCID / Silver stain of Pneumocystis jiroveci&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image23.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image23.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The thymus in severe combined immunodeficiency (SCID) showing only reticulum cells and fatty tissue. Prior to this, the thymus was markedly hypoplastic with no corticomedullary differentiation and no Hassal’s corpuscles.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;chronic granulomatous disease&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;decreased oxidative burst.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;Phagocytic disorders&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Chronic granulomatous disease&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Myeloperoxidase deficiency&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Job syndrome&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Chédiak-Higashi syndrome&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Disorders associated with chemotactic dysfunction&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image34.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/PrimaryImmunodeficiences/image34.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;Patient with hereditary angioedema due to C1 esterase inhibitor deficiency&lt;/p&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/HIVlecture/image32.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/HIVlecture/image32.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Pneumocystis jirovec in bronchial washings of AIDS patient&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/HIVlecture/image33.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/HIVlecture/image33.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Pneumocystis jiroveci in transbronchial biopsy of lung in AIDS patient&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/HIVlecture/image35.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/HIVlecture/image35.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Mycobacterium avium intercellulare infection of lung in AIDS&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/HIVlecture/image36.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/HIVlecture/image36.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;High power mag. Mycobacterium avium intercellulare in lung in AIDS&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/HIVlecture/image37.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/HIVlecture/image37.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Cryptosporidium, a protozoan parasite that causes severe diarrhea in AIDS patients (red stained in fecal contents)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/HIVlecture/image38.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/HIVlecture/image38.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;CMV inclusion bodies in rectal mucosa in AIDS patient&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/HIVlecture/image39.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/HIVlecture/image39.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;CMV inclusion bodies in rectal mucosa in AIDS patient&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/HIVlecture/image40.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/HIVlecture/image40.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Giardia lamblia (a protozoan) in the gut of AIDS patient&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/HIVlecture/image43.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/HIVlecture/image43.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Kaposi sarcoma histopathology in HIV infection&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;https://www.youtube.com/watch?v=ZXk5k6k5-Ks&quot;&gt;video explanation for Kaposi Sarcoma&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/HIVlecture/image64.jpeg&quot;&gt;Immune reconstitution inflammatory syndrome (IRIS)/ Immune restoration disease (IRD)&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.who.int/topics/antiretroviral_therapy/en/&quot;&gt;HAART&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;flow-cytometry&quot;&gt;flow cytometry&lt;/h3&gt;

&lt;p&gt;cd45 leukocyte common antigen&lt;/p&gt;

&lt;p&gt;CD34 stem cell&lt;/p&gt;

&lt;p&gt;CD 33 myeloid cell marker&lt;/p&gt;

&lt;p&gt;CD 13 myeloid cell marker&lt;/p&gt;

&lt;h3 id=&quot;hiv&quot;&gt;HIV&lt;/h3&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/HIVlecture/image19.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/HIVlecture/image19.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
&lt;a&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;neoplasia&quot;&gt;Neoplasia&lt;/h3&gt;

&lt;p&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image32.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/neoplasiafigures/image16.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;&lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/InjuryStudyFigure/image32.jpeg&quot;&gt;
&lt;img src=&quot;/assets/pathology/test1/neoplasiafigures/image18.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;&lt;/a&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://patient.info/education/cervical-carcinoma&quot;&gt;Cervical intraepithelial neoplasia explanation&lt;/a&gt;&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Immunopathology figures review</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/09/10/immunopathology-figures2/"/>
   <updated>2015-09-10T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/09/10/immunopathology-figures2</id>
   <content type="html">&lt;style&gt;
div.img {
    margin: 5px;
    padding: 5px;
    border: 1px solid #cccccc;
    height: auto;
    width: auto;
    float: left;
    text-align: center;
}

div.img img {
    display: inline;
    margin: 5px;
    border: 1px solid #cccccc;
}

div.img a:hover img {
    border:1px solid #cccccc;
}

div.desc {
    text-align: center;
    font-weight: normal;
    font-size: 12px;
    width: 200px;
    margin: 5px;
}
&lt;/style&gt;

&lt;body&gt;

&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image2.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image2.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Type I hypersensitivity reaction &lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image3.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image3.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Stomach, pernicious anemia&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image4.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image4.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Indirect Immunofluorescence: Anti-mitochondrial antibodies demonstrated in kidney proximal tubule cells&lt;/div&gt;
&lt;/div&gt;
&lt;!--break--&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image5.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image5.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Skin Biopsy, Pemphigus vulgaris&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image6.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image6.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Direct Immunofluorescence: Pemphigus vulgaris&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image7.png&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image7.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Systemic sclerosis with cutaneous fibrosis and ulcerations&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image8.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image8.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Indirect Immunofluorescence:  Anti-parietal cell antibodies&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image9.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image9.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Kidney, hyperacute rejection&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image10.png&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image10.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Transplanted kidney showing changes of antibody-mediated acute rejection within a blood vessel&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image11.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image11.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Type IV Hypersensitivity&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image12.png&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image12.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Patient with Lupus&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/bb.png&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/bb.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;skin biopsy showing a positive lupus band test at the dermal-epidermal junction&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image13.png&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image13.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Hashimoto Thyroiditis&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image14.png&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image14.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Kidney, hyperacute rejection&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/cc.png&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/cc.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Patient with Hashimoto Thyroiditis&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/dd.png&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/dd.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;normal thyroid (left) germinal center and tissue destruction (right)&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image18.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image18.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Kidney, acute rejection&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image19.png&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image19.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Glomerulus: PAS stain showing “wire loops” in patient with SLE&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image20.png&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image20.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Skin with Type IV hypersensitivity reaction&lt;/div&gt;
&lt;/div&gt;
&lt;/body&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image21.png&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image21.png&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Skin with Type IV hypersensitivity reaction&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image22.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image22.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Mast cells in Type I hypersensitivity reactions&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image23.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image23.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Skin rash: graft-versus-host disease&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image24.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image24.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Kaposi Sarcoma&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image25.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image25.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Skin biopsy showing graft-versus-host disease&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image26.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image26.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Graft-versus-host disease, colon&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image27.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image27.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Rheumatoid nodule&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image28.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image28.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Graft-versus-host disease, colon&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image29.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image29.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Graft-versus-host disease, liver&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image30.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image30.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Skin biopsy of SLE&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image31.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image31.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Lupus nephritis&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image32.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image32.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;diffuse prolifrative lupus nephritis&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image33.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image33.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Libman-Sacks endocarditis of the mitral valve in SLE&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image34.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image34.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;H&amp;amp;E stain of Salivary gland, Sjogren Syndrome&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image35.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image35.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Synovial histology in RA&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image36.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image36.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Pneumocystis jiroveci pneumonia, silver stain&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image37.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image37.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Lymphoid hyperplasia in HIV&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;img&quot;&gt;
  &lt;a target=&quot;_blank&quot; href=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image38.jpeg&quot;&gt;
    &lt;img src=&quot;/assets/pathology/test1/Immunopathologyfigures/media/image38.jpeg&quot; alt=&quot;Klematis&quot; width=&quot;200&quot; height=&quot;180&quot; /&gt;
  &lt;/a&gt;
  &lt;div class=&quot;desc&quot;&gt;Direct Immunofluorescence: Bullous pemphigoid&lt;/div&gt;
&lt;/div&gt;
&lt;p style=&quot;clear: both;&quot;&gt;





&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>How to create a photo gallery with HTML and CSS</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/09/10/how-to-make-a-photo-gallery/"/>
   <updated>2015-09-10T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/09/10/how-to-make-a-photo-gallery</id>
   <content type="html">&lt;p&gt;This will work on platforms like Wordpress or Jekyll that let you minipulate “code” and input HTML directly. Although there are many web publishing tools included with photo gallery widgets or other plugins which can take care of this task for you, but knowing how to code it yourself is still something enjoyable to do!&lt;/p&gt;

&lt;!--break--&gt;

&lt;p&gt;Here is an example which I built for my pathology review.&lt;/p&gt;

&lt;p&gt;Before we start, we need to get some photos. To make thing easy for you, I have already prepare some lovely&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/blogimages/build%20a%20photo%20gallery/cat.zip&quot;&gt;cat&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;for you. Please go ahead and download them and unzip the files and place them into your Jekyll blog’s main directory. In my case, I created a folder “asset” which store all my media files there.&lt;/p&gt;

&lt;p&gt;Once you get the previous steps setup, it is time to create a new post. If you are a beginner and do not know Jekyll well you could certainly learn all the basic quickly by visitting &lt;a href=&quot;http://joshualande.com/jekyll-github-pages-poole/&quot;&gt;Joshua Lande’s&lt;/a&gt;blog, where you should find all the necessary information to help you get started.&lt;/p&gt;

&lt;p&gt;Once you created a new post, add the following chunk of code to the start, this is to set up the CSS style of the gallery layout.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;&amp;lt;style&amp;gt;
div.img {
    margin: 5px;
    padding: 5px;
    border: 1px solid #cccccc;
    height: auto;
    width: auto;
    float: left;
    text-align: center;
}

div.img img {
    display: inline;
    margin: 5px;
    border: 1px solid #cccccc;
}

div.img a:hover img {
    border:1px solid #cccccc;
}

div.desc {
    text-align: center;
    font-weight: normal;
    font-size: 12px;
    width: 200px;
    margin: 5px;
}
&amp;lt;/style&amp;gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;
</content>
 </entry>
 
 <entry>
   <title>Pathology quiz 2 answer and explaination</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/09/06/pathology-quiz-2/"/>
   <updated>2015-09-06T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/09/06/pathology-quiz-2</id>
   <content type="html">&lt;h3 id=&quot;question-1&quot;&gt;Question 1&lt;/h3&gt;

&lt;p&gt;Within minutes after a bee sting, a 15 year-old girl suddenly has difficulty breathing. There is marked urticaria and marked edema of the hand that was stung. Which of the following is the best pharmacologic agent to treat these signs and symptoms?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Penicillin&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Epinephrine&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Glucocorticoids&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Methotrexate&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Cyclosporine&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;!--break--&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;This girl has experienced a systemic anaphylactic reaction from a type I hypersensitivity reaction. Epinephrine is the fastest acting agent to treat this life-threatening condition. Cyclosporine is used to minimize transplant rejection. Penicillin is an antibiotic that often induces a type I hypersensitivity reaction. Glucocorticoids can reduce immune reactions, although this occurs over days to weeks, not minutes. Methotrexate is useful in the treatment of graft-versus-host disease.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-2&quot;&gt;Question 2&lt;/h3&gt;

&lt;p&gt;A 20 year-old man steps into an elevator full of people who are coughing and sneezing, all of whom appear to have colds or the flu. The influenza viral particles that he inhales attach to the respiratory epithelium, and viral transformation reduces the MHC class I molecules on these epithelial cells. Which of the following cells is most likely to respond to destroy these infected cells?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Natural killer cell&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Dendritic cell&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD4 cell&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Neutrophil&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Macrophage&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Natural killer (NK) cells have the ability to respond without prior sensitization. They carry receptors for MHC class I molecules, which inhibit their lytic function. When expression of class I MHC molecules is reduced on a cell surface by viral interference, the inhibitory receptors on NK cells do not receive a negative signal, and the targeted cell is killed. NK cells are often the first line of defense against viral infection. CD4+ cells are helper T cells that assist other cells, such as NK cells, macrophages, and B cells, in the immune response. Dendritic cells aid in antigen presentation. Mac- rophages can phagocytize necrotic cells, then process and display any foreign antigens within those cells. Neutrophils provide a nonspecific immune response, primarily to bacte- rial infections and not to intracellular viral infections.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-3&quot;&gt;Question 3&lt;/h3&gt;

&lt;p&gt;A 30 year-old woman has had fever and arthralgia for the past two weeks. On physical examination, she has a temperature of 37.6 degrees C and an erythematous malar rash. Initial laboratory studies are also positive for ANAs at 1:1600 and anti-double-stranded DNA antibodies at 1:3200. Serum creatinine is markedly elevated, and serum complement levels are decreased. A VDRL test for syphilis is positive, and in vitro tests of coagulation (prothrombin time and partial thromboplastin time) are prolonged. Which of the following clinical features of her illness is most likely caused by antibodies that interfere with the coagulation tests?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Arthritis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Rash&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Renal failure&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Recurrent thrombosis&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Fever&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;This patient has clinical and serologic features of systemic lupus erythematosus (SLE). She also has a false-positive test result for syphilis, indicating the presence of anticardiolipin antibodies. These antibodies against phospholipid-protein complexes (antiphospholipid antibodies) also are called lupus anticoagulants because they interfere with in vitro clotting tests. In vivo, they are thrombogenic. Hence, these patients can have recurrent thrombosis. Lupus anticoagulants also can occur in the absence of SLE. The other listed options can occur in SLE, but they are not mediated by antiphospholipid antibodies.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-4&quot;&gt;Question 4&lt;/h3&gt;

&lt;p&gt;A 35 year-old man has a history of mild infections of the upper respiratory tract. He also has had diarrhea for most of his life, although it was not severe enough to cause malabsorption and weight loss. After an episode of trauma with blood loss, he receives a blood transfusion and has an anaphylactic reaction. Which of the following underlying conditions best explains these findings?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Selective IgA deficiency&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;DiGeorge syndrome&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Severe combined immunodeficiency&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;HIV infection&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Wiskott-Aldrich syndrome&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Patients with IgAD are at some increased risk of developing severe reactions after receiving blood products.[13, 14, 15] IgG anti-IgA antibodies may cause severe transfusion reactions if patients with IgAD are given whole blood; therefore, IgA-poor blood or washed red cells are preferred for those patients. IgA-deficient patients with immunoglobulin E (IgE)–class anti-IgA antibodies are at risk for anaphylaxis if they receive blood or intravenous immunoglobulin, but this situation is extremely rare. Individuals with such an unusual profile should receive only low IgA intravenous immunoglobulin preparations. However, caution must be used when administering IGIV to patients with IgAD if their anti-IgA status is unknown.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;a href=&quot;http://emedicine.medscape.com/article/136580-overview&quot;&gt;source of explanation&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;question-5&quot;&gt;Question 5&lt;/h3&gt;

&lt;p&gt;Laboratory tests are ordered for two hospitalized patients. During the phleobotomy procedure, the Vacutainer tubes drawn from these patients are mislabeled. One of the patients receives a blood transfusion later that day. Within one hour after the transfusion of RBCs begins, the patient becomes tachycardic and hypotensive and passes pink-colored urine. Which of the following statements best describes how the reaction is mediated?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Mast cell degranulation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Release of tumor necrosis factor alpha into the circulation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Antigen-antibody compex deposition in glomeruli&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Antibody-dependent cellular cytotoxicity by natural killer cells&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Complement-mediated lysis of RBCs&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;A major transfusion reaction results from a type II hypersensitivity reaction. The patient’s serum contains natu- rally occurring antibodies to the incompatible donor RBCs. They attach to the donor RBCs and induce complement activation that results in generation of the C5-9 membrane attack complex. Major transfusion reactions are rare, and&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-6&quot;&gt;Question 6&lt;/h3&gt;

&lt;p&gt;A 40 year-old laboratory technician accidentally injects a chemical into his skin. The next day, he notes that an area of erythematous, indurated skin is forming around the site of injection. Two days later, the induration measures 10mm in diameter. A microscopic section from this area, with immunostaining using an antibody to CD4, shows many positive lymphocytes. Which of the following immunologic reactions is most consistent with this appearance?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Systemic anaphylaxis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Delayed-type hypersensitivity&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Graft-versus-host disease&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Serum sickness&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Arthus reaction&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Perivascular accumulation of T cells, particularly CD4+ cells, is typical of delayed hypersensitivity skin reactions, driven by a TH1 response mediated largely by release of the cytokine interleukin-2. Systemic anaphylaxis typically occurs within minutes after an encounter with the antigen. Systemic and localized immune complex diseases (serum sickness and Arthus reactions) are type III hypersensitivity reactions; they often exhibit vasculitis. Graft-versus-host disease is characterized by epidermal apoptosis and rash.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-7&quot;&gt;Question 7&lt;/h3&gt;

&lt;p&gt;A 45 year-old woman has had a burning sensation with increasing blurring of vision for the past five years. On physical examination, she has keratoconjunctivitis. Atrophy of the oral mucosa, with buccal mucosal ulcerations, is also present. A biopsy specimen of the lip shows marked lymphocytic and plasma cell infiltration of the minor salivary glands. Which of the following antibodies is most likely to be identified on laboratory testing?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Anti-double-standed DNA&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anti-centromere&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Scl-70&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;SS-B&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Jo-1&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Sjogren syndrome primarily involves salivary and lacrimal glands. Antibodies to SS-B are found in the majority of these patients. Anti–double-stranded DNA is a specific autoantibody for systemic lupus erythematosus. Anticen- tromere antibody is seen most often in limited systemic sclerosis, whereas anti–DNA topoisomerase most often ap- pears with diffuse systemic sclerosis. U1-RNP is a marker for mixed connective tissue disease (MCTD).&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-8&quot;&gt;Question 8&lt;/h3&gt;

&lt;p&gt;A 22 year-old man has had a urethral discharge for the past week. A culture of the exudate from the urethra grows Neisseria gonorrhoeae. He is treated with penicillin G, but within minutes after injection, he develops itching and erythema of the skin. This is quickly followed by severe respiratory difficulty with wheezing and stridor. Which of the following immunoglobulins has most likely become attached to the penicillin G and mast cells to produce these symptoms?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;IgG&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;IgD&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;IgA&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;IgE&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Ig M&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;This patient is experiencing a systemic anaphylactic reaction, a form of type I hypersensitivity. IgE is bound to mast cells, after previous sensitization, so that a repeat encounter with the antigen results in mast cell degranulation and the release of mediators, such as histamine, which lead to anaphylaxis. IgE also is important in mediating more localized inflammatory reactions such as allergic rhinitis (hay fever). Other immunoglobulins do not bind so readily to mast cells.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-9&quot;&gt;Question 9&lt;/h3&gt;

&lt;p&gt;A 37 year-old man who is HIV positive has noticed multiple 0.5 to 1.2 cm plaque-like, reddish-purple skin lesions on his face, trunk, and extremities. Some of the larger lesions appear to be nodular. These lesions have appeared over the past six months and have slowly enlarged. Molecular analysis of the spindle cells found in these skin lesions is likely to reveal a genome of which of the following viruses?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Cytomegalovirus&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;HIV-1&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Adenovirus&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Epstein-Barr virus&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Human herpesvirus-8&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Human herpesvirus-8 has been associated with Kaposi sarcoma and can be acquired as a sexually transmitted disease. Kaposi sarcoma is a complication of AIDS. Individuals with HIV infection can be infected with various viruses, including Epstein-Barr virus (EBV) and cytomegalovirus (CMV), but these have no etiologic association with Kaposi sarcoma. EBV is a factor in the development of non-Hodgkin lymphoma, and CMV can cause colitis or retinitis or can be disseminated. Hepatitis B virus can be seen in HIV-infected patients as well, particularly patients with a risk factor of injection drug use. Adenovirus, which, although rare, can be seen in HIV-infected individuals, tends to be a respiratory or gastrointestinal infection.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-10&quot;&gt;Question 10&lt;/h3&gt;

&lt;p&gt;A 31 year-old woman has had increasing edema, chest pain, and an erythematous rash for the past six months. Laboratory studies show increasing serum creatinine, and urinalysis shows proteinuria with RBC casts. If present, which of the following antibodies is most helpful in diagosing this patient’s condition?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Jo-1&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anti-HLA-B27&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anti-Sm&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Anti-centromere&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Scl-70&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Anti-Sm and anti–double-stranded DNA are specific for systemic lupus erythematosus. Anti-Sm is present in only 25% of cases, however. Scl-70 is a marker for diffuse systemic sclerosis. Jo-1 is most specific for polymyositis. HLA-B27 is seen in ankylosing spondylitis. Anticentromere antibody is seen most often with limited scleroderma.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

</content>
 </entry>
 
 <entry>
   <title>Pathology quiz 1 answer and explaination</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/09/06/pathology-quiz-1/"/>
   <updated>2015-09-06T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/09/06/pathology-quiz-1</id>
   <content type="html">&lt;h3 id=&quot;question-1&quot;&gt;Question 1&lt;/h3&gt;

&lt;p&gt;At autopsy, the heart of a 63 year-old man weighs only 250 grams and has small right and left ventricles. The myocardium is firm, with a dark chocolate-brown color throughout. The coronary arteries show minimal atherosclerotic changes. An excessive amount of which of the following substances will be found in the myocardial fibers of this heart?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Lipofuscin&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Bilirubin&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Hemosiderin&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Melanin&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;!--break--&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Lipofuscin is a “wear-and-tear” pigment that in- creases with aging, particularly in liver and myocardium. This granular golden brown pigment seen adjacent to the myocyte nucleus in the figure has minimal effect on cellu- lar function in most cases. Rarely, there is marked lipofus- cin deposition in a small heart, a so-called brown atrophy. Bilirubin, another breakdown product of hemoglobin, im- parts a yellow appearance (icterus) to tissues. Hemosiderin is the breakdown product of hemoglobin that contains the iron. Hearts with excessive iron deposition tend to be large. Glycogen is increased in some inherited enzyme disorders, and when the heart is involved, heart size increases. Melanin pigment is responsible for skin tone: the more melanin, the darker the skin.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-2&quot;&gt;Question 2&lt;/h3&gt;

&lt;p&gt;A 40 year-old woman has had chronic congestive heart failure for the past three years. In the past two months, she developed a cough productive of rust-colored sputum. A sputum cytology specimen shows numerous hemosiderin-laden macrophages. Which of the following subcellular structures in macrophages is most important for the accumulation of this pigment?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Chromosome&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Ribosome&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Endoplasmic reticulum&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Lysosome&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Golgi apparatus&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Heterophagocytosis by macrophages requires that endocytosed vacuoles fuse with lysosomes to degrade the engulfed material. With congestive heart failure, extravasation&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-3&quot;&gt;Question 3&lt;/h3&gt;

&lt;p&gt;A 38 year-old man has had headaches and nausea for the past 2 months. Laboratory findings show hypercalcemia and hypophosphatemia and normal serum albumin. Urine microscopic analysis shows deposition of calcium salts in the renal tubular epithelium. Which of the following processes has most likely produced this change in the kidney?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Cellular aging&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Dystrophic calcification&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Autophagocytosis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Metastatic calcification&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Renal tubular atrophy&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Metastatic calcification can occur widely throughout the body but principally affects the interstitial tissues of the vas- culature, kidneys, lungs, and gastric mucosa. The calcium deposits morphologically resemble those described in dys- trophic calcification&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-4&quot;&gt;Question 4&lt;/h3&gt;

&lt;p&gt;A 38 year-old man has had headaches and nausea for the past 2 months. Laboratory findings show hypercalcemia and hypophosphatemia and normal serum albumin. Urine microscopic analysis shows deposition of calcium salts in the renal tubular epithelium. Which of the following processes has most likely produced this change in the kidney?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Dystrophic calcification&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Autophagocytosis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Cellular aging&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Metastatic calcification&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Renal tubular atrophy&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Metastatic calcification can occur widely throughout the body but principally affects the interstitial tissues of the vas- culature, kidneys, lungs, and gastric mucosa. The calcium deposits morphologically resemble those described in dys- trophic calcification&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-5&quot;&gt;Question 5&lt;/h3&gt;

&lt;p&gt;An experiment introduces bacteria into a perfused tissue preparation. Leukocytes then leave the vasculature and migrate to the site of bacterial inoculation. The movement of these leukocytes is most likely to be mediated by which of the following substances?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Prostaglandins&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Bradykinin&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Chemokines&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Histamine&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Complement C3a&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Chemokines include many molecules that are chemotactic for neutrophils, eosinophils, lymphocytes, monocytes, and basophils. Bradykinin causes pain and increased vascu- lar permeability. Complement C3a causes increased vascular permeability by releasing histamine from mast cells. Hista- mine causes vascular leakage. Prostaglandins have multiple actions, but they do not cause chemotaxis.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-6&quot;&gt;Question 6&lt;/h3&gt;

&lt;p&gt;An 18 year-old man lacerated his left hand and required sutures. The sutures were removed one week later. Wound healing continued, but the site became disfigured by a prominent raised, nodular scar that developed over the next two months. Which of the following terms best describes the process that occurred during this 2-month period?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Keloid formation&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Dehiscence&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Secondary union&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Organization&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Resolution&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;The healing process sometimes results in an exuber- ant production of collagen, giving rise to a keloid, which is a prominent raised, nodular scar, as shown in the figure. This tendency may run in families. Dehiscence occurs when a wound pulls apart. Organization occurs as granulation tissue is replaced by fibrous tissue. If normal tissue architecture is restored, resolution of inflammation has occurred. Second- ary union describes the process by which large wounds fill in and contract.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-7&quot;&gt;Question 7&lt;/h3&gt;

&lt;p&gt;A 59 year-old man has had a cough and fever for the past week. On physical exam, his temperature is 38.5 degrees Celsius. On auscultation, he has decreased breath sounds and dullness to percussion over the right lung. A chest radiograph shows fluid in the right pleural cavity. Thoracentesis yields 500 mL of cloudy yellow fluid. Which of the following cell types is most likely to be abundant in this fluid?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Eosinophils&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;CD4 lymphocytes&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Macrophages&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Plasma cells&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Neutrophils&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Bacterial infections often evoke an acute inflammatory response dominated by neutrophils. The extravasated neutro- phils attempt to phagocytose and kill the bacteria. In the pro- cess, some neutrophils die, and the release of their lysosomal enzymes can cause liquefactive necrosis of the tissue. This liquefied tissue debris and both live and dead neutrophils comprise pus, or purulent exudate. Such an exudate is typi- cal of bacterial infections that involve body cavities. Another term for purulent exudate in the pleural space is empyema.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-8&quot;&gt;Question 8&lt;/h3&gt;

&lt;p&gt;A 5 year-old child has a history of recurrent bacterial infections, inluding pneumonia and otitis media. Analysis of leukocytes collected from the peripheral blood shows a deficiency of myeloperoxidase. Which of the following is the most likely cause of this child’s increased susceptibility to infections?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Defective neutrophil degranulation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Defective production of prostaglandins&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Decreased oxygen consumption after phagocytosis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Failure to produce hydroxy-halide radicals (HOCL-)&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Failure to produce hydrogen peroxide&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Myeloperoxidase is present in the azurophilic gran- ules of neutrophils. It converts H2O2 into HOCl–, a power- ful oxidant and antimicrobial agent. Degranulation occurs as phagolysosomes are formed with engulfed bacteria in phagocytic vacuoles within the neutrophil cytoplasm. Oxy- gen consumption with an oxidative or respiratory burst after phagocytosis is aided by glucose oxidation and activation of neutrophil NADPH oxidase, resulting in generation of superoxide that is converted by spontaneous dismutation to H2O2. In contrast, prostaglandin production depends on a functioning cyclooxygenase pathway of arachidonic acid metabolism.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-9&quot;&gt;Question 9&lt;/h3&gt;

&lt;p&gt;A 35 year-old woman takes acetysalicylic acid (aspirin) for arthritis. Although her joint pain is reduced with this therapy, the inflammation process continues. The aspirin therapy alleviates her pain mainly through reduction in the synthesis of which of the following mediators?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Leukotriene E4&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Complement C1q&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Prostaglandins&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Nitric Oxide&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Histamine&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;Prostaglandins are produced through the cyclooxy- genase pathway of arachidonic acid metabolism. Aspirin and other nonsteroidal anti-inflammatory drugs block the synthesis of prostaglandins, which can produce pain. Com- plement C1q is generated in the initial stage of complement activation, which can eventually result in cell lysis. Hista- mine is mainly a vasodilator. Leukotrienes are generated by the lipoxygenase pathway, which is not blocked by aspirin. Nitric oxide released from endothelium is a vasodilator.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;question-10&quot;&gt;Question 10&lt;/h3&gt;

&lt;p&gt;On a routine visit to the physician, an otherwise healthy 51 year-old man has a blood pressure of 150/95 mmHg. If the patient’s hypertension remains untreated for years, which of the following cellular alterations will most likely be seen in the myocardium?&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Hyperplasia&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;strong&gt;Hypertrophy&lt;/strong&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Metaplasia&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Hemosiderosis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Atrophy&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;The pressure load on the left ventricle results in an increase in myofilaments in the existing myofibers, so they enlarge. The result of continued stress from hypertension is eventual heart failure with decreased contractility. Apoptosis would lead to loss of cells and diminished size. Dysplasia is not a diagnosis made for the heart. Hemosiderin deposition in the heart is a pathologic process resulting from increased iron stores in the body. Though hyperplasia from prolifera- tion of myofibroblasts is possible, this does not contribute significantly to cardiac size. Metaplasia of muscle does not occur, although loss of muscle occurs with aging and ischemia as myofibers are replaced by fibrous tissue.&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

</content>
 </entry>
 
 <entry>
   <title>Pathology reiew part IV Graphic recognication</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/09/04/pathology-review-4/"/>
   <updated>2015-09-04T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/09/04/pathology-review-4</id>
   <content type="html">&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/1.png&quot;&gt;Figure 1&lt;/a&gt;
diffuse reticulonodular pulmonary densities&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/2.png&quot;&gt;Figure 2&lt;/a&gt;
hows noncaseating granulomas with many epithelioid cells and two prominent large Langhans gi- ant cells. If special stains and/or cultures for organisms (usu- ally mycobacteria or fungi) are negative, then this is likely sarcoidosis.
&lt;!--break--&gt;
&lt;a href=&quot;/assets/pathology/test1/3.png&quot;&gt;Figure 3&lt;/a&gt;
shows a subacute infarction with granu- lation tissue formation containing numerous capillaries stimulated by vascular endothelial growth factor, repre- senting a healing response.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/4.png&quot;&gt;Figure 4&lt;/a&gt;
 shows dense collagen with some remaining dilated blood vessels, typical of the final phase of wound healing, which is extensive by the end of the first month.&lt;/p&gt;

&lt;p&gt;&lt;em&gt;note&lt;/em&gt;
 * On day 1, the wound is filled only with fibrin and inflammatory cells. 
 * Macrophages and granulation tissue are seen 2 to 3 days postoperatively. 
 * Neovascularization is most prominent by days 4 and 5.
 * By week 2, collagen is prominent, and fewer vessels and inflammatory cells are seen.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/5.png&quot;&gt;Figure 5&lt;/a&gt;
 The figure shows the so-called wire loop glomeru- lar capillary lesions of lupus nephritis. Anti-Smith and anti– double-stranded DNA are more specific for systemic lupus erythematosus, but sensitivity is low: anti-Smith is present in only 25% of SLE cases.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/6.png&quot;&gt;Figure 6&lt;/a&gt;
 immune complex–mediated glomerulonephritis
 The immune complexes activate complement and result in acute inflammation&lt;/p&gt;

&lt;h3 id=&quot;neoplastic-diseases&quot;&gt;Neoplastic diseases&lt;/h3&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/7.png&quot;&gt;Figure 7&lt;/a&gt;
The figure shows an in situ carcinoma of the squamous cervical epithelium with neoplastic growth only above the basement membrane.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/8.png&quot;&gt;Figure 8&lt;/a&gt;
The cells shown in the figure show marked pleomorphism and hyperchromatism (anaplasia), and it is difficult to discern the cell of origin because no differentiation is noted. A bizarre tripolar mitotic figure is present. This de- gree of anaplasia is consistent with an aggressive, high-grade malignancy called anaplastic carcinoma.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/9.png&quot;&gt;Figure 9&lt;/a&gt;
In the figure the disorderly, atypical epithelial cells involve the entire thickness of the epithelium. They extend through the underlying basement membrane and into the underlying stroma as rounded nests at the right, a process known as invasion. The ectocervix and the squamous metaplasia of endocervix give rise to dysplasia from which squamous cell carcinoma can arise.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/10.png&quot;&gt;Figure 10&lt;/a&gt;
The figure shows the appearance of multiple vari- ably sized tan metastatic lesions in the liver from hematogenous spread of carcinoma&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/11.png&quot;&gt;Figure 11&lt;/a&gt; 
Infiltrating ductal and intraductal carcinoma are present in the figure. Increased expression of ERBB2 (HER2) can be detected immunohistochemically and by fluorescence in situ hybridization (FISH) in the biopsy specimen. One third of breast cancers may show this change. Such amplifi- cation is associated with a poorer prognosis.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;/assets/pathology/test1/12.png&quot;&gt;Figure 12&lt;/a&gt; 
Thesmallcellshavescantcytoplasmbutmarkedhy- perchromatism, consistent with small cell anaplastic carcino- ma. This patient has Cushing syndrome resulting from ectopic corticotropin production by the tumor, a form of paraneoplas- tic syndrome common to small cell carcinomas of the lung. Such small cell carcinomas are of neuroendocrine derivation.&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Pathology reiew part III drugs</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/09/04/pathology-review-3/"/>
   <updated>2015-09-04T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/09/04/pathology-review-3</id>
   <content type="html">&lt;p&gt;NSAIDs
Naproxen&lt;/p&gt;

&lt;p&gt;Glucocorticoids&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;inhibit wound healing by impairing collagen synthesis.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;can be used to treat acute cellular rejection&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Penicillin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;an antibiotic that can induce a type I hypersensitivity reaction in sensitized persons.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;isoniazid&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;prophylactic therapy, TB&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;drug-induced systemic lupus erythematosus (SLE)&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;procainamide&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;drug-induced systemic lupus erythematosus (SLE)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;hydralazine&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;drug-induced systemic lupus erythematosus (SLE)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;imatinib&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;chronic myelogenous leukemia&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Agents that activate caspases&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;help in many cases, e.g. apoptosis is blocked as in tumors with BCL2 overexpression&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Antibodies to epithelial growth factor receptors&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;such as ERBB2 (HER2) receptors, are beneficial in certain breast tumors with amplification of this gene.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;methotrexate&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;treat graft-versus-host disease&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;penicillin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;antibiotics, and can induce type I hypersensitivity reaction in sensitized persons.&lt;/li&gt;
&lt;/ul&gt;

</content>
 </entry>
 
 <entry>
   <title>Pathology reiew part II diseases and symtoms</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/09/04/pathology-review-2/"/>
   <updated>2015-09-04T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/09/04/pathology-review-2</id>
   <content type="html">&lt;h3 id=&quot;inflammation-and-repair&quot;&gt;Inflammation and repair&lt;/h3&gt;

&lt;p&gt;Ankle swelling&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is most likely to result from peripheral edema secondary to congestive heart failure&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Increased susceptibility to bruising&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;prolonged glucocorticoid administration&lt;/li&gt;
&lt;/ul&gt;

&lt;!--break--&gt;

&lt;ul&gt;
  &lt;li&gt;also leukopenia&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Asthma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;results from bronchoconstriction mediated by leukotrienes&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Fever&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;prostaglandin release&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;chronic inflammation&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;mononuclear cell infiltration&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;fibrosis and angiogenesis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;repair&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Serous inflammation&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;exudation of fluid into the subcorneal or subepidermal space and the fluid is relatively protein-poor.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;fibrin accumulation&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;protein-rich exudate&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Granulomatous inflammation&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;collections of transformed macrophages called epithelioid cells&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Purulent inflammation&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Acute inflammatory cells, mainly neutrophils, exuded into a body cavity or space form a purulent (suppurative) exudate, typically associated with liquefactive necrosis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Ulceration&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Loss of the epithelium&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Candida&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a commensal organism in the oropharyngeal region and rarely causes pneumonia in healthy &lt;strong&gt;(non-immunosuppressed)&lt;/strong&gt; individuals.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Cytomegalovirus&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;produce a mononuclear interstitial inflammatory cell response&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Enterobacter aerogenes&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;produce acute inflammation.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Plasmodium falciparum&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;produces malaria, a parasitic infection without a significant degree of lung involvement.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Mixed connective tissue disease&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;have some features of systemic lupus erythematosus (SLE), myo- sitis, rheumatoid arthritis, scleroderma, and Sjögren syn- drome.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Staphylococcus aureus&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;endocarditis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;endocarditis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Cardiac murmurs&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;nonbacterial thrombotic endocarditis&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Streptococcus pyogenes(strep throat)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;acute inflammation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;fever caused by bacterial organisms through release of pyrogen.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Acute hepatitis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;hepatocyte necrosis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;elevations in AST and ALT&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;immune-diseases&quot;&gt;immune diseases&lt;/h3&gt;

&lt;p&gt;advanced HIV infection.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;the CD4+:CD8+ ratio is reversed so that it is typically less than 1&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;gout&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;urate crystals deposition&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Type I Hypersensisty&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;with antigen triggering mast cell–bound IgE with release of preformed mediators such as histamine.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Leukotriene C4&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Mast cells degranulate with antigen attachment to IgE&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;In tuberculosis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;macrophages further transform into epithelioid cells that can contribute to granulomatous inflammation.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Type II Hypersensisty&lt;/p&gt;

&lt;p&gt;Type III Hypersensisty&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Arthus reaction&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Type IV Hypersensisty&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Langhans giant cells are seen in granulomatous inflammation&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;urticarial rash&lt;/p&gt;

&lt;p&gt;type I hypersensitivity&lt;/p&gt;

&lt;p&gt;Goodpasture syndrome&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;an autoantibody is directed against type IV collagen in basement membranes of the glomeruli (causing glomerulonephritis) and in the&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;lung. This is a form of type&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;microscopically shows glomerular dam- age and linear immunofluorescence with labeled complement C3 and anti-IgG antibody.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Urinalysis shows high hematuria, proteinuria, and no glucose&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;DiGeorge anomaly&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;deletion of chromosome 22q11 and it affects T cell differentiation and maturation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The size of the 22q11.2 deletion determines the severity of the disease&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;hypocalcemic tetany, as well as additional midline developmental abnormalities&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;II hypersensitivity reaction.&lt;/p&gt;

&lt;p&gt;lesions of lupus nephritis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;wire loop glomerular capillary lesions of lupus nephritis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;severe combined immunodeficiency (SCID)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;deficient T cell and B cell arms of the immune system&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Absence of adenosine deaminase&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;X-linked SCID&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;due to mutations in the common γ chain that is a part of many cytokine receptors, such as interleukin (IL)-2, IL-4, IL-7, and IL- 15.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;A major transfusion reaction&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;results from a type II hypersensitivity reaction.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The patient’s serum contains naturally occurring antibodies to the incompatible donor RBCs.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;C5-9 membrane attack complex&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;hyper-IgM syndrome&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;lack of isotype switching from IgM to other immunoglobulins&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Mutation in the CD40 ligand&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Antigen-antibody complex formation&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is typical of a type III hypersensitivity reaction.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;common variable immunodeficiency&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Impaired B cell maturation to plasma cells&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Mast cells degranulate&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;with antigen attachment to IgE in type I hypersensitivity reactions.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Hashimoto Thyroiditis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;caused by a breakdown in self- tolerance (Chapter 4) to thyroid autoantigens&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Myasthenia gravis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;a form of type II hypersensitivity reaction in which antibody is directed against cell surface receptors.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Thymic hyperplasia or thymoma is likely to be present.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Antibodies to acetylcholine receptors impair skeletal muscle motor end plates function&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;dermatomyositis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Immune complex–mediated injury&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Ewing sarcoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;t(11;22)(q24;12) translocation in that results in fusion of the EWS transcription factor with Fli-1&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;polymyositis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Muscle lysis by CD8+ T cells&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;criteria for SLE&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Delayed-type hypersensitivity&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;more likely in parasitic infestations of muscles.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Macrophages play an important role, associated with cell-mediated immunity&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;tuberculin skin test works through this pathway&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;perivascular accumulation of T cells, particularly CD4+ cells.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;parasitic infection&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;IgG and IgE antibodies bearing Fc receptors coat the parasite.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Antibody-mediated cellular cytotoxicity (ADCC) receptor–mediated inflammation and phagocytosis, characteristic for ADCC.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Macrophages, natural killer cells, neutrophils recognize the Fc receptor, then destroy the antibody-coated target cells.&lt;/p&gt;

&lt;p&gt;C3 deficiency&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;accompanied by recurrent infections with pyogenic bacteria.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;hemolysis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Complement-mediated lysis, typical of immune destruction of RBCs&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;IgA deficiency&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;leads to mild recurrent gastrointestinal and respiratory tract infections and predisposes to anaphylactic transfusion reaction.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;serum sickness&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;in response to the injected foreign protein&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;produced widespread antigen-antibody complex deposition, particularly in the kidneys.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;urticaria&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;A skin rash triggered by a reaction to food, medicine, or other irritants.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Thrombocytopenia&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;thrombotic microangiopathy such as thrombotic thrombocytopenic purpura&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Hereditary angioedema&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;autosomal-reces- sive disorder of the complement pathway in which there is a deficiency of antigenic or functional C1 inhibitor, resulting in recurrent episodes of edema.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Hypocomplementemia&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;In the localized immune complex reaction (Arthus reaction), activation and depletion of complement C3.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Arthus reaction&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;type III hypersensitivity reactions; they often exhibit vascu- litis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Systemic and localized immune complex diseases&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Graft-versus-host disease&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;characterized by epidermal apoptosis and rash in persons receiving an allogeneic hematopoietic stem cell transplant.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;rheumatic heart disease&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Streptococcal M proteins cross-react with cardiac glycoproteins, resulting in rheumatic heart disease&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;a form of autoimmunity&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Molecular mimicry&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;occurs when a microbial antigen cross-reacts with a normal tissue&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;may follow an infec- tion and lead to polyclonal B cell activation&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;ophthalmia&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Ophthalmia (also called ophthalmitis) is inflammation of the eye.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Prothrombin time (PT)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is a blood test that measures how long it takes blood to clot.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Breakdown of T cell anergy&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;localized tissue damage and inflammation -&amp;gt; up-regulation of co-stimulatory molecules on the target tissues.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;brain and in pancreatic islet β cells&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;thromboplastin time (PTT) or activated partial thromboplastin time ( aPTT or APTT)&lt;/p&gt;

&lt;p&gt;is a medical test that characterizes blood coagulation polyclonal lymphocyte activation&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Microbial products such as endotoxin or bacterial superantigens&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Release of sequestered antigens&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;can cause autoimmunity&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;coagulopathy&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Antiphospholipid antibodies&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;rheumatic fever&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a microbial antigen cross-reacts with a normal tissue&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;toxic shock syndrome&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Widespread and non- specific activation of T cells by superantigens&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;glomerulonephritis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;proteinuria with hematuria, renal failure.(SLE)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;scleroderma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Raynaud phenomenon&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Esophageal dysmotility&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Bronchoconstriction&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;bronchial asthma, allergies as type I hypersensitivity reaction&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Cerebral lymphomas&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;may occur in immunodeficient patients, patients with AIDS.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Keratoconjunctivitis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Sjögren syndrome -&amp;gt; decreased tear production (lacrimal gland inflammation.)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Sacroiliitis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;feature of many of the spondyloarthropathies, such as ankylosing spondylitis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Sclerodactyly&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;in scleroderma&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;CREST syndrome(limited scleroderma)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;when it involves only a few areas of the skin (e.g., just the hands), it is more likely to indicate limited scleroderma&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;anticentromere antibody&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;anti–DNA topoisomerase I is found with diffuse scleroderma&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;A drug-induced systemic lupus erythematosus (SLE)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Caused by drugs such as isoniazid, pro- cainamide, and hydralazine&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;ANA are often positive&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;But anti–double-stranded DNA are negative&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Antibody-dependent cell-mediated cytotoxicity&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is initiated when IgG or IgE coats a target to attract cells that affect lysis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;discoid lupus erythematosus&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;skin lesions similar to those of systemic lupus erythematosus (SLE), but with systemic involvement much less likely to occur.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Self nucleic acids mimic their microbial counterparts, and in conjunction with TLRs, they incite type I interferon production to activate dendritic cells and B cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;They also promote a TH1 response, which contributes to autoimmunity.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;immune complex deposition only in sun-exposed areas of the skin,&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;a positive ANA test result in a few cases,&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;absence of anti-Smith or anti–double-stranded DNA antibodies&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;absence of serious renal disease.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;sympathetic ophthalmia&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Release of sequestered antigens&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Non-Hodgkin lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;maybe triggered by Sjögren syndrome&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Libman-Sacks endocarditis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;SLE&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Nongonococcal urethritis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;seen in reactive arthritis, along with conjunctivitis and arthritis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Diffuse systemic sclerosis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;initially skin involvement&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;rapidly progresses to visceral organ involvement, including the small arteries of the kidney.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;These are damaged by a hyperplastic arteriolosclerosis, complicated by very high blood pressure and renal failure.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;esophageal squamous carcinoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;include smoking and alcohol abuse.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Ankylosing spondylitis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;is one of the spondyloarthropathies&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;it is characterized by low back pain from sacroiliitis and positive serology for HLA-B27.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;sacroiliitis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;sacroiliitis is an inflammation of the sacroiliac joint&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;HLA-B27&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;present in ankylosing spondylitis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;rheumatoid arthritis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;progressive joint deformity&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;rheumatoid factor and antibodies to cyclic citrullinated peptide (anti-CCP)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The antibody to cyclic citrullinated peptide is present&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Bony ankylosis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a feature of progressive or recurrent joint inflammation with rheumatoid arthritis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Pericarditis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a feature of systemic lupus erythematosus or diffuse systemic sclerosis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Sjogren syndrome&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Xerophthalmia (usually with accompanying xerostomia)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;keratoconjunctivitis predominates, and antibodies to SS-A and SS-B are often present.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;fascicular myocyte necrosis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The perivascular and perimysial inflammatory infiltrates result in peripheral muscle&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Dermatomyositis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;a form of inflammatory myopathy in which capillaries are the primary target for antibody and complement-mediated injury&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;causes muscle pain, and the rash is typically a subtle heliotrope rash with a violaceous appearance to the eyelids&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The violaceous, or heliotrope, rash is a characteristic feature&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;reactive arthritis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;(with conjunctivitis, arthritis, and nongonococcal urethritis)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;positive serology for HLA-B27&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;a history of either nongonoccocal urethritis with Chlamydia or gastrointestinal infection with Campylobacter, Salmonella, or Shigella&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;organisms.&lt;/p&gt;

&lt;p&gt;Antibody-dependent cell-mediated cytotoxicity&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is initiated when IgG or IgE coats a target to attract cells that affect lysis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Complement- mediated cell lysis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;when antidonor antibodies are preformed in the host and lead to hyperacute rejection.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;peripheral muscle fascicular myocyte necrosis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The perivascular and perimysial inflammatory infiltrates result.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;acute rejection&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;occurs weeks, months, or even years after transplantation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Endothelitis with intimal injury&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;infiltration with CD3+ T cells that include the CD4+ and CD8+ subsets.(acute cellular rejection)&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Her graft-versus-host disease (GVHD)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;engrafted marrow is not completely matched for major histocompatibility loci and thus contains immunocompetent donor cells that can proliferate, recognize host cells as foreign, and attack host tissues.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;hyperacute rejection&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Fibrinoid necrosis and thrombosis, occurs within minutes placement of the transplant into the recipient&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Veno-Occlusive Disease of Central Vein in Liver&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;GVH Disease&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;chronic rejection&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Interstitial and glomerular fibrosis and blood vessel thickening (ireversible)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;X-linked agammaglobulinemia of Bruton&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;a condition in which B cell maturation stops after the rearrangement of heavy-chain genes, and light chains are not produced.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;IgA deficiency is marked by a more benign course&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Mutations in the BTK gene&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;neopastic-diseases&quot;&gt;Neopastic diseases&lt;/h3&gt;

&lt;p&gt;adenocarcinoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;arise from a colonic adenoma, such malignant lesions tend to be larger and more irregular.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;endocervix or endometrium&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;choristoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a benign mass composed of tissues not found at the site of origin.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;hamartoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;a rare benign mass composed of tissues usually found at the site of origin.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;the lung is common site&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Bile duct hamartoma&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Peutz-Jeghers (hamartomatous) polyp&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;hyperplastic colonic lesion&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;tends to be small and flat.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;sarcoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;a malignant neoplasm arising in mesenchymal tissues, not in epithelium&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;express TGFα and TGFα receptor&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Adenoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;small mass arise from epithelial surfaces.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;glandular tissues&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;An adnexal mass&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;a lump in tissue of the adnexa of uterus&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;can be benign or cancerous&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;can be categorized as simple or complex.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;teratoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a neoplasm derived from totipotential germ cells that differentiate into tissues that represent all three germ layers: ectoderm,&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;endoderm, and mesoderm.&lt;/p&gt;

&lt;p&gt;Fibroadenomas&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a benign glandular and stromal component; common in the breast.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Gliomas&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;found in the central nervous system.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;mesothelioma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;arises from the lining of thoracic and abdominal body cavities.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;rhabdomyosarcoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;comprises cells that poorly resemble striated muscle; most arise in soft tissues.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Urothelial carcinomas&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;associated with smoking.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;papilloma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is a benign, localized mass that has an exophytic growth pattern.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;hemangioma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a common benign lesion of the skin.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Leiomyomas&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;white, arise from smooth muscle and are most common in the uterus&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Lipomas&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;yellow fatty tumors that can occur beneath the epidermis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Melanomas&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;malignant, tend to increase in size quickly;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;darkly pigmented&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;nevus&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;benign counterpart to the melanoma&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;light to dark brown&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Well-differentiated neoplasms&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;tend to be less aggressive and slower growing and resemble the cell of origin.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Carcinoma in situ&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is confined to the epithelium&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;metaplasia&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;human papillomavirus (HPV) and other inflammatory conditions&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;carcinoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Lymphatic spread, especially to regional lymph nodes draining from the primary site&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;breast abscess&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;can spread to the lymph nodes, resulting nodal enlargement is associated with pain&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;hemoptysis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;coughing up of blood&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;cerebral metastases&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;arise from lung primary carcinomas half of the time.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Angiosarcomas(liver)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;linked to vinyl chloride exposure&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;chronic myelogenous leukemia&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;t(9;22)translocation causes uncontrolled nonreceptor tyrosine kinase activity of the BCR-ABL fusion gene.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;imatinib that inhibit tyrosine kinases.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;colon cancers&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Translocation of β-catenin to the nucleus, when there is mutational loss of APC genes.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;non-Hodgkin lymphomas&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The BCL1 and BCL2 genes are mutated&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;T cell neoplasms&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The IL2 mutation may be present&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Melanoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;In melanomas, the implicated gene is called p16, or INK4a. The product of the p16 gene is an inhibitor of cyclin-dependent kinases.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Germline mutations in CDKN2A may also underlie familial melanomas. With loss of control over cyclin-dependent kinases, the cell cycle&lt;/p&gt;

&lt;p&gt;cannot be regulated, favoring neoplastic transformation.&lt;/p&gt;

&lt;p&gt;neurofibromatosis type 1&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The NF1 gene encodes for a GTPase-activating protein that facilitates the conversion of active (GTP-bound) RAS to inactive (GDP-bound) 
RAS. Loss of NF1 prevents such conversion and traps RAS in the active signal-transmitting stage that drives cell proliferation&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;pheochromocytoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a small vascular tumor of the adrenal medulla, causing irregular secretion of epinephrine and norepinephrine, leading to attacks of&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;raised blood pressure, palpitations, and headache.&lt;/p&gt;

&lt;p&gt;Hemangioblastoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;are tumors of the central nervous system that originate from the vascular system usually during middle-age&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;hepatosplenomegaly&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Resulted in storage of insoluble intermediates in the mononuclear phagocyte system&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Neuroblastoma (small round blue cell)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;HSRs and double minutes of N-myc&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;pediatric tumor&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;AIDS from HIV&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;B cell lymphomas of the brain are 1000-fold more common in HIV patients with infection than in the general population.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;amyloidosis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;extracellular deposits of fibrillar proteins are responsible for tissue damage and functional compromise.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;hereditary nonpolyposis colon carcinoma (HNPCC)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;inheritance of one defective copy of mismatch repair genes.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Several human mismatch repair genes are involved in the development of HNPCC.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Mismatch repair defects have microsatellite instability.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Microsatellites are tandem repeats found throughout the genome.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;mutations of mismatch repair “proof reader” or “spell checker” genes MSH2 (2p16), MLH1 (3p21), MSH6, PMS, PMS2 as well as other&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;similar genes.&lt;/p&gt;

&lt;p&gt;xeroderma pigmentosum (XP)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;extreme photosensitivity, high risk of skin cancers.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;DNA damage is initiated by exposure to ultraviolet light and nucleotide excision repair cannot occur normally in XP because&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;inheritance of one of several XP genes is abnormal.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;autosomal recessive, because new mutations are unlikely to occur.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;paraneoplastic syndrome&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;results from ectopic secretion of a hormone by tumor (e.g., lung cancer cells producing corticotropin)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;symptoms that can not be explained by tumor spread.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Hepatocellular carcinomas&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;can arise in cirrhosis caused by chronic alcoholism&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Ataxia telangiectasia&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is an inherited syndrome that carries an increased risk of development of leukemias and lymphomas.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;human T cell lymphotropic virus type 1&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;T cell leukemia.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Epstein-Barr virus&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;associated with various cancers, including Burkitt lymphoma and nasopharyngeal carcinoma&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;H. pylori&lt;/p&gt;

&lt;p&gt;promotes chronic gastritis with increased risk for gastric adenocarcinomas and B cell lymphomas.&lt;/p&gt;

&lt;p&gt;Cachexia&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;common in advanced cancers, and weight loss without dieting in an adult is a “red flag” for malignancy&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;increases in circulating factors such as tumor necrosis factor (TNF) may play a role.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Tympany&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;A low-pitched, resonant, drumlike note obtained by percussing the surface of a large air-containing space, such as the distended&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;abdomen or the thorax with or without pneumothorax.&lt;/p&gt;

&lt;p&gt;small cell carcinomas of the lung&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;inappropriate antidiuretic hormone (SIADH) secretion leads to hyponatremia as well as edema&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;renal cell carcinoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Erythropoietin production with polycythemia&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;pulmonary squamous cell carcinomas&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Hypercalcemia from a parathyroid hormone-related peptide (PTHrP)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Glioblastomas (paracrine action)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;secrete PDGF and express PDGF receptor&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Microsatellites&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;repeated sequences of DNA, 1-6 bp in length&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;unique to each individual, “DNA fingerprint”&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Microsatellite instability (MSI)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;increased variation of microsatellites within an individual&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;an indicator of deficiency in DNA mismatch repair&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;confer an increased risk of neoplasia&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;desmoplasia&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;the growth of fibrous or connective tissue. alled desmoplastic reaction –&amp;gt; secondary to an insult.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Desmoplasia may occur around a neoplasm, causing dense fibrosis around the tumor&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;EBV&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;nasopharyngeal cancer&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;HPV&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;cervical cancer&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;inappropriate antidiuretic hormone (SIADH) secretion&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;A syndrome from small cell carcinomas, and leads to hyponatremia as well as edema.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;cor pulmonale&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;abnormal enlargement of the right side of the heart as a result of disease of the lungs or the pulmonary blood vessels.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Wiskott-Aldrich syndrome&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;associated with eczema and thrombocytopenia.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;SLAM-associated protein (SAP)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;that binds to a family of cell surface molecules involved in the activation of NK cells and T and B lymphocytes, and result in&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;increased susceptibility to viral infections, particularly Epstein-Barr virus (EBV).&lt;/p&gt;

&lt;p&gt;rheumatoid arthritis&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;in some patients methotrexate treatment promotes nodule formation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;DMARDs - fundamental treatment for inflammatory arthritis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;In any given patient, any of the DMARDs can be efficacious and well tolerated, but no one DMARD is efficacious and safe in every patient&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;MNEMONIC  DOPAMIN RASH&lt;/p&gt;

&lt;p&gt;DISCOID RASH
ORAL ULCERS
PHOTOSENSITIVITY
ANA
MALAR RASH
IMMUNOLOGICAL PHENOMENON(Le Cell, Ds DNA, Sm, APL ab, false + RPR, )
NEUROLOGICAL(Seizures,Psychosis)
RENAL(Nephrotic,Nephritic)
ARTHRITIS	
SEROSITIS
HEMATOLOGICAL(Leukopenia,Thrombocytopenia, anemia)&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Pathology reiew part I factors, cyctokines, cells</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/09/04/pathology-review-1/"/>
   <updated>2015-09-04T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/09/04/pathology-review-1</id>
   <content type="html">&lt;h3 id=&quot;inflammation-and-repair&quot;&gt;Inflammation and Repair&lt;/h3&gt;

&lt;p&gt;myeloperoxidase&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;present in neutrophils&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;converts H2O2 into HOCl–&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;antimicrobial agent.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;!--break--&gt;

&lt;p&gt;lack of β2 integrin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Inadequate adhesion on cytokine-activated endothelium&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Natural killer cells&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Has Fc receptors, lyse IgG-coated target cells&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Monocytes&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;transform to macrophages, contain(iNOS), which generates NO, NO has antimicrobial activity.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Activated macrophages produces&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Interleukin-1 (IL-1)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;(TNF)&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Il12&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;helps triggers granulomatous inflammation&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;neutrophils&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;NAPDH oxidase&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;prostaglandin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;promote vasodilation&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;interferon-γ&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;transform Macrophage to epithelioid cells&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;stimulate monocyte&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Leukotriene B4&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;potent neutrophil chemotactic factor&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;generated by the lipoxygenase pathway of arachidonic acid metabolism&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Nitric oxide&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;mediates vasodilation, inhibits platelet&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;thromboxane A2&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;vasoconstrictive properties&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Plasmin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;from plasminogen&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;helps lyse clots&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Protein C&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;antagonizes coagulation factor V, in turn stop prothrombin to thrombin&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Kallikrein&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;generated by activation of Hageman factor (XII)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;generation of bradykinin and plasmin and C5a&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Thrombin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;coagulation cascade.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Fibrin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;end product of coagulation pathways&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;forms a meshwork entrapping platelets and creating a plug.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Tumor necrosis factor (TNF)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Produced by activated macrophages, mediates fever, metabolic wasting, and hypotension.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Bradykinin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;from the kinin system on surface contact of Hageman factor with collagen and basement membrane from vascular injury, vascular permeability, smooth muscle contraction, and pain.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Complement C5a&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;is chemotactic factor for neutrophils.&lt;/p&gt;

&lt;p&gt;complement C3b&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;an opsonin may promote phagocytosis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;complement C5-9&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;membrane attack complex&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;complement C1q&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;generated in the initial stage of complement activation, eventually result in cell lysis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Interleukin-1 (IL-1)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;produced by activated macrophages&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;leukocyte release from bone marrow&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Tumor Necrosis factor (TNF)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;produced by activated macrophages&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;leukocyte release from bone marrow&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;upregulate fibrinogen and SAA&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Phospholipase C&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;from platelet activation&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;release of arachidonic acid&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Histamine&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;vasodilator&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Commplement activation&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;polysaccharides (alternative pathway)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;mannose (lectin pathway)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;antibody attached to surface antigens (classic pathway)&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Fibroblasts&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;chronic inflammatory responses&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Mononuclear infiltrates&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;typical of chronic inflammation&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Epithelioid cells&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;granulomatous inflammation&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;granulomatous inflammation&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a form of type IV hypersensitivity&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;pyrogens&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;TNF&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;IL 1&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Hageman factor&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;initiates the coagulation cascade.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Immunoglobulin E&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;in response to inflammatory responses with allergens and with invasive parasites.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Interleukin-12 (IL-12)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;released by macrophages stimulates T-cell responses&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;SAA&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;serum amyloid A&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;anti–streptolysin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is the antibody made against streptolysin O, an immunogenic, oxygen-labile hemolytic toxin produced by most strains of group A and&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;many strains of groups C and G streptococci.&lt;/p&gt;

&lt;p&gt;CRP&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;C-reactive protein&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Interleukin-2 (IL-2)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;act as autocrine growth factor promote lymphocyte proliferation.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;IFN-γ&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a product of CD4+ T cells and NK cells&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;IL-5&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;activates eosinophils (part of a TH2 response.)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;IL-6&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;interleukin-6&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;IL-10&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;immunosuppressive cytokine -&amp;gt; diminishes lymphocyte activation&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;IL-17&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;delayed- type hypersensitivity reactions.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;recruiting neutrophils to fight bacterial and fungal infections (aspergillosis and candidiasis)&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;IL-12&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;stimulate NK cells to secrete interferon-γ&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Eosinophils&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;accumulate in acute interstitial nephritis owing to drug reactions.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;ALT&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Serum Glutamic-Pyruvic Transaminase&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;AST&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Serum Glutamic-Oxaloacetic Transaminase&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;fibronectin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;maintain a cellular scaffolding for growth and repair, and do not contract.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;metalloproteinases&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;degradation of collagen and connective tissue remodeling in wound repair&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Myofibroblast contraction&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Wound contraction&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Integrins&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;interact with the extracellular matrix proteins (e.g. fibronectin)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Platelet-drived growth factor (PDGF)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;mediates migration and proliferation of fibroblasts and smooth muscle cells and migration of monocytes.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Serine proteinases&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;are important in wound remodeling.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;creatine kinase&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;elevated level indicates that myocardial necrosis has occurred.&lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;immune-system-diseases&quot;&gt;Immune System Diseases&lt;/h3&gt;

&lt;p&gt;HBsAg&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Surface antigen of the hepatitis B virus (HBV)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;HBcAb&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Hepatitis B core Antibody (HBcAb)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;D8+ T cells&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;binds to the complex of viral peptide and MHC class I mol- ecules displayed on the surface of the infected cell&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Natural killer (NK)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;recognize MHC class I molecules with self-peptides and self-recognition inhibits NK cell killing.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;NOD-like receptors (NLRs)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The nucleotide-binding oligomerization domain receptors&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;The NLR-inflammasome&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;this pathway plays a role in the innate immune system recognition of urate crystals and promoting the inflammation associated with&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;gout.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;These receptors may also contribute to inflammation of atherosclerosis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;C-type lectin receptors (CLRs)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;expressed on the plasma membrane of macrophages and dendritic cells detect fungal glycans and elicit inflammatory reactions to fungi.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Mannose receptors&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;On phagocytes recognize microbial sugars with terminal mannose residues and induce microbial phagocytosis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;RIG-like receptors (RLRs)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;are located in the cytosol of most cell types and detect nucleic acids of viruses that replicate in the cytoplasm of infected cells&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;to stimulate production of antiviral cytokines.&lt;/p&gt;

&lt;p&gt;β2-Microglobulin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;is a component of MHC class I&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;it can be increased with HIV infection and can be a substrate for amyloid fibrils in patients receiving longterm hemodialysis.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Toll-like receptors (TLRs)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;in the plasma membrane and endosomal vesicles activate transcription factors that stimulate synthesis and secretion of cytokines and&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;expression of adhesion molecules to recruit and activate leukocytes.&lt;/p&gt;

&lt;p&gt;C1 inhibitor&lt;/p&gt;

&lt;p&gt;block activation of C1.&lt;/p&gt;

&lt;p&gt;Neutrophils&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;provide a nonspecific immune response, primarily to bacterial infections and not to intracellular viral infections.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;C2 (complement component)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Lacking complement component have some increase in infections, but mainly develop a disease resembling systemic lupus erythematosus&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;CD16&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Natural killer(NK)cells haveCD16,and Fc receptor&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;CD19&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;B cells have surface immunoglobulin, are CD19 positive, and participate in humoral immunity&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;CD3&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;T lymphocytes, both CD4+ and CD8+.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;CD8+
* kill melanoma cells&lt;/p&gt;

&lt;p&gt;CD4&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;(TH2) essential to the induction of type I hypersensitivity with cytokines secretion e.g. interleukin (IL)-3, IL-4, IL-5 and macrophage colony-stimulating factor&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;TLRs&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;they incite type I interferon production to activate dendritic cells and B cells.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;promote a TH1 response, which contributes to autoimmunity&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;macrophage colony-stimulating factor&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;the growth, recruitment, and activation of mast cells and eosinophils.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Dendritic cells&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;trap antigen and aid in antigen presentation.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;follicular dendritic cells (FDCs)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;The FDCs may become infected but not killed by HIV.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;elaborate type I interferons that up-regulate antiviral proteins in neighbor- ing cells&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Blood monocytes&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;expressing MHC class II antigenscan migrate into tissues and become longer-lived macrophages.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Anticardiolipin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;along with anti–β2-glycoprotein “lupus anticoagulant,”&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;found with antiphospholipid syndrome, which may appear in systemic lupus erythematosus (SLE).&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;patients who has serologic testing for syphilis will yield a false-positive result&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Anti–double-stranded DNA antibodies&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;have specificity for SLE&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;antihistone antibodies&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;are characteristic of drug-induced SLE.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Anti–SS-A antibody&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is seen in Sjögren syndrome.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;The anti–U1-ribonucleoprotein antibody&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is seen in mixed connective tissue disease (MCTD).&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Smith&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Anti-Smith, specific for SLE&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Anti–Jo-1 antibody&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;specificity for polymyositis/dermatomyositis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Anti–U1-ribonucleotide protein&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;specificity for mixed connective tissue disease(MCTD).&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Antibody-mediated cellular cytotoxicity (ADCC)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;there is Fc receptor–mediated inflammation and phagocytosis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Anticentromeric antibody&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;limited scleroderma (CREST syndrome).&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Histidyl-tRNA synthetase&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Inflammatory Myopathies&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Anti–SS-A antibody&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;characteristic of Sjögren syndrome.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;TH17&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;may be present in chronic inflammatory conditions such as inflammatory bowel diseases with macrophage and neutrophilic infiltrates.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;SS-B&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;characteristic of Sjögren syndrome.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;MALT lymphoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;The immune dysregulation that accompanies autoimmune diseases increas- es the risk for B cell lymphoid malignancies&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Anticentromere antibody&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is seen most often in limited systemic sclerosis,&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;anti–DNA topoisomerase&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;appears with diffuse systemic sclerosis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Amyloid&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;derived from serum amyloid-associated protein can occur in chronic infections and inflammation.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;cyclic citrullinated peptide (anti-CCP)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;autoantibodies (antibodies directed against an individual’s own proteins) that are directed against peptides and proteins that are&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;citrullinated. specific for rheumatoid arthritis&lt;/p&gt;

&lt;p&gt;Eosinophils&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;accumulate in acute interstitial nephritis owing to drug reactions.&lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;neoplastic-diseases&quot;&gt;Neoplastic diseases&lt;/h3&gt;

&lt;p&gt;CA-125&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a tumor marker for ovarian cancer.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;MYC oncogene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;activated in Burkitt lymphoma because of a t(8;14) translocation.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;binds DNA to cause transcriptional activation of growth-related genes (cyclin D1), resulting in activation of the cell cycle.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;EGF&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;(such as HER2 in breast cancers) encodes the epithelial growth factor receptor located on the cell surface&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;p53 and APC&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;tumor suppressor genes that are inactivated in many cancers, including colon cancer&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;RAS oncogene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;encodes a GTP-binding protein that is located under the cell membrane.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;N-MYC gene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Double minutes and homogeneously staining regions seen on a karyotype represent gene amplifications.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;K-RAS mutations&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;present in many cancers, but not typically childhood neoplasms.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Lyn mutation&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;seen in some immunodeficiency states.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;SLAM-associated protein (SAP)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;binds to a family of cell surface molecules involved in the activation of NK cells and T and B lymphocytes, and result in increased&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;susceptibility to viral infections, particularly Epstein-Barr virus (EBV)&lt;/p&gt;

&lt;p&gt;Epithelial dysplasias&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;can be precursors of carcinomas&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Ovarian neoplasms&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;not related to cervical dysplasias or carcinomas&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;cervical cancers&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;not related to hereditary syndromes&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;cervical dysplasias are not hereditary&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;mutant RB gene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;lead to childhood retinoblastomas and osteosarcomas.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;EMA&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;many adenocarcinomas&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Carcinoembryonic antigen (CEA)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;colon cancers&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Alpha fetoprotein(AFP)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;germ cell tumors&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;liver cancers&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;A serum immunoglobulin level with protein electro- phoresis aids in the diagnosis of myeloma.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;CD 10 (CALLA)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;acute lymphoblastic leukemia (ALL)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;PSA&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;prostate cancer&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Melanoma-associated antigen (MAGE)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Also normally present in the testis&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;icterus&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Jaundice&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;RAS oncogene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Mutations of the RAS oncogene reduce GTPase activity, and RAS is trapped in an activated GTP-bound state. RAS then signals the&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;not typically lymphoid malignancies.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;nucleus through cytoplasmic kinases.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;The APC gene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;can cause activation of the WNT signaling pathway&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;The RET proto-oncogene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;encodes a receptor tyrosine kinase involved in neuroendocrine cells of the thyroid, adrenal medulla, and parathyroids.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;p16 (INK4a)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;In melanomas, the product of the p16 gene is an inhibitor of cyclin-dependent kinases. Germline mutations in CDKN2A may also underlie&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;familial melanomas. With loss of control over cyclin-dependent kinases, the cell cycle cannot be regulated, favoring neoplastic&lt;/p&gt;

&lt;p&gt;transformation.&lt;/p&gt;

&lt;p&gt;hMSH2 gene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;is present in most cases of hereditary nonpolyposis colon cancer and functions in DNA repair.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Microsatellite instability&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;NF1 gene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;acts as a tumor suppressor; this is a component of neurofibromatosis&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;appear at a later age.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;TGF-β&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;inhibits cell proliferation by activation of growth-inhibiting genes, such as the CDKIs.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;All pancreatic cancers and 83% of colon cancers have at least one mutational event in a TGF-β pathway.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;PTEN&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;inhibits tumor cell autophagy, giving cancer cells an edge in growth&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;hypoxia-inducible factor 1-alpha (HIF-1-alpha)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Activation of this factor up-regulate VEGF for angiogensis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Von Hipple–Lindau (VHL) gene (3p25)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;acts as a tumor suppressor, and it normally produces a protein that binds to hypoxia-inducible factor 1-alpha so that it is cleared.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;VHL mutation leads to loss of this binding protein and activation of angiogenesis factors.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;TMPRSS-ETS fusion genes&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;found in prostate carcinomas place ETS family transcription factor genes under the control of the TMPRSS promoter, which is activated by&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;androgens.&lt;/p&gt;

&lt;p&gt;CXCR4 chemokines&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Expressed by the carcinoma cells,in the case of breast cancer&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;EML4-ALK fusion gene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;which is present in roughly 4% of lung carcinomas&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;HSR&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;homogeneously staining regions&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;CD44&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;plays a role in cell adhesion and enables malignant cells to metastasize.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;Solid tumors can express CD44 to enhance their spread to lymph nodes and other metastatic sites.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Vimentin&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;a protein expressed in mesenchymal neoplasms, such as sarcomas&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;also up-regulated in EMT.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Aspergillus flavus&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;found on moldy peanuts and other foods, produces the potent hepatic carcinogen aflatoxin B1.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Human papillomavirus (HPV)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;is a sexually transmitted disease that is associated with the development of genital squamous cell carcinomas.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;produces E7 protein binds to RB protein to cause displacement of normally sequestered transcription factors, which nullifies tumor&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;suppressor activity of the RB protein&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;E6 protein binds to and inactivates the p53 gene product.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;HST1&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;mutation is seen in some gastric cancers.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;MicroRNAs (miRNAs)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;5% of the human genome&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;miRNAs do not encode for proteins, but bind and inactivate or cleave mRNA, preventing translation of proteins by mRNA.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Phorbol esters&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;examples of promoters of chemical carcinogenesis that cause tumor promotion by activating protein kinase C.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Vinyl chloride&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;rare cause of liver cancer.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Arsenic&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;is a risk factor for skin cancer.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Asbestos&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;exposure is linked to pleural malignant mesothelioma and to bronchogenic carcinomas in smokers.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Benzene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;exposure is linked to leukemias&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Beryllium&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;exposure leads to interstitial lung disease and lung cancer&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Nickel&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;exposure increases the risk of respiratory tract cancers.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;naphthalene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a risk factor for cancers of the urinary tract.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;HBx&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;disrupts normal growth of infected hepatocytes.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;carcinoembryonic antigen level&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Gastrointestinal tract adenocarcinomas, including those arising in the stomach, colon, and pancreas, as well as some lung carcinomas&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;CA-19-9&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;a tumor marker for colonic and pancreatic carcinomas&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;serum immunoglobulin level&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;protein electrophoresis aids in the diagnosis of myeloma.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;protooncogenes&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;dominant&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;tumor suppressor genes&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;recessive, require only 1 allele to function.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Bax/Bak&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;triggered by P53 and cause mitochondria to have more membrane permeability. then cytochrome C which activates caspase 9.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Caspase 3&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;executioner caspase, bind to dead substrate and induce apotosis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;FasL/Fas(cd 95)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Fas ligand/receptor belongs to TNF family. Its binding induces apotosis.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Fas-Associated protein with Death Domain (FADD)&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;bridges Fas receptor to procaspases 8.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Diversification&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Clonal expansion and tumor progression&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;squamous cell carcinoma&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;intercellular bridges and keratin production&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;PTEN&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;PTEN acts as a tumor suppressor gene through the action of its phosphatase protein product. This phosphatase is involved in the regulation of the cell cycle, preventing cells from growing and dividing too rapidly&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;c-MYC gene&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;found on chromosome 8, and the t(8;14) translocation seen in many Burkitt lymphomas leads to MYC overexpression.&lt;/li&gt;
&lt;/ul&gt;

</content>
 </entry>
 
 <entry>
   <title>Pathology cases study</title>
   <link href="http://lanyon.getpoole.com/2015/08/29/ddd/"/>
   <updated>2015-08-29T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/2015/08/29/ddd</id>
   <content type="html">
&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-r&quot; data-lang=&quot;r&quot;&gt;&lt;span class=&quot;kn&quot;&gt;library&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;biomaRt&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;
mart &lt;span class=&quot;o&quot;&gt;&amp;lt;-&lt;/span&gt; useMart&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;s&quot;&gt;&amp;quot;ensembl&amp;quot;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;
datasets &lt;span class=&quot;o&quot;&gt;&amp;lt;-&lt;/span&gt; listDatasets&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;mart&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;
par&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;mar &lt;span class=&quot;o&quot;&gt;=&lt;/span&gt; &lt;span class=&quot;kt&quot;&gt;c&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;m&quot;&gt;4&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; &lt;span class=&quot;m&quot;&gt;4&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; &lt;span class=&quot;m&quot;&gt;0.1&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; &lt;span class=&quot;m&quot;&gt;0.1&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;),&lt;/span&gt; omi &lt;span class=&quot;o&quot;&gt;=&lt;/span&gt; &lt;span class=&quot;kt&quot;&gt;c&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;m&quot;&gt;0&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; &lt;span class=&quot;m&quot;&gt;0&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; &lt;span class=&quot;m&quot;&gt;0&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; &lt;span class=&quot;m&quot;&gt;0&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;))&lt;/span&gt;
plot&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;cars&lt;span class=&quot;p&quot;&gt;)&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/figs/dddddd/unnamed-chunk-1-1.png&quot; alt=&quot;center&quot; /&gt;&lt;/p&gt;

</content>
 </entry>
 
 <entry>
   <title>Pathology cases study</title>
   <link href="http://lanyon.getpoole.com/2015/08/28/class-discussion/"/>
   <updated>2015-08-28T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/2015/08/28/class-discussion</id>
   <content type="html">&lt;h2 id=&quot;case-1&quot;&gt;Case 1&lt;/h2&gt;

&lt;p&gt;Clinical History:&lt;/p&gt;

&lt;p&gt;A 30-year-old &lt;a href=&quot;http://www.lupusny.org/about-lupus/who-gets-lupus&quot;&gt;African American woman&lt;/a&gt; presented to her family physician with nonradiating chest pain, shortness of breath, fever, weight-loss, malaise, lethargy and arthralgia.  She exhibited an &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image1.jpeg&quot;&gt;erythematous skin rash&lt;/a&gt; involving areas of the body exposed to sunlight. She noticed hair loss during the months prior to seeking medical attention.  She was admitted to the hospital for observation and tests.&lt;/p&gt;

&lt;!--break--&gt;

&lt;p&gt;Laboratory Findings and X-Ray:&lt;br /&gt;
A chest X-ray revealed cardiomegaly and &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;pleural effusion&lt;/a&gt;.  A complete blood count (CBC) identified a normochromic, normocytic anemia.  Urinalysis revealed &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.27.33.png&quot;&gt;hematuria, proteinuria and erythrocyte and leukocyte casts&lt;/a&gt;.  Analysis of the blood serum revealed the presence of autoantibodies against double-stranded DNA (p127).  &lt;a href=&quot;http://images.rheumatology.org/viewphoto.php?albumId=75690&amp;amp;imageId=2862319&quot;&gt;Immunofluorescence staining&lt;/a&gt; for antinuclear antibodies showed a &lt;a href=&quot;http://www.thelupussite.com/lupus_diagnosis_tests/ana_antinuclear_antibody.html&quot;&gt;peripheral pattern&lt;/a&gt; using human leukocytes as the substrate.  The serum also contained &lt;a href=&quot;http://www.healthline.com/health-slideshow/lupus-and-ra#1&quot;&gt;rheumatoid factor&lt;/a&gt; and &lt;a href=&quot;http://www.cidjournal.com/article/0738-081X%2885%2990074-4/abstract&quot;&gt;anticytoplasmic antibodies&lt;/a&gt;.&lt;/p&gt;

&lt;p&gt;Clinical Course of Disease:
A renal biopsy was performed and revealed diffuse &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;proliferative glomerulonephritis&lt;/a&gt; characterized by extensive cellular proliferation in more than 50% of glomeruli.  Immune complexes were deposited mainly in a &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;subendothelial distribution&lt;/a&gt;.  Immunofluorescence microscopy revealed that the immune deposits stained positively for all three major immunoglobulin classes and complement indicating a polyclonal activation of the immune system.  &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;Electron microscopy&lt;/a&gt; confirmed the subendothelial as well as intramembranous deposition of immune deposits.&lt;/p&gt;

&lt;h3 id=&quot;what-information-provided-above-is-of-the-greatest-assistance-in-reaching-a-diagnosis-of-systemic-lupus-erythematosus-in-this-patient&quot;&gt;1. What information provided above is of the greatest 	assistance in reaching a diagnosis of systemic lupus erythematosus in this patient?&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image1.jpeg&quot;&gt;erythematous skin rash&lt;/a&gt; 
􏰡&lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.31.43.png&quot;&gt;hematuria, proteinuria and erythrocyte and leukocyte casts&lt;/a&gt; 7th criterion&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;􏰞https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.31.43.png&quot;&gt;pleural effusion&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;autoantibodies against double-stranded DNA&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;antinuclear antibodies showed a &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image5.jpeg&quot;&gt;peripheral pattern&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;http://www.cidjournal.com/article/0738-081X%2885%2990074-4/abstract&quot;&gt;anticytoplasmic antibodies&lt;/a&gt;.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;proliferative glomerulonephritis&lt;/a&gt; &lt;em&gt;class V&lt;/em&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;subendothelial distribution&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;Electron microscopy&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;why-did-this-patient-present-with-chest-pain&quot;&gt;2.	Why did this patient present with chest pain?&lt;/h3&gt;

&lt;p&gt;&lt;strong&gt;class answer&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;perual efusion.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;The patient may suffer &lt;a href=&quot;p 89 &amp;amp; p 130&quot;&gt;Libman-Sacks endocarditis&lt;/a&gt;, possiblely related Thrombi, which can develop anywhere in the cardiovascular system due to &lt;a href=&quot;http://www.hopkinslupus.org/lupus-tests/antiphospholipid-antibodies/&quot;&gt;lupus anticoagulant&lt;/a&gt; which increases the ability of the blood to clot.&lt;/p&gt;

&lt;h3 id=&quot;what-are-the-major-immunologic-features-of-systemic-lupus-erythematosus-sle&quot;&gt;3. What are the major immunologic features of systemic lupus erythematosus (SLE)?&lt;/h3&gt;

&lt;p&gt;&lt;strong&gt;class answer&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Anti-DNA. Antibody to native DNA, Anti-Sm. Presence of AB to &lt;strong&gt;Smith&lt;/strong&gt; nuclear antigen.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;depostion of immune complex&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;epidermal and dermal junction&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image3.jpeg&quot;&gt;3.	LUPUS SKIN BIOPSY, THICKENED BASEMENT MEMBRANE&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image4.jpeg&quot;&gt;4.	LUPUS BAND TEST, ANTI IgG STAIN&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image5.jpeg&quot;&gt;5. PERIPHERAL RIM PATTERN&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;LE test is no longer performed.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The patient may suffer Libman-Sacks endocarditis (p 89 &amp;amp; p 130) Note that this is not infected, it is just fribid, so it is&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;not sigificant.&lt;/p&gt;

&lt;h3 id=&quot;is-lupus-more-likely-to-occur-in-males-or-females-and-in-caucasians-or-african-americans&quot;&gt;4. Is lupus more likely to occur in males or females and in Caucasians or African Americans?&lt;/h3&gt;

&lt;p&gt;More likely to occur in &lt;a href=&quot;http://www.lupusny.org/about-lupus/who-gets-lupus&quot;&gt;females&lt;/a&gt; and in African Americans.&lt;/p&gt;

&lt;h3 id=&quot;what-are-lupus-anti-coagulants-and-anti-phospholipid-antibodies-and-what-role-do-they-play-in-the-pathogenesis-of-sle&quot;&gt;5.What are lupus anti-coagulants and anti-phospholipid antibodies and what role do they play in the pathogenesis of SLE?&lt;/h3&gt;

&lt;p&gt;Antiphospholipid antibodies are present in 40% to 50% of patients with lupus and react with a wide variety of proteins in complex with phospholipids. Some bind to cardiolipin antigen, used in serologic tests for syphilis, so patients with lupus may have a false-positive test result for syphilis. Antiphos- pholipid antibodies contribute to coagulation abnormalities (p127)&lt;/p&gt;

&lt;p&gt;patients prolong pt are at risk of bleeding. not have a risk of bleeding, but have a risk of thomboli.&lt;/p&gt;

&lt;p&gt;Paradoxically, these antibodies interfere with clotting tests and are actually called “lupus anticoagulants.” Autoantibodies are also produced against clotting factors such as thrombin, and these too may contribute to clotting disorders. the term Lupus -anti-coagulants are actually a &lt;a href=&quot;http://www.hopkinslupus.org/lupus-tests/antiphospholipid-antibodies/&quot;&gt;misnomer&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-does-a-biopsy-of-the-erythematous-skin-rash-involving-areas-of-the-body-exposed-to-sunlight-reveal&quot;&gt;6. What does a biopsy of the erythematous skin rash involving areas of the body exposed to sunlight reveal?&lt;/h3&gt;

&lt;p&gt;Histopathologic findings include &lt;strong&gt;liquefactive degeneration&lt;/strong&gt; of the basal layer of the epidermis, &lt;strong&gt;edema&lt;/strong&gt; at the dermoepidermal junction, and &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image2.jpeg&quot;&gt;mononuclear infiltrates&lt;/a&gt; around blood vessels and skin appendages. also see &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image3.jpeg&quot;&gt;figure&lt;/a&gt; Immunofluorescence microscopy reveals deposition of immunoglobulin and complement at the &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2023.27.19.png&quot;&gt;dermoepidermal junction&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-percentage-of-patients-with-sle-has-renal-involvement&quot;&gt;7. What percentage of patients with SLE has renal involvement?&lt;/h3&gt;

&lt;p&gt;&lt;strong&gt;class answer&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;75 %&lt;/p&gt;

&lt;p&gt;**from book **&lt;/p&gt;

&lt;p&gt;Although the kidney appears normal by light microscopy in 25% to 30% of cases, almost all cases of SLE show some renal abnormality if examined by immuno- fluorescence and electron microscopy.(p128)&lt;/p&gt;

&lt;h3 id=&quot;why-did-the-patient-develop-exacerbations-and-remissions&quot;&gt;8.	Why did the patient develop exacerbations and remissions?&lt;/h3&gt;

&lt;h3 id=&quot;why-does-a-sle-patient-have-rheumatoid-factors-in-the-serum&quot;&gt;9.	Why does a SLE patient have rheumatoid factors in the serum?&lt;/h3&gt;

&lt;p&gt;class answers&lt;/p&gt;

&lt;p&gt;a lot of autoimmune diseases have rheumatoid factors.&lt;/p&gt;

&lt;p&gt;polyarthritis does not destroy the joints.&lt;/p&gt;

&lt;p&gt;supplementary&lt;/p&gt;

&lt;p&gt;Because in lupus, the immune system attacks the body, including the joints. Rheumatoid factor is an antibody that becomes connected to another type of antibody called immunoglobulin. Together, these form an immune complex that can become involved in inflammation. 
&lt;a href=&quot;http://www.everydayhealth.com/rheumatoid-arthritis/testing-for-rheumatoid-factor.aspx&quot;&gt;source&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-differential-diagnosis-of-sle&quot;&gt;10.	What is the differential diagnosis of SLE?&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;MNEMONIC  DOPAMIN RASH&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;DISCOID RASH&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;ORAL ULCERS&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;PHOTOSENSITIVITY&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;ANA&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;MALAR RASH&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;IMMUNOLOGICAL PHENOMENON(Le Cell, Ds DNA, Sm, APL ab, false + RPR, )&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;NEUROLOGICAL(Seizures,Psychosis)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;RENAL(Nephrotic,Nephritic)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;ARTHRITIS&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;SEROSITIS&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;HEMATOLOGICAL(Leukopenia,Thrombocytopenia, anemia)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.38.42.png&quot;&gt;slide 16 from sle ppt&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;what-are-the-complications-and-prognosis-of-sle&quot;&gt;11. What are the complications and prognosis of SLE?&lt;/h3&gt;

&lt;p&gt;good outlook&lt;/p&gt;

&lt;p&gt;Prognosis&lt;/p&gt;

&lt;p&gt;A primary cause of death among patients with lupus is atherosclerosis and SLE is unpredictable and varies greatly form one individual to the next.&lt;/p&gt;

&lt;p&gt;Mild SLE.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;skin rashes of discoid lupus erythematosus (DLE) or subacute cutaneous lupus erythematosus (SCLE) with or without joint aches.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Widespread SLE.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;SLE is a chronic, life-long disease, alternating between periods of symptom relapse, (called flares), and remission. The disease&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;may begin in any of the various systems of the body and progress unpredictably to others.&lt;/p&gt;

&lt;p&gt;The following are typical patterns:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Symptom relapses, or flares, occur on the average of two or three times a year.&lt;/li&gt;
  &lt;li&gt;Between flares, most patients with SLE function at about 90% of normal capacity.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;The degree of severity depends on different factors:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Severity of the inflammatory response&lt;/li&gt;
  &lt;li&gt;Frequency of episodes&lt;/li&gt;
  &lt;li&gt;The degree of organ or system involvement&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Vital organs or systems,joints, skin, and others are affected.&lt;/p&gt;

&lt;p&gt;Infections followed by kidney failure are the chief causes of death in patients with SLE.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.nytimes.com/health/guides/disease/systemic-lupus-erythematosus/prognosis.html&quot;&gt;source&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-five-year-survival-rate-of-patients-with-sle&quot;&gt;12.	What is the five-year survival rate of patients with SLE?&lt;/h3&gt;

&lt;p&gt;About 95% in the US, see the &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/Screenshot%202015-08-27%2014.20.33.png&quot;&gt;table&lt;/a&gt;
from the book&lt;a href=&quot;https://books.google.com/books?id=qqq450swSv0C&amp;amp;pg=PA685&amp;amp;lpg=PA685&amp;amp;dq=five-year+survival+rate+of+sle&amp;amp;source=bl&amp;amp;ots=sJPHBW-jv0&amp;amp;sig=w3asQB_Jsjymaz1pxhh4GLGRLmk&amp;amp;hl=en&amp;amp;sa=X&amp;amp;ved=0CDcQ6AEwBGoVChMI-LDk_fDJxwIVgVk-Ch2FwQII#v=onepage&amp;amp;q&amp;amp;f=false&quot;&gt;Systemic Lupus Erythematosus&lt;/a&gt; by Robert G. Lahita, George Tsokos&lt;/p&gt;

&lt;h3 id=&quot;figure-from-powerpoint-sides&quot;&gt;Figure from powerpoint sides&lt;/h3&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image1.jpeg&quot;&gt;1.	LUPUS BUTTERFLY RASH&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image2.jpeg&quot;&gt;2.	LUPUS SKIN BIOPSY&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image3.jpeg&quot;&gt;3.	LUPUS SKIN BIOPSY, THICKENED BASEMENT MEMBRANE&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image4.jpeg&quot;&gt;4.	LUPUS BAND TEST, ANTI IgG STAIN&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image5.jpeg&quot;&gt;5. PERIPHERAL RIM PATTERN&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image6.jpeg&quot;&gt;6.	DIFFUSE PROLIFERATIVE LUPUS NEPHRITIS&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image7.jpeg&quot;&gt;7.	L.E. CELL PREPARATION&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Picture%20clipping.pictClipping&quot;&gt;8.	LIBMAN-SACKS ENDOCARDITIS&lt;/a&gt;&lt;/p&gt;

&lt;h2 id=&quot;case-2&quot;&gt;Case 2&lt;/h2&gt;

&lt;h3 id=&quot;clinical-history&quot;&gt;CLINICAL HISTORY:&lt;/h3&gt;

&lt;p&gt;A 45-year-old white male previously diagnosed with a T cell leukemia developed skin rash, severe diarrhea and jaundice after receiving repeated blood transfusions.  The skin exhibited a fine, diffuse, erythematous, macular rash that began on the palms, soles and head and spread to the entire trunk as well as to extremities.  The rash became desquamative and resembled an extensive second-degree burn.  There was watery diarrhea associated with malabsorption, cramps and gastrointestinal bleeding.  Blood chemistry analysis revealed &lt;a href=&quot;p139&quot;&gt;hyperbilirubinemia&lt;/a&gt; and an elevated serum alkaline phosphatase level.  There was only a mild elevation in the alanine aminotransferase (ALT) and aspartate aminotransferase levels (AST).&lt;/p&gt;

&lt;p&gt;those sites have vast proliferative of immune cells, espeically the basal layers of the skin.&lt;/p&gt;

&lt;p&gt;eradated the blood, so the lymphocyte will be deactivated.&lt;/p&gt;

&lt;p&gt;alkaline phosphatase level will rise if the kidney ducts are damaged.&lt;/p&gt;

&lt;h3 id=&quot;are-the-clinical-events-described-above-attributable-to-the-leukemia-process-or-to-some-other-factor&quot;&gt;1.	Are the clinical events described above attributable to the leukemia process or to some other factor?&lt;/h3&gt;
&lt;p&gt;To some other factor.&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-most-likely-cause-of-the-signs-and-symptoms-described-in-this-patient&quot;&gt;2.	What is the most likely cause of the signs and symptoms described in this patient?&lt;/h3&gt;

&lt;p&gt;graft-versus-host diseases&lt;/p&gt;

&lt;h3 id=&quot;how-could-a-leukemia-patient-in-hospital-develop-signs-and-symptoms-of-graft-versus-host-disease&quot;&gt;3. How could a leukemia patient in hospital develop signs and symptoms of graft-versus-host disease?&lt;/h3&gt;

&lt;p&gt;GVHD occurs when immunologically competent cells are introduced into an immunoincompetent host. GVHD refers to the immunologic insult and to the consequences to the organism. The patient must have had a Hematopoietic cell transplation, Solid organ transplants, or blood transfusions.&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-mechanism-of-the-skin-rash&quot;&gt;4. What is the mechanism of the skin rash?&lt;/h3&gt;

&lt;p&gt;&lt;strong&gt;from textbook&lt;/strong&gt;
It resemble those of SS (p139), In the early stages, affected skin areas are somewhat edematous and have a doughy consistency. Capillaries and small arteries (as large as 500 μm in diameter) may show thickening of the basal lamina, endothelial cell damage, and partial occlusion. With progression, the edema- tous phase is replaced by progressive fibrosis of the dermis, which becomes tightly bound to the subcutaneous structures. There is marked increase of compact collagen in the dermis along with thinning of the epidermis, atrophy of the dermal appendages, and hyaline thickening of the walls of dermal arterioles and capillaries (P133)&lt;/p&gt;

&lt;p&gt;or&lt;/p&gt;

&lt;p&gt;Skin — In most patients, the first (and most common) clinical manifestation of acute GVHD is a maculopapular rash, usually occurring at or near the time of the white blood cell engraftment (picture 1). The rash initially involves the nape of the neck, ears, shoulders, the palms of the hands (picture 2), and the soles of the feet. It can be described as a sunburn and may be pruritic or painful (picture 3). From these initial areas of presentation, the rash may spread to involve the whole integument, eventually becoming confluent. In severe GVHD, the maculopapular rash forms bullous lesions with toxic epidermal necrolysis mimicking Stevens-Johnson syndrome
&lt;a href=&quot;http://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-grading-of-acute-graft-versus-host-disease&quot;&gt;source&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-cause-of-the-hyperbilirubinemia&quot;&gt;5. What is the cause of the hyperbilirubinemia&lt;/h3&gt;

&lt;p&gt;Destruction of small bile ducts gives rise to jaundice, thus resulted in hyperbilirubinemia&lt;/p&gt;

&lt;h3 id=&quot;what-subset-of-t-lymphocytes-is-found-in-biopsies-of-skin-intestine-and-liver&quot;&gt;6. What subset of T lymphocytes is found in biopsies of skin, intestine and liver?&lt;/h3&gt;

&lt;p&gt;CD 4+ and CD 8+&lt;/p&gt;

&lt;h3 id=&quot;how-could-graft-versus-host-disease-be-prevented-in-patients-receiving-blood-transfusions&quot;&gt;7. How could graft-versus-host disease be prevented in patients receiving blood transfusions?&lt;/h3&gt;

&lt;p&gt;GVHD is a potentially lethal complication that can be minimized but not eliminated by HLA matching. As another potential solution, donor T cells can be depleted before marrow transplant.&lt;/p&gt;

&lt;h3 id=&quot;when-is-graft-versus-host-disease-most-often-observed&quot;&gt;8. When is graft-versus-host disease most often observed?&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;Degree of mismatch between HLA types&lt;/li&gt;
  &lt;li&gt;“minor” histocompatibility antigens&lt;/li&gt;
  &lt;li&gt;Age – possible thymic influence&lt;/li&gt;
  &lt;li&gt;Germ free environment&lt;/li&gt;
  &lt;li&gt;Pre-treatment with cytotoxic drugs&lt;/li&gt;
  &lt;li&gt;Sex mismatch&lt;/li&gt;
  &lt;li&gt;Transfusion presensitization&lt;/li&gt;
&lt;/ul&gt;

&lt;ol&gt;
  &lt;li&gt;What types of GVH disease follow bone marrow transplantation?
The small bowel and colon are involved in most cases. Intestinal graft-versus-host disease often manifests as a watery diarrhea.&lt;/li&gt;
&lt;/ol&gt;

&lt;h3 id=&quot;figures&quot;&gt;figures&lt;/h3&gt;
&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.44.57.png&quot;&gt;1.	List of target tissues of acute G-V-H disease&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image9.jpeg&quot;&gt;2.	Baby with maculopapular rash of  G-V-H 	disease&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image10.jpeg&quot;&gt;3. 	Adult with acute G-V-H skin reaction&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image11.jpeg&quot;&gt;4.	Micro–skin interface dermatitis with basal cell destruction&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image12.jpeg&quot;&gt;5.	Micro–skin interface dermatitis with basal cell destruction&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image13.jpeg&quot;&gt;6.	Micro–liver G-V-H with bile-duct injury and early cell infiltrate&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image14.jpeg&quot;&gt;7.	Micro-liver G-V-H, chronic with inflammation and fibrosis&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image15.jpeg&quot;&gt;8.	Micro–enteritis in G-V-H in lower 1/3 of crypt, early&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image16.jpeg&quot;&gt;9.	Micro–enterocyte necrosis and crypt destruction&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image17.jpeg&quot;&gt;10. Gross–intestinal G-V-H with bleeding and superinfection&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image18.jpeg&quot;&gt;11. Gross–intestinal G-V-H with intermittent involved areas&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image19.jpeg&quot;&gt;12. Gross–intestinal G-V-H with bleeding and 	superinfection&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image20.jpeg&quot;&gt;13. Gross–intestinal G-V-H with mucosal sloughing and scarring&lt;/a&gt;&lt;/p&gt;

&lt;h2 id=&quot;case-3&quot;&gt;Case 3&lt;/h2&gt;

&lt;h3 id=&quot;clinical-history-1&quot;&gt;CLINICAL HISTORY:&lt;/h3&gt;

&lt;p&gt;A 60-year-old white male presented to his family physician with complaints of weakness, anorexia, weight loss and severe back pain.&lt;/p&gt;

&lt;h3 id=&quot;laboratory-and-x-ray-findings&quot;&gt;LABORATORY AND X-RAY FINDINGS:&lt;/h3&gt;

&lt;p&gt;Radiologic examination revealed  “punched out” &lt;a href=&quot;&quot;&gt;skeletal lesions&lt;/a&gt; with sharply demarcated margins in vertebral bodies, skull, ribs, and pelvis.  Blood chemistry showed hypercalcemia and hyperglobulinemia.  The serum globulin concentration was &lt;a href=&quot;http://www.drstandley.com/labvalues_proteins.shtml&quot;&gt;6.0 g/dl&lt;/a&gt;.  Both the serum and urine revealed a homogeneous protein by electrophoresis, which was identified as &lt;a href=&quot;p437&quot;&gt;IgA&lt;/a&gt;.  The urine contained free light chains.  The urinary protein was insoluble at acid pH between &lt;a href=&quot;http://basicprotein.blogspot.com/2012/11/tests-for-detection-of-bence-jones.html&quot;&gt;40º and 60ºC but redissolved at 95ºC.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;Hematologic examination revealed a normochromic normocytic anemia with leukopenia and thrombocytopenia.  The blood smear revealed rouleaux formation of red cells.  There was an elevated sedimentation rate and marked plasma cell proliferation in the bone marrow.   Flow cytometric analysis of the bone marrow revealed an abnormal CD45 negative cell population that expressed CD38, CD56 and CD138 with cytoplasmic kappa light chain restriction.  This cell population was negative for CD19, CD20 and surface immunoglobulin.&lt;/p&gt;

&lt;p&gt;A renal biopsy was performed and revealed large numbers of eosinophilic lamellated casts in the renal tubules.  The tubular cells were markedly atrophic and contained hyaline droplets and some crystalline material. The glomeruli appeared normal, yet they were surrounded by interstitial fibrosis as a result of tubular destruction.  The patient received supportive therapy including local radiation therapy to relieve pain.  He experienced repeated bouts of respiratory infection with Streptococcus pneumoniae.  After reaching a diagnosis, cytotoxic therapy was instituted, yet the patient died within 12 months of diagnosis.&lt;/p&gt;

&lt;p&gt;cd 138 is specific for plasma cells
cd 19 is B cell marker
kappa or lambda restricted&lt;/p&gt;

&lt;h3 id=&quot;what-information-provided-above-is-of-the-greatest-assistance-in-reaching-a-diagnosis-of-plasma-cell-multiple-myeloma-in-this-patient&quot;&gt;1. What information provided above is of the greatest assistance in reaching a diagnosis of plasma cell 	(multiple) myeloma in this patient?&lt;/h3&gt;

&lt;h3 id=&quot;why-did-this-patient-present-with-severe-back-pain&quot;&gt;2. Why did this patient present with severe back pain?&lt;/h3&gt;
&lt;p&gt;It is due to pathologic fractures. Pathologic fractures of vertebrae may lead to spinal cord impingement, an oncologic emergency.&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-cause-of-the-punched-out-osteolytic-lesions&quot;&gt;3. What is the cause of the “punched out” osteolytic lesions?&lt;/h3&gt;

&lt;p&gt;Bone destruction by osteolytic lesions is caused by two separate events. Rapid growth of myeloma cells inhibits normal bone-forming cells, damaging bone. In addition, production of substances that activate the cells that resorb bone, called osteoclasts, is increased.&lt;/p&gt;

&lt;p&gt;The lesions generally arise in the medullary cavity, erode cancellous bone, and progressively destroy the cortical bone.&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-significance-of-the-light-chain-proteinuria-described-in-this-patient&quot;&gt;4. What is the significance of the light chain proteinuria described in this patient.&lt;/h3&gt;
&lt;p&gt;Light chain deposition in the glomeruli or the interstitium, either as amyloid or linear deposits, also may contribute to renal dysfunction.&lt;/p&gt;

&lt;h3 id=&quot;since-the-patient-was-hypergammaglobulinemic-why-did-he-suffer-repeated-bouts-of-pneumococcal-infection&quot;&gt;5. Since the patient was hypergammaglobulinemic, why did he suffer repeated bouts of pneumococcal infection?&lt;/h3&gt;

&lt;p&gt;Patients with myeloma are immunosuppressed. Through uncertain mechanisms, myeloma cells interfere with the function of normal plasma cells, leading to defects in antibody production. Thus, although the plasma usually contains increased immunoglobulin owing to the pres- ence of an M protein, the levels of functional antibodies often are profoundly depressed, leaving patients at high risk for bacterial infections. (p438)&lt;/p&gt;

&lt;h3 id=&quot;which-part-of-the-skeletal-system-is-most-frequently-affected-in-plasma-cell-myeloma&quot;&gt;6. Which part of the skeletal system is most frequently affected in plasma cell myeloma?&lt;/h3&gt;

&lt;p&gt;Multiple myeloma usually manifests with multifocal destructive skeletal lesions, which most commonly involve the vertebral column, ribs, skull, pelvis, femur, clavicle, and scapula. The lesions generally arise in the medullary cavity, erode cancellous bone, and progressively destroy the cortical bone.&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-differential-diagnosis-of-plasma-cell-myeloma&quot;&gt;7. What is the differential diagnosis of plasma cell 	myeloma?&lt;/h3&gt;
&lt;p&gt;we
The main differential is that of widespread bony metastases. Findings that favour the diagnosis of bony metastases over that of multiple myeloma include:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;more commonly affect the vertebral pedicles rather than vertebral bodies&lt;/li&gt;
  &lt;li&gt;rarely involve mandible, distal axial skeleton&lt;/li&gt;
  &lt;li&gt;although both entities have variable bone scan appearances (both hot and cold) unlike myeloma, extensive bony metastases rarely have a normal appearance&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Other rare entities include:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Waldenstrom macroglonulinaemia&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;http://radiopaedia.org/articles/multiple-myeloma-1&quot;&gt;source&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;which-immunoglobulins-may-be-increased-in-plasma-cell-myeloma&quot;&gt;8. Which immunoglobulins may be increased in plasma cell myeloma?&lt;/h3&gt;

&lt;p&gt;he most frequent M protein produced by myeloma cells is IgG (60%), followed by IgA (20% to 25%); only rarely are IgM, IgD, or IgE M proteins observed.&lt;/p&gt;

&lt;h3 id=&quot;do-all-cases-of-plasma-cell-myeloma-have-the-monoclonal-serum-paraprotein-identifiable-electrophoresis&quot;&gt;9. Do all cases of plasma cell myeloma have the monoclonal serum paraprotein identifiable 	electrophoresis?&lt;/h3&gt;

&lt;p&gt;Electrophoresis of the serum and urine is an important diagnostic tool. In 99% of cases, either a monoclonal com- plete immunoglobulin or a monoclonal free immunoglobu- lin light chain is present in the serum, the urine, or both&lt;/p&gt;

&lt;p&gt;Because these immunoglobulins can be detected in the serum, these disorders are also referred to as monoclonal gammopathies, and the associated immuno- globulin is often referred to as an M protein&lt;/p&gt;

&lt;ol&gt;
  &lt;li&gt;What is the meaning of the results of flow cytometric analysis of the bone marrow.&lt;/li&gt;
&lt;/ol&gt;

&lt;p&gt;figures&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image21.jpeg&quot;&gt;1.	Plasma cell in smear&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image22.jpeg&quot;&gt;2.	Plasma cell (drawing)&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image23.jpeg&quot;&gt;3.	Plasma cell cluster in smear&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image24.jpeg&quot;&gt;4.	Gross of vertebral bodies eroded by plasmacytoma&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image25.jpeg&quot;&gt;5.	Gross of vertebral bodies eroded by plasmacytoma&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image26.jpeg&quot;&gt;6.	Gross of vertebral bodies eroded by plasmacytoma&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image27.jpeg&quot;&gt;7.	Gross of rib with protruding plasma cell proliferation&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image28.jpeg&quot;&gt;8.	Gross of osteolytic lesions of skull in plasma cell myeloma&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image29.jpeg&quot;&gt;9.	X-rays of osteolytic lesions of skull in plasma cell myeloma&lt;/a&gt;&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Pathology cases study</title>
   <link href="http://lanyon.getpoole.com/pathology/2015/08/27/pathology-cases/"/>
   <updated>2015-08-27T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/pathology/2015/08/27/pathology-cases</id>
   <content type="html">&lt;h2 id=&quot;case-1&quot;&gt;Case 1&lt;/h2&gt;

&lt;p&gt;Clinical History:&lt;/p&gt;

&lt;p&gt;A 30-year-old &lt;a href=&quot;http://www.lupusny.org/about-lupus/who-gets-lupus&quot;&gt;African American woman&lt;/a&gt; presented to her family physician with nonradiating chest pain, shortness of breath, fever, weight-loss, malaise, lethargy and arthralgia.  She exhibited an &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image1.jpeg&quot;&gt;erythematous skin rash&lt;/a&gt; involving areas of the body exposed to sunlight. She noticed hair loss during the months prior to seeking medical attention.  She was admitted to the hospital for observation and tests.&lt;/p&gt;

&lt;!--break--&gt;

&lt;p&gt;Laboratory Findings and X-Ray:&lt;br /&gt;
A chest X-ray revealed cardiomegaly and &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;pleural effusion&lt;/a&gt;.  A complete blood count (CBC) identified a normochromic, normocytic anemia.  Urinalysis revealed &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.27.33.png&quot;&gt;hematuria, proteinuria and erythrocyte and leukocyte casts&lt;/a&gt;.  Analysis of the blood serum revealed the presence of autoantibodies against double-stranded DNA (p127).  &lt;a href=&quot;http://images.rheumatology.org/viewphoto.php?albumId=75690&amp;amp;imageId=2862319&quot;&gt;Immunofluorescence staining&lt;/a&gt; for antinuclear antibodies showed a &lt;a href=&quot;http://www.thelupussite.com/lupus_diagnosis_tests/ana_antinuclear_antibody.html&quot;&gt;peripheral pattern&lt;/a&gt; using human leukocytes as the substrate.  The serum also contained &lt;a href=&quot;http://www.healthline.com/health-slideshow/lupus-and-ra#1&quot;&gt;rheumatoid factor&lt;/a&gt; and &lt;a href=&quot;http://www.cidjournal.com/article/0738-081X%2885%2990074-4/abstract&quot;&gt;anticytoplasmic antibodies&lt;/a&gt;.&lt;/p&gt;

&lt;p&gt;Clinical Course of Disease:
A renal biopsy was performed and revealed diffuse &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;proliferative glomerulonephritis&lt;/a&gt; characterized by extensive cellular proliferation in more than 50% of glomeruli.  Immune complexes were deposited mainly in a &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;subendothelial distribution&lt;/a&gt;.  Immunofluorescence microscopy revealed that the immune deposits stained positively for all three major immunoglobulin classes and complement indicating a polyclonal activation of the immune system.  &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;Electron microscopy&lt;/a&gt; confirmed the subendothelial as well as intramembranous deposition of immune deposits.&lt;/p&gt;

&lt;h3 id=&quot;what-information-provided-above-is-of-the-greatest-assistance-in-reaching-a-diagnosis-of-systemic-lupus-erythematosus-in-this-patient&quot;&gt;1. What information provided above is of the greatest 	assistance in reaching a diagnosis of systemic lupus erythematosus in this patient?&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;http://www.lupusny.org/about-lupus/who-gets-lupus&quot;&gt;American woman&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image1.jpeg&quot;&gt;erythematous skin rash&lt;/a&gt; 
􏰡&lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.31.43.png&quot;&gt;hematuria, proteinuria and erythrocyte and leukocyte casts&lt;/a&gt; 7th criterion&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;􏰞https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.31.43.png&quot;&gt;pleural effusion&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;autoantibodies against double-stranded DNA&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;antinuclear antibodies showed a &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image5.jpeg&quot;&gt;peripheral pattern&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;http://www.cidjournal.com/article/0738-081X%2885%2990074-4/abstract&quot;&gt;anticytoplasmic antibodies&lt;/a&gt;.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;proliferative glomerulonephritis&lt;/a&gt; &lt;em&gt;class V&lt;/em&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;subendothelial distribution&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;Electron microscopy&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;why-did-this-patient-present-with-chest-pain&quot;&gt;2.	Why did this patient present with chest pain?&lt;/h3&gt;

&lt;p&gt;&lt;strong&gt;class answer&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;perual efusion.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;The patient may suffer &lt;a href=&quot;p 89 &amp;amp; p 130&quot;&gt;Libman-Sacks endocarditis&lt;/a&gt;, possiblely related Thrombi, which can develop anywhere in the cardiovascular system due to &lt;a href=&quot;http://www.hopkinslupus.org/lupus-tests/antiphospholipid-antibodies/&quot;&gt;lupus anticoagulant&lt;/a&gt; which increases the ability of the blood to clot.&lt;/p&gt;

&lt;h3 id=&quot;what-are-the-major-immunologic-features-of-systemic-lupus-erythematosus-sle&quot;&gt;3. What are the major immunologic features of systemic lupus erythematosus (SLE)?&lt;/h3&gt;

&lt;p&gt;&lt;strong&gt;class answer&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;Anti-DNA. Antibody to native DNA, Anti-Sm. Presence of AB to &lt;strong&gt;Smith&lt;/strong&gt; nuclear antigen.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;depostion of immune complex&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;epidermal and dermal junction&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image3.jpeg&quot;&gt;3.	LUPUS SKIN BIOPSY, THICKENED BASEMENT MEMBRANE&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image4.jpeg&quot;&gt;4.	LUPUS BAND TEST, ANTI IgG STAIN&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image5.jpeg&quot;&gt;5. PERIPHERAL RIM PATTERN&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;LE test is no longer performed.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;The patient may suffer Libman-Sacks endocarditis (p 89 &amp;amp; p 130) Note that this is not infected, it is just fribid, so it is&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;not sigificant.&lt;/p&gt;

&lt;h3 id=&quot;is-lupus-more-likely-to-occur-in-males-or-females-and-in-caucasians-or-african-americans&quot;&gt;4. Is lupus more likely to occur in males or females and in Caucasians or African Americans?&lt;/h3&gt;

&lt;p&gt;More likely to occur in &lt;a href=&quot;http://www.lupusny.org/about-lupus/who-gets-lupus&quot;&gt;females&lt;/a&gt; and in African Americans.&lt;/p&gt;

&lt;h3 id=&quot;what-are-lupus-anti-coagulants-and-anti-phospholipid-antibodies-and-what-role-do-they-play-in-the-pathogenesis-of-sle&quot;&gt;5.What are lupus anti-coagulants and anti-phospholipid antibodies and what role do they play in the pathogenesis of SLE?&lt;/h3&gt;

&lt;p&gt;Antiphospholipid antibodies are present in 40% to 50% of patients with lupus and react with a wide variety of proteins in complex with phospholipids. Some bind to cardiolipin antigen, used in serologic tests for syphilis, so patients with lupus may have a false-positive test result for syphilis. Antiphos- pholipid antibodies contribute to coagulation abnormalities (p127)&lt;/p&gt;

&lt;p&gt;patients prolong pt are at risk of bleeding. not have a risk of bleeding, but have a risk of thomboli.&lt;/p&gt;

&lt;p&gt;Paradoxically, these antibodies interfere with clotting tests and are actually called “lupus anticoagulants.” Autoantibodies are also produced against clotting factors such as thrombin, and these too may contribute to clotting disorders. the term Lupus -anti-coagulants are actually a &lt;a href=&quot;http://www.hopkinslupus.org/lupus-tests/antiphospholipid-antibodies/&quot;&gt;misnomer&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-does-a-biopsy-of-the-erythematous-skin-rash-involving-areas-of-the-body-exposed-to-sunlight-reveal&quot;&gt;6. What does a biopsy of the erythematous skin rash involving areas of the body exposed to sunlight reveal?&lt;/h3&gt;

&lt;p&gt;Histopathologic findings include &lt;strong&gt;liquefactive degeneration&lt;/strong&gt; of the basal layer of the epidermis, &lt;strong&gt;edema&lt;/strong&gt; at the dermoepidermal junction, and &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image2.jpeg&quot;&gt;mononuclear infiltrates&lt;/a&gt; around blood vessels and skin appendages. also see &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image3.jpeg&quot;&gt;figure&lt;/a&gt; Immunofluorescence microscopy reveals deposition of immunoglobulin and complement at the &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2023.27.19.png&quot;&gt;dermoepidermal junction&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-percentage-of-patients-with-sle-has-renal-involvement&quot;&gt;7. What percentage of patients with SLE has renal involvement?&lt;/h3&gt;

&lt;p&gt;&lt;strong&gt;class answer&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;75 %&lt;/p&gt;

&lt;p&gt;**from book **&lt;/p&gt;

&lt;p&gt;Although the kidney appears normal by light microscopy in 25% to 30% of cases, almost all cases of SLE show some renal abnormality if examined by immuno- fluorescence and electron microscopy.(p128)&lt;/p&gt;

&lt;h3 id=&quot;why-did-the-patient-develop-exacerbations-and-remissions&quot;&gt;8.	Why did the patient develop exacerbations and remissions?&lt;/h3&gt;

&lt;h3 id=&quot;why-does-a-sle-patient-have-rheumatoid-factors-in-the-serum&quot;&gt;9.	Why does a SLE patient have rheumatoid factors in the serum?&lt;/h3&gt;

&lt;p&gt;class answers&lt;/p&gt;

&lt;p&gt;a lot of autoimmune diseases have rheumatoid factors.&lt;/p&gt;

&lt;p&gt;polyarthritis does not destroy the joints.&lt;/p&gt;

&lt;p&gt;supplementary&lt;/p&gt;

&lt;p&gt;Because in lupus, the immune system attacks the body, including the joints. Rheumatoid factor is an antibody that becomes connected to another type of antibody called immunoglobulin. Together, these form an immune complex that can become involved in inflammation. 
&lt;a href=&quot;http://www.everydayhealth.com/rheumatoid-arthritis/testing-for-rheumatoid-factor.aspx&quot;&gt;source&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-differential-diagnosis-of-sle&quot;&gt;10.	What is the differential diagnosis of SLE?&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;MNEMONIC  DOPAMIN RASH&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;DISCOID RASH&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;ORAL ULCERS&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;PHOTOSENSITIVITY&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;ANA&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;MALAR RASH&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;IMMUNOLOGICAL PHENOMENON(Le Cell, Ds DNA, Sm, APL ab, false + RPR, )&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;NEUROLOGICAL(Seizures,Psychosis)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;RENAL(Nephrotic,Nephritic)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;ARTHRITIS&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;SEROSITIS&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;HEMATOLOGICAL(Leukopenia,Thrombocytopenia, anemia)&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.38.42.png&quot;&gt;slide 16 from sle ppt&lt;/a&gt;&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;what-are-the-complications-and-prognosis-of-sle&quot;&gt;11. What are the complications and prognosis of SLE?&lt;/h3&gt;

&lt;p&gt;Prognosis&lt;/p&gt;

&lt;p&gt;A primary cause of death among patients with lupus is atherosclerosis and SLE is unpredictable and varies greatly form one individual to the next.&lt;/p&gt;

&lt;p&gt;Mild SLE.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;skin rashes of discoid lupus erythematosus (DLE) or subacute cutaneous lupus erythematosus (SCLE) with or without joint aches.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Widespread SLE.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;SLE is a chronic, life-long disease, alternating between periods of symptom relapse, (called flares), and remission. The disease&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;may begin in any of the various systems of the body and progress unpredictably to others.&lt;/p&gt;

&lt;p&gt;The following are typical patterns:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Symptom relapses, or flares, occur on the average of two or three times a year.&lt;/li&gt;
  &lt;li&gt;Between flares, most patients with SLE function at about 90% of normal capacity.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;The degree of severity depends on different factors:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Severity of the inflammatory response&lt;/li&gt;
  &lt;li&gt;Frequency of episodes&lt;/li&gt;
  &lt;li&gt;The degree of organ or system involvement&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Vital organs or systems,joints, skin, and others are affected.&lt;/p&gt;

&lt;p&gt;Infections followed by kidney failure are the chief causes of death in patients with SLE.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.nytimes.com/health/guides/disease/systemic-lupus-erythematosus/prognosis.html&quot;&gt;source&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-five-year-survival-rate-of-patients-with-sle&quot;&gt;12.	What is the five-year survival rate of patients with SLE?&lt;/h3&gt;

&lt;p&gt;About 95% in the US, see the &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/Screenshot%202015-08-27%2014.20.33.png&quot;&gt;table&lt;/a&gt;
from the book&lt;a href=&quot;https://books.google.com/books?id=qqq450swSv0C&amp;amp;pg=PA685&amp;amp;lpg=PA685&amp;amp;dq=five-year+survival+rate+of+sle&amp;amp;source=bl&amp;amp;ots=sJPHBW-jv0&amp;amp;sig=w3asQB_Jsjymaz1pxhh4GLGRLmk&amp;amp;hl=en&amp;amp;sa=X&amp;amp;ved=0CDcQ6AEwBGoVChMI-LDk_fDJxwIVgVk-Ch2FwQII#v=onepage&amp;amp;q&amp;amp;f=false&quot;&gt;Systemic Lupus Erythematosus&lt;/a&gt; by Robert G. Lahita, George Tsokos&lt;/p&gt;

&lt;h3 id=&quot;figure-from-powerpoint-sides&quot;&gt;Figure from powerpoint sides&lt;/h3&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image1.jpeg&quot;&gt;1.	LUPUS BUTTERFLY RASH&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image2.jpeg&quot;&gt;2.	LUPUS SKIN BIOPSY&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image3.jpeg&quot;&gt;3.	LUPUS SKIN BIOPSY, THICKENED BASEMENT MEMBRANE&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image4.jpeg&quot;&gt;4.	LUPUS BAND TEST, ANTI IgG STAIN&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image5.jpeg&quot;&gt;5. PERIPHERAL RIM PATTERN&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image6.jpeg&quot;&gt;6.	DIFFUSE PROLIFERATIVE LUPUS NEPHRITIS&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image7.jpeg&quot;&gt;7.	L.E. CELL PREPARATION&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Picture%20clipping.pictClipping&quot;&gt;8.	LIBMAN-SACKS ENDOCARDITIS&lt;/a&gt;&lt;/p&gt;

&lt;h2 id=&quot;case-2&quot;&gt;Case 2&lt;/h2&gt;

&lt;h3 id=&quot;clinical-history&quot;&gt;CLINICAL HISTORY:&lt;/h3&gt;

&lt;p&gt;A 45-year-old white male previously diagnosed with a T cell leukemia developed skin rash, severe diarrhea and jaundice after receiving repeated blood transfusions.  The skin exhibited a fine, diffuse, erythematous, macular rash that began on the palms, soles and head and spread to the entire trunk as well as to extremities.  The rash became desquamative and resembled an extensive second-degree burn.  There was watery diarrhea associated with malabsorption, cramps and gastrointestinal bleeding.  Blood chemistry analysis revealed &lt;a href=&quot;p139&quot;&gt;hyperbilirubinemia&lt;/a&gt; and an elevated serum alkaline phosphatase level.  There was only a mild elevation in the alanine aminotransferase (ALT) and aspartate aminotransferase levels (AST).&lt;/p&gt;

&lt;h3 id=&quot;are-the-clinical-events-described-above-attributable-to-the-leukemia-process-or-to-some-other-factor&quot;&gt;1.	Are the clinical events described above attributable to the leukemia process or to some other factor?&lt;/h3&gt;
&lt;p&gt;To some other factor.&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-most-likely-cause-of-the-signs-and-symptoms-described-in-this-patient&quot;&gt;2.	What is the most likely cause of the signs and symptoms described in this patient?&lt;/h3&gt;
&lt;p&gt;graft-versus-host diseases&lt;/p&gt;

&lt;h3 id=&quot;how-could-a-leukemia-patient-in-hospital-develop-signs-and-symptoms-of-graft-versus-host-disease&quot;&gt;3. How could a leukemia patient in hospital develop signs and symptoms of graft-versus-host disease?&lt;/h3&gt;
&lt;p&gt;GVHD occurs when immunologically competent cells are introduced into an immunoincompetent host. GVHD refers to the immunologic insult and to the consequences to the organism. The patient must have had a Hematopoietic cell transplation, Solid organ transplants, or blood transfusions.&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-mechanism-of-the-skin-rash&quot;&gt;4. What is the mechanism of the skin rash?&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;from textbook&lt;/strong&gt;
It resemble those of SS (p139), In the early stages, affected skin areas are somewhat edematous and have a doughy consistency. Capillaries and small arteries (as large as 500 μm in diameter) may show thickening of the basal lamina, endothelial cell damage, and partial occlusion. With progression, the edema- tous phase is replaced by progressive fibrosis of the dermis, which becomes tightly bound to the subcutaneous structures. There is marked increase of compact collagen in the dermis along with thinning of the epidermis, atrophy of the dermal appendages, and hyaline thickening of the walls of dermal arterioles and capillaries (P133)&lt;/p&gt;

&lt;p&gt;or&lt;/p&gt;

&lt;p&gt;Skin — In most patients, the first (and most common) clinical manifestation of acute GVHD is a maculopapular rash, usually occurring at or near the time of the white blood cell engraftment (picture 1). The rash initially involves the nape of the neck, ears, shoulders, the palms of the hands (picture 2), and the soles of the feet. It can be described as a sunburn and may be pruritic or painful (picture 3). From these initial areas of presentation, the rash may spread to involve the whole integument, eventually becoming confluent. In severe GVHD, the maculopapular rash forms bullous lesions with toxic epidermal necrolysis mimicking Stevens-Johnson syndrome
&lt;a href=&quot;http://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-grading-of-acute-graft-versus-host-disease&quot;&gt;source&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-cause-of-the-hyperbilirubinemia&quot;&gt;5. What is the cause of the hyperbilirubinemia&lt;/h3&gt;
&lt;p&gt;Destruction of small bile ducts gives rise to jaundice, thus resulted in hyperbilirubinemia&lt;/p&gt;

&lt;h3 id=&quot;what-subset-of-t-lymphocytes-is-found-in-biopsies-of-skin-intestine-and-liver&quot;&gt;6. What subset of T lymphocytes is found in biopsies of skin, intestine and liver?&lt;/h3&gt;
&lt;p&gt;CD 4+ and CD 8+&lt;/p&gt;

&lt;h3 id=&quot;how-could-graft-versus-host-disease-be-prevented-in-patients-receiving-blood-transfusions&quot;&gt;7. How could graft-versus-host disease be prevented in patients receiving blood transfusions?&lt;/h3&gt;
&lt;p&gt;GVHD is a potentially lethal complication that can be minimized but not eliminated by HLA matching. As another potential solution, donor T cells can be depleted before marrow transplant.&lt;/p&gt;

&lt;h3 id=&quot;when-is-graft-versus-host-disease-most-often-observed&quot;&gt;8. When is graft-versus-host disease most often observed?&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;Degree of mismatch between HLA types&lt;/li&gt;
  &lt;li&gt;“minor” histocompatibility antigens&lt;/li&gt;
  &lt;li&gt;Age – possible thymic influence&lt;/li&gt;
  &lt;li&gt;Germ free environment&lt;/li&gt;
  &lt;li&gt;Pre-treatment with cytotoxic drugs&lt;/li&gt;
  &lt;li&gt;Sex mismatch&lt;/li&gt;
  &lt;li&gt;Transfusion presensitization&lt;/li&gt;
&lt;/ul&gt;

&lt;ol&gt;
  &lt;li&gt;What types of GVH disease follow bone marrow transplantation?
The small bowel and colon are involved in most cases. Intestinal graft-versus-host disease often manifests as a watery diarrhea.&lt;/li&gt;
&lt;/ol&gt;

&lt;h3 id=&quot;figures&quot;&gt;figures&lt;/h3&gt;
&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.44.57.png&quot;&gt;1.	List of target tissues of acute G-V-H disease&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image9.jpeg&quot;&gt;2.	Baby with maculopapular rash of  G-V-H 	disease&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image10.jpeg&quot;&gt;3. 	Adult with acute G-V-H skin reaction&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image11.jpeg&quot;&gt;4.	Micro–skin interface dermatitis with basal cell destruction&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image12.jpeg&quot;&gt;5.	Micro–skin interface dermatitis with basal cell destruction&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image13.jpeg&quot;&gt;6.	Micro–liver G-V-H with bile-duct injury and early cell infiltrate&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image14.jpeg&quot;&gt;7.	Micro-liver G-V-H, chronic with inflammation and fibrosis&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image15.jpeg&quot;&gt;8.	Micro–enteritis in G-V-H in lower 1/3 of crypt, early&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image16.jpeg&quot;&gt;9.	Micro–enterocyte necrosis and crypt destruction&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image17.jpeg&quot;&gt;10. Gross–intestinal G-V-H with bleeding and superinfection&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image18.jpeg&quot;&gt;11. Gross–intestinal G-V-H with intermittent involved areas&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image19.jpeg&quot;&gt;12. Gross–intestinal G-V-H with bleeding and 	superinfection&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image20.jpeg&quot;&gt;13. Gross–intestinal G-V-H with mucosal sloughing and scarring&lt;/a&gt;&lt;/p&gt;

&lt;h2 id=&quot;case-3&quot;&gt;Case 3&lt;/h2&gt;

&lt;h3 id=&quot;clinical-history-1&quot;&gt;CLINICAL HISTORY:&lt;/h3&gt;

&lt;p&gt;A 60-year-old white male presented to his family physician with complaints of weakness, anorexia, weight loss and severe back pain.&lt;/p&gt;

&lt;h3 id=&quot;laboratory-and-x-ray-findings&quot;&gt;LABORATORY AND X-RAY FINDINGS:&lt;/h3&gt;

&lt;p&gt;Radiologic examination revealed  “punched out” &lt;a href=&quot;&quot;&gt;skeletal lesions&lt;/a&gt; with sharply demarcated margins in vertebral bodies, skull, ribs, and pelvis.  Blood chemistry showed hypercalcemia and hyperglobulinemia.  The serum globulin concentration was &lt;a href=&quot;http://www.drstandley.com/labvalues_proteins.shtml&quot;&gt;6.0 g/dl&lt;/a&gt;.  Both the serum and urine revealed a homogeneous protein by electrophoresis, which was identified as &lt;a href=&quot;p437&quot;&gt;IgA&lt;/a&gt;.  The urine contained free light chains.  The urinary protein was insoluble at acid pH between &lt;a href=&quot;http://basicprotein.blogspot.com/2012/11/tests-for-detection-of-bence-jones.html&quot;&gt;40º and 60ºC but redissolved at 95ºC.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;Hematologic examination revealed a normochromic normocytic anemia with leukopenia and thrombocytopenia.  The blood smear revealed rouleaux formation of red cells.  There was an elevated sedimentation rate and marked plasma cell proliferation in the bone marrow.   Flow cytometric analysis of the bone marrow revealed an abnormal CD45 negative cell population that expressed CD38, CD56 and CD138 with cytoplasmic kappa light chain restriction.  This cell population was negative for CD19, CD20 and surface immunoglobulin.&lt;/p&gt;

&lt;p&gt;A renal biopsy was performed and revealed large numbers of eosinophilic lamellated casts in the renal tubules.  The tubular cells were markedly atrophic and contained hyaline droplets and some crystalline material. The glomeruli appeared normal, yet they were surrounded by interstitial fibrosis as a result of tubular destruction.  The patient received supportive therapy including local radiation therapy to relieve pain.  He experienced repeated bouts of respiratory infection with Streptococcus pneumoniae.  After reaching a diagnosis, cytotoxic therapy was instituted, yet the patient died within 12 months of diagnosis.&lt;/p&gt;

&lt;h3 id=&quot;what-information-provided-above-is-of-the-greatest-assistance-in-reaching-a-diagnosis-of-plasma-cell-multiple-myeloma-in-this-patient&quot;&gt;1. What information provided above is of the greatest assistance in reaching a diagnosis of plasma cell 	(multiple) myeloma in this patient?&lt;/h3&gt;

&lt;h3 id=&quot;why-did-this-patient-present-with-severe-back-pain&quot;&gt;2. Why did this patient present with severe back pain?&lt;/h3&gt;
&lt;p&gt;It is due to pathologic fractures. Pathologic fractures of vertebrae may lead to spinal cord impingement, an oncologic emergency.&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-cause-of-the-punched-out-osteolytic-lesions&quot;&gt;3. What is the cause of the “punched out” osteolytic lesions?&lt;/h3&gt;

&lt;p&gt;Bone destruction by osteolytic lesions is caused by two separate events. Rapid growth of myeloma cells inhibits normal bone-forming cells, damaging bone. In addition, production of substances that activate the cells that resorb bone, called osteoclasts, is increased.&lt;/p&gt;

&lt;p&gt;The lesions generally arise in the medullary cavity, erode cancellous bone, and progressively destroy the cortical bone.&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-significance-of-the-light-chain-proteinuria-described-in-this-patient&quot;&gt;4. What is the significance of the light chain proteinuria described in this patient.&lt;/h3&gt;
&lt;p&gt;Light chain deposition in the glomeruli or the interstitium, either as amyloid or linear deposits, also may contribute to renal dysfunction.&lt;/p&gt;

&lt;h3 id=&quot;since-the-patient-was-hypergammaglobulinemic-why-did-he-suffer-repeated-bouts-of-pneumococcal-infection&quot;&gt;5. Since the patient was hypergammaglobulinemic, why did he suffer repeated bouts of pneumococcal infection?&lt;/h3&gt;

&lt;p&gt;Patients with myeloma are immunosuppressed. Through uncertain mechanisms, myeloma cells interfere with the function of normal plasma cells, leading to defects in antibody production. Thus, although the plasma usually contains increased immunoglobulin owing to the pres- ence of an M protein, the levels of functional antibodies often are profoundly depressed, leaving patients at high risk for bacterial infections. (p438)&lt;/p&gt;

&lt;h3 id=&quot;which-part-of-the-skeletal-system-is-most-frequently-affected-in-plasma-cell-myeloma&quot;&gt;6. Which part of the skeletal system is most frequently affected in plasma cell myeloma?&lt;/h3&gt;

&lt;p&gt;Multiple myeloma usually manifests with multifocal destructive skeletal lesions, which most commonly involve the vertebral column, ribs, skull, pelvis, femur, clavicle, and scapula. The lesions generally arise in the medullary cavity, erode cancellous bone, and progressively destroy the cortical bone.&lt;/p&gt;

&lt;h3 id=&quot;what-is-the-differential-diagnosis-of-plasma-cell-myeloma&quot;&gt;7. What is the differential diagnosis of plasma cell 	myeloma?&lt;/h3&gt;

&lt;p&gt;The main differential is that of widespread bony metastases. Findings that favour the diagnosis of bony metastases over that of multiple myeloma include:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;more commonly affect the vertebral pedicles rather than vertebral bodies&lt;/li&gt;
  &lt;li&gt;rarely involve mandible, distal axial skeleton&lt;/li&gt;
  &lt;li&gt;although both entities have variable bone scan appearances (both hot and cold) unlike myeloma, extensive bony metastases rarely have a normal appearance&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Other rare entities include:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Waldenstrom macroglonulinaemia&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;http://radiopaedia.org/articles/multiple-myeloma-1&quot;&gt;source&lt;/a&gt;&lt;/p&gt;

&lt;h3 id=&quot;which-immunoglobulins-may-be-increased-in-plasma-cell-myeloma&quot;&gt;8. Which immunoglobulins may be increased in plasma cell myeloma?&lt;/h3&gt;

&lt;p&gt;he most frequent M protein produced by myeloma cells is IgG (60%), followed by IgA (20% to 25%); only rarely are IgM, IgD, or IgE M proteins observed.&lt;/p&gt;

&lt;h3 id=&quot;do-all-cases-of-plasma-cell-myeloma-have-the-monoclonal-serum-paraprotein-identifiable-electrophoresis&quot;&gt;9. Do all cases of plasma cell myeloma have the monoclonal serum paraprotein identifiable 	electrophoresis?&lt;/h3&gt;

&lt;p&gt;Electrophoresis of the serum and urine is an important diagnostic tool. In 99% of cases, either a monoclonal com- plete immunoglobulin or a monoclonal free immunoglobu- lin light chain is present in the serum, the urine, or both&lt;/p&gt;

&lt;p&gt;Because these immunoglobulins can be detected in the serum, these disorders are also referred to as monoclonal gammopathies, and the associated immuno- globulin is often referred to as an M protein&lt;/p&gt;

&lt;ol&gt;
  &lt;li&gt;What is the meaning of the results of flow cytometric analysis of the bone marrow.&lt;/li&gt;
&lt;/ol&gt;

&lt;p&gt;figures&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image21.jpeg&quot;&gt;1.	Plasma cell in smear&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image22.jpeg&quot;&gt;2.	Plasma cell (drawing)&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image23.jpeg&quot;&gt;3.	Plasma cell cluster in smear&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image24.jpeg&quot;&gt;4.	Gross of vertebral bodies eroded by plasmacytoma&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image25.jpeg&quot;&gt;5.	Gross of vertebral bodies eroded by plasmacytoma&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image26.jpeg&quot;&gt;6.	Gross of vertebral bodies eroded by plasmacytoma&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image27.jpeg&quot;&gt;7.	Gross of rib with protruding plasma cell proliferation&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image28.jpeg&quot;&gt;8.	Gross of osteolytic lesions of skull in plasma cell myeloma&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image29.jpeg&quot;&gt;9.	X-rays of osteolytic lesions of skull in plasma cell myeloma&lt;/a&gt;&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Pathology cases</title>
   <link href="http://lanyon.getpoole.com/2015/08/27/pathology-case/"/>
   <updated>2015-08-27T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/2015/08/27/pathology-case</id>
   <content type="html">&lt;p&gt;Clinical History: 
A 30-year-old &lt;a href=&quot;http://www.lupusny.org/about-lupus/who-gets-lupus&quot;&gt;African American woman&lt;/a&gt; presented to her family physician with nonradiating chest pain, shortness of breath, fever, weight-loss, malaise, lethargy and arthralgia.  She exhibited an &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image1.jpeg&quot;&gt;erythematous skin rash&lt;/a&gt; involving areas of the body exposed to sunlight. She noticed hair loss during the months prior to seeking medical attention.  She was admitted to the hospital for observation and tests.&lt;/p&gt;

&lt;!--break--&gt;

&lt;p&gt;Laboratory Findings and X-Ray:&lt;br /&gt;
A chest X-ray revealed cardiomegaly and &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;pleural effusion&lt;/a&gt;.  A complete blood count (CBC) identified a normochromic, normocytic anemia.  Urinalysis revealed &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.27.33.png&quot;&gt;hematuria, proteinuria and erythrocyte and leukocyte casts&lt;/a&gt;.  Analysis of the blood serum revealed the presence of autoantibodies against double-stranded DNA (p127).  &lt;a href=&quot;http://images.rheumatology.org/viewphoto.php?albumId=75690&amp;amp;imageId=2862319&quot;&gt;Immunofluorescence staining&lt;/a&gt; for antinuclear antibodies showed a &lt;a href=&quot;http://www.thelupussite.com/lupus_diagnosis_tests/ana_antinuclear_antibody.html&quot;&gt;peripheral pattern&lt;/a&gt; using human leukocytes as the substrate.  The serum also contained &lt;a href=&quot;http://www.healthline.com/health-slideshow/lupus-and-ra#1&quot;&gt;rheumatoid factor&lt;/a&gt; and &lt;a href=&quot;http://www.cidjournal.com/article/0738-081X%2885%2990074-4/abstract&quot;&gt;anticytoplasmic antibodies&lt;/a&gt;.&lt;/p&gt;

&lt;p&gt;Clinical Course of Disease:
A renal biopsy was performed and revealed diffuse &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;proliferative glomerulonephritis&lt;/a&gt; characterized by extensive cellular proliferation in more than 50% of glomeruli.  Immune complexes were deposited mainly in a &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;subendothelial distribution&lt;/a&gt;.  Immunofluorescence microscopy revealed that the immune deposits stained positively for all three major immunoglobulin classes and complement indicating a polyclonal activation of the immune system.  &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;Electron microscopy&lt;/a&gt; confirmed the subendothelial as well as intramembranous deposition of immune deposits.&lt;/p&gt;

&lt;p&gt;What information provided above is of the greatest 	assistance in reaching a diagnosis of systemic lupus 	erythematosus in this patient?
a: &lt;a href=&quot;http://www.lupusny.org/about-lupus/who-gets-lupus&quot;&gt;American woman&lt;/a&gt;
b: &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image1.jpeg&quot;&gt;erythematous skin rash&lt;/a&gt; 
􏰡c: &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.31.43.png&quot;&gt;hematuria, proteinuria and erythrocyte and leukocyte casts&lt;/a&gt; 7th criterion
d: &lt;a href=&quot;􏰞6th criterion- Serositis&quot;&gt;pleural effusion&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;** e: autoantibodies against &lt;a href=&quot;p127&quot;&gt;double-stranded DNA&lt;/a&gt;**
f: antinuclear antibodies showed a &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image5.jpeg&quot;&gt;peripheral pattern&lt;/a&gt;
g: &lt;a href=&quot;http://www.cidjournal.com/article/0738-081X%2885%2990074-4/abstract&quot;&gt;anticytoplasmic antibodies&lt;/a&gt;. 
h: &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;proliferative glomerulonephritis&lt;/a&gt; &lt;em&gt;class V&lt;/em&gt;
i: &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;subendothelial distribution&lt;/a&gt;
j: &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.29.18.png&quot;&gt;Electron microscopy&lt;/a&gt;&lt;/p&gt;

&lt;ol&gt;
  &lt;li&gt;Why did this patient present with chest pain?
The patient may suffer &lt;a href=&quot;p 89 &amp;amp; p 130&quot;&gt;Libman-Sacks endocarditis&lt;/a&gt;, possiblely related Thrombi, which can develop anywhere in the cardiovascular system due to &lt;a href=&quot;http://www.hopkinslupus.org/lupus-tests/antiphospholipid-antibodies/&quot;&gt;lupus anticoagulant&lt;/a&gt; which increases the ability of the blood to clot.&lt;/li&gt;
&lt;/ol&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;ol&gt;
      &lt;li&gt;What are the major immunologic features of systemic lupus erythematosus (SLE)?
** from SLE ppt slide 15** 
Positive LE cell preparation. 
Anti-DNA. Antibody to native DNA, Anti-Sm. Presence of AB to Smith nuclear antigen. 
False-positive serologic test for syphilis known to be positive for at least 6 months and confirmed by TPI or FTA test.
** from book Immunologic Abnormalities on page 126**
Type 1 interferons
TLR signals
Failure of B cell tolerance&lt;/li&gt;
    &lt;/ol&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;ol&gt;
      &lt;li&gt;Is lupus more likely to occur in males or females and in Caucasians or African Americans?&lt;/li&gt;
    &lt;/ol&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;More likely to occur in &lt;a href=&quot;http://www.lupusny.org/about-lupus/who-gets-lupus&quot;&gt;females&lt;/a&gt; and in African Americans.&lt;/p&gt;

&lt;h5 id=&quot;what-are-lupus-anti-coagulants-and-anti-phospholipid-antibodies-and-what-role-do-they-play-in-the-pathogenesis-of-sle&quot;&gt;5.What are lupus anti-coagulants and anti-phospholipid antibodies and what role do they play in the pathogenesis of SLE?&lt;/h5&gt;

&lt;p&gt;Antiphospholipid antibodies are present in 40% to 50% of patients with lupus and react with a wide variety of proteins in complex with phospholipids. Some bind to cardiolipin antigen, used in serologic tests for syphilis, so patients with lupus may have a false-positive test result for syphilis. Antiphos- pholipid antibodies contribute to coagulation abnormalities (p127)&lt;/p&gt;

&lt;p&gt;Paradoxically, these antibodies interfere with clotting tests and are actually called “lupus anticoagulants.” Autoantibodies are also produced against clotting factors such as thrombin, and these too may contribute to clotting disorders. the term Lupus -anti-coagulants are actually a &lt;a href=&quot;http://www.hopkinslupus.org/lupus-tests/antiphospholipid-antibodies/&quot;&gt;misnomer&lt;/a&gt;&lt;/p&gt;

&lt;h5 id=&quot;what-does-a-biopsy-of-the-erythematous-skin-rash-involving-areas-of-the-body-exposed-to-sunlight-reveal&quot;&gt;6. What does a biopsy of the erythematous skin rash involving areas of the body exposed to sunlight reveal?&lt;/h5&gt;

&lt;p&gt;Histopathologic findings include &lt;strong&gt;liquefactive degeneration&lt;/strong&gt; of the basal layer of the epidermis, &lt;strong&gt;edema&lt;/strong&gt; at the dermoepidermal junction, and &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image2.jpeg&quot;&gt;mononuclear infiltrates&lt;/a&gt; around blood vessels and skin appendages. also see &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image3.jpeg&quot;&gt;figure&lt;/a&gt; Immunofluorescence microscopy reveals deposition of immunoglobulin and complement at the dermoepi- dermal junction (Fig. 4–19, B)&lt;/p&gt;

&lt;h5 id=&quot;what-percentage-of-patients-with-sle-has-renal-involvement&quot;&gt;7. What percentage of patients with SLE has renal involvement?&lt;/h5&gt;

&lt;p&gt;Although the kidney appears normal by light microscopy in 25% to 30% of cases, almost all cases of SLE show some renal abnormality if examined by immuno- fluorescence and electron microscopy.(p128)&lt;/p&gt;

&lt;h5 id=&quot;why-did-the-patient-develop-exacerbations-and-remissions&quot;&gt;8.	Why did the patient develop exacerbations and remissions?&lt;/h5&gt;

&lt;h5 id=&quot;why-does-a-sle-patient-have-rheumatoid-factors-in-the-serum&quot;&gt;9.	Why does a SLE patient have rheumatoid factors in the serum?&lt;/h5&gt;

&lt;p&gt;Because in lupus, the immune system attacks the body, including the joints. Rheumatoid factor is an antibody that becomes connected to another type of antibody called immunoglobulin. Together, these form an immune complex that can become involved in inflammation. 
&lt;a href=&quot;http://www.everydayhealth.com/rheumatoid-arthritis/testing-for-rheumatoid-factor.aspx&quot;&gt;source&lt;/a&gt;&lt;/p&gt;

&lt;h5 id=&quot;what-is-the-differential-diagnosis-of-sle&quot;&gt;10.	What is the differential diagnosis of SLE?&lt;/h5&gt;

&lt;p&gt;MNEMONIC  DOPAMIN RASH&lt;/p&gt;

&lt;p&gt;DISCOID RASH
ORAL ULCERS
PHOTOSENSITIVITY
ANA
MALAR RASH
IMMUNOLOGICAL PHENOMENON(Le Cell, Ds DNA, Sm, APL ab, false + RPR, )
NEUROLOGICAL(Seizures,Psychosis)
RENAL(Nephrotic,Nephritic)
ARTHRITIS	
SEROSITIS
HEMATOLOGICAL(Leukopenia,Thrombocytopenia, anemia)
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.38.42.png&quot;&gt;slide 16 from sle ppt&lt;/a&gt;&lt;/p&gt;

&lt;h5 id=&quot;what-are-the-complications-and-prognosis-of-sle&quot;&gt;11. What are the complications and prognosis of SLE?&lt;/h5&gt;

&lt;p&gt;Prognosis&lt;/p&gt;

&lt;p&gt;A primary cause of death among patients with lupus is atherosclerosis and SLE is unpredictable and varies greatly form one individual to the next.&lt;/p&gt;

&lt;p&gt;Mild SLE.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;skin rashes of discoid lupus erythematosus (DLE) or subacute cutaneous lupus erythematosus (SCLE) with or without joint aches.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Widespread SLE.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;SLE is a chronic, life-long disease, alternating between periods of symptom relapse, (called flares), and remission. The disease&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;may begin in any of the various systems of the body and progress unpredictably to others.&lt;/p&gt;

&lt;p&gt;The following are typical patterns:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Symptom relapses, or flares, occur on the average of two or three times a year.&lt;/li&gt;
  &lt;li&gt;Between flares, most patients with SLE function at about 90% of normal capacity.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;The degree of severity depends on different factors:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Severity of the inflammatory response&lt;/li&gt;
  &lt;li&gt;Frequency of episodes&lt;/li&gt;
  &lt;li&gt;The degree of organ or system involvement&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Vital organs or systems,joints, skin, and others are affected.&lt;/p&gt;

&lt;p&gt;Infections followed by kidney failure are the chief causes of death in patients with SLE.&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;http://www.nytimes.com/health/guides/disease/systemic-lupus-erythematosus/prognosis.html&quot;&gt;source&lt;/a&gt;&lt;/p&gt;

&lt;h5 id=&quot;what-is-the-five-year-survival-rate-of-patients-with-sle&quot;&gt;12.	What is the five-year survival rate of patients with SLE?&lt;/h5&gt;

&lt;p&gt;About 95% in the US, see the &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/Screenshot%202015-08-27%2014.20.33.png&quot;&gt;table&lt;/a&gt;
from the book&lt;a href=&quot;https://books.google.com/books?id=qqq450swSv0C&amp;amp;pg=PA685&amp;amp;lpg=PA685&amp;amp;dq=five-year+survival+rate+of+sle&amp;amp;source=bl&amp;amp;ots=sJPHBW-jv0&amp;amp;sig=w3asQB_Jsjymaz1pxhh4GLGRLmk&amp;amp;hl=en&amp;amp;sa=X&amp;amp;ved=0CDcQ6AEwBGoVChMI-LDk_fDJxwIVgVk-Ch2FwQII#v=onepage&amp;amp;q&amp;amp;f=false&quot;&gt;Systemic Lupus Erythematosus&lt;/a&gt; by Robert G. Lahita, George Tsokos&lt;/p&gt;

&lt;h3 id=&quot;figure-from-powerpoint-sides&quot;&gt;Figure from powerpoint sides&lt;/h3&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image1.jpeg&quot;&gt;1.	LUPUS BUTTERFLY RASH&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image2.jpeg&quot;&gt;2.	LUPUS SKIN BIOPSY&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image3.jpeg&quot;&gt;3.	LUPUS SKIN BIOPSY, THICKENED BASEMENT MEMBRANE&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image4.jpeg&quot;&gt;4.	LUPUS BAND TEST, ANTI IgG STAIN&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image5.jpeg&quot;&gt;5. PERIPHERAL RIM PATTERN&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image6.jpeg&quot;&gt;6.	DIFFUSE PROLIFERATIVE LUPUS NEPHRITIS&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image7.jpeg&quot;&gt;7.	L.E. CELL PREPARATION&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Picture%20clipping.pictClipping&quot;&gt;8.	LIBMAN-SACKS ENDOCARDITIS&lt;/a&gt;&lt;/p&gt;

&lt;h2 id=&quot;case-2&quot;&gt;Case 2&lt;/h2&gt;

&lt;h3 id=&quot;clinical-history&quot;&gt;CLINICAL HISTORY:&lt;/h3&gt;

&lt;p&gt;A 45-year-old white male previously diagnosed with a T cell leukemia developed skin rash, severe diarrhea and jaundice after receiving repeated blood transfusions.  The skin exhibited a fine, diffuse, erythematous, macular rash that began on the palms, soles and head and spread to the entire trunk as well as to extremities.  The rash became desquamative and resembled an extensive second-degree burn.  There was watery diarrhea associated with malabsorption, cramps and gastrointestinal bleeding.  Blood chemistry analysis revealed &lt;a href=&quot;p139&quot;&gt;hyperbilirubinemia&lt;/a&gt; and an elevated serum alkaline phosphatase level.  There was only a mild elevation in the alanine aminotransferase (ALT) and aspartate aminotransferase levels (AST).&lt;/p&gt;

&lt;ol&gt;
  &lt;li&gt;Are the clinical events described above attributable to the leukemia process or to some other factor?
To some other factor.&lt;/li&gt;
&lt;/ol&gt;

&lt;h5 id=&quot;what-is-the-most-likely-cause-of-the-signs-and-symptoms-described-in-this-patient&quot;&gt;2.	What is the most likely cause of the signs and symptoms described in this patient?&lt;/h5&gt;
&lt;p&gt;graft-versus-host diseases&lt;/p&gt;

&lt;h5 id=&quot;how-could-a-leukemia-patient-in-hospital-develop-signs-and-symptoms-of-graft-versus-host-disease&quot;&gt;3. How could a leukemia patient in hospital develop signs and symptoms of graft-versus-host disease?&lt;/h5&gt;
&lt;p&gt;GVHD occurs when immunologically competent cells are introduced into an immunoincompetent host. GVHD refers to the immunologic insult and to the consequences to the organism. The patient must have had a Hematopoietic cell transplation, Solid organ transplants, or blood transfusions.&lt;/p&gt;

&lt;h5 id=&quot;what-is-the-mechanism-of-the-skin-rash&quot;&gt;4. What is the mechanism of the skin rash?&lt;/h5&gt;
&lt;p&gt;&lt;strong&gt;from textbook&lt;/strong&gt;
It resemble those of SS (p139), In the early stages, affected skin areas are somewhat edematous and have a doughy consistency. Capillaries and small arteries (as large as 500 μm in diameter) may show thickening of the basal lamina, endothelial cell damage, and partial occlusion. With progression, the edema- tous phase is replaced by progressive fibrosis of the dermis, which becomes tightly bound to the subcutaneous structures. There is marked increase of compact collagen in the dermis along with thinning of the epidermis, atrophy of the dermal appendages, and hyaline thickening of the walls of dermal arterioles and capillaries (P133)&lt;/p&gt;

&lt;p&gt;or&lt;/p&gt;

&lt;p&gt;Skin — In most patients, the first (and most common) clinical manifestation of acute GVHD is a maculopapular rash, usually occurring at or near the time of the white blood cell engraftment (picture 1). The rash initially involves the nape of the neck, ears, shoulders, the palms of the hands (picture 2), and the soles of the feet. It can be described as a sunburn and may be pruritic or painful (picture 3). From these initial areas of presentation, the rash may spread to involve the whole integument, eventually becoming confluent. In severe GVHD, the maculopapular rash forms bullous lesions with toxic epidermal necrolysis mimicking Stevens-Johnson syndrome
&lt;a href=&quot;http://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-grading-of-acute-graft-versus-host-disease&quot;&gt;source&lt;/a&gt;&lt;/p&gt;

&lt;h5 id=&quot;what-is-the-cause-of-the-hyperbilirubinemia&quot;&gt;5. What is the cause of the hyperbilirubinemia&lt;/h5&gt;
&lt;p&gt;Destruction of small bile ducts gives rise to jaundice, thus resulted in hyperbilirubinemia&lt;/p&gt;

&lt;h5 id=&quot;what-subset-of-t-lymphocytes-is-found-in-biopsies-of-skin-intestine-and-liver&quot;&gt;6. What subset of T lymphocytes is found in biopsies of skin, intestine and liver?&lt;/h5&gt;
&lt;p&gt;CD 4+ and CD 8+&lt;/p&gt;

&lt;h5 id=&quot;how-could-graft-versus-host-disease-be-prevented-in-patients-receiving-blood-transfusions&quot;&gt;7. How could graft-versus-host disease be prevented in patients receiving blood transfusions?&lt;/h5&gt;
&lt;p&gt;GVHD is a potentially lethal complication that can be minimized but not eliminated by HLA matching. As another potential solution, donor T cells can be depleted before marrow transplant.&lt;/p&gt;

&lt;h5 id=&quot;when-is-graft-versus-host-disease-most-often-observed&quot;&gt;8. When is graft-versus-host disease most often observed?&lt;/h5&gt;

&lt;ul&gt;
  &lt;li&gt;Degree of mismatch between HLA types&lt;/li&gt;
  &lt;li&gt;“minor” histocompatibility antigens&lt;/li&gt;
  &lt;li&gt;Age – possible thymic influence&lt;/li&gt;
  &lt;li&gt;Germ free environment&lt;/li&gt;
  &lt;li&gt;Pre-treatment with cytotoxic drugs&lt;/li&gt;
  &lt;li&gt;Sex mismatch&lt;/li&gt;
  &lt;li&gt;Transfusion presensitization&lt;/li&gt;
&lt;/ul&gt;

&lt;ol&gt;
  &lt;li&gt;What types of GVH disease follow bone marrow transplantation?
The small bowel and colon are involved in most cases. Intestinal graft-versus-host disease often manifests as a watery diarrhea.&lt;/li&gt;
&lt;/ol&gt;

&lt;h3 id=&quot;figures&quot;&gt;figures&lt;/h3&gt;
&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/Screenshot%202015-08-27%2022.44.57.png&quot;&gt;1.	List of target tissues of acute G-V-H disease&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image9.jpeg&quot;&gt;2.	Baby with maculopapular rash of  G-V-H 	disease&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image10.jpeg&quot;&gt;3. 	Adult with acute G-V-H skin reaction&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image11.jpeg&quot;&gt;4.	Micro–skin interface dermatitis with basal cell destruction&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image12.jpeg&quot;&gt;5.	Micro–skin interface dermatitis with basal cell destruction&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image13.jpeg&quot;&gt;6.	Micro–liver G-V-H with bile-duct injury and early cell infiltrate&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image14.jpeg&quot;&gt;7.	Micro-liver G-V-H, chronic with inflammation and fibrosis&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image15.jpeg&quot;&gt;8.	Micro–enteritis in G-V-H in lower 1/3 of crypt, early&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image16.jpeg&quot;&gt;9.	Micro–enterocyte necrosis and crypt destruction&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image17.jpeg&quot;&gt;10. Gross–intestinal G-V-H with bleeding and superinfection&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image18.jpeg&quot;&gt;11. Gross–intestinal G-V-H with intermittent involved areas&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image19.jpeg&quot;&gt;12. Gross–intestinal G-V-H with bleeding and 	superinfection&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image20.jpeg&quot;&gt;13. Gross–intestinal G-V-H with mucosal sloughing and scarring&lt;/a&gt;&lt;/p&gt;

&lt;h2 id=&quot;case-3&quot;&gt;Case 3&lt;/h2&gt;

&lt;h3 id=&quot;clinical-history-1&quot;&gt;CLINICAL HISTORY:&lt;/h3&gt;

&lt;p&gt;A 60-year-old white male presented to his family physician with complaints of weakness, anorexia, weight loss and severe back pain.&lt;/p&gt;

&lt;h3 id=&quot;laboratory-and-x-ray-findings&quot;&gt;LABORATORY AND X-RAY FINDINGS:&lt;/h3&gt;

&lt;p&gt;Radiologic examination revealed  “punched out” &lt;a href=&quot;&quot;&gt;skeletal lesions&lt;/a&gt; with sharply demarcated margins in vertebral bodies, skull, ribs, and pelvis.  Blood chemistry showed hypercalcemia and hyperglobulinemia.  The serum globulin concentration was &lt;a href=&quot;http://www.drstandley.com/labvalues_proteins.shtml&quot;&gt;6.0 g/dl&lt;/a&gt;.  Both the serum and urine revealed a homogeneous protein by electrophoresis, which was identified as &lt;a href=&quot;p437&quot;&gt;IgA&lt;/a&gt;.  The urine contained free light chains.  The urinary protein was insoluble at acid pH between &lt;a href=&quot;http://basicprotein.blogspot.com/2012/11/tests-for-detection-of-bence-jones.html&quot;&gt;40º and 60ºC but redissolved at 95ºC.&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;Hematologic examination revealed a normochromic normocytic anemia with leukopenia and thrombocytopenia.  The blood smear revealed rouleaux formation of red cells.  There was an elevated sedimentation rate and marked plasma cell proliferation in the bone marrow.   Flow cytometric analysis of the bone marrow revealed an abnormal CD45 negative cell population that expressed CD38, CD56 and CD138 with cytoplasmic kappa light chain restriction.  This cell population was negative for CD19, CD20 and surface immunoglobulin.&lt;/p&gt;

&lt;p&gt;A renal biopsy was performed and revealed large numbers of eosinophilic lamellated casts in the renal tubules.  The tubular cells were markedly atrophic and contained hyaline droplets and some crystalline material. The glomeruli appeared normal, yet they were surrounded by interstitial fibrosis as a result of tubular destruction.  The patient received supportive therapy including local radiation therapy to relieve pain.  He experienced repeated bouts of respiratory infection with Streptococcus pneumoniae.  After reaching a diagnosis, cytotoxic therapy was instituted, yet the patient died within 12 months of diagnosis.&lt;/p&gt;

&lt;h5 id=&quot;what-information-provided-above-is-of-the-greatest-assistance-in-reaching-a-diagnosis-of-plasma-cell-multiple-myeloma-in-this-patient&quot;&gt;1. What information provided above is of the greatest assistance in reaching a diagnosis of plasma cell 	(multiple) myeloma in this patient?&lt;/h5&gt;

&lt;h5 id=&quot;why-did-this-patient-present-with-severe-back-pain&quot;&gt;2. Why did this patient present with severe back pain?&lt;/h5&gt;
&lt;p&gt;It is due to pathologic fractures. Pathologic fractures of vertebrae may lead to spinal cord impingement, an oncologic emergency.&lt;/p&gt;

&lt;h5 id=&quot;what-is-the-cause-of-the-punched-out-osteolytic-lesions&quot;&gt;3. What is the cause of the “punched out” osteolytic lesions?&lt;/h5&gt;

&lt;p&gt;Bone destruction by osteolytic lesions is caused by two separate events. Rapid growth of myeloma cells inhibits normal bone-forming cells, damaging bone. In addition, production of substances that activate the cells that resorb bone, called osteoclasts, is increased.&lt;/p&gt;

&lt;p&gt;The lesions generally arise in the medullary cavity, erode cancellous bone, and progressively destroy the cortical bone.&lt;/p&gt;

&lt;h5 id=&quot;what-is-the-significance-of-the-light-chain-proteinuria-described-in-this-patient&quot;&gt;4. What is the significance of the light chain proteinuria described in this patient.&lt;/h5&gt;
&lt;p&gt;Light chain deposition in the glomeruli or the interstitium, either as amyloid or linear deposits, also may contribute to renal dysfunction.&lt;/p&gt;

&lt;h5 id=&quot;since-the-patient-was-hypergammaglobulinemic-why-did-he-suffer-repeated-bouts-of-pneumococcal-infection&quot;&gt;5. Since the patient was hypergammaglobulinemic, why did he suffer repeated bouts of pneumococcal infection?&lt;/h5&gt;

&lt;p&gt;Patients with myeloma are immunosuppressed. Through uncertain mechanisms, myeloma cells interfere with the function of normal plasma cells, leading to defects in antibody production. Thus, although the plasma usually contains increased immunoglobulin owing to the pres- ence of an M protein, the levels of functional antibodies often are profoundly depressed, leaving patients at high risk for bacterial infections. (p438)&lt;/p&gt;

&lt;h5 id=&quot;which-part-of-the-skeletal-system-is-most-frequently-affected-in-plasma-cell-myeloma&quot;&gt;6. Which part of the skeletal system is most frequently affected in plasma cell myeloma?&lt;/h5&gt;

&lt;p&gt;Multiple myeloma usually manifests with multifocal destructive skeletal lesions, which most commonly involve the vertebral column, ribs, skull, pelvis, femur, clavicle, and scapula. The lesions generally arise in the medullary cavity, erode cancellous bone, and progressively destroy the cortical bone.&lt;/p&gt;

&lt;h5 id=&quot;what-is-the-differential-diagnosis-of-plasma-cell-myeloma&quot;&gt;7. What is the differential diagnosis of plasma cell 	myeloma?&lt;/h5&gt;

&lt;p&gt;The main differential is that of widespread bony metastases. Findings that favour the diagnosis of bony metastases over that of multiple myeloma include:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;more commonly affect the vertebral pedicles rather than vertebral bodies&lt;/li&gt;
  &lt;li&gt;rarely involve mandible, distal axial skeleton&lt;/li&gt;
  &lt;li&gt;although both entities have variable bone scan appearances (both hot and cold) unlike myeloma, extensive bony metastases rarely have a normal appearance&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Other rare entities include:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Waldenstrom macroglonulinaemia&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;http://radiopaedia.org/articles/multiple-myeloma-1&quot;&gt;source&lt;/a&gt;&lt;/p&gt;

&lt;h5 id=&quot;which-immunoglobulins-may-be-increased-in-plasma-cell-myeloma&quot;&gt;8. Which immunoglobulins may be increased in plasma cell myeloma?&lt;/h5&gt;

&lt;p&gt;he most frequent M protein produced by myeloma cells is IgG (60%), followed by IgA (20% to 25%); only rarely are IgM, IgD, or IgE M proteins observed.&lt;/p&gt;

&lt;h5 id=&quot;do-all-cases-of-plasma-cell-myeloma-have-the-monoclonal-serum-paraprotein-identifiable-electrophoresis&quot;&gt;9. Do all cases of plasma cell myeloma have the monoclonal serum paraprotein identifiable 	electrophoresis?&lt;/h5&gt;

&lt;p&gt;Electrophoresis of the serum and urine is an important diagnostic tool. In 99% of cases, either a monoclonal com- plete immunoglobulin or a monoclonal free immunoglobu- lin light chain is present in the serum, the urine, or both&lt;/p&gt;

&lt;p&gt;Because these immunoglobulins can be detected in the serum, these disorders are also referred to as monoclonal gammopathies, and the associated immuno- globulin is often referred to as an M protein&lt;/p&gt;

&lt;ol&gt;
  &lt;li&gt;What is the meaning of the results of flow cytometric analysis of the bone marrow.&lt;/li&gt;
&lt;/ol&gt;

&lt;p&gt;figures&lt;/p&gt;

&lt;p&gt;&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image21.jpeg&quot;&gt;1.	Plasma cell in smear&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image22.jpeg&quot;&gt;2.	Plasma cell (drawing)&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image23.jpeg&quot;&gt;3.	Plasma cell cluster in smear&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image24.jpeg&quot;&gt;4.	Gross of vertebral bodies eroded by plasmacytoma&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image25.jpeg&quot;&gt;5.	Gross of vertebral bodies eroded by plasmacytoma&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image26.jpeg&quot;&gt;6.	Gross of vertebral bodies eroded by plasmacytoma&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image27.jpeg&quot;&gt;7.	Gross of rib with protruding plasma cell proliferation&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image28.jpeg&quot;&gt;8.	Gross of osteolytic lesions of skull in plasma cell myeloma&lt;/a&gt;
&lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/temp%20images/small%20group%201/image29.jpeg&quot;&gt;9.	X-rays of osteolytic lesions of skull in plasma cell myeloma&lt;/a&gt;&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Graphing with Stata Part I</title>
   <link href="http://lanyon.getpoole.com/2015/08/24/graphing_with_stata/"/>
   <updated>2015-08-24T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/2015/08/24/graphing_with_stata</id>
   <content type="html">&lt;p&gt;Analytical graphics have always been one of Stata’s strengths, and reason enough for many users to choose Stata over other packages. Attractive and publishable basic graphs are easy to draw, using commands or choices from the menus under Graphics. Users who imagine more elaborate or creative graphs will find their efforts supported by an impressive array of tools and options, described in the Graphics Reference Manual, and illustrated by many examples in A Visual Guide to Stata Graphics (Mitchell 2012).
&lt;!--break--&gt;
 The above statement was taken from&lt;a href=&quot;http://www.stata.com/bookstore/statistics-with-stata/&quot;&gt;2012 Statistics with Stata 12-8&lt;/a&gt;
 by Lawrence C. Hamilton and it shows how important it is to develop good statistical graphing skills as a statistican. In this tutorial series, I will share how to use some of the most useful graphing techinques with Stata and I hope it is helpful to you. Let’s get started and go through some examples one by one and you can also download the &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/stata%20blog/log/graphing.do&quot;&gt;do file&lt;/a&gt;&lt;/p&gt;

&lt;h2 id=&quot;import-and-explore-the-data-set&quot;&gt;Import and explore the data set&lt;/h2&gt;
&lt;p&gt;We use the data set &lt;a href=&quot;https://dl.dropboxusercontent.com/u/49272502/stata%20blog/Nations2.dta&quot;&gt;Nations2.dta&lt;/a&gt; in this tutorial, you could either download it and manually import it to Stata or you can simply use the following code to import the data set.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;use https://dl.dropboxusercontent.com/u/49272502/stata%20blog/Nations2.dta, clear&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;Next, use describe have an idea how the data looks like.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;describe&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h3 id=&quot;histogram&quot;&gt;Histogram&lt;/h3&gt;

&lt;p&gt;First, let’s plot a basic histogram for the variable adfert, which stands for adolescent fertility rate.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;histogram adfert, percent&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/hist1.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;Looking at the result, we can tell that the distribution is positively skew, with a mode not far above 0 and upper limit around 200. However, it is hard to describe the graph more specifically because the bars do not line up with the x axis tick marks. We can do a little improvement with the &lt;em&gt;options&lt;/em&gt; , for example&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;frequency&lt;/strong&gt; 	Frequencies are shown on the vertical (y) axis.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;start(0)&lt;/strong&gt;	The histogram’s first bar (bin) starts at 0.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;width(10)&lt;/strong&gt;	The width of each bar (bin) is 10.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;xlabel(0(20)200)&lt;/strong&gt;	The x axis is labeled from 0 to 200, in increments of 20.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;xtick(10(20)210)&lt;/strong&gt;	The x axis has tick marks from 10 to 210, in increments of 20.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;ylabel(0(5)35, grid gmax)&lt;/strong&gt; The y axis is labeled from 0 to 35, in increments of 5. A grid of horizontal lines is drawn, including a * line at the maximum value.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;title(“Adolescent fertility rate in 194 nations”)&lt;/strong&gt; 	The graph has a title at top.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;You can put all of the above items together in the following fashion&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;histogram adfert, frequency start(0) width(10) xlabel(0(20)200) xtick(10(20)210)
ylabel(0(5)35, grid gmax)
title(&amp;quot;Adolescent fertility rate in 194 nations&amp;quot;)&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/hist2.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;How, we can see the improved result describes the distribution more specifically. For example, we now see that in 34 nations, the adolescent fertility rates are between 10 and 20. You can type &lt;strong&gt;help histogram&lt;/strong&gt; in stata console to learn more about histogram plotting.&lt;/p&gt;

&lt;p&gt;To explore the variable &lt;em&gt;adfert&lt;/em&gt; further, we can use a &lt;strong&gt;by&lt;/strong&gt;(varname) option. For example, if we want to illustrate with histograms of &lt;em&gt;adfert&lt;/em&gt; for each of the five regions, along with a sixth &lt;strong&gt;(total)&lt;/strong&gt; histogram showing the distribution for all nations. We can use the following code&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;histogram adfert, percent start(0) width(10) by(region, total)&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/hist3.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;Next, we explore the Box Plots&lt;/p&gt;

&lt;h3 id=&quot;box-plots&quot;&gt;Box Plots&lt;/h3&gt;

&lt;p&gt;Box plots convey information about center, spread, symmetry and outliers at a glance. For example&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;graph box adfert&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/box1.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;The result confirms the positive skew of this distribution, and shows five high outliers. The box plot extends from approximately 1st to third quartiles, a distance called the interquartile range (IQR).&lt;/p&gt;

&lt;p&gt;If we want to identify the adfert outliers by with labels, we can add a &lt;strong&gt;marker&lt;/strong&gt; option as follow.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;graph box adfert, marker(1, mlabel(country)) ytitle(&amp;quot;Births per 1,000 females 15-19&amp;quot;)&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/box2.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;Now, if we want to compare the distributions of &lt;em&gt;adfert&lt;/em&gt; from all 5 regions with a baseline, for instance 40, as well as labelling the outliers with their country names. We can use the option &lt;strong&gt;over&lt;/strong&gt; and the &lt;strong&gt;yline()&lt;/strong&gt; as following.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;graph box adfert, marker(1, mlabel(country)) yline(39.3) over(region)&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/box3.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;We can also plot the boxplots horizontally by using the command &lt;strong&gt;hbox&lt;/strong&gt;&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;graph hbox co2, over(region)
note(&amp;quot;note: {bf:Statistics with Stata}, version 12&amp;quot;) caption(&amp;quot;caption: United Nations Human Development Report 2011&amp;quot;) title(&amp;quot;title: {it:Example of horizontal box plots}&amp;quot;) ytitle(&amp;quot;ytitle: Tons of CO{subscript:2} emitted per capita&amp;quot;)&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/box4.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;Note that individual outliers are not labeled in the figure because they would be hard to read in the horizontal format. To explore more about boxplot you can type &lt;strong&gt;help graph box&lt;/strong&gt; in the console. Now, we are going to explore Scatterplots and Overlays&lt;/p&gt;

&lt;h3 id=&quot;scatterplots-and-overlays&quot;&gt;Scatterplots and Overlays&lt;/h3&gt;

&lt;p&gt;Stata’s basic scatterplot command has the form&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;graph twoway scatter y x&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;Now, let’s make a twoway scatterplot with the variable &lt;strong&gt;life&lt;/strong&gt; and &lt;strong&gt;school&lt;/strong&gt;&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;graph twoway scatter life school&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/scatter1.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;To make thing more interesting, we can manipulate the &lt;strong&gt;frequency weight feature&lt;/strong&gt; with &lt;strong&gt;[fweight = varname]&lt;/strong&gt; as follow&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;graph twoway scatter life school [fweight=pop], msymbol(Oh)&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/scatter2.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;The result is simply a redrawn scatterplot of &lt;em&gt;life&lt;/em&gt; againist &lt;em&gt;school&lt;/em&gt;, but make the symbol size reflect each country’s population &lt;em&gt;pop&lt;/em&gt;. Note that it also include &lt;strong&gt;msymbol(Oh)&lt;/strong&gt; to change the default dot from the previous scatterplot into &lt;em&gt;hollow circle&lt;/em&gt;.&lt;/p&gt;

&lt;p&gt;Now, let’s explore a key feature of Stata’s graph twoway family, that is we can overlay two or more graphs to build a more complex images. For example, we can plot a regression lines **lfit) on top of the scatter plot.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;twoway (scatter life school, msymbol(Oh))(lfit life school, lwidth(medthick))&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/scatter3.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;We can also add x and y labels and tick mark as well as legend, for example&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;twoway (scatter life school, msymbol(Oh))(lfit life school, lwidth(medthick)ylabel(45(5)85) xlabel(2(2)12) xtick(1(2)13) legend(col(1) ring(0) position(11)))&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/scatter4.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;note
The &lt;em&gt;legend option&lt;/em&gt; in the figure specifies three things:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;col(1)&lt;/strong&gt; The legend should have just one column, and hence two rows.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;ring(0)&lt;/strong&gt; The legend is placed within the plot region, instead of outside it.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;position(11)&lt;/strong&gt; The legend goes at the &lt;em&gt;11 o’clock position&lt;/em&gt;, which in this graph happens to
be empty of data.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Finally, let’s try to graph a more advanced regression scatterplot shows also the confident bands for the &lt;em&gt;conditonal mean of y&lt;/em&gt;.  We can do so with the command &lt;strong&gt;lfitci&lt;/strong&gt; and &lt;strong&gt;stdp&lt;/strong&gt;. note that the &lt;em&gt;ci&lt;/em&gt; in &lt;strong&gt;lfitci&lt;/strong&gt; refers to &lt;em&gt;confident interval&lt;/em&gt; and &lt;strong&gt;stdp&lt;/strong&gt; refers to standard erors for the conditional mean as “standard deviation of prediction”&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;twoway (lfitci life school, stdp)(scatter life school, msymbol(Th))(scatter life school if school &amp;gt; 8 &amp;amp; life &amp;lt; 55, msymbol(S) mlabel(country)legend(col(1) ring(0) position(11) label(3 &amp;quot;Life expectancy&amp;quot;)order(3 2 1)))&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/scatter5.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;From the result, we see that normal data points are plotted as hollow triangles and the two outliers are solid squares. This can be accomplished by the option &lt;strong&gt;msymbol(Th)&lt;/strong&gt; and &lt;strong&gt;msymbol(S)&lt;/strong&gt; and you can type &lt;strong&gt;help scatter&lt;/strong&gt; to learn more about the other options.&lt;/p&gt;

&lt;p&gt;Lastly, we wrap up this tutorial with introducing the &lt;strong&gt;scatterplot matrices&lt;/strong&gt;. Scatterplot matrices are different from other twoway plots types that it can not be overlaid. Nevertheless, it is possible to include multiple plots in a single plot and it follows the same marker symbol conventions. Let’s create an example.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;graph matrix gdp school adfert chldmort life, half msymbol(oh)&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;img src=&quot;/assets/stata/graphing/scatter6.png&quot; alt=&quot;My helpful screenshot&quot; /&gt;&lt;/p&gt;

&lt;p&gt;From the result, we see that scatterplot mattrix is the visual counterpart to a correlation mattrix, which is very helpful tool for multivariate analysis. It shows the relationships between variables pairs and thus helpful for the detection of &lt;strong&gt;nonlinear relationships&lt;/strong&gt;. For instance, the scatterplot matrix above shows that &lt;em&gt;gdp&lt;/em&gt; (per capita Gross Domestic Product) seems to be nonlinearly distributed and we could not have detected this pattern through correlation matrix alone. You can type &lt;strong&gt;help graph matrix&lt;/strong&gt; to learn more about scatterplot mattrix.&lt;/p&gt;

&lt;p&gt;Congradulation, now you have completed part I of this tutorial and in part II we will explore &lt;strong&gt;Line Plots and Connected-Line Plots&lt;/strong&gt;. Thank you for sticking around and please leave your comment and advise so that I can imporve it.&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Use Slidify to create cool slides</title>
   <link href="http://lanyon.getpoole.com/2015/08/21/using-slidify/"/>
   <updated>2015-08-21T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/2015/08/21/using-slidify</id>
   <content type="html">&lt;p&gt;&lt;a href=&quot;https://github.com/ramnathv/slidify/issues/407&quot;&gt;Slidify error with update to stringr&lt;/a&gt;
install_github(‘ramnathv/slidify’, ref = github_pull(425))&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>How to create your web Gravatar</title>
   <link href="http://lanyon.getpoole.com/2015/08/20/making-your-gravatar/"/>
   <updated>2015-08-20T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/2015/08/20/making-your-gravatar</id>
   <content type="html">&lt;p&gt;Gravatar is such a handy tool that has many applications and can save you a lot of time and make things pretty. You can check out &lt;a href=&quot;https://en.gravatar.com/&quot;&gt;Gravatar&lt;/a&gt; to learn all the details. The objective of this post is to show you how you can use your gravatar ID for your blog or website built by &lt;a href=&quot;http://jekyllrb.com/&quot;&gt;Jekyll&lt;/a&gt; the static site generator, in order to show your ownership of your site. &lt;!--break--&gt;&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;First, register a &lt;a href=&quot;https://en.gravatar.com/&quot;&gt;Gravatar&lt;/a&gt; account and following all the instruction to set up your account.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;In order for Gravatar to work on your blog, you need to create a Hash for your Gravatar ID, and you can learn more about this from &lt;a href=&quot;http://en.gravatar.com/site/implement/hash/&quot;&gt;Create the Hash&lt;/a&gt;. But if you do not know PHP and want to speed thing up, you can use this trick I will show you here. First, you need to use &lt;a href=&quot;https://en.wikipedia.org/wiki/MD5&quot;&gt;a MD5 Encoder&lt;/a&gt; to encode your gravatar email account address. To do so go to &lt;a href=&quot;http://7thspace.com/webmaster_tools/online_md5_encoder.html&quot;&gt;7th Space&lt;/a&gt; and key in your registered email for Gravatar to get your MD5 Hash. It should look something like this&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;{&amp;quot;f9879d71855b5ff21e4963273a886bfc&amp;quot;}&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

</content>
 </entry>
 
 <entry>
   <title>Step by Step of building a Jekyll blog</title>
   <link href="http://lanyon.getpoole.com/2015/08/19/Jekyll-tutorial/"/>
   <updated>2015-08-19T00:00:00-05:00</updated>
   <id>http://lanyon.getpoole.com/2015/08/19/Jekyll-tutorial</id>
   <content type="html">&lt;p&gt;So when I learned about Jekyll, it seemed like a great alternative. I like the idea that my entire blog is a set of static files. Besides its simplicity, it makes backups so much easier and avoids most common security concerns caused by running dynamic websites. I could write my posts in Markdown which I know from Confluence and GitHub. Also, Jekyll allows for code examples to be very nicely embedded in the website. Finally, Jekyll is very lightweight and allows for very minimal websites without any bloat.
&lt;!--break--&gt;
The fact that GitHub provides free hosting for Jekyll blogs is just icing on the cake. It will save me ~$50 per year in hosting. GitHub provides automatic version control of my blog. I can use GitHub’s web editor to write blog posts online. And I can still connect it to my custom domain (joshualande.com).&lt;/p&gt;

&lt;h2 id=&quot;set-up-disqus-comments&quot;&gt;Set up Disqus Comments&lt;/h2&gt;
&lt;p&gt;If you want to add a comment function to you blog, you can following the following steps&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;
    &lt;p&gt;1: Go to&lt;a href=&quot;https://disqus.com&quot;&gt;DISQUS&lt;/a&gt; and register an account, then following the instuction there to add Disqus to your site and it will give you unique code to use for your site, save the code for later use.&lt;/p&gt;
  &lt;/li&gt;
  &lt;li&gt;
    &lt;p&gt;2: Modify the file&lt;a href=&quot;https://github.com/JizongL/jizongL.github.io/blob/master/_layouts/default.html&quot;&gt;_layouts/default.html&lt;/a&gt; in your 
layouts folder by including the following line after &lt;strong&gt;comment&lt;/strong&gt; in the default code.&lt;/p&gt;
  &lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;&lt;span class=&quot;p&quot;&gt;{{&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;nv&quot;&gt;content&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;p&quot;&gt;}}&lt;/span&gt;
&lt;span class=&quot;p&quot;&gt;{%&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;nt&quot;&gt;include&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;comments.html&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;p&quot;&gt;%}&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;ul&gt;
  &lt;li&gt;3: Next create a file &lt;a href=&quot;https://github.com/JizongL/jizongL.github.io/blob/master/_includes/comments.html&quot;&gt;_includes/comments.html&lt;/a&gt;     and paste the code given to me by Disqus as follow:&lt;/li&gt;
&lt;/ul&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;&lt;span class=&quot;p&quot;&gt;{%&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;kr&quot;&gt;if&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;nv&quot;&gt;page&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;.&lt;/span&gt;&lt;span class=&quot;nv&quot;&gt;comments&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;p&quot;&gt;%}&lt;/span&gt;
&amp;lt;!-- Add Disqus comments. --&amp;gt;
&amp;lt;div id=&amp;quot;disqus_thread&amp;quot;&amp;gt;&amp;lt;/div&amp;gt;
&amp;lt;script type=&amp;quot;text/javascript&amp;quot;&amp;gt;
  /* * * CONFIGURATION VARIABLES: EDIT BEFORE PASTING INTO YOUR WEBPAGE * * */
  var disqus_shortname = &amp;#39;&amp;lt;USERNAME&amp;gt;&amp;#39;; // required: replace example with your forum shortname
  var disqus_identifier = &amp;quot;&lt;span class=&quot;p&quot;&gt;{{&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;nv&quot;&gt;site&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;.&lt;/span&gt;&lt;span class=&quot;nv&quot;&gt;disqusid&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;p&quot;&gt;}}{{&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;nv&quot;&gt;page&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;.&lt;/span&gt;&lt;span class=&quot;nv&quot;&gt;url&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;p&quot;&gt;|&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;nf&quot;&gt;replace&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;:&lt;/span&gt;&lt;span class=&quot;s1&quot;&gt;&amp;#39;index.html&amp;#39;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt;&lt;span class=&quot;s1&quot;&gt;&amp;#39;&amp;#39;&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;p&quot;&gt;}}&lt;/span&gt;&lt;span class=&quot;nf&quot;&gt;&amp;quot;;&lt;/span&gt;&lt;span class=&quot;w&quot;&gt;&lt;/span&gt;

&lt;span class=&quot;w&quot;&gt;  &lt;/span&gt;/*&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;*&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;*&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;DON&lt;span class=&quot;s1&quot;&gt;&amp;#39;T EDIT BELOW THIS LINE * * */&lt;/span&gt;
&lt;span class=&quot;s1&quot;&gt;  (function() {&lt;/span&gt;
&lt;span class=&quot;s1&quot;&gt;    var dsq = document.createElement(&amp;#39;&lt;/span&gt;script&lt;span class=&quot;s1&quot;&gt;&amp;#39;); dsq.type = &amp;#39;&lt;/span&gt;text/javascript&lt;span class=&quot;s1&quot;&gt;&amp;#39;; dsq.async = true;&lt;/span&gt;
&lt;span class=&quot;s1&quot;&gt;    dsq.src = &amp;#39;&lt;/span&gt;//&lt;span class=&quot;s1&quot;&gt;&amp;#39; + disqus_shortname + &amp;#39;&lt;/span&gt;.disqus.com/embed.js&lt;span class=&quot;s1&quot;&gt;&amp;#39;;&lt;/span&gt;
&lt;span class=&quot;s1&quot;&gt;    (document.getElementsByTagName(&amp;#39;&lt;/span&gt;head&lt;span class=&quot;s1&quot;&gt;&amp;#39;)[0] || document.getElementsByTagName(&amp;#39;&lt;/span&gt;body&amp;#39;)[&lt;span class=&quot;mi&quot;&gt;0&lt;/span&gt;]).appendChild(dsq);
  })();
&amp;lt;/script&amp;gt;
&amp;lt;noscript&amp;gt;Please enable JavaScript to view the &amp;lt;a href=&amp;quot;http://disqus.com/?ref_noscript&amp;quot;&amp;gt;comments powered by Disqus.&amp;lt;/a&amp;gt;&amp;lt;/noscript&amp;gt;
&amp;lt;a href=&amp;quot;http://disqus.com&amp;quot; class=&amp;quot;dsq-brlink&amp;quot;&amp;gt;comments powered by &amp;lt;span class=&amp;quot;logo-disqus&amp;quot;&amp;gt;Disqus&amp;lt;/span&amp;gt;&amp;lt;/a&amp;gt;
&lt;span class=&quot;p&quot;&gt;{%&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;kr&quot;&gt;endif&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;p&quot;&gt;%}&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;h2 id=&quot;enabling-google-analytics&quot;&gt;Enabling Google Analytics&lt;/h2&gt;

&lt;p&gt;This is very straightforward and follows the same pattern as setting up the Disqus comments. Go to the &lt;a href=&quot;http://www.google.com/analytics/&quot;&gt;Google Analytics&lt;/a&gt; sign up for an account if you don’t have one already, use universal tracking and copy the code that they provide. Create a file in the &lt;code&gt;_includes&lt;/code&gt; folder and name it something like &lt;code&gt;google_analytics.html&lt;/code&gt;. &lt;!--break--&gt;
Paste in the code Google gave you and save the file. Now all that’s left is to open &lt;code&gt;layouts/default.html&lt;/code&gt; and add the following line:&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-liquid&quot; data-lang=&quot;liquid&quot;&gt;&lt;span class=&quot;p&quot;&gt;{%&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;nt&quot;&gt;include&lt;/span&gt;&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;google_analytics.html&lt;span class=&quot;w&quot;&gt; &lt;/span&gt;&lt;span class=&quot;p&quot;&gt;%}&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;&lt;a href=&quot;https://truongtx.me/2013/04/05/google-analytics-for-jekyll-bootstrap/&quot;&gt;Google Analytics&lt;/a&gt;&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Introducing Lanyon</title>
   <link href="http://lanyon.getpoole.com/2014/01/02/introducing-lanyon/"/>
   <updated>2014-01-02T00:00:00-06:00</updated>
   <id>http://lanyon.getpoole.com/2014/01/02/introducing-lanyon</id>
   <content type="html">&lt;p&gt;Lanyon is an unassuming &lt;a href=&quot;http://jekyllrb.com&quot;&gt;Jekyll&lt;/a&gt; theme that places content first by tucking away navigation in a hidden drawer. It’s based on &lt;a href=&quot;http://getpoole.com&quot;&gt;Poole&lt;/a&gt;, the Jekyll butler.&lt;/p&gt;

&lt;h3 id=&quot;built-on-poole&quot;&gt;Built on Poole&lt;/h3&gt;

&lt;p&gt;Poole is the Jekyll Butler, serving as an upstanding and effective foundation for Jekyll themes by &lt;a href=&quot;https://twitter.com/mdo&quot;&gt;@mdo&lt;/a&gt;. Poole, and every theme built on it (like Lanyon here) includes the following:&lt;/p&gt;

&lt;!--break--&gt;

&lt;ul&gt;
  &lt;li&gt;Complete Jekyll setup included (layouts, config, &lt;a href=&quot;/404&quot;&gt;404&lt;/a&gt;, &lt;a href=&quot;/atom.xml&quot;&gt;RSS feed&lt;/a&gt;, posts, and &lt;a href=&quot;/about&quot;&gt;example page&lt;/a&gt;)&lt;/li&gt;
  &lt;li&gt;Mobile friendly design and development&lt;/li&gt;
  &lt;li&gt;Easily scalable text and component sizing with &lt;code&gt;rem&lt;/code&gt; units in the CSS&lt;/li&gt;
  &lt;li&gt;Support for a wide gamut of HTML elements&lt;/li&gt;
  &lt;li&gt;Related posts (time-based, because Jekyll) below each post&lt;/li&gt;
  &lt;li&gt;Syntax highlighting, courtesy Pygments (the Python-based code snippet highlighter)&lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;lanyon-features&quot;&gt;Lanyon features&lt;/h3&gt;

&lt;p&gt;In addition to the features of Poole, Lanyon adds the following:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Toggleable sliding sidebar (built with only CSS) via &lt;strong&gt;☰&lt;/strong&gt; link in top corner&lt;/li&gt;
  &lt;li&gt;Sidebar includes support for textual modules and a dynamically generated navigation with active link support&lt;/li&gt;
  &lt;li&gt;Two orientations for content and sidebar, default (left sidebar) and &lt;a href=&quot;https://github.com/poole/lanyon#reverse-layout&quot;&gt;reverse&lt;/a&gt; (right sidebar), available via &lt;code&gt;&amp;lt;body&amp;gt;&lt;/code&gt; classes&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;https://github.com/poole/lanyon#themes&quot;&gt;Eight optional color schemes&lt;/a&gt;, available via &lt;code&gt;&amp;lt;body&amp;gt;&lt;/code&gt; classes&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;https://github.com/poole/lanyon#readme&quot;&gt;Head to the readme&lt;/a&gt; to learn more.&lt;/p&gt;

&lt;h3 id=&quot;browser-support&quot;&gt;Browser support&lt;/h3&gt;

&lt;p&gt;Lanyon is by preference a forward-thinking project. In addition to the latest versions of Chrome, Safari (mobile and desktop), and Firefox, it is only compatible with Internet Explorer 9 and above.&lt;/p&gt;

&lt;h3 id=&quot;download&quot;&gt;Download&lt;/h3&gt;

&lt;p&gt;Lanyon is developed on and hosted with GitHub. Head to the &lt;a href=&quot;https://github.com/poole/lanyon&quot;&gt;GitHub repository&lt;/a&gt; for downloads, bug reports, and features requests.&lt;/p&gt;

&lt;p&gt;Thanks!&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Example content</title>
   <link href="http://lanyon.getpoole.com/2014/01/01/example-content/"/>
   <updated>2014-01-01T00:00:00-06:00</updated>
   <id>http://lanyon.getpoole.com/2014/01/01/example-content</id>
   <content type="html">&lt;div class=&quot;message&quot;&gt;
  Howdy! This is an example blog post that shows several types of HTML content supported in this theme.
&lt;/div&gt;

&lt;p&gt;Cum sociis natoque penatibus et magnis &lt;a href=&quot;#&quot;&gt;dis parturient montes&lt;/a&gt;, nascetur ridiculus mus. &lt;em&gt;Aenean eu leo quam.&lt;/em&gt; Pellentesque ornare sem lacinia quam venenatis vestibulum. Sed posuere consectetur est at lobortis. Cras mattis consectetur purus sit amet fermentum.&lt;/p&gt;

&lt;blockquote&gt;
  &lt;p&gt;Curabitur blandit tempus porttitor. Nullam quis risus eget urna mollis ornare vel eu leo. Nullam id dolor id nibh ultricies vehicula ut id elit.&lt;/p&gt;
&lt;/blockquote&gt;

&lt;!--break--&gt;

&lt;p&gt;Etiam porta &lt;strong&gt;sem malesuada magna&lt;/strong&gt; mollis euismod. Cras mattis consectetur purus sit amet fermentum. Aenean lacinia bibendum nulla sed consectetur.&lt;/p&gt;

&lt;h2 id=&quot;inline-html-elements&quot;&gt;Inline HTML elements&lt;/h2&gt;

&lt;p&gt;HTML defines a long list of available inline tags, a complete list of which can be found on the &lt;a href=&quot;https://developer.mozilla.org/en-US/docs/Web/HTML/Element&quot;&gt;Mozilla Developer Network&lt;/a&gt;.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;To bold text&lt;/strong&gt;, use &lt;code&gt;&amp;lt;strong&amp;gt;&lt;/code&gt;.&lt;/li&gt;
  &lt;li&gt;&lt;em&gt;To italicize text&lt;/em&gt;, use &lt;code&gt;&amp;lt;em&amp;gt;&lt;/code&gt;.&lt;/li&gt;
  &lt;li&gt;Abbreviations, like &lt;abbr title=&quot;HyperText Markup Langage&quot;&gt;HTML&lt;/abbr&gt; should use &lt;code&gt;&amp;lt;abbr&amp;gt;&lt;/code&gt;, with an optional &lt;code&gt;title&lt;/code&gt; attribute for the full phrase.&lt;/li&gt;
  &lt;li&gt;Citations, like &lt;cite&gt;— Mark otto&lt;/cite&gt;, should use &lt;code&gt;&amp;lt;cite&amp;gt;&lt;/code&gt;.&lt;/li&gt;
  &lt;li&gt;&lt;del&gt;Deleted&lt;/del&gt; text should use &lt;code&gt;&amp;lt;del&amp;gt;&lt;/code&gt; and &lt;ins&gt;inserted&lt;/ins&gt; text should use &lt;code&gt;&amp;lt;ins&amp;gt;&lt;/code&gt;.&lt;/li&gt;
  &lt;li&gt;Superscript &lt;sup&gt;text&lt;/sup&gt; uses &lt;code&gt;&amp;lt;sup&amp;gt;&lt;/code&gt; and subscript &lt;sub&gt;text&lt;/sub&gt; uses &lt;code&gt;&amp;lt;sub&amp;gt;&lt;/code&gt;.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Most of these elements are styled by browsers with few modifications on our part.&lt;/p&gt;

&lt;h2 id=&quot;heading&quot;&gt;Heading&lt;/h2&gt;

&lt;p&gt;Vivamus sagittis lacus vel augue rutrum faucibus dolor auctor. Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Morbi leo risus, porta ac consectetur ac, vestibulum at eros.&lt;/p&gt;

&lt;h3 id=&quot;code&quot;&gt;Code&lt;/h3&gt;

&lt;p&gt;Cum sociis natoque penatibus et magnis dis &lt;code&gt;code element&lt;/code&gt; montes, nascetur ridiculus mus.&lt;/p&gt;

&lt;div class=&quot;highlight&quot;&gt;&lt;pre&gt;&lt;code class=&quot;language-js&quot; data-lang=&quot;js&quot;&gt;&lt;span class=&quot;c1&quot;&gt;// Example can be run directly in your JavaScript console&lt;/span&gt;

&lt;span class=&quot;c1&quot;&gt;// Create a function that takes two arguments and returns the sum of those arguments&lt;/span&gt;
&lt;span class=&quot;kd&quot;&gt;var&lt;/span&gt; &lt;span class=&quot;nx&quot;&gt;adder&lt;/span&gt; &lt;span class=&quot;o&quot;&gt;=&lt;/span&gt; &lt;span class=&quot;k&quot;&gt;new&lt;/span&gt; &lt;span class=&quot;nb&quot;&gt;Function&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;s2&quot;&gt;&amp;quot;a&amp;quot;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; &lt;span class=&quot;s2&quot;&gt;&amp;quot;b&amp;quot;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; &lt;span class=&quot;s2&quot;&gt;&amp;quot;return a + b&amp;quot;&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;);&lt;/span&gt;

&lt;span class=&quot;c1&quot;&gt;// Call the function&lt;/span&gt;
&lt;span class=&quot;nx&quot;&gt;adder&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;(&lt;/span&gt;&lt;span class=&quot;mi&quot;&gt;2&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;,&lt;/span&gt; &lt;span class=&quot;mi&quot;&gt;6&lt;/span&gt;&lt;span class=&quot;p&quot;&gt;);&lt;/span&gt;
&lt;span class=&quot;c1&quot;&gt;// &amp;gt; 8&lt;/span&gt;&lt;/code&gt;&lt;/pre&gt;&lt;/div&gt;

&lt;p&gt;Aenean lacinia bibendum nulla sed consectetur. Etiam porta sem malesuada magna mollis euismod. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa.&lt;/p&gt;

&lt;h3 id=&quot;lists&quot;&gt;Lists&lt;/h3&gt;

&lt;p&gt;Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Aenean lacinia bibendum nulla sed consectetur. Etiam porta sem malesuada magna mollis euismod. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Praesent commodo cursus magna, vel scelerisque nisl consectetur et.&lt;/li&gt;
  &lt;li&gt;Donec id elit non mi porta gravida at eget metus.&lt;/li&gt;
  &lt;li&gt;Nulla vitae elit libero, a pharetra augue.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Donec ullamcorper nulla non metus auctor fringilla. Nulla vitae elit libero, a pharetra augue.&lt;/p&gt;

&lt;ol&gt;
  &lt;li&gt;Vestibulum id ligula porta felis euismod semper.&lt;/li&gt;
  &lt;li&gt;Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.&lt;/li&gt;
  &lt;li&gt;Maecenas sed diam eget risus varius blandit sit amet non magna.&lt;/li&gt;
&lt;/ol&gt;

&lt;p&gt;Cras mattis consectetur purus sit amet fermentum. Sed posuere consectetur est at lobortis.&lt;/p&gt;

&lt;dl&gt;
  &lt;dt&gt;HyperText Markup Language (HTML)&lt;/dt&gt;
  &lt;dd&gt;The language used to describe and define the content of a Web page&lt;/dd&gt;

  &lt;dt&gt;Cascading Style Sheets (CSS)&lt;/dt&gt;
  &lt;dd&gt;Used to describe the appearance of Web content&lt;/dd&gt;

  &lt;dt&gt;JavaScript (JS)&lt;/dt&gt;
  &lt;dd&gt;The programming language used to build advanced Web sites and applications&lt;/dd&gt;
&lt;/dl&gt;

&lt;p&gt;Integer posuere erat a ante venenatis dapibus posuere velit aliquet. Morbi leo risus, porta ac consectetur ac, vestibulum at eros. Nullam quis risus eget urna mollis ornare vel eu leo.&lt;/p&gt;

&lt;h3 id=&quot;tables&quot;&gt;Tables&lt;/h3&gt;

&lt;p&gt;Aenean lacinia bibendum nulla sed consectetur. Lorem ipsum dolor sit amet, consectetur adipiscing elit.&lt;/p&gt;

&lt;table&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th&gt;Name&lt;/th&gt;
      &lt;th&gt;Upvotes&lt;/th&gt;
      &lt;th&gt;Downvotes&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tfoot&gt;
    &lt;tr&gt;
      &lt;td&gt;Totals&lt;/td&gt;
      &lt;td&gt;21&lt;/td&gt;
      &lt;td&gt;23&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tfoot&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td&gt;Alice&lt;/td&gt;
      &lt;td&gt;10&lt;/td&gt;
      &lt;td&gt;11&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Bob&lt;/td&gt;
      &lt;td&gt;4&lt;/td&gt;
      &lt;td&gt;3&lt;/td&gt;
    &lt;/tr&gt;
    &lt;tr&gt;
      &lt;td&gt;Charlie&lt;/td&gt;
      &lt;td&gt;7&lt;/td&gt;
      &lt;td&gt;9&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;Nullam id dolor id nibh ultricies vehicula ut id elit. Sed posuere consectetur est at lobortis. Nullam quis risus eget urna mollis ornare vel eu leo.&lt;/p&gt;

&lt;hr /&gt;

&lt;p&gt;Want to see something else added? &lt;a href=&quot;https://github.com/poole/poole/issues/new&quot;&gt;Open an issue.&lt;/a&gt;&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>Introducing Lanyon</title>
   <link href="http://lanyon.getpoole.com/2014/01/01/Introducing-Lanyon/"/>
   <updated>2014-01-01T00:00:00-06:00</updated>
   <id>http://lanyon.getpoole.com/2014/01/01/Introducing-Lanyon</id>
   <content type="html">&lt;p&gt;Lanyon is an unassuming &lt;a href=&quot;http://jekyllrb.com&quot;&gt;Jekyll&lt;/a&gt; theme that places content first by tucking away navigation in a hidden drawer. It’s based on &lt;a href=&quot;http://getpoole.com&quot;&gt;Poole&lt;/a&gt;, the Jekyll butler.&lt;/p&gt;

&lt;h3 id=&quot;built-on-poole&quot;&gt;Built on Poole&lt;/h3&gt;

&lt;p&gt;Poole is the Jekyll Butler, serving as an upstanding and effective foundation for Jekyll themes by &lt;a href=&quot;https://twitter.com/mdo&quot;&gt;@mdo&lt;/a&gt;. Poole, and every theme built on it (like Lanyon here) includes the following:&lt;/p&gt;

&lt;!--break--&gt;

&lt;ul&gt;
  &lt;li&gt;Complete Jekyll setup included (layouts, config, &lt;a href=&quot;/404&quot;&gt;404&lt;/a&gt;, &lt;a href=&quot;/atom.xml&quot;&gt;RSS feed&lt;/a&gt;, posts, and &lt;a href=&quot;/about&quot;&gt;example page&lt;/a&gt;)&lt;/li&gt;
  &lt;li&gt;Mobile friendly design and development&lt;/li&gt;
  &lt;li&gt;Easily scalable text and component sizing with &lt;code&gt;rem&lt;/code&gt; units in the CSS&lt;/li&gt;
  &lt;li&gt;Support for a wide gamut of HTML elements&lt;/li&gt;
  &lt;li&gt;Related posts (time-based, because Jekyll) below each post&lt;/li&gt;
  &lt;li&gt;Syntax highlighting, courtesy Pygments (the Python-based code snippet highlighter)&lt;/li&gt;
&lt;/ul&gt;

&lt;h3 id=&quot;lanyon-features&quot;&gt;Lanyon features&lt;/h3&gt;

&lt;p&gt;In addition to the features of Poole, Lanyon adds the following:&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;Toggleable sliding sidebar (built with only CSS) via &lt;strong&gt;☰&lt;/strong&gt; link in top corner&lt;/li&gt;
  &lt;li&gt;Sidebar includes support for textual modules and a dynamically generated navigation with active link support&lt;/li&gt;
  &lt;li&gt;Two orientations for content and sidebar, default (left sidebar) and &lt;a href=&quot;https://github.com/poole/lanyon#reverse-layout&quot;&gt;reverse&lt;/a&gt; (right sidebar), available via &lt;code&gt;&amp;lt;body&amp;gt;&lt;/code&gt; classes&lt;/li&gt;
  &lt;li&gt;&lt;a href=&quot;https://github.com/poole/lanyon#themes&quot;&gt;Eight optional color schemes&lt;/a&gt;, available via &lt;code&gt;&amp;lt;body&amp;gt;&lt;/code&gt; classes&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;a href=&quot;https://github.com/poole/lanyon#readme&quot;&gt;Head to the readme&lt;/a&gt; to learn more.&lt;/p&gt;

&lt;h3 id=&quot;browser-support&quot;&gt;Browser support&lt;/h3&gt;

&lt;p&gt;Lanyon is by preference a forward-thinking project. In addition to the latest versions of Chrome, Safari (mobile and desktop), and Firefox, it is only compatible with Internet Explorer 9 and above.&lt;/p&gt;

&lt;h3 id=&quot;download&quot;&gt;Download&lt;/h3&gt;

&lt;p&gt;Lanyon is developed on and hosted with GitHub. Head to the &lt;a href=&quot;https://github.com/poole/lanyon&quot;&gt;GitHub repository&lt;/a&gt; for downloads, bug reports, and features requests.&lt;/p&gt;

&lt;p&gt;Thanks!&lt;/p&gt;
</content>
 </entry>
 
 <entry>
   <title>What's Jekyll?</title>
   <link href="http://lanyon.getpoole.com/2013/12/31/whats-jekyll/"/>
   <updated>2013-12-31T00:00:00-06:00</updated>
   <id>http://lanyon.getpoole.com/2013/12/31/whats-jekyll</id>
   <content type="html">&lt;p&gt;&lt;a href=&quot;http://jekyllrb.com&quot;&gt;Jekyll&lt;/a&gt; is a static site generator, an open-source tool for creating simple yet powerful websites of all shapes and sizes. From &lt;a href=&quot;https://github.com/mojombo/jekyll/blob/master/README.markdown&quot;&gt;the project’s readme&lt;/a&gt;:&lt;/p&gt;

&lt;!--break--&gt;

&lt;blockquote&gt;
  &lt;p&gt;Jekyll is a simple, blog aware, static site generator. It takes a template directory […] and spits out a complete, static website suitable for serving with Apache or your favorite web server. This is also the engine behind GitHub Pages, which you can use to host your project’s page or blog right here from GitHub.&lt;/p&gt;
&lt;/blockquote&gt;

&lt;p&gt;It’s an immensely useful tool and one we encourage you to use here with Lanyon.&lt;/p&gt;

&lt;p&gt;Find out more by &lt;a href=&quot;https://github.com/mojombo/jekyll&quot;&gt;visiting the project on GitHub&lt;/a&gt;.&lt;/p&gt;
</content>
 </entry>
 

</feed>
